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ABSTRACT 
 
This research analyses the role and action of the Trade Related Intellectual 
Property Agreements (TRIPS) and pharmaceutical patents in the public health 
network of Djibouti, by using an approach largely inspired by actor-network 
theory (ANT). In doing so, it addresses issues that run beyond the specificities 
of this case study and relate more broadly to the relevance of ANT to socio-
legal analysis.  
 
The relation between TRIPS, pharmaceutical patents and public health in 
developing countries has been a widely debated issue in the past decade. 
However, the field remains limited by a relative uniformity in the range of 
approaches and case studies chosen in existing research. This project aims to 
address some of these limits, by looking at the role of TRIPS and 
pharmaceutical patents in a small country with no local pharmaceutical 
industry, no pre-existing official system of intellectual property, and with a 
largely undocumented public health system.  
 
Using ANT in this project allowed for the complexity of the mechanisms of 
both TRIPS and pharmaceutical patents to be highlighted. It participated in 
emphasising that they need to be understood as made of multiple, co-existing 
dimensions. By demonstrating how specific connections and associations have 
shaped what TRIPS and pharmaceutical patents are and do in the networks of 
 3 
Djibouti, this research emphasises the artificiality of the dichotomy between 
social and legal, and proposes an understanding of social connections as 
symmetrical and co-dependent. It discusses the more general relevance of this 
approach to socio-legal research. 
 
The example of Djibouti also allows for new questions to be raised in relation 
WR WKH DFWXDO LPSDFW RI 75,36 DQG SKDUPDFHXWLFDO SDWHQWV LQ ³GHYHORSLQJ
countrLHV´ ,QSDUWLFXODU LW HPSKDVLVHV WKHQHHG WR UHWXUQ WR DPRUHEDODQFHG
approach to the relation between pharmaceutical patents and health in poor 
countries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Acknowledgements  
 
I would like to thank my supervisors, Prof. Robert Dingwall, Prof. Tamara 
Hervey and Dr. Paul Street for all their help, advice and support during my 
PhD. 
 
I am also most grateful to all those who helped me by reading and discussing 
aspects of my work, and those who introduced me to new, much needed 
vocabulary and helped me correct the most clumsy of my sentences. 
 
The past three years ± and even more so the last few months ± would never 
have been as manageable without the great support that I enjoyed from my 
friends, in England and in France. Although I cannot thank everyone 
individually, I want to put a special note to Jemima Agyare and Juliette 
Salabert who have been the most efficient answer to any stress attack I might 
have had in the last few months. In the same way, and as always, I am very 
grateful to my family for simply caring and being there, and for always 
encouraging and supporting me. 
 
I also need to thank everyone in Djibouti for making my fieldwork not only 
possible and instructive, but a highly enjoyable experience. 
 
 5 
Finally, I need to give the biggest thanks to my partner, Pritesh Shah, for all his 
patience, care and support, which made the last three years not only possible, 
but also very happy times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
TABLE OF CONTENTS 
 
 
 
 
 
INTRODUCTION                  p.1 
 
 
CHAPTER 1 - TRIPS, PHARMACEUTICAL PATENTS AND 
38%/,&+($/7+,1³'(9(/23,1*&28175,(6´            p. 18 
 
SECTION 1: PATENTS BEFORE TRIPS ± A VARIETY OF APPROACHES  
JUSTIFIED ON ECONOMIC GROUNDS                  p. 20 
SECTION 2: TRIPS AND THE FRAMING OF PHARMACEUTICAL  
PATENTS AS A PUBLIC HEALTH ISSUE               p. 53 
 
CHAPTER 2 - INTRODUCING ACTOR-NETWORK THEORY           p. 77 
 
SECTION 1: SOCIOLOGICAL RESEARCH AND  
MOBILITY OF ORDERINGS                p. 79 
SECTION 2: UNDERSTANDING TRIPS AND  
PHARMACEUTICAL PATENTS THROUGH ANT               p. 105 
 
CHAPTER 3 - METHODOLOGY               p. 116 
 
SECTION 1: +2:72%($³&216758&7,9,67´ 
 $1'$³6&,(17,67´"                 p. 118 
SECTION 2: NARROWING DOWN THE FOCUS OF ANALYSIS              p. 130 
SECTION 3:  METHODS FOR DATA COLLECTION               p. 138 
SECTION 4:  ETHICS                  p. 158 
 7 
SECTION 5:  APPROACH TO DATA ANALYSIS              p. 163 
SECTION 6: ASSESSING THE VALIDITY OF RESEARCH  
METHODS AND FINDINGS                p. 166 
 
CHAPTER 4 - FINDING TRIPS AND PATENTS: AN  
INTRODUCTION TO THE VIEWPOINTS CHOSEN          p. 174 
 
SECTION 1: INTRODUCING DJIBOUTI               p. 176 
SECTION 2. DJIBOUTI AND IPR LAW ± PRE-TRIPS  
³,356<67(0´                 p.183 
SECTION 3: PUBLIC HEALTH IN DJIBOUTI: DEFINING  
SOME TERMS AND NETWORKS               p. 188 
SECTION 4: DEVELOPMENT OF A LOCAL PHARMACEUTICAL 
 INDUSTRY IN DJIBOUTI ± IS IT A TRIPS ISSUE?             p. 203 
 
CHAPTER 5 - 75,36$1'³/(*$/´$662&,$7,216- 
UNDERSTANDINGTHE ROLE OF TRIPS 
 AS PRESCRIPTION               p. 210 
 
SECTION 1: TR,36,6&+$1*,1*:5,77(11$7,21$//$:«           p. 212 
6(&7,21«%87'2(6,75($//<0$77(5"             p. 219 
SECTION 3: ACTION AND CIRCULATION IN DJIBOUTI              p. 230 
 
CHAPTER 6 - EMBEDMENT OF PHARMACEUTICAL  
PATENTS IN THE DRUGS USED IN DJIBOUTI            p. 249 
 
 8 
SECTION 1: PHARMACEUTICAL PATENTS AS  
DETERMINANT TO THE LOCAL PHARMACEUTICAL MARKET            p. 251 
SECTION 2: ENROLMENT AND ACTION OF PATENTS IN THE 
 PHARMACEUTICAL MARKET OF DJIBOUTI 
 ± HOW DO THEY GET THERE?              p. 262 
 
CHAPTER 7 - TRIPS, PHARMACEUTICAL PATENTS  
AND HEALTH IN DJIBOUTI - UNDERSTANDING TRIPS 
 IN ITS NETWORKED EFFECTS             p. 287 
SECTION 1:  UNDERSTANDING THE LINKS BETWEEN TRIPS,  
PATENTS AND HEALTH                p. 289 
SECTION 2: RE-ORDERING OF HEALTH NETWORKS  
AND DISLOCATED EFFECTS OF TRIPS            p. 298 
 
 
CHAPTER 8 - CONCLUSION             p.329
  
SECTION 1: EXPECTATIONS AND DISRUPTIONS:  
TRIPS AND PHARMACEUTICAL PATENTS IN ACTION IN DJIBOUTI                p. 331 
SECTION 2: UNDERSTANDING SOCIO-LEGAL  
OBJECTS THROUGH ANT: STRENGTHS AND LIMITS 
 OF THE METHOD                                                          p. 346 
 
BIBLIOGRAPHY                                                                                      p. 354 
 
APPENDIX I: LIST OF INFORMANTS 
 
 9 
INTRODUCTION 
 
This research discusses the role and impact of pharmaceutical patents and the 
Trade Related Intellectual Property Agreement (TRIPS) on health networks in 
Djibouti. Based on actor-network theory (ANT), it provides an understanding 
of these two instruments as multi-dimensional and fragile systems, enrolled in 
a multiplicity of mobile and changing social networks. It emphasises their 
QDWXUH DV ³VRFLR-OHJDO REMHFWV´1. Overall, this research explains how the 
complexity of the links between TRIPS, pharmaceutical patents and health can 
best be understood by looking at the different roles and mechanisms of each 
instrument within the several networks of which they are part. The impact of 
these instruments on health can then be explained while acknowledging the 
complexity of the changes generated, as the result of the multiple actions and 
shapes of both TRIPS and pharmaceutical patents as complex actor-networks. 
 
 
 
 
                                                 
1
 Although the term will become clearer throughout the following chapters, the notion of 
³VRFLR-OHJDOREMHFWV´QHHGVWREHEULHIO\H[SODLQHG)LUVWWKHWHUP³VRFLR-legDO´LVXVHG
throughout when designating TRIPS and pharmaceutical patents, as a way to emphasise the 
DEVHQFHRIGLFKRWRP\EHWZHHQZKDWLVVRPHWLPHVXQGHUVWRRGDVWZR³ILHOGV´RU³GLPHQVLRQV´
but is considered throughout this project as series of fluid and interrelated associations. Second, 
LWVKRXOGEHHPSKDVLVHGWKDWWKHWHUP³REMHFW´VKRXOGQRWEHXQGHUVWRRGDVSUH-determining 
DQ\IRUPRI³SDVVLYLW\´± partly because ANT puts forward the idea that any entity is always 
both acting and acted upon. Although WKHWHUP³DFWDQW´XVHGLQVRPH$17ZULWLQJVFRXOGKDYH
PRUHH[SOLFLWO\HPSKDVLVHGWKLVLGHDLWZDVGHFLGHGWKDWWKHOHVV³FU\SWLF´QRWLRQRI³VRFLR-
OHJDOREMHFW´ZRXOGEHXVHGWKURXJKRXWZKLOHHPSKDVLVLQJHDUO\LQWKLVSURMHFWWKDWWKLVVKRXOG
not preclude their active role. 
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TRIPS and pharmaceutical patents in a least developed country 
 
Although intellectual property has been a matter of national law and policy for 
a long time, the adoption of the TRIPS agreement in 1995 has created new 
international standards and requirements in the field. The adoption of TRIPS 
has generated important debates and disagreements amongst actors. Opposition 
to the text focused in particular on the potential risks and benefits that these 
new intellectual property (IP) standards would have for poorer countries.  
 
Within TRIPS, pharmaceutical patents has been one of the most controversial 
areas, and has been taken up as a key ethical problem in a wide range of arenas. 
They have generated oppositional discourses and positions, in which TRIPS 
and pharmaceutical patents have been framed and understood in a 
fundamentally different way by different groups.  
 
Broadly, the relation between TRIPS, pharmaceutical patents and health in 
poor countries has been fitted within two main sets of discourses. On the one 
hand, many have expressed the view that pharmaceutical patents in the form 
required by the TRIPS agreement would create obstacles to access to health. 
Based on the idea that stronger patents would have a negative effect on the 
availability of generic drugs, and therefore on the cost of medical treatment 
worldwide, this position explained how strengthening patents would make 
modern drugs unaffordable for people already in a critical health situation. This 
idea has been reframed in similar terms in the media, and has resulted in a 
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QXPEHU RI ³KHDOWK VFDQGDOV´ LQ ZKLFK WKH 1RUWK6RXWK GLPHQVLRQ RI the 
conflict has often been stressed.  
 
On the other hand, those supporting the TRIPS agreement have generally 
framed the link between pharmaceutical patents and health in poor countries in 
fundamentally different terms. They insist, in particular, on the idea that 
patents are necessary to maintain a high standard of research in the 
pharmaceutical field worldwide, and that weak pharmaceutical patents are 
therefore a danger to the availability of new drugs.  
 
This key disagreement is also reflected in debates on the role of TRIPS in 
generating the development of a pharmaceutical industry in developing 
countries. While opponents to TRIPS have emphasised the idea that 
introducing patents at an early stage of development would hamper the 
initiation of a basic pharmaceutical industry, those defending the text have 
highlighted the need to implement patents to ensure that this basic industry 
could evolve into a research-based industry. 
 
However, both sides of the debate leave a set of questions unanswered. 
Although they clearly illustrate two different versions of TRIPS and two 
different stories about pharmaceutical patents, they provide schematic and 
unspecific views of some of the links that can be made between the different 
relevant elements. In particular, the analysis they provide is essentially based 
on an understanding of current systems and future changes elaborated on the 
basis of written legal prescriptions. The potential for differences between the 
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content of legal prescriptions and social change is generally not addressed in 
most research in this field. Most literature rests, in addition, on deep 
assumptions about the needs of poor populations ± such as the relation between 
health and modern drugs and the actual role of medication in the health 
networks of poor countries ± and does not necessarily grasp the complexity and 
specificity of the different networks concerned.  
 
A wide range of academic literature has developed in recent years, questioning 
the impact of TRIPS in developing countries in terms of public health and 
GHYHORSPHQW([DPSOHVRI³GHYHORSLQJFRXQWULHV´KDYHJHQHUDOO\EHHQSLFNHG
from amongst those states that most actively opposed TRIPS, which has 
resulted in the focus of research being essentially turned towards a few 
developing countries with a local generic industry, and with an official model 
of law in clear contradiction with that of TRIPS. One of the main stances taken 
is then to discuss whether the implementation of TRIPS and the subsequent 
revision of both patent law and public health and development strategies, 
would be likely to have negative impacts on the developing country chosen as 
an example. It is clearly understandable that most literature has in fact 
concentrated on the example of India, as one of the strongest opponents to 
TRIPS, and a country in which internal disagreements on the cost and benefits 
of TRIPS have emerged at an early stage. Although these early case studies 
have participated in presenting some of the issues raised in this particular set of 
countries, they have generated a range of arguments that are based on rather 
KRPRJHQHRXVDVVXPSWLRQVLQUHODWLRQWRWKHQHHGVRI³GHYHORSLQJFRXQWULHV´LQ
health and industrial development. 
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However, this literature overlooks the experiences of a number of states, and in 
particular overlooks the smallest and least developed countries. These countries 
have no existing pharmaceutical industry and rely exclusively on imports for 
their pharmaceutical market. Several of these are also in a legal situation 
completely different from that of larger developing states, and have no system 
of patents or intellectual property that pre-exists TRIPS.  
 
These key differences make the situation of these small states worth 
investigating for several practical and theoretical reasons. Practically, least 
developed countries have come to the forefront of recent debates on TRIPS, 
following the discussions surrounding Paragraph 6 of the Doha declaration that 
will be explained in this research. The necessity to integrate safeguards that 
respond to the needs of countries with no local pharmaceutical industry within 
the TRIPS framework therefore became an important priority. However, the 
differences in the situation of small least developed states and large 
industrialised countries, on which most literature has concentrated, runs further 
than these practical issues. In particular, while countries like India need to 
reform laws in a field where positive policies have already been developed, and 
institutions created over a long period of time, states with no pre-existing IP 
system need not only to create a new law, but also to build expertise and create 
institutions. The task of generating a wholly new system in this way is 
fundamentally different from that of implementing written legal changes. One 
potential consequence of this lack of expertise and institutions, in particular, is 
a specific type of social understanding of TRIPS and pharmaceutical patents, 
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which might differ from that observed in countries where patents have been 
part of policy discourses for a long time. Other differences between states also 
need to be highlighted, and it is worth re-emphasising that the pharmaceutical 
market of each individual state is specific, and requires studying rather than 
assuming what pharmaceutical patents might mean for this market.  
 
In this research, the need to understand the impact of the changes generated by 
TRIPS on health in a small least developed country, with no preexisting patent 
law and no local industry was therefore considered a priority. The research 
complements what has already been written on pharmaceutical patents and 
developing countries but also represents a necessary challenge to a field of 
research in which uniformity and simplification have sometimes been 
privileged over differences and complexity. Because little investigation has 
been carried out in the area on least developed countries, the focus of the 
research was defined as broadly as possible within the field of interest, in order 
to avoid making assumptions in advance.  
 
The aim of this research is therefore to understand what TRIPS and 
pharmaceutical patents mean for public health in a small, least developed 
country, without existing laws in the field. It aims to study how each 
instrument was received and understood in the networks of this small state, 
what is their current role and impact and how this was expected to change with 
the legal implementation of TRIPS. It is also directed at understanding the 
modes of action of both instruments, and at offering a view of the nature and 
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mechanisms of these specific objects through social interactions. The focus of 
this research is therefore socio-legal in nature.  
 
Focus of the research 
 
In this research, the example of the Republic of Djibouti has been chosen. 
Djibouti represents an example of one of the poorest countries in the world, 
that is currently developing its first patent law following the adoption of 
TRIPS, and does not currently have any active form of pharmaceutical 
industry. It is also a state in which public health is a crucial issue, and there are 
a wide range of difficulties in this field. Although Djibouti was chosen as an 
example of a least developed country, it was accepted at an early stage that the 
pitfalls of existing simplifications of the field should be avoided, and that 
generalisation should therefore be kept to a minimum. To that extent, although 
this research is about the impact of TRIPS and pharmaceutical patents on 
health in a small least developed country, it does not claim to be about the 
impact of these instruments in ³OHDVW GHYHORSHG FRXQWULHV´ 2QH RI WKH PDLQ
positions taken throughout this research is that claims made in this complex 
field ± and in socio-legal research more generally ± need to be empirically 
based, and that the situation of each network and society is unique. 
 
The story of TRIPS and pharmaceutical patents in Djibouti soon became a 
story of contradictions and discrepancies. Written legal prescriptions became 
only a rather minor element of understanding what TRIPS and pharmaceutical 
patents as socio-legal objects were doing in practice in Djibouti. The 
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expectations that I had built from existing literature were revealed as flawed 
and were soon revised. This appeared to be due to two major elements: on the 
one hand, the networks of Djibouti were fundamentally different from those of 
countries more traditionally chosen as examples. On the other hand, the 
relation between written legal prescriptions and the social action of both TRIPS 
and pharmaceutical patents appeared to be more complex than existing 
literature represents. The story of TRIPS and pharmaceutical patents in 
Djibouti that could be told based on what they are supposed to do if taken as a 
set of written prescriptions, was fundamentally different from what was 
happening in reality. Comments made by informants about TRIPS and 
pharmaceutical patents were slightly in contradiction with some of the other 
results of the empirical work. Overall, what appeared throughout the research 
was not one story of TRIPS and pharmaceutical patents, but many different 
stories about them, or, rather, many versions of the same complex story. 
Similarly, understanding the relation between these instruments and health in 
Djibouti appeared to be more complex, and more flexible, than what has often 
been assumed by the diffHUHQW³VLGHV´RIWKH75,36GHEDWH7KHOLQNVEHWZHHQ
TRIPS, patents and health appeared to result from a set of complex stories and 
relations. Based on the idea that these multiple aspects of reality are all part of 
the story to be told, this research will explain the different dimensions and the 
different sides of TRIPS and pharmaceutical patents in Djibouti, and what this 
means for the impact of both socio-legal objects on health. 
 
The contrast between the different perspectives and the different stories told 
about TRIPS and pharmaceutical patents, and the originality of the type of 
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network chosen as case study called for a flexible form of analysis. The 
relevance of ANT to this research was based on different elements, including 
the complexity of the case study, the multiple versions and dimensions of 
TRIPS and pharmaceutical patents, and the involvement of a wide range of 
interrelated networks. Each of these elements related strongly to many of the 
ideas and concepts put forward by ANT. In addition, given that the aim is to 
understand and describe the situation on the ground in its complexity, and to 
grasp the co-existing realities of TRIPS and pharmaceutical patents in different 
networks, the ethnographic methods commonly used in ANT appeared most 
suitable. Although the use of ANT for socio-legal research is rather new and 
unexplored, its relevance to this particular research emerged at different stages 
of the project and allowed for a complete exploration of the issues raised by the 
case study.  
 
Understanding TRIPS and pharmaceutical patents through actor-network 
theory 
 
Emphasis on complexity, continuity and the fragility of social orderings has 
been one of the main elements of actor-network theory, and these appeared to 
be crucial dimensions in this research. The elements relate neatly to the 
complexity of the area under investigation, and the fragility of meaning of both 
TRIPS and pharmaceutical patents, as described in the background reading and 
emerging from the empirical research.  
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ANT ± defined by /DWRXU DV WKH ³VRFLRORJ\ RI DVVRFLDWLRQV´2 ± has been 
created as an alternative to traditional approaches to sociology that were based 
RQDQXQGHUVWDQGLQJRI ³WKHVRFLDO´ %DVHGRQ WKH LGHD WKDW WKHUH LVQR VXFK
thing as a stable and pre-determined social order, ANT prescribes the 
understanding of social orderings as changing sets of interrelations. By denying 
the possibility of determining a social context as a stable framework for 
analysis, ANT emphasises the need to understand mechanisms and connections 
within their inherent fragility. It defines and explains actor-networks as multi-
dimensional systems that are constantly reshaped by the many networks in 
which they become enrolled, at the same time as they impact on these networks 
and participate in their re-ordering. 
 
$17DOVRSXWVIRUZDUGWKHFUXFLDOLGHDVRI³FRQWLQXLW\´DQG³V\PPHWU\´DQG
calls for a uniform approach to the understanding of what have traditionally 
been defined as different spheres. These ideas have resulted in a challenge to 
several key dichotomies often used in other types of sociological analysis ± 
such as nature/society, human/non-human. Networks come to be understood as 
heterogeneous systems from which pre-determined distinctions should be 
excluded.  
 
Overall, from an ANT perspective, the role of sociologists is to retrace 
heterogeneous social networks in their entirety, and to question the relation 
between actor-networks, and the interrelation between their links and the 
movements of social orderings. In this research, these ideas were applied 
                                                 
2
 For example in Latour B. (2005) Reassembling the Social: an Introduction to Actor-network 
Theory, Oxford: Oxford University Press. 
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throughout to socio-legal research. The aim of the work undertaken, 
particularly empirically, was to understand the elements relevant to TRIPS, 
pharmaceutical patents and health in Djibouti, in their complexity, and to frame 
the pattern of their links and interdependency. The overall story became one in 
which TRIPS and pharmaceutical patents were enrolled and embedded in 
different networks that were shaping them in different ways, and in which the 
links between TRIPS, patents and health could only be understood as the 
intersection of these different actor-networks and as mobile and changing 
elements. 
 
In this research, the complexity of understanding the role of TRIPS and 
pharmaceutical patents in relation to health is illustrated through their 
description as multi-dimensional objects. The role each object plays in relation 
to health is understood while acknowledging the different dimensions and 
effects generated through each network they have become enrolled into. The 
written creation and existence of both objects therefore becomes only one of 
the elements to consider when discussing the impact of TRIPS and patents on 
health. In order to carry out an analysis of each object it is necessary to grasp 
amongst others the commercial, political and practical dimensions of each 
object. These dimensions are part of their socio-legal nature, and are co-
existing realities generated in particular networks. The role of each object, in 
relation to health, can then be understood by addressing TRIPS and 
pharmaceutical patents through the many versions of their reality provided by 
the different networks of Djibouti. 
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The story of TRIPS and pharmaceutical patents in this research is presented as 
challenging some of the assumptions that are inherent in understanding them as 
a simple and stable set of written prescriptions. The role and action of TRIPS 
and pharmaceutical patents is understood outside of the legal/social dichotomy, 
and offers a way to grasp the nature and role of each object without relying too 
heavily on assumptions as to the links between written rules and the role of 
socio-legal objects. 
 
In addition to this particular understanding of both TRIPS and pharmaceutical 
patents, this research also has a more general aim in testing the relevance of 
ANT to socio-legal research. Through the particular example of TRIPS and 
pharmaceutical patents in Djibouti, it aims to provide an example of how ANT 
can prove useful to empirical research in the socio-legal field. It offers a 
conceptualisation of socio-legal objects as elements of complex networks more 
flexible than their textual dimension might suggest, and always subject to 
modification by the networks in which they are enrolled.  This research 
therefore aims to locate itself within two distinct research areas, and builds its 
relevance from two different fields. First, it is a reply to existing literature on 
³75,36 DQG GHYHORSLQJ FRXQWULHV´ DQG UHHPSKDVLVHV WKH GLIIHUHQFHV DQG
contrasts between the experiences of a wide range of states. Second, it 
elaborates on some key concepts of ANT to offer a particular approach to 
socio-legal research based on notions of continuity, flexibility and 
interdependency. 
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The research questions that this study will answer therefore revolve around the 
role and mechanisms of TRIPS and pharmaceutical patents in Djibouti: 
 
What are the role and impact of TRIPS and pharmaceutical patents in health 
networks in Djibouti? 
x What is the impact of TRIPS as official prescription in Djibouti? 
x What is the role of pharmaceutical patents in shaping the 
pharmaceutical market of Djibouti? 
x How can the action of TRIPS in other places impact on social 
orderings in Djibouti? 
x How can understanding TRIPS and pharmaceutical patents as 
multi-dimensional actor-networks contribute to explaining their 
impact on health?  
 
In order to answer these different questions, several elements need to be taken 
into consideration. Overall, the questions will be answered by describing the 
role and action of both TRIPS and pharmaceutical patents in three key 
networks in Djibouti ± policy-making/the import system/the public health 
system. The study will question both the nature and modes of action of these 
instruments in each system, and each step will emphasise the potential 
discrepancies between the prescriptions of written law and the action of both 
socio-legal objects.  
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The research questions set for this project will be answered throughout eight 
chapters, including three background chapters and four empirically based 
chapters.  
 
Chapter 1 will present the underlying doctrinal issues raised by TRIPS and 
pharmaceutical patents, and will explain the legal background on which this 
research has developed. It will introduce the pre-TRIPS situation worldwide 
ZLWKUHJDUGWRSKDUPDFHXWLFDOSDWHQWVDQGZLOOORFDWH'MLERXWL¶VOHJDOsituation 
within this field. It will then provide an introduction to the legal dispositions of 
TRIPS and explain why they have been so controversial with regard to 
developing countries.  Finally, this chapter will explain the shaping of TRIPS 
as a public health issue in both academic literature and political discourses, and 
why this is important to understand the mechanisms of TRIPS. 
 
Chapter 2 will offer a detailed introduction to ANT, and emphasise the key 
concepts that will be used throughout this thesis. It will explain the emphasis of 
the theory on symmetry, continuity and complexity, and how this can be 
applied in practice to empirically based socio-legal research. It will explain 
how ANT can assist in offering a new conceptualisation of TRIPS and 
pharmaceutical patents. 
 
Chapter 3 will present the methodology used in this research, and explain why 
a case study based approach was chosen and how empirical research was 
carried out. It will present the sources used for data collection, and explain how 
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the potential limits of the methods chosen have been avoided or restrained in 
this project. 
 
Chapter 4 will provide a background introduction to the Republic of Djibouti in 
relation to its public health, intellectual property system and pharmaceutical 
industry. It will provide the information necessary for the reader to understand 
some key elements of the issues that surround the fields investigated 
throughout. It will also begin to describe some of the networks that will be 
studied in the following data chapters, and present some of the key actors. 
 
The following three chapters of the thesis will present the different dimensions 
of TRIPS and pharmaceutical patents as expressed in different networks, and 
will aim to define how both objects relate to health in Djibouti. 
 
Chapter 5 will present TRIPS as prescription in a pharmaceutical patents policy 
network. It will analyse how TRIPS as written prescription has become 
enrolled in policy networks in Djibouti and will discuss its circulation amongst 
actors expected WRFRQVWLWXWHD³SKDUPDFHXWLFDOSDWHQWVSROLF\-QHWZRUN´$ILUVW
set of discrepancies between the written dimension of TRIPS and its role in 
social networks will be highlighted, by showing the contrast between the role 
of TRIPS within the office in charge of its written implementation and its role 
within larger policy networks. The impact of weak network connections on the 
circulation of TRIPS and on the shaping of TRIPS will be explained. 
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Chapter 6 will analyse the role of pharmaceutical patents within the 
pharmaceutical import network of Djibouti, and in relation to its 
pharmaceutical market in particular. It will demonstrate how, in spite of the 
absence of the official existence of patents in the country, they have become a 
central actor in the shaping of the local market. The modes of action of patents 
outside of national written law will be questioned, and this chapter will 
demonstrate how sets of commercial, personal and practical networks have 
participated in generating and maintaining this action. 
 
Chapter 7 will discuss the role of TRIPS and pharmaceutical patents within the 
public health network of Djibouti, and will build on the findings presented in 
Chapter 5 and 6. It will emphasise how different understandings and the 
different dimensions of TRIPS and pharmaceutical patents have participated in 
creating complexity in this particular network, and why understanding the role 
of both objects in relation to health can only be achieved by looking at their 
nature outside of the official/written dimension. This chapter will start by 
questioning the links between patents, health and disease, on the basis of earlier 
discussion of the role of patents in the pharmaceutical market, and in relation to 
existing literature in the field. It will then move on to questioning the role of 
TRIPS and pharmaceutical patents in shaping health policies, in particular the 
need to understand TRIPS within wider international health policy networks. 
This will be done by reflecting on how two specific health programmes 
recently created in Djibouti can be read within the light of recent emphasis on 
access to generic drugs in poor countries. Overall, the links between TRIPS, 
patents and health will be presented by acknowledging the need to understand 
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both TRIPS and pharmaceutical patents as socio-legal objects. In order to 
understand the impact of both objects on health, their potentiality for acting 
further than written prescription in multiple networks needs to be fully 
understood and detailed. 
 
Finally, the conclusion of this thesis will bring these different findings together 
to present a view of TRIPS and pharmaceutical patents as complex, multi-
layered and multi-dimensional socio-legal objects. The relevance of the 
methods applied throughout for socio-legal research more generally will then 
be discussed, and the wider value of ANT for socio-legal research will be 
presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
CHAPTER 1 - TRIPS, PHARMACEUTICAL PATENTS AND PUBLIC 
+($/7+,1³'(9(/23,1*&28175,(6´ 
 
This chapter considers the issues raised by the impact of TRIPS and 
pharmaceutical patents on developing countries, and highlights some of the 
limitations of the way it has been discussed and understood in recent years. It 
introduces the doctrinal dimension of the issues at stake, and reflects on how 
different arguments have participated in providing different views about TRIPS 
and pharmaceutical patents. It explains how TRIPS and pharmaceutical patents 
have progressively become framed as public health issues, and why their public 
health impact has become the key element considered in relation to developing 
countries. Finally, it presents the need for further empirical research on the 
links between patents, TRIPS and public health in a wider range of countries, 
and explains how this study will fill some of the remaining gaps in existing 
literature. 
 
In 1994 the Trade Related aspects of Intellectual Property rights (TRIPS) 
agreement was signed, as part of the measures taken in the Uruguay Round of 
the General Agreement on Tariffs and Trade (GATT) to limit existing barriers 
to free trade. The distortions created by the widely non-harmonised nature of 
the existing IP system were considered as one of the elements that needed to be 
addressed. TRIPS introduced detailed and controversial international standards 
in the field of intellectual property, binding on every member of the newly 
created World Trade Organisation (WTO). The adoption of TRIPS was the 
result of several years of increasing pressure from industry towards a strong 
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protection of intellectual property worldwide3. It created a large amount of 
resistance and opposition in several fields ± public health in particular, as will 
be explained below4. While TRIPS was originally thought of as an intellectual 
property and trade instrument, international opposition and discourses have 
made it a key actor in relation to public health in what has often been defined 
DVWKH³GHYHORSLQJZRUOG´7KLVFKDSWHUH[SODLQVKRZWKLVLQVWUXPHQWFKDQJHG
a number of relations and links between pharmaceutical patents, health and 
developing countries, and presents how these links are generally portrayed in 
WKH³SRVW-75,36HUD´ 
 
This chapter begins by introducing the international regulation of patents, by 
first presenting the nationally determined system that pre-existed TRIPS. It 
emphasises the diversity of approaches to pharmaceutical patents in the pre-
TRIPS system, and explains how these have traditionally been justified. This 
will highlight some of the key arguments that have been made about the 
potential benefits or risks of strong patent laws for many years and participate 
in understanding the opposition to TRIPS described throughout this chapter 
(Section 1). It then introduces TRIPS itself and its framing in international 
discourses, by reviewing the history of TRIPS, its content, and its progressive 
integration in public health networks (Section 2).  
 
 
                                                 
3
 Sell S. (2003) Private Power, Public Law, Cambridge: Cambridge University Press. 
4
 See also Sell S. ³75,36DQGWKH$FFHVVWR0HGLFLQHV&DPSDLJQ´Wisconsin 
International Law Journal Summer 20(2) 481-522 
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SECTION 1: PATENTS BEFORE TRIPS ± A VARIETY OF 
APPROACHES JUSTIFIED ON ECONOMIC GROUNDS 
 
This section explains how pharmaceutical patents were regulated in the pre-
TRIPS system. It discusses the legal concept of patents, before considering the 
specificities of the pharmaceutical field and how states had approached it up to 
TRIPS. It finally explains how the variety of national policies in the field up to 
TRIPS was justified by the diverging interests in this area. 
 
1. NATURE AND MECHANISMS OF PATENTS ± SOME BASIC 
CHARACTERISTICS  
  
This section introduces the notion of patents and their mechanisms. It explains 
their rationale, and offers a brief overview of the social role of patents as 
traditionally understood. It begins by discussing the rationale for patents. It 
then explains how they have been regulated at international level until TRIPS. 
It provides a discussion of the common characteristics of the concept of 
patentability in different legal systems, and emphasises the complexity of the 
notion. Finally, it introduces some key elements in relation to the exploitation 
of patent rights and its limits. 
 
Patents are considered both a social and economic tool. They represent a quasi-
monopoly granted by states for a limited period of time on an industrial 
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invention, in exchange for publication5. In practice, they result in patentees 
being able to exclude others from using their invention commercially, for a 
period of time limited by law6. Although a patent does not offer inventors an 
immediate right to market their invention, as this right might be subject to other 
national laws7, it guarantees them a commercial quasi-exclusivity from the 
moment the patent is granted. It is therefore a very strong advantage that will 
result in inventors being able to commercialise their invention for the highest 
price that the market will sustain, without being limited by competition. The 
duration of patents has varied according to different national laws. The new 
standards of international law defined by TRIPS impose a minimum of twenty 
years for patent rights in any field8. This is similar to what has been adopted for 
example in Europe9 and the US10 for several years. However, this has not been 
a fully universal practice, and many states had chosen to offer patents only for 
                                                 
5
 For different definitions of the concept, see for example: Holyoak and Torremans (2001, 3rd 
Ed) Intellectual Property Law, London: Butterworth; Grubb P. (1999) Patents for Chemicals, 
Pharmaceuticals and Biotechnology, Oxford: Oxford University Press; Domeij B. (2000) 
Pharmaceutical Patents in Europe, Cambridge (US): Kluwer Law International. 
6
 See for example in the TRIPS agreement Article 28(1): ³A patent shall confer on its owner 
the following exclusive rights: 
(a) Where the subject matter of a patent is a product, to prevent third parties not having 
WKH RZQHU¶V FRQVHQW IURP WKH DFWV RI PDNLQJ XVLQJ RIIHULQJ IRU VDOH VHOOLQJ RU
importing for any of these purposes that product; 
(b) Where the subject matter of a patent is a process, to prevent third parties not having 
WKH RZQHU¶V FRQVHQW IURP WKH DFW RI XVLQJ WKH SURFHVV DQG IURP WKH DFWV RI XVLQJ
offering for sale, selling or importing for these purposes at least the product obtained 
GLUHFWO\E\WKDWSURFHVV´ 
7
 Such as health and safety regulations. 
8
 TRIPS Article 33. 
9
 See the European Patent Convention, Article 63.  
10
 35 US 154(2) 
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a shorter term11, or to offer different durations in different fields of 
technology12. 
 
The rationale for the existence of patents has been widely debated within 
broader discussions on intellectual property. Most commonly, utilitarian 
arguments can be found to explain their role. In this perspective, intellectual 
property rights are perceived as necessary to social welfare13. If looking back at 
the history of patents and their original role in England in the Middle Ages, it is 
clear that the notion of public interest soon became central to the grant of 
patents14. Several elements are essential in understanding the relevance of 
patents for the public interest. First, and this was particularly important when 
patents were first created, patents were originally seen as an efficient way to 
³LPSRUW´ QHZ WHFKQRORJLHV LQWR D FRXQWU\15. Second, patents are always 
associated with a condition of disclosure. When a patent is granted, full details 
of the nature of the invention and ways of making it will be disclosed, and 
                                                 
11
 For example, Australian patents were granted for 16 years up to the Patents (WTO 
Amendment) Act 1994. 
12
 For example the Indian 1970 patent act (Patent Act, 1970, 27 India A.I.R Manual 450 (1979) 
VKRUWHQVWKHVWDQGDUGWHUPRI\HDUVIRUSDWHQWVWR³5 years from the date of sealing or 7 
years from the date of the patenWZKLFKHYHULVVKRUWHU´ for pharmaceutical process patents. 
(Article 53) 
13
 6HHIRUH[DPSOHLQWKHDUHDRIFRS\ULJKWV/DQGHV:0DQG3RVQHU5$³$Q
(FRQRPLF$QDO\VLVRI&RS\ULJKW/DZ´Journal of Legal Studies 18(2) pp.325-363. See also 
the underlying approach in Bentham J. (1839) A Manual of Political Economy, New-York: 
Putnam. 
14
 See the Darcy and Allin decision, (1602) Noy 173, 74 ER 1131. It confirmed for the first 
time the views of English courts that patent should not be granted only as a privilege but had to 
be dependent on public benefits. 
15
 6HH'DYLHV6³7KH(DUO\+LVWRU\RIWKH3DWHQW6SHFLILFDWLRQ´Law Quarterly Review 
(50) pp. 260-337  
 31 
whatever was in the private knowledge of the inventor will become public 
knowledge16. Consequently, patents guarantee that public knowledge will be 
improved, which justifies the advantages given. While inventors see their 
inventions protected from counterfeit, public knowledge is improved by the 
disclosure of the details of this invention ± and potential new developments can 
therefore be facilitated. The third argument relating to utilitarian theories for 
justifying patent law is often the one that is most centrally supported, or 
implicitly undertaken by authors in the field, and was largely put forward by 
lobby groups during the years leading to TRIPS: patents are a central incentive 
to research and development. Under this argument, the main aim of patents is 
to ensure that researchers are not discouraged from investing in research 
activities because of the risk of not recovering fully their investment. Patents 
provide a guarantee that inventors will have a wide margin of action in 
deciding the marketing price of their product, and participate in making 
research a rewarding activity. At national level, patents are therefore an 
important part of policies aiming at encouraging research and development 
activities17. However, it is important to emphasise that in addition to these 
economic arguments, intellectual property has sometimes been framed in terms 
of rights, and related to the natural origins of the right to property18. Although 
                                                 
16
 Publication is central to every patent system. See for example TRIPS Article 29. 
17
 Drahos P (1996) A Philosophy of Intellectual Property, Dartmouth: Aldershot. For specific 
details on this, see discussion on the role of pharmaceutical patents in Section 2. 
18
 )RUH[DPSOH6KLIIULQ69³/RFNHDQ$UJXPHQWVIRU3ULYDWH,QWHOOHFWXDO3URSHUW\´LQ
Munzer S. R. (ed) New Essays in the Legal and Political Theory of Property, Cambridge: 
&DPEULGJH 8QLYHUVLW\ 3UHVV 0RRUH $  ³7RZDUGV D /RFNHDQ 7KHRU\ RI ,QWHOOHFWXDO
3URSHUW\´LQ0RRUH$(GIntellectual Property, Lanham: Rowman and Littlefield; Machlup 
) DQG 3HQURVH (  ³7KH 3DWHQW &RQWURYHUV\ LQ WKH th &HQWXU\´ The Journal of 
Economic History 10(1) p.1-29. 
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the theory behind these arguments has been opposed, in particular on the basis 
of the diversity of understandings of intellectual property worldwide, the 
history of TRIPS shows an increase in the use of the rights discourses in 
relation to intellectual property used by lobby groups.19 
 
International regulation of patents 
 
In terms of territoriality, patent systems are in principle organised at national 
level, each state deciding which set of rules to apply. A patent granted in one 
country is valid only on its territory, and patent applicants wanting to see their 
rights protected in different states will have to apply for as many patents, in 
principle. However, the lack of harmonisation of patent systems worldwide, 
and the procedural complexity of the system have both created difficulties for 
international trade, and a number of international agreements have been signed 
in order to limit the potential problems created. The first international 
development in the area of patent law was the Paris Industrial Property 
Convention, originally signed in 1883 by eleven countries. Membership to the 
Paris Convention has progressively increased since it was signed, and most 
countries worldwide are now signatories20. The convention requires member 
states to treat patent applicants from all nationalities in the same way ± the 
³QDWLRQDO WUHDWPHQW´21 rule. In addition to this, the Convention contains 
                                                 
19
 Sell S. (2002) "TRIPS and the Access to Medicines Campaign", op. cit ± when looking at the 
framing of patent law by the pharPDFHXWLFDOOREE\LQSDUWLFXODUQRWLRQVRI³SLUDF\´DQG
³VWHDOLQJ´DUHIUHTXHQWO\GUDZQXSRQZKHQFRPPHQWLQJRQWKHODZRIVWDWHVWKDWKDYHFKRVHQ
to exclude pharmaceuticals from the patentability field. 
20
 For a list, see the WIPO website at www.wipo.org/treaties/documents/english/pdf/d-paris.pdf 
21
 Article 2(1). 
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LPSRUWDQWGLVSRVLWLRQV LQUHODWLRQWR WKHTXHVWLRQRI³SULRULW\RIDSSOLFDWLRQV´
that will be looked at again below. It states that an applicant who has made an 
application in one of the member states will automatically get priority over 
later applications in other member states22. However, the content of the Paris 
Convention is essentially procedural, and remains far from the substantive 
harmonisation created by TRIPS, as will be explained below. 
 
The second step towards an international harmonisation of patent systems was 
the Patent Co-operation Treaty, signed in 197023. Its aim is to ease the 
administrative burden of patent applications24, by providing a centralised 
system in which applicants can apply in one office for every national patent 
they want to be granted25. Applicants submit one application either to a 
national patent office or the International Bureau of the World Intellectual 
Property Organisation (WIPO)26, and specify the list of member states in which 
they wish to apply for a patent27. This particular office investigates relevant 
aspects of the state of the art28, and the application is published through the 
WIPO29. However, this system remains harmonised only as far as procedures 
are concerned, and the final substantive decision of whether or not to grant a 
patent is taken by each national patent office30. 
                                                 
22
 Article 4(1) 
23
 Full text of the treaty can be accessed at: http://www.wipo.int/pct/en/texts/pdf/pct.pdf 
24
 Article 1 
25
 Article 4(1) 
26
 Article 2 (xv) and Article 2 (xviii) 
27
 Article 3 (1) 
28
 Article 15(1) and Article 15(2)  
29
 Article 21(1) 
30
 Article 27 (5) 
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It is useful at this stage to mention a further evolution in the international 
harmonisation of patents ± in particular because it will be referred to 
throughout this section. Although until TRIPS no substantive rules had been 
created at international level in relation to patents, regional agreements have 
been signed that create this type of standards. The European Patent Convention 
(EPC), signed in 1973, is a good example of a strong regional system of 
harmonisation for intellectual property, and it is useful to explain its 
mechanisms31. The EPC has created the European Patent Organisation, in 
which the Patent Office (EPO) grants European Patents under the supervision 
of the Administrative Council32. It has set up a centralised system through 
which a patent applied for through the EPO will be valid in all EPC member 
states. However, as soon as the patent has been granted by the EPO, it becomes 
HTXLYDOHQW WR D QXPEHU RU ³EXQGOH´ RI QDWLRQDO SDWHQWV DQG LV VXEPLWWHG WR
further challenges at the national level only33. The main development created 
by the EPC, however, is to create harmonised substantive standards for patent 
systems in member states34. In addition to this and at European level, however, 
the most recent developments have been taking place in the European Union 
(EU), where attempts to create a newly integrated EU-level patent system are 
taking shape35. 
                                                 
31
 Although the European Patent system is not the only regional IP system (the Organisation 
Africaine de la Propriete Intellectuelle  and The African Regional Intellectual Property 
Organization are two other examples that could have been taken), its influence worldwide and 
its efficient development justify chosing it as the clearest example of regional integration for 
the purpose of this chapter. 
32
 EPC Article 4. 
33
 EPC Article 2. 
34
 Articles 52 to 74. 
35
 See for comments: http://www.eubusiness.com/imported/2003/03/104634 
 35 
 
Overall, the international harmonisation of patent systems until TRIPS has 
been limited, and for many years the creation of international substantive 
standards has been limited to regional systems. However, in 1994, the Uruguay 
round of the GATT addressed the range of issues that have been seen as 
barriers to free trade worldwide ± and this lack of harmonisation of IP systems, 
including patents, was one of the key issues discussed. This resulted in the 
signature of the TRIPS agreement, as part of the newly created WTO system. 
Although TRIPS will be discussed more in detail below, it is worth mentioning 
briefly at this stage that it represents a key step in the evolution of the 
international patent system, in that it creates a detailed set of substantive 
standards to be respected by all WTO member states. This was particularly 
crucial in relation to pharmaceutical patents, due to the variety of systems that 
existed when TRIPS was signed, as will be detailed in this chapter. However, 
before analysing more specifically the field of pharmaceutical patents, it is 
necessary to discuss further elements of patent law, in order to understand the 
content and mechanisms of patents, as well as the complexity of this particular 
legal area. 
 
Patentability 
 
Because patent systems have so far been nationally determined, it is difficult to 
provide a detailed overview of patentability criteria worldwide in this chapter. 
However, certain characteristics have been common to all patent systems ± 
although they have often been applied, interpreted and delimited in different 
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ways. In particular, patents are only granted to inventions that are not explicitly 
excluded by national law36 WKDWDUHQRWFRQWUDU\ WR³RUGUHSXEOLF´RU³SXEOLF
SROLF\´DQGPRUDOLW\37 and that are novel, inventive, and capable of industrial 
application38. In order to understand the essence of the concept of patents, it is 
useful to review the range of issues that have arisen in relation to the notion of 
patentability. In this section, the main criteria for patentability found in patent 
systems will be discussed, and the complexity of interpreting and applying 
them will be illustrated by examples borrowed from patent decisions 
essentially in the UK and the EPO. Although this does not claim to provide a 
full description of jurisprudential debates worldwide, it highlights some of the 
complexities of patent law, and introduces further elements necessary to 
understand what are patents and how they work according to written law. 
 
Novelty 
 
A patent can only be graQWHGWRDQLQYHQWLRQWKDWLV³QHZ´± which means that 
it is adding something to the state of the art and therefore that it is not a claim 
                                                 
36
 This is the case for example of the exceptions presented in the UK Patent Act 1977 Section 
1(2) or the EPC Article 52(2) ± VXFK DV ³discoveries, scientific theories and mathematical 
methods; aesthetic creations;  schemes, rules and methods for performing mental acts, playing 
JDPHV RU GRLQJ EXVLQHVV DQG SURJUDPV IRU FRPSXWHUV SUHVHQWDWLRQV RI LQIRUPDWLRQ´; it is 
also the case of plant and animals, and processes for the production of these, excluding 
microbiological processes and their product (UK Patent Act 1977 Schedule A2 Paragraph 3(f) 
and EPC article 53(b). 
37
 See for example EPC Art 53(a). The jurisprudence of the EPO has introduced the need to 
balance the risks to public order and morality with the potential benefits to be gained from the 
invention see Harvard/Onco-mouse (1990) EPOR 4. 
38
 See UK Patents Act 1977 Article 1(1); EPC article 52; Bangui Agreement 1977 Article 2, for 
examples. 
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over a product or process already disclosed to the public39. The state of the art 
is evaluated both by comparison to existing publications ± individual 
documents, to be interpreted according to the knowledge existing on the date of 
publication40 ± and to the use of particular products or processes. 
 
Although it might appear as a straightforward concept at first consideration, the 
notion of state of the art has created intense legal debate, and understandings of 
the concept of novelty have varied both in national laws and court cases. Only 
a few elements need to be presented here as illustration of the difficulties of the 
concept.  
 
The first element that has not been fully agreed on by states has been the 
geographical aspect of the notion of state of the art ± where does something 
QHHG WR EH NQRZQ WR EH FRQVLGHUHG DV ³VWDWH RI WKH DUW´" )RU D QXPEHU RI
countries, the state of the art encompasses anything known anywhere in the 
world, even if it is in a form hardly accessible for patent applicants. This 
system has been adopted by the European Patent Convention41 and had 
previously also been integrated to the system of some states, such as France, 
for many years42. In 1977, the UK adopted this form of approach in accordance 
with the law of the EPO43. However, until 1977, the British understanding of 
                                                 
39
 EPC Article 54 (1); See also 35 USC  102; UK Patent Act 1977 article 2(1) 
40
 In the UK see General Tire& Rubber v. Firestone Tyre and Rubber (1972) RPC 457; in the 
EPO Tektronix/Scottky barrier diode (1995) EPOR 384. 
41
 Article 54 (2). 
42
 Code de la Propriete Intellectuelle, Art. L611-11. 
43
 Patent Act 1977, Section 2(1) and Section 2(2). 
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public disclosure from a geographical perspective was different44. In order for a 
product or process to be considered as part of the state of the art, it had to have 
been disclosed to the public in the UK. The US has adopted an intermediary 
approach, and distinguishes between disclosure in the US and abroad when 
looking at the means for disclosure45. On the one hand, disclosure by any 
means, prior use or publication, would invalidate a patent if this has taken 
place in the US. On the other hand, for an invention to be considered as part of 
the state of the art for the purpose of US law because it was known abroad, the 
invention needs to have been published in written form in another country. 
Disclosure by prior use outside the US territory would not invalidate a US 
patent.  
 
These different approaches have been subject to different criticisms. While on 
the one hand the approach adopted by the US has been criticised in relation to 
the patenting of inventions involving traditional knowledge46, the European 
approach has sometimes been presented as unrealistic, in the sense that 
inventors might see a patent application rejected because of prior use in a small 
community on the other side of the world of which it was hardly possible for 
them to have heard. However, the risk of double patenting remains essential to 
keep in mind, and approaches extending WKHLU XQGHUVWDQGLQJ RI ³VWDWH RI WKH
DUW´ZRUOGZLGHDUHWKHUHIRUHJHQHUDOO\SUHIHUUHG47. 
                                                 
44
 This was the case in the Patent Act 1949. 
45
 35 USC 102. 
46
 Dutfield G. and Posay D.  (1996) Beyond Intellectual Property, Towards Traditional 
Resources Rights for Indigenous People and Local Communities, Ottawa: International 
Development Research Centre. 
47
 Torremans P. (2005) Intellectual Property Law, Oxford: Oxford University Press, pp. 54-55. 
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However, the complexity of the notion of novelty, and of the associated 
concepts of state of the art and public disclosure runs much deeper than this 
specific issue. In many circumstances, the difficulty faced by judges when 
dealing with the notion of novelty has been to determine how much of an 
invention had to have been disclosed in order for it to be disqualified from 
patenting possibilities. Although it is not directly relevant to the purpose of this 
research to provide full details on these issues, it is important to specify that 
they have been the focused of extensive case-law48.  
 
Finally, a last element linked to the concept of novelty is the question of 
priority of claims. Simply, it is the question of the value of patent claims that 
are not yet published when considering the state of the art. In particular, the 
concept of state of the art is, as just mentioned, linked to the question of 
availability to the public. To that extent, an unpublished patent claim, as it is 
not available to the public should not be considered as part of the state of the 
art. However, this could result in granting two patents on the same invention. 
Most states have answered this difficulty by considering that an unpublished 
patent claim should be part of the state of the art49, and this has for example 
been so in the European Patent Convention50. In particular, this aims to avoid 
                                                 
48
 For examples from the UK and the EPO, see Thomson/Electron Tube T953/90 (1998) EPOR 
415; Windsurfing international Inc vs Tabur Marine (1985) RPC 59; General Tire and Rubber 
Co v Firestone Tyre and Rubber Co (1972) RPC 457; Van Der Lely (L) NV v Bamfords (1963) 
RPC 61. 
49
 In the UK, Patent Act 1977, Section 2(3); in France, Code de la Propriete Intellectuelle, Art. 
L611-11 to L611-13. 
50
 EPC Article 54(3). 
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the conceptual and practical difficulties that granting two similar patents could 
have created. 
 
Inventive step 
 
7KH VHFRQG FHQWUDO FRQGLWLRQ IRU SDWHQWDELOLW\ LV WKH QHHG IRU DQ ³LQYHQWLYH
VWHS´51. This allows for a distinction to be made between what is a patentable 
invention, and what is a simple discovery that cannot be protected by patent 
rights. The question has arisen in particular both when inventors build on 
existing products or processes for their invention52, and when they associate 
known products or processes in a new way53. Similarly, it can appear in 
relation to a new use of a known product54. 
 
The concept of inventive step has also created a wide range of debates and 
been at the centre of many court cases. The starting point of most debates is 
WKDWIRUDQLQYHQWLYHVWHSDQHZGHYHORSPHQWVKRXOGQRWEH³REYLRXV´55. The 
matter has thus become for courts to identify whether or not a new 
development was obvious. The reference for this question has generally been 
WKH ³SHUVRQ VNLOOHG LQ WKH DUW´56, considered as a person qualified in the field 
considered, knowledgeable but without inventive capacities. Depending on the 
                                                 
51
 EPC Article 56; UK Patent Act 1977, Section 3; 35 USC 103. 
52
 For example Biogen Inc v Medeva plc (1997) RPC 1. 
53
 Williams vs Nye (1890) 7 RPC 62; 35 USC 103; UK Patent Act 1977, Section 3. 
54
 Burroughs Application (1974) RPC 147. 
55
 See EPC Article 56.  
56
 UK Patent Act 1977 Article 3; for application of the concept, see for example Windsurfing 
international Inc vs Tabur Marine (1985) RPC 59; Great Britain Ltd (1985) RPC 59 ; EPO 
Board of Appeal, decision T36/82, OJEPO 7/83. 
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type of inventions and on the field considered, the qualification of the referee 
can vary significantly, and in fields as specialised as new biotechnological 
developments it will be a highly qualified researcher57. 
 
However, this has raised new issues, and the fast evolution of high 
WHFKQRORJLHV KDV VKDGRZHG VRPH GRXEWV DV WR ZKHWKHU WKH QRWLRQ RI ³SHUVRQ
VNLOOHGLQWKHDUW´ZDVVWLOOYLDEOHLQILHOGVZKHUHWKHDYHUDJHZRUNHULVDKLJKO\
skilled professional, and the example of the decision taken in the UK in 
*HQHQWHFK ,QF¶V 3DWHQW58 is particularly illustrative in that respect. In this 
example, the court decided that a highly technical development was not to be 
considered as inventive, because other highly skilled teams could have 
achieved the result on which the patent claim was based. What has become 
particularly difficult, overall, is to imagine a fictional scientist who would 
know everything but invent nothing ± and in highly technical fields it becomes 
SDUWLFXODUO\GLIILFXOWWRDFFHSWWKDWWKH³DYHUDJHZRUNHU´LVQRWLQYHQWLYH7KLV
H[DPSOHGHPRQVWUDWHVKRZLQKLJKO\WHFKQLFDODUHDVWKH³DYHUDJHZRUNHU´KDV
in fact become to be considered as gifted with inventive skills. The threshold of 
inventiveness could be raised so high that patents would become increasingly 
difficult to obtain in highly specialised fields. The exact weight of this 
particular decision should not, however, be stretched too far, and remains more 
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 Biogen Inc v Medeva plc  (1997) RPC 1. 
58
 *HQHQWHFK,QF¶V3DWHQW53&0XVWLOO/-LQWKLVFDVHVWDWHG³It is inventiveness 
that counts, and I cannot find it here in any degree that exceeds the amount of resource 
expected the amount of resource expected of a group mustering the skills, remarkable as they 
seem to the layman, ordinarily to be expected of persons skilled in this most difficult array of 
arts´ 
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an exception than a general approach59. Even so, it is likely that further 
questions of this type will arise in the future until a clear adaptation of the 
approach to new fields of technology is found. 
 
Industrial application 
 
The last criterion used in patent law requires that the invention presented shall 
be of industrial use60. This can relate to any form of industry, and can relate to 
either making industrially the product considered or using industrially the 
process considered for a particular result. One of the key fields in which this 
has been a relevant issue has been the biomedical field, which can be read in 
association with the exclusion common to many patent laws of methods of 
treatment from their patentability field617KHQRWLRQRI³WUHDWPHQW´LWVHOIDQG
the clear boundary between ZKDWFDQEHFRQVLGHUHGDVD³PHWKRGRIWUHDWPHQW´
has raised jurisprudential debate, and the scope of the exception had to be 
delimited.62  
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 For a critique of the approach in this decision, see Torremans P. (2005) op. cit, pp.68-70. 
60
 EPC Article 57; UK Patent Act 1977 Section 4(1); Code de la propriete intellectuelle 
francais, art 612-15. 
61
 See for example the UK 1977 patent act, Section 4(2) and 4(3). 
62
 In the UK, see for example Stafford-0LOOHU¶VDSSOLFDWLRQ (1984) FSR 258 in which a method 
IRUWUHDWLQJKHDGOLFHLVQRWFRQVLGHUHGDVD³PHWKRGRIWUHDWPHQW´DQG%UXNHU¶VDSSOLFDWLRQ 
(1988) OJ EPO 308, in which the EPO decided that a method for determining the presence of a 
disease could be patented. 
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Exercising patent rights ± within their limitations 
 
The exercise of patent rights resembles that of other property rights in many 
respects, and in particular because patents can be traded and transferred like 
tangible property rights63. In many cases, patent holders are not able to market 
their own invention. The best financial option open to them in order to see their 
invention become rewarding is to license their invention to others. The 
potentially most rewarding way to do so is to sign an exclusive license 
agreement with one specific licensee ± although an agreement can legally be 
signed with several licensees. In this particular case, the rights granted to the 
patentee will be fully transferred to the exclusive licensee.  
 
However, patents are not exactly similar to other forms of property. One of the 
differences is that patents are granted for the public benefit. Therefore, states 
maintain specific powers over patents, in order to ensure that the way they are 
used does not threaten the public interest. Compulsory licences are the most 
central tools kept by states to ensure that this is the case. They allow a 
government to permit a company to obtain a licence over a patented invention 
without the agreement of the patent holder, for reasons related to the public 
interest64 and under some strict conditions. In addition to cases of national 
emergency (often symbolic of the relevance of compulsory licences), an 
example of such a reason is the national working requirement, and when a 
patent is taken out in a state and not industrially used in that particular country, 
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 See for example UK Patent Act 1977 sect. 30(1). 
64
 )RUH[DPSOH,QGLD3DWHQW$FW$UWLFOH6HHDOVRWKHFRQFHSWRI³OLFHQFHRIULJKWV´
under the Indian 1970 Patent Act ± granted at the initiative of the patent office. 
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competitors can sometimes apply for compulsory licences on the ground that 
the patent is hampering the development of local capacities65. Compulsory 
licences have been allowed in most patent law systems66, and in recent years 
became considered as a potentially useful safeguard in relation to public health, 
as will be developed when discussing TRIPS. However, in practice they have 
been used only exceptionally by developing countries, and that the price to be 
paid to inventors for their use is still an important element that could stop the 
poorest countries from using it67. In addition, it is worth mentioning that in 
many patent systems, governmental use can be exempt from patent rights ± 
once again, this is related to the idea of public interest, and will only be done if 
it is proven to be in the public interest68. 
 
Finally, other limits exist to the rights granted by a patent, and in specific cases 
a person will be able to use commercially a patented product without the 
explicit consent of the patent owner. This is in particular so following the 
doctrine of exhaustion of rights. This doctrine has been at the centre of many 
debates in relation to public health in poor countries69, and is therefore 
specifically relevant to this project. According to this doctrine, patentees 
cannot claim to use their exclusive rights any more once they have made their 
invention available on the market ± whether national, regional or perhaps more 
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 See for example India Patent Act 1970, Article 83. See also Article 84 (1) 
66
 See UK Patent Act 1977 section 48; Indian Patent Act Article 84.  
67
 See for example Torremans P. (2005) op. cit pp. 98-100 
68
 This is the case in India - India Patent Act 1970, Article 100. 
69
 6HHIRUH[DPSOH&RUUHD&³3XEOLF+HDOWK and Patent Legislation in Developing 
&RXQWULHV´Tulane Journal of Technology and Intellectual property (3) pp. 1-53; Heath C. 
³3DUDOOHO,PSRUWVDQG,QWHUQDWLRQDO7UDGH´The International Review of Industrial 
Property and Copyright Law, 28(5), pp. 623-632 
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controversially international70. Once an invention is transferred by sale, it is 
considered as available for re-sale, and the buyer can therefore market it again 
without penalty. The practical implication of this doctrine relates to the notion 
of parallel imports. Purchasers can decide whether it is financially more 
beneficial for them to buy a particular product from their own market or to 
import it from another country where it has been marketed by the patent holder, 
and where it might be available for a lower price71. We will see that this is 
particularly relevant in relation to public health and although the validity of this 
theory at international level has been questioned, the TRIPS agreement 
explicitly excludes the issue from WTO competencies72.  
 
2. PHARMACEUTICAL PATENTS IN THE PRE-TRIPS ERA: 
NATIONAL REGULATION OF PATENT POLICIES 
 
This section describes how the specific area of pharmaceutical patents was 
regulated at national and international level before TRIPS, and emphasises the 
diversity of policies adopted by national states in this field. It explains how this 
diversity was justified by considering the role that patents play in processes of 
industrial development, and why this role is particularly debated in the 
pharmaceutical field. Overall, this section shows how pharmaceutical patents 
as a development tool have framed different policies in different countries, and 
                                                 
70
 The European Community is an example widely chosen to illustrate the question of 
exhaustion of patent rights, and has a complex jurisprudence in this area ± for an early 
acceptance of the doctrine in relation to patents, see Centrafarm v. Sterling Drug, Case 15/74 
(1975) ECR 1147.  
71
 6HH&RUUHD&³RSFLW+HDWK&RSFLW 
72
 Article (6). 
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how opposite arguments have presented patents as useful or hindering 
instruments. This will provide the necessary background to understanding the 
role and significance of TRIPS, and how TRIPS has resulted in a shift in the 
XQGHUVWDQGLQJRISKDUPDFHXWLFDOSDWHQWVIURPD³GHYHORSPHQW´LVVXHWREHLQJD
public health matter. 
 
2.1 Pre-TRIPS system. 
 
When looking at pharmaceutical patents in the pre-TRIPS era, existing 
literature on IPR generally highlights a broad division between the approaches 
RI ³GHYHORSHG´ DQG ³GHYHORSLQJ´ FRXQWULHV +Rwever, a wide range of 
approaches have existed across the world ± even if a global tendency to extend 
the field of pharmaceutical patents in most industrialised states can be seen 
while less industrialised states have generally limited their role. Overall, VWDWHV¶
policies have been established according to national interest and public benefit, 
and have therefore varied according to the situation of each particular state. For 
the purpose of this section, three main categories of approaches will be 
presented ± states that have traditionally offered strong protection for 
pharmaceutical patents; states that have limited the extent of pharmaceutical 
patents within their national IP system; and states that have not developed any 
actual IP system at national level. Although this broad division does not reflect 
the diversity of approaches and the complexity of the worldwide context in 
relation to pharmaceutical patents, it is useful to portray some key differences 
in the policy aims justifying these different approaches.  
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Before entering into the description of the different legal systems in the field of 
SKDUPDFHXWLFDO SDWHQWV LW LV XVHIXO WR GHILQH WKH FRQFHSW RI ³JHQHULF
PHGLFLQHV´ WKDWZLOOEH UHIHUUHG WR WKURXJKRXW WKLVSURMHFW DQG WRHPSKDVLVH
the two different meanings that are given to the term. Broadly speaking, 
generic drugs are the non-patented/non-branded version of a particular 
pharmaceutical product. However, this description can cover two different 
legal situations. First, generics can be understood as new versions of a drug 
that was under a patent now expired ± or versions produced by non-exclusive 
licensees, for example following a compulsory licence. These can be legally 
marketed anywhere in the world ± or, in case of compulsory licences, on the 
markets of the countries covered by the licence - provided that they meet health 
related criteria. The second type of situation, which has generated significant 
controversies, refers to the commercialisation of new versions of a drug that is 
still under patent in some countries, made in another country where 
pharmaceutical patents are not legally protected.  It is this second type of 
situation that has produced the pre-TRIPS controversies, as well as the debates 
that have followed the adoption of TRIPS, as will be developed below.  
 
In relation to the pre-TRIPS situation of states with regards to pharmaceutical 
patents, firstly, until now, several countries did not develop any form of patent 
system, either for pharmaceuticals or for other types of inventions. This was 
the case with Djibouti, as will be detailed further in Chapter 4. Patents were 
officially non-existent within the territory of these states ± and still are for least 
developed states in this category that have not yet implemented TRIPS. In 
relation to pharmaceuticals, generic versions of drugs patented elsewhere could 
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thus be legally marketed on the territory of these states and the patent situation 
of specific pharmaceuticals did not have to be a consideration for any policy-
maker or importer of drugs locally. We will see throughout this research that 
this lack of regulation did not necessarily mean that such drugs were in fact 
available, or that pharmaceutical patents were totally irrelevant to the public 
health system of the countries concerned. Indeed, definite and clear 
information on the state of affairs in a number of the least developed countries 
that potentially belong to this category is difficult to obtain. The example of 
Djibouti has shown that diverging information was available even from official 
sources73. It is therefore difficult to provide a definite list of countries that have 
followed this example. In addition, it could be argued that there might be more 
states without effective patent laws than there are states without a patent law 
officially existing. No empirical research exists in this field on many 
developing countries, and in particular most least developed countries, that 
could confirm whether laws adopted have been applied in practice. We will see 
that the situation in relation to copyrights in Djibouti is a clear example of the 
contrasts between existing and effective IP laws. 
 
Within countries that have implemented a patent system, some states have 
adopted a particular approach in relation to pharmaceutical patents, which is 
directed at limiting the potentially negative effects of patents in the field that 
will be explained below. First, pharmaceuticals have been in some cases 
                                                 
73
 Contradictory information is therefore available from the WIPO website on 
http://www.wipo.int/eds/en/ccs/pdf/dj.pdf and http://www.wipo.int/about-
ip/en/ipworldwide/pdf/dj.pdf  
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excluded from the patent field74, and generic versions of any modern drug 
could thus be marketed (provided that other pharmaceutical regulations are 
respected). In a second case, pharmaceutical products could not be patented, 
while pharmaceutical processes remained patentable75. While a particular way 
of making a drug could be protected through patents, the drug itself could not 
be patented. Consequently, companies could develop new ways of making a 
specific drug and legally market it. This type of policy was designed to 
encourage the development of a local generic industry, and has been beneficial 
from that perspective in several countries76, as will be explained below. In 
addition, the high competitiveness of the local industry ensured that the price 
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 See Patent regime in Brazil between 1971 and 1997 and for comments see Braune F. and 
MenezHV1-³7KH3DWHQWLELOLW\RI&KHPLFDO%LRFKHPLFDO3KDUPDFHXWLFDODQG
%LRWHFKQRORJLFDO,QYHQWLRQVLQ%UD]LO´Patent World (108) pp. 46-48; see also Bass N. (2002) 
³,PSOLFDWLRQVRIWKH75,36$JUHHPHQWIRU'HYHORSLQJ&RXQWULHV3KDUPDFHXWLFDO3DWHnt Laws 
in Brazil and South Africa in the 21st &HQWXU\´George Washington University International 
Law Review (34) pp. 191-222. In relation to the comparatively relevant examples, see the case 
of Thailand until 1992 Thai Patent Act, B. E. 2535 (1992) and for comments Park J. S. (1993) 
³3KDUPDFHXWLFDO3DWHQWVLQWKH*OREDO$UHQD7KDLODQG¶V6WUXJJOHEHWZHHQ3URJUHVVDQG
3URWHFWLRQLVP´Boston College Third World Law Journal 13(1) pp. 121-154; China until 1992 
± IRUFRPPHQWVVHH-LDQJ3³)LJKWLQJWKH $,'6(SLGHPLFV&KLQD¶V2SWLRQVXQGHUWKH
:7275,36$JUHHPHQW´Albany Law Journal of Science and Technology (13) pp. 223-248 
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 See for example the Indian 1970 Patent Act, Art.5; or the Egyptian system, Egyptian Patent 
Law No 132, 1949. For comments, see Al-$OL1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³7KH(J\SWLDQ3KDUPDFHXWLFDO
Industry After TRIPS ± DSUDFWLWLRQHU¶VYLHZ´Fordham International Law Journal, 26(2) pp. 
274-314. 
76
 0D\HU&6³7KH%UD]LOLDQ3KDUPDFHXWLFDO,QGXVWU\*RHV:DONLQJIURP,SDQHPDWR
Prosperity: Will the 1HZ ,QWHOOHFWXDO 3URSHUW\ /DZ 6SXU 'RPHVWLF (FRQRP\"´ Temple 
International and Comparative Law Journal (12) 377-389; See also for example Seeratan N. 
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 ³7KH 1HJDWLYH ,PSDFW RI ,QWHOOHFWXDO 3DWHQW 5LJKWV RQ 'HYHORSLQJ &RXQWULHV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Examination of the ,QGLDQ3KDUPDFHXWLFDO,QGXVWU\´6W0DU\¶V/DZ5HYLHZRQ0LQRULW\,VVXHV
(3) Spring 2001 pp.339-412; Karandikar S. M. (1994) Indian Drug Industry After GATT, 
Bombay: MVIRDC World Trade Centre; Redwood H. (1994) New Horizons in India: The 
Consequences of Pharmaceutical Patent Protection, Felixtowe: Oldwicks Press. 
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of drugs remained fairly low and helped widen access to drugs77. Finally, 
particular tools mentioned above, such as compulsory licences and parallel 
imports have been used by some of these states either in order to promote 
development78 or in relation to public health79. We will see how critics of 
TRIPS have emphasised this aspect of this type of policy. 
 
Finally, the tendency in other states, including in Europe, North America and 
Japan, after a certain stage of development was reached80, was to widen 
progressively the scope of patents, and to limit any form of exclusions. In the 
pharmaceutical field, patents were allowed on products and processes81. 
Companies have sought the possibilities for patenting extended and have used 
many strategies in that regard. The results are often perceived as having 
potentially excessive consequences, where patents can be held virtually 
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 Keayla B.K. (1999) Pharmaceutical Industry and Patent System in India: A Case Study, in 
TRIPS Agreement on Patent Law: Impact on pharmaceuticals and health for all, New Delhi: 
Centre for the study of global trade systems and development. 
78See for example the importance given to working requirements in the Indian Patent Act 1970, 
Article 83  
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 See for example the dispositions contained in the South African Medicines and Related 
Substances Control Act 1977 Art. 10, related to parallel imports as modified in 1997. 
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 6HHWKHKLVWRU\RI,WDO\&KDOOX30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patentability such as new therapeutic uses - See Domeij B. (2000) op. cit, and for 
jurisprudential steps in this area Eisai/Second Medical Indication, G5/83 (1985) OJEPO 64; 
Wyeth Application (1985) RPC 545; Bristol-Myers Squibb Corpn v. Baker Norton 
Pharmaceuticals Inc (2001) RPC 1.  
 51 
indefinitely if a company successively patents different elements of its 
invention. 
 
It should be noted, however, that these positions are not necessarily exclusive, 
and that many states have widely reviewed their patent policies at specific 
stages ± either because national needs had changed or because of new legal 
obligations, as is the case with TRIPS. In particular, a number of countries with 
a strong research-based pharmaceutical industry have only offered possibilities 
to patent pharmaceutical products once their national industry had reached a 
certain level of development ± and had excluded pharmaceuticals from the 
patentability field for many years before that stage was reached82. 
 
)URP WKH ¶V WKH QRQ-generic pharmaceutical industry ± located in a 
handful of countries ± started lobbying against the approach of what they called 
³IUHH-ULGHUV´ ± states and generic companies that were using what they 
FRQVLGHUHG WR EH ³WKHLU´ LQYHQWLRQV83. In the United States in particular, the 
industry lobbied the government heavily into taking unilateral measures against 
countries that were deemed to have excessively weak protection for patents84. 
This growing pressure was not limited to the pharmaceutical field, although 
that industry was particularly pro-active. It needs to be understood as a whole, 
within an overall disagreement amongst governments, and between the 
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 The example of Italy mentioned above is often given. The case of the US is more generally a 
clear illustration of the way states have adopted patent laws during the industrial development 
(not only in the pharmaceutical field). For a historical description of US patent laws, see for 
example Sell S. (2003) Private power, Public Law op. cit, pp. 61-72. 
83
 Sell S. (2003) Private Power, Public Law, op. cit. 
84
 See Sell S. (2003) Private Power, Public Law, op. cit. 
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industry in different sectors and states, as to what should be considered as an 
³DSSURSULDWH´ ,3 UHJLPH :H ZLOO VHH LQ WKH QH[W VHFWLRQ KRZ WKLV JURZLQJ 
pressure resulted in the negotiation and signature of the TRIPS agreement. At 
this stage, however, it is convenient to present some of the key reasons that 
have justified the variation in national policies presented above, in the field of 
pharmaceutical patents. 
 
2.2 Pharmaceutical patents, research and development ± 
arguments behind policy choices 
 
As illustrated by the range of approaches presented above in the pre-TRIPS 
era, the regulation of policies in the field of pharmaceutical patents has been a 
debated and controversial issue. This section illustrates two key elements that 
explain why countries with a different industrial background have ultimately 
chosen fundamentally different approaches to pharmaceutical patents policies. 
It will emphasise the key arguments that have explained why some states chose 
a strong protection for pharmaceutical patents on their territory, while others 
have chosen to limit their impact.  
 
Patents and pharmaceutical research 
 
The central argument for defenders of patent law has been the role of patents as 
an incentive for research. In countries where research and investment has been 
encouraged, patent policy has played a determinant role, particularly in the 
pharmaceutical field. Overall, the significance of patents for research is highly 
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dependent on the cost of research and the cost of production. If the cost of 
research on a product is low compared to the cost of producing it, inventors 
will quickly recover their investment in research, and possible competitors will 
not be able to charge consumers much less than the original researcher. By 
opposition, if most of the costs involved in marketing a product come from 
research activities, and making the product itself is cheap, researchers will bear 
costs much higher than other producers, and the importance of limiting 
competition in order to recover the investment in research will be greater. The 
role of patents in limiting competition in this latter situation is thus said to be 
essential85. The pharmaceutical industry can be one of the clearest examples of 
this second situation86. While research on a new drug often requires high 
investments in terms of cost and time, producing the same drug by reverse 
engineering can be comparatively cheap and easy.  
 
One of the reasons for the high cost of pharmaceutical research is that only a 
very limited part of research activities will offer marketing possibilities. Many 
new compounds developed during pharmaceutical research can never be 
marketed87. In addition, the many clinical trials and procedures necessary to 
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 0DQVILHOG(6FKZDUW]0DQG:DJQHU6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 On the role of patents in pharmaceutical development, see for example Scherer F. M. (2000) 
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³6XFFHVV
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introduce a drug on the market make the development of any new drug 
particularly long and consequently costly88. In general, research on one 
particular drug involves years of highly specialised work, and many 
commercial failures, the cost of which must be recovered. In contrast, making a 
drug by reverse engineering is of limited cost and approval procedures are 
faster than for new drugs89. Marketing the reverse-engineered drug will then be 
possible if it can be proven that it is technically similar to the patented drug, 
and the many clinical trials followed by the original researchers will not need 
to be undertaken again. Authorization to put the drug on the market will of 
course be needed, but both research activities and marketing requirements will 
be much less costly for the generic competitor.  
 
Overall, because they are able to avoid the cost of research into new drugs and 
limit their investment to production, generic companies are able to market 
drugs at much lower prices than companies which have developed the product 
through research. As a result, where pharmaceuticals are excluded from the 
field of patentability, researchers creating a new drug could face a situation 
where they have invested large amounts of money and time in a drug that can 
be cheaply reproduced by competitors. On a national scale, this could be a 
strong disincentive for companies considering investing in research, and 
                                                                                                                                 
5DWHVIRU1HZ'UXJV(QWHULQJ&OLQLFDO7HVWLQJLQWKH86´Clinical Pharmacology and 
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1HZHVWLPDWHV
RI'UXJ'HYHORSPHQW&RVW´Journal of Health Economics (22) pp. 151-185. 
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economists have emphasised the crucial role of pharmaceutical patents in 
maintaining a strong research-based industry90.  
 
Even so, this understanding of the need for patents in the pharmaceutical field 
as crucial for research and investment could be questioned. In particular, the 
high profits made by the pharmaceutical industry could be seen as proving that 
the impact of patents runs further than what is in fact needed as an incentive for 
research and development. The need to conceive patents as a tool to be used in 
the public interest has been re-emphasised in that respect, and it can be argued 
that excessive opportunities for patenting could be essentially positive for 
private interests. In addition, the analysis and arguments provided above are 
only valid in countries where there is already a potential for research and 
investment. It is now useful to explain why many states have felt that it was not 
in their interest ± or not yet in their interest ± to introduce strong 
pharmaceutical patents systems. 
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Pharmaceutical patents and the development of a pharmaceutical industry 
 
7KHVLWXDWLRQRI³GHYHORSLQJ´states in relation to patent rights has generated 
significant controversies91. Historically, patent systems were first created in 
European states, and exported subsequently to their colonies92. However, soon 
after the decolonization process, many newly independent states felt the need 
to re-adapt their patent systems to their national needs, and have proceeded to 
make wide revisions of their patent laws. In India, for example, the 1970 Patent 
Act was the product of these post-colonial revisions. The arguments put 
forward for those changes were both practical and theoretical. They mainly 
relied on the idea that, until a certain level of industrialisation was reached, a 
strong patent system may create more costs than benefits for the country 
concerned. In the case of most newly independent states, most of the patents 
conferred were given to nationals from European states and from the US, and 
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the benefits for the local industry were questionable93. In a way similar to what 
KDGEHHQGRQH LQPDQ\³GHYHORSHG´VWDWHV Ln the past ± the US being a clear 
example94 ± they considered that adopting more restricted forms of protections 
for patent rights would provide greater advantages to their own nationals and to 
their local industry.  
 
Although this remained a debated issue, and the role of patents in economic 
development has been widely discussed95, in particular in relation to foreign 
direct investment, this position has been defended particularly successfully in 
relation to the pharmaceutical field, where the potential benefits of introducing 
a patent system at a later stage of development can be particularly clearly 
illustrated. Being a very advanced type of industry in terms of research 
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infrastructures as well as in terms of investment, an innovative pharmaceutical 
industry has been developed in only a few countries. According to a WTO 
UHSRUWRQO\WHQFRXQWULHVKDYHD³VRSKLVWLFDWHGSKDUPDFHXWLFDOLQGXVWU\DQGD
VLJQLILFDQW UHVHDUFK EDVH´ DQG DQRWKHU VHYHQWHHQ KDYH ³LQQRYDWLYH
FDSDELOLWLHV´$OPRVWDOO³GHYHORSLQJFRXQWULHV´± as classified by the WTO - 
are considered as having no pharmaceutical industry, or producing only 
finished products96. To the extent that such a limited number of countries have 
inventive capacities, and can thus be expected to offer an important part of 
their patents to their own nationals, the role of patents in the pharmaceutical 
field for the majority of states has been questioned. The debate in this field has 
been strongly grounded in the example given by some countries which now 
have a strong and competitive pharmaceutical industry, and had chosen in the 
past to exclude pharmaceuticals ± or pharmaceutical products only - from the 
patentability field. Examples such as Switzerland, Italy97, or India98 are 
amongst the most commonly given. These different examples have proven that 
it can be economically beneficial for a country to limit pharmaceutical patents 
in order to give a sound basis to its local industrial capabilities, and to 
introduce pharmaceutical patents only when a certain level of innovative 
capacity has been reached. Aiming for the development of a generic industry 
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can thus become a strategy for the progressive development of a future 
research capacity. 
 
If a country is aiming for the development of a generic industry, the role of 
patents can obviously be constraining. In particular, it might not be in the 
interest of small companies starting up activities of production to see their 
activities limited to producing versions of drugs which have come out of 
patents. The first stage of development of a pharmaceutical industry is often 
limited to making drugs, before investment in research can be considered. To 
that extent, it might be more beneficial at an early stage for a local industry to 
be allowed to produce any modern drugs by reverse engineering than to be 
limited in this activity by a strong patent system. Ways of encouraging the 
development of a local industry in the pharmaceutical field included primarily 
the distinction between product and patents as well as further measures such as 
the introduction of a local working requirement. Policies in which a local 
working requirement was integrated were centrally aimed at ensuring that 
patents would bring benefits to the country concerned since those working 
within local industries would be trained to produce the particular product. 
Distinctions between products and processes, similarly, aimed to encourage 
local industries to develop new ways of manufacturing, without limiting the 
productive possibilities of non-research based companies. Country case 
studies99 as well as wide economic analyses100 were undertaken in this area, 
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reaching variable conclusions. Many of the arguments used by states with a 
strong pharmaceutical industry to emphasise the importance of patents for 
economic development could not in practice apply to states at a very different 
stage of development and at a very different stage of international competition. 
 
These two sets of arguments can explain what have been two fundamentally 
diverging strands in patent policies worldwide. While, on the one hand, 
countries with a strong research-based pharmaceutical industry were willing to 
see pharmaceutical inventions strongly protected, countries with only a generic 
industry limited the potentially negative impact of strong patent rights on their 
industrial development. These diverging views and interests soon created 
conflicts and controversies between states. In addition to this, it is useful to 
reflect on what has justified the approach of countries like Djibouti that have 
not implemented any type of patent system so far. We will see through Chapter 
5 in particular that this needs to be understood by stepping away from the 
arguments presented above. It can be thought of essentially as the result of 
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indifference and lack of expertise in this particular field. As existing literature 
does not concentrate on the situation of these states, it will be discussed 
specifically through presenting the empirical findings of this study. First, 
however, the legal developments created by TRIPS need to be discussed, and 
the debates that TRIPS has opened in relation to public health need to be 
analysed. This is necessary to understand more clearly how TRIPS has in 
recent years become part of many discourses on access to health in developing 
countries. 
 
SECTION 2: TRIPS AND THE FRAMING OF PHARMACEUTICAL 
PATENTS AS A PUBLIC HEALTH ISSUE 
 
TRIPS has been at the forefront of international discourses in recent years, 
often in relation to public health. However, it is useful to emphasise that this 
shaping of TRIPS as a public health agreement is the result of a slow evolution 
of perceptions and discourses. In that respect, it is necessary to reflect on the 
origins of the text, and to highlight how it has progressively moved from being 
a trade and intellectual property instrument to become shaped as a public health 
actor. It will be emphasised, in particular, that this framing of TRIPS as a 
public health actor was essentially done on the basis of research carried out in a 
few specific states. 
 
This section presents a short history of the negotiation of TRIPS, and 
emphasises in particular the role of the pharmaceutical industry in the process 
of negotiation. It then presents the key dispositions of TRIPS that are relevant 
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to the pharmaceutical field. It explains how TRIPS and pharmaceutical patents 
KDYHEHFRPHFHQWUDOLQGLVFRXUVHVRQSXEOLFKHDOWKLQ³GHYHORSLQJFRXQWULHV´
and how their expected impact has been framed. Finally, it examines how this 
new framing has allowed for important debates on the possible use of 
safeguards in the light of the public health impact of TRIPS, and how the Doha 
declaration on TRIPS and public health was signed as a way to cope with the 
expected impact of TRIPS on health in developing countries.  
 
1. LOBBYING AND NEGOTIATION OF TRIPS 
 
The history of TRIPS is best understood as a long-term process that moved 
from state level to an international debate. Pressure from industry to create new 
IP standards that would be respected by countries worldwide arose in a number 
of key fields101. The pharmaceutical industry was particularly pro-active in that 
respect, and lobbied governments for several years in order to obtain a wider 
protection for their inventions. Overall, by jointly lobbying for a stronger 
protection of intellectual property worldwide, different sectors of the industry, 
essentially in Europe and North America, organised into a strong policy-
network in which national governments became key players102. An example of 
the type of pressure that they exerted, and of the support they gained from their 
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own government, can be found in the commercial action of the US against 
VWDWHVZLWKD³ZHDN´,3V\VWHP103. The pressure put on countries with weak IP 
protection, and in particular in the pharmaceutical field, was maintained for 
several years.104 
 
However, this approach presented some weaknesses. In particular, some states 
resisted the pressure they were put under by commercial measures105. In 
addition to this, the legitimacy of unilateral commercial actions began to be 
questioned. It appeared clearer that the best way to ensure that minimum 
standards would be respected worldwide would be to create an international 
agreement in which these standards would be set. Progressively, pressure for 
such an agreement increased, and it was finally discussed in the Uruguay 
Round, as part of the questions that needed to be tackled in order to limit 
barriers to free trade. 
 
In the Uruguay Round itself, disagreements between states on the most 
appropriate way to tackle patent issues and other intellectual property matters 
were debated until states came to an agreement on the appropriate standards for 
intellectual property. Considering the opposition from states that grew around 
TRIPS after its adoption, the fact that the agreement was signed by sovereign 
states on a voluntary basis might seem surprising. However, TRIPS had to be 
signed by any state willing to join the WTO. In addition, the negotiations that 
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took place at the Uruguay round are often characterised as a meeting in which 
only some voices could be heard106. Some therefore considered that the final 
outcome of the text seems to reflect more strongly the views of Europe, North 
America and Japan than the proposals of any other state or group of states. The 
process of adoption of TRIPS is often presented as having virtually excluded 
most states from the real decisions107.  
 
 ³7KH QHJRWLDWLRQV RQ 75,36 DUH RIWHQ VDLG WR KDYH EHJXQ SURSHUO\ LQ WKH
second half of 1989, when a number of countries made proposals, or the first 
part of 1990, when five draft texts of an agreement were submitted to the 
negotiating group. A more sceptical view is that the negotiations were by then 
largely over. An even more sceptical view is to say that no real negotiation 
ever took place. Developing countries had simply run out of alternatives and 
optLRQV´108 
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2. CONTENT OF THE TRIPS AGREEMENT: NEW STANDARDS FOR 
PHARMACEUTICAL PATENTS 
 
The TRIPS agreement sets minimum standards that countries must respect in 
their national IPR system. However, it allows states a certain margin of action 
when implementing the text nationally:  
 
³Members shall give effect to the provisions of this Agreement.  Members may, 
but shall not be obliged to, implement in their law more extensive protection 
than is required by this Agreement, provided that such protection does not 
contravene the provisions of this Agreement.  Members shall be free to 
determine the appropriate method of implementing the provisions of this 
Agreement within their own legal system and practice´109 
 
As TRIPS is part of the WTO system, enforcement mechanisms are provided 
through the WTO itself. The TRIPS council was created to facilitate dispute 
settlement and provide advice to member states110. 
 
The field of application of patent law is defined in Article 27(1): 
 
³6XEMHFWWRWKHSURYLVLRQVRISDUDJUDSKV and 3, patents shall be available for 
any inventions, whether products or processes, in all fields of technology, 
provided they are new, involve an inventive step and are capable of industrial 
application. Subject to paragraph 4 of article 65, paragraph 8 of article 70 and 
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paragraph 3 of this article, patents shall be available and patent rights 
enjoyable without discrimination as to the place of invention, the field of 
technology and whether products are imported or locally produced´ 
 
The usual conditions of patentability are therefore stated in TRIPS, and 
inventions can be deemed patentable in any field of technology. This second 
point is crucial in relation to pharmaceutical patents, as it makes national laws 
that exclude pharmaceutical patents from the field of patentability incompatible 
with TRIPS. Implicitly, the claims of the pharmaceutical industry to protect 
pharmaceutical inventions worldwide were thus satisfied at international 
level.111 This particular disposition was at the centre of an important part of the 
debates at the Uruguay round, which highlights the importance that 
pharmaceutical patents ± as well as protection for chemical and 
biotechnological inventions ± played in the decision-making on this agreement. 
This disposition has been consideUHG³the reason of being of the whole TRIPS 
DJUHHPHQW´112. Although this was originally conceived as a research and 
industry issue, subsequently it became shaped into a key public health matter. 
 
The specific case of pharmaceutical patents is referred to in Article 70(8) ± in 
UHODWLRQWRZKDWKDVEHFRPHZLGHO\NQRZQDVWKH³PDLOER[UHTXLUHPHQWV´7KLV
disposition creates specific obligations with regard to pharmaceutical patents, 
during the transitional period granted for implementation. In particular, it 
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requires states that did not provide patents in the pharmaceutical field when 
TRIPS was adopted to create a system that would allow inventors to submit a 
patent application before the end of the transitional period ± although the patent 
itself would only be granted once the national law implementing TRIPS comes 
into place. The obligation of member states to respect the dispositions of 
TRIPS with regard to pharmaceutical patents is reinforced, and the clear 
intention of the creators of TRIPS to enforce pharmaceutical patents worldwide 
appears. 
 
Specific exceptions to patentability are presented, in order to protect ordre 
public and morality in particular, including health113, although the practical use 
that can be made of them has not yet been clarified. The political pressure for 
strong patent rights could to result in a restrictive understanding of these 
exceptions. 
 
The rights conferred on a patent owner are presented in Article 28, and have 
the commercial consequences presented earlier in this chapter when discussing 
the concept of patents. In practice, they offer to patent holders a temporary 
commercial quasi-monopoly. It is economically a very strong right, as has been 
detailed above. On the other hand, the patentee has the obligation to disclose 
clearly his invention114, as is traditionally the case. Patent rights should be 
conferred for at least twenty years115, which is a reflection of the most pro-
patent claims and legislations116. 
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In terms of deadlines for implementation, and after negotiation, developing 
states should have implemented TRIPS by 2000117, although an extended 
period of 5 years was offered for introducing protection into fields of 
technology that were previously excluded ± such as pharmaceuticals118. Least 
developed states were given until 2006 to implement TRIPS119 ±later extended 
by the Doha declaration, as far as pharmaceutical patents are concerned 
(discussed below)120. However, states have to comply immediately with the 
mailbox requirement mentioned above121. 
 
As a whole, the protection offered to patent holders through TRIPS seems to 
answer most of the claims of the pharmaceutical lobby. In particular, laws of 
countries having deliberately chosen to exclude pharmaceutical products from 
patentability on clearly defined grounds will now have to be revised in order to 
satisfy the new requirements. However, pressure from the industry on 
developing countries has continued after the signature of TRIPS, through a 
series of complaints put forward in the WTO. Pharmaceutical patents were at 
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the centre of these debates, and demonstrated the eagerness of the industry to 
see IP standards modified as extensively as possible in this area122.  
 
The actual impact of TRIPS in relation to pharmaceutical patents has been a 
widely debated issue in academic literature and the media alike. In particular, 
the potential consequences that TRIPS might be having on public health in 
poor countries has been at the centre of heated debates. The interrelation 
between TRIPS and public health raises important issues which developed a 
clearer focus of attention in the few years following the adoption of the text. 
The way TRIPS has become enrolled into public health discourses will now be 
discussed, before looking at how the safeguards offered by TRIPS have 
EHFDPH³UHDG´LQUHODWLRQWRWKLVSXEOic health dimension.  
 
3. FROM INTELLECTUAL PROPERTY TO PUBLIC HEALTH  
 
Although TRIPS was originally thought of as an intellectual property matter, 
and remains technically a set of regulations in this particular field, it soon 
became shaped as a public health actor in many discourses. The resistance to 
TRIPS by states and health activists that appeared in relation to access to 
medicines soon resulted in TRIPS becoming shaped into a key player in public 
health worldwide.  
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In the text of TRIPS itself, mention is made of public health a few times, as one 
of the issues with which intellectual property might need to be balanced. This 
is the case in Article 27.2, as mentioned before. The second example of this 
can be found in Article 8:  
 
³0HPEHUVPD\LQIRUPXOating or amending their laws and regulations, adopt 
measures necessary to protect public health and nutrition, and to promote the 
public interest in sectors of vital importance to their socio-economic and 
technological development, provided that such measures are consistent with 
WKLV$JUHHPHQW´ 
 
Overall, it shows that member states acknowledged public health and nutrition 
concerns, as well as other interests of vital importance, but the article has a 
limited legal impact in increasing the margin of action left to states123.  
 
However, at the time of its adoption, TRIPS was still essentially perceived as 
mainly related to the industrial development aims with which intellectual 
property is traditionally associated, and did not have the health dimension that 
future developments would lend it. Soon after the adoption of TRIPS, 
opposition to the text started growing from new actors, and in particular from 
public health activists. These actors organised in a new, more efficient, manner 
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 %ORFKH*³:72'HIHUHQFHWR1DWLRQDO+HDOWK3ROLF\7RZDUGVDQ,QWHUSUHWLYH
princLSOH´Journal of International Economic Law 5(4) pp. 825-848; WTO secretariat and 
WHO, WTO Agreements and Public Health, 2002. 
WTO/WHO (2002) WTO agreements and public health, available at 
http://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf#search= 'WTO%20agreements%20
and%20public%20health 
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and started lobbying and working on issues related to TRIPS. The key point of 
departure was the potential impact of pharmaceutical patents on the price of 
medication, and how this would worsen the health situation of people who 
were already in critical health conditions in poor countries. 
 
Pharmaceutical patents and public health 
 
By their very nature, and as mentioned earlier, patents allow producers to 
market their products for the price that the market will tolerate without having 
to consider elements of competition. In the absence of competition, prices are 
maintained much higher than if a larger number of producers were allowed on 
the market. In the pharmaceutical field, this means that drugs will be much 
more expensive than if they were produced by several competitors124. The 
potential impact of pharmaceutical patents on the cost of medication has 
become a highly controversial issue in recent years, which has been increased 
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 Velasquez G. (2000) « Medicaments Essentiels et Mondialisation », Revue Internationale 
de Droit Economique, 2000/1. Numero Special: Brevets Pharmaceutiques, Innovation et Sante 
Publique pp.38- 1RJXHV -  ³6RFLDO &RVWV DQG %HQHILWV RI ,QWURGXFLQJ 3DWHQW
3URWHFWLRQ IRU 3KDUPDFHXWLFDO 'UXJV LQ 'HYHORSLQJ &RXQWULHV´ The Developing Economies, 
31(1) pp. 24-5R]HN5DQG%HUNRZLW]5 ³WKH(IIHFWVRI3DWHQW3URWHFWLRQRQ WKH
Prices of Pharmaceutical Products: is Intellectual Property Raising the Drug Bill in Developing 
&RXQWULHV"´ Journal of World Intellectual property (1) pp. 179-244; Subramanian A. (1995) 
³3XWWLQJ VRPH 1XPEHUV RQ WKH 75,36 3KDUPDFHXWLFDO 'HEDWH´ International Journal of 
Technology Management (10) pp. 252-268; Watal J. (1999) op. cit; Marques M. B. (2000) 
³%UHYHWV3KDUPDFHXWLTXHVHW$FFHVVLELOLWHGHV0HGLFDPHQWVDX%UHVLO´Revue Internationale 
de Droit Economique, (1) Numero Special: Brevets Pharmaceutiques, Innovation et Sante 
Publique pp. 97-107; Muennich F. E. (2000) « /HV %UHYHWV 3KDUPDFHXWLTXHV HW O¶$FFHV DX[
Medicaments », Revue Internationale de Droit Economique, 2000/1. Numero Special: Brevets 
Pharmaceutiques, Innovation et Sante Publique pp. 71-81. 
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by the impact of specific health-related scandals125. The worsening AIDS crisis 
in many developing countries, and the difficulties experienced by poor 
populations in buying anti-HIV/AIDS drugs that are still under patents, have 
made the controversies around pharmaceutical patents stark. Similarly, the 
argument made by pharmaceutical companies for rights over their inventions 
has been challenged increasingly by contrary arguments in favour of the right 
to life. A narrative where the right to life and right to health prevailed was 
opposed to the narrative of right to property126.   
 
The debate around TRIPS has grown to include a range of health and 
development NGOs arguing for the need to improve access to medication on 
the one hand127 and, on the other hand, drug companies insisting on the 
pressing necessity to improve IP standards in order to maintain a high level of 
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 The action of the pharmaceutical industry against the South African government in Pretoria 
can be seen as crucial in making the links between patents and health more broadly accepted in 
international discourses, and in increasing mobilisation against TRIPS ± and against the 
pharmaceutical industry in developing countries. The example of the strong pressure put onto 
Brazil while the country was trying to implement a policy based on parallel imports and 
compulsory licences to keep the price and anti-HIV/AIDS as low as possible. Bass N. (2002) 
op. cit. 
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 6HOO6³75,36DQGWKH$FFHVVWR0HGLFLQHV&DPSDLJQ´RSFLW6HHDOVR6HOO6
(2003) Private power, public law, op. cit. 
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 For example, MSF reports: Doha Derailed: a progress report on TRIPS and access to 
medicines, 27 August 2003, available at http://www.accessmed-
msf.org/prod/publications.asp?scntid=27820031110385&contenttype=PARA&; TRIPS, 
Pharmaceutical Patents and Access to Medicines: Seattle, Doha and Beyond: 24 July 2003, 
available at: http://www.accessmed-
msf.org/prod/publications.asp?scntid=24720031521553&contenttype=PARA&; See also 
Oxfam access to medicine campaign and press releases such as: Flawed WTO drugs deal will 
to little to secure future access to medicines in developing countries, 27 August 2003, available 
at: http://www.oxfam.org/eng/pr030830_wto_final.htm  
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research and investment128. Overall, the action of health activists soon started 
making the links between patents and health in developing countries appear as 
stable and rather simple ± pharmaceutical patents were likely to make drugs 
more expensive, and therefore to have a negative impact on access to health. 
$,'6ZDVSUHVHQWHGDVWKHFOHDUHVWH[DPSOHRIWKLV³IDFW´ 
 
 ³« consumer and health groups on the front lines of the anti-HIV/AIDS 
pandemic mobilised to protest the high cost of HIV/AIDS drugs, the subsequent 
lack of access to the drugs, and the dangers of overly strong intellectual 
property protection as embodied in TRIPS. They presented an alternative 
framing of IP as a public health issue, not a trade issue.´129 
 
However, it should be emphasised at this stage that most studies or texts 
discussing the links between TRIPS, pharmaceutical patents and health were 
based on analyses of the situation of a few specific states ± essentially 
industrialised states that had positively chosen to exclude pharmaceuticals from 
their patentability field before TRIPS came into place130. The example of these 
IHZ FRXQWULHV EHFDPH JHQHUDOL]HG ZLWKLQ WKH QRWLRQ RI ³GHYHORSLQJ VWDWHV´
6LPLODUO\ WKH SXEOLF KHDOWK DQG SKDUPDFHXWLFDO QHHGV RI ³GHYHORSLQJ
FRXQWULHV´ KDYH PDLQO\ EHHQ GHVcribed generalizing from those specific 
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 See for example Pharmaceutical Research and Manufacturers of America (Pharma) website 
for comments such as: Health Care in the Developing World dossier, available at: 
http://world.phrma.org/ and see specifically Intellectual Property and Access to Drugs at 
http://world.phrma.org/ip.access.aids.drugs.html  
129
 6HOO6³75,36DQGWKH$FFHVVWR0HGLFLQHV&DPSDLJQ´RSFLWRQS 
130
 6HHIRUH[DPSOH6HHUDWDQ11RSFLW-RQL-³$FFHVVWR7reatment for 
+,9$,'6D+XPDQ5LJKW,VVXHLQWKH'HYHORSLQJ:RUOG´Connecticut Journal of 
International Law (17) pp.273-280; Bass N. (2002) op. cit. 
 74 
countries ± including a large majority of states for which AIDS is the key 
public health priority at the moment. The specificity of the issue of AIDS as 
compared to other public health needs has not always been clarified, and the 
LVVXHRI³DFFHVVWRWUHDWPHQW´KDVRIWHQEHHQSRUWUD\HGDVEHVWLOOXVWUDWHGE\WKH
TXHVWLRQVUDLVHGE\³DFFHVVWRDQWL-+,9$,'6GUXJV´131. By contrast, this thesis 
re-emphasises the need to avoid undue generalisations, and to widen the range 
of situations looked at when discussing what TRIPS and pharmaceutical 
SDWHQWV PHDQ IRU SXEOLF KHDOWK LQ ³GHYHORSLQJ FRXQWULHV´ 7KH H[DPSOH RI
Djibouti was chosen, as will be explained further in chapter 3, as a counter-
example to the focus of most of the dominant literature discussed above.  
 
The increasing public health dimension of TRIPS, and the new framing 
produced by resistant groups, resulted in an increasing pressure on states to 
address specifically the relation between TRIPS and public health in post-
TRIPS negotiations. This was completed in Doha. The declaration on TRIPS 
and public health was the outcome of a gradual realisation that TRIPS had 
become an issue for networks larger than trade and intellectual property 
activists. In addition to this, a large academic legal literature has been devoted 
to analysing the safeguards offered by TRIPS that could be used to limit the 
potential impact of TRIPS on public health132. These different attempts to 
balance TRIPS and health requirements will now briefly be examined. 
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 )RUH[DPSOH6KRHOO6³:K\FDQ¶WWKH3RRU$FFHVV/LIHVDYLQJ0HGLFLQHV"$Q
Exploration of Solving the Patent Issue´0LQQHVRWD,QWHOOHFWXDO3URSHUW\5HYLHZ(4) pp. 151-
182. 
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 &RUUHD&0³,PSOHPHQWLQJWKH75,36$JUHHPHQWLQWKH3DWHQW)LHOG2SWLRQVIRU
'HYHORSLQJ&RXQWULHV´the Journal of World Intellectual Property, 1(1), pp. 75-100; Scherer 
 75 
 
4. BALANCING INTELLECTUAL PROPERTY RIGHTS AND 
HEALTH CONCERNS ± SAFEGUARDS AND THE DOHA 
DECLARATION 
 
The increasing concern for the public health aspect of TRIPS resulted in two 
elements. First, the possibility to use the safeguards offered by TRIPS in 
relation to public health was widely discussed, including in academic research. 
Second, the limitations of this possibility became apparent and resulted in the 
adoption of the Doha Declaration in 2001. This section will review the 
potential for protecting public health within the legal TRIPS framework that 
has been put forward by legal commentators. It will then present the Doha 
declaration and explain how it aimed to offer stronger guarantees that public 
health would not be affected by TRIPS. This will delimit the public health 
dimension of TRIPS, and explain how it has been discussed in discourses 
linking its legal dimension to its potential impact on health.  
 
TRIPS safeguards: does the text of TRIPS offer a way to protect public 
health? 
 
The main elements that have been put forward as potential safeguards to be 
used in relation to public health are compulsory licences and the remaining 
possibility to allow parallel imports. We will look at these in turn. 
                                                                                                                                 
)0DQG:DWDO-³3RVW-TRIPS Options for Access to Patented Medicines in 
'HYHORSLQJ1DWLRQV´Journal of International Economic Law 5(4): 313-319.  
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The text of TRIPS explicitly excluded parallel imports from the WTO field of 
decision133. Consequently, states have been strongly advised to make the theory 
of exhaustion of rights explicit in their national law.134 This could prove 
essential in the pharmaceutical field, where parallel imports allow consumers 
to obtain patented drugs for the cheapest price that the patent holder has 
marketed it for135, which can be crucial in relation to access to medication136. 
However, in recent years and in response to the lobbying of several NGOs, 
some pharmaceutical companies have agreed to make some of their modern 
drugs available in poor countries for a cheaper price than in others. To that 
extent, parallel imports should be limited so that those cheap drugs do not 
come back on the markets excluded from this advantage. The risk otherwise 
would be to discourage drug companies from offering their drugs at a cheap 
                                                 
133
 Article 6. 
134$EERWW)$³)LUVW5HSRUWWRWKH&RPPLWWHHRQ,QWHUQDWLRQDO7UDGH/DZRIWKH
InWHUQDWLRQDO/DZ$VVRFLDWLRQRQWKH6XEMHFWRI3DUDOOHO,PSRUWDWLRQ´Journal of International 
Economic Law (1) pp.607-%DOH+(³7KH&RQIOLFWVEHWZHHQ3DUDOOHO7UDGHDQG
3URGXFW$FFHVVDQG,QQRYDWLRQWKH&DVHRI3KDUPDFHXWLFDOV´Journal of International 
Economic Law 4(1) pp. 637-+HDWK&RSFLW5R]HN53³3DUDOOHO7UDGHLQ
3KDUPDFHXWLFDOVWKH,PSDFWRQ:HOIDUHDQG,QQRYDWLRQ´Journal of Economic Integration 
37(2) pp. 181-203. 
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 It prevents patent holders from marketing products for a higher price in a country where the 
market would be more beneficial if producers aimed, for example, at selling their product only 
to a rich minority. In the pharmaceutical field, this form of practice has sometimes existed in 
states where companies can aim either at a market of a very poor majority, which could buy the 
drug only at a very low price, or at a market of a very rich minority which could afford very 
high prices. 
136
 %DODVXEUDPDQLDP.³3DWHQWV3ULFHVDQG3XEOLF3ROLF\´LQ'rahos P and Mayne R 
(eds), Global Intellectual Property Rights: Knowledge, Access and Development, London: 
Palgrave MacMillan, pp. 90-6HHIRUH[DPSOH&RUUHD&³3XEOLF+HDOWKDQG3DWHQW
/HJLVODWLRQLQ'HYHORSLQJ&RXQWULHV´op. cit; Heath C. (1997) op. cit. 
 77 
price to poor populations137. Currently, many states have allowed parallel 
imports in their national law138. Important debates remain, however, on this 
issue, combining politics and law ± for example, the US have challenged laws 
specifically using parallel imports as a legal tool, as was the case in the Pretoria 
trial139.  
 
A key-safeguard offered by TRIPS that could be used in relation to public 
health is the compulsory license system. The conditions for a state to issue a 
compulsory licence legally under TRIPS are presented in Article 31140. One 
particularly debated element of Article 31 is paragraph (f), which states that 
compulsory licences shall be used mainly for domestic purposes. This 
paragraph has created important discussion in the pharmaceutical field in 
particular, and its interpretation and application has been contested by member 
states. In particular, in the terms of Article 31(f), it appears that a licence could 
not legally be given by a state with no pharmaceutical industry to a company in 
another country to respond to a health crisis. In that respect, the relevance of 
compulsory licences for most least developed states has been strongly 
undermined141. This has been discussed in and after Doha, as will be explained 
below.  
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 These include a limited scope and duration and the adequate remuneration of the patentee. 
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³7KH'RKD'HFODUDWLRQRQWKH75,36$JUHHPHQWDQG3XEOLF+HDOWK
/LJKWLQJD'DUN&RUQHUDWWKH:72´Journal of International Economic Law 5(2) pp. 469-
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Additionally, based on the text of TRIPS, a further question has been raised as 
to whether or not the text of Article 30 could be read as opening a possibility to 
create an exception to the limitations of other compulsory licences in relation 
to health. Article 30 states: ³PHPEHUV PD\ SURYLGH OLPLWHG H[FHSWLRQV WR WKH
exclusive rights conferred by a patent, provided that such exceptions do not 
unreasonably conflict with a normal exploitation of the patent and do not 
unreasonably prejudice the legitimate interests of the patent owner, taking 
DFFRXQWRIWKHOHJLWLPDWHLQWHUHVWRIWKLUGSDUWLHV´ 
 
Article 30 is an exception to patent rights that should, according to panel 
reports142, be strictly limited. The three conditions for application ± limited 
exceptions, no unreasonable conflict with a normal exploitation of the patent, 
no unreasonable prejudice to the interest of the patent owner taking into 
account the legitimate interests of third parties - are enumerated in the article 
and should be cumulatively applied. The use that can be made of this article in 
the context of pharmaceutical patents and in relation to compulsory licences is 
still unclear143, and the answers provided partly in Doha, but mainly after the 
                                                                                                                                 
505; Abbott )0³&RPSXOVRU\/LFHQVLQJIRU3XEOLF+HDOWK1HHGVWKH75,36$JHQGD
DWWKH:72DIWHUWKH'RKD'HFODUDWLRQRQ3XEOLF+HDOWK´Quaker UN Office, Occasional 
Paper 9, available at http://www.accessmed-
msf.org/upload/ReportsandPublications/25620021018167/fred%20abbott.pdf. 
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 Panel Report of the 7th June 2000: Canada ± Patent Protection of Pharmaceutical Products, 
WTO document WT/DS114/R, 17th  March 2000.  
143
 The EC and developing countries in the WTO have emphasised the possibilities of using 
this article with a public health aim. WTO document WT/MIN(01)/DEC/2, 20th November 
2001; WTO document IP/C/W/355, 24th June 2002. 
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meeting, to some of these questions have limited the need to investigate this 
option.  
 
Overall, there are complex conditions that need to be satisfied for a compulsory 
licence to be taken under TRIPS. Combined with the high cost of 
compensation to be paid to the patentee, they are likely to limit the relevance of 
this safeguard for poor countries. We will see below how practical issues also 
need to be kept in mind when investigating this potential role for least 
developed states144. 
 
In addition, it might be said that legal arguments have often appeared to be less 
relevant than political issues. As pressure for implementation of the strongest 
standards of patent rights started growing, it appeared correspondingly unlikely 
that countries would be politically enabled to make use of any of these 
options145. 
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 In addition to those crucial safeguards, a number of elements are believed to be of use for 
states willing to limit the immediate impact that pharmaceutical patents could have on their 
territory. The Bolar exception is one of those. It allows researchers to proceed to all steps 
leading to future marketing while an invention is still patented, in order to be able to 
commercialise a generic version straight after the patent expires. In the pharmaceutical field, 
procedures can be particularly lengthy, and this form of exception can thus be particularly 
valuable. 
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 3UHWRULXV:³75,36DQG'HYHORSLQJ&RXQWULHV+RZOHYHOLVWKH3OD\LQJ)LHOG"´LQ
Drahos P. and Mayne R. (eds) Global Intellectual Property Rights: Knowledge, Access and 
Development, London: Palgrave; Bond P. (1999) ³*OREDOL]DWLRQ3KDUPDFHXWLFDO3ULFLQJDQG
6RXWK$IULFDQ+HDOWK3ROLF\0DQDJLQJ&RQIURQWDWLRQZLWK86)LUPVDQG3ROLWLFLDQV´
International Journal of Health services, 29(4) pp.765-792. 
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The Doha Declaration on TRIPS and public health 
 
In the few years following TRIPS, disagreement and debate remained in 
relation to the potential impact of the text on public health and the use that 
could be made of specific safeguards. In 2001, member states held a meeting in 
Doha, Qatar, in which an important part of the debates related specifically to 
the relationship between TRIPS and public health. The outcome was a 
declaration aimed at clarifying some specific elements146. 
The declaration is essentially political, and does not add any new legal element 
to the TRIPS system, other than new extended deadlines for developing and 
least developed countries in relation to pharmaceutical patents. In addition to 
this, a few specific elements are aimed at specifying more clearly how states 
should be enabled to make use of particular safeguards. In particular, paragraph 
5(c) reaffirms the right of each member state to determine what constitutes a 
national emergency, which emphasises the power of decision of developing 
states in a controversial area147.  
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 $EERWW)0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 The question of whether or not to integrate a list of diseases that could give rise to a national 
emergency in the text of the declaration created intense debates. While the US was particularly 
eager to create an exhaustive list of disease, developing countries fought to maintain a margin 
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As mentioned earlier, one particularly debated issue was that of the use of 
compulsory licences for countries with no manufacturing industry, and the 
impact of Article 31(f) in that respect. No agreement was reached on this issue 
at Doha, and paragraph 6 simply defers the issue to future meetings. However, 
on the 30th August 2003, an agreement was reached in the WTO on this 
particular matter148. The agreement waives the effects of Article 31(f) when 
countries with no pharmaceutical industry are involved ± under a number of 
conditions. Consequently states with no pharmaceutical industry will be able to 
issue a compulsory licence on a particular drug, and will be entitled to allow 
producers in another state to make it for them and export it. The impact of this 
specific decision has been praised in the press internationally, and presented by 
the WTO149 as a central step in solving access to drugs issues related to TRIPS. 
However, NGOs have emphasised that this impact is only partial, and that the 
number of conditions associated with the use of a compulsory licence in these 
circumstances would mean that states will be discouraged from using it in 
many circumstances150.  
 
                                                                                                                                 
of decision as wide as possible. The result is a compromise which, while emphasising on 
several epidemics, does not seem to present them as an exhaustive list. 
148
 WTO Document IP/C/W/405, available at 
www.wto.int/english/tratop_e/trips_e/implem_para6_e.htm 
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 See for example http://www.wto.org/english/news_e/pres03_e/pr350_e.htm 
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 See Oxfam, 27th $XJXVW³:72SDWHQWUXOHVZLOOVWLOOGHQ\PHGLFLQHVWRWKHSRRU´
available at:  http://www.oxfam.org/eng/pr030827_wto_patents.htm and MSF, 27th August 
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This decision is unlikely to solve the central practical problem associated with 
the production of generic drugs for a very limited market. It is likely that 
companies will take a limited interest in producing drugs exclusively for a least 
developed state in a temporary health crisis. The incentive for a licensee to 
produce a generic version of a drug needs to be mainly market-based. If there 
is no sufficient market for the generic drug to be sold and bring benefits back 
to the company, it is unlikely that a producer would want to take up a license. 
Currently, in countries where there is no pharmaceutical patent system, a local 
generic industry has developed on the basis that the local market is important, 
and that exports are possible. From 2005, most countries with a generic 
industry had implemented protection for pharmaceutical products. In the case 
where a drug was to become urgently available in a least developed country 
without a manufacturing capacity, the use of compulsory licences could be 
considered, but the practical question of commercial viability would remain ± 
combined with its practical feasibility, as will be discussed in the case of 
Djibouti. 
 
In addition, the debate continues within the WTO, as this system is to be 
reviewed annually.  As a whole, the Doha declaration has been an important 
text politically, and it is likely to help answer some questions regarding the 
relation between TRIPS and public health. It has also opened legal debates in 
this same field that are expected to be solved in the next few years. 
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CONCLUSION: TRIPS, PUBLIC HEALTH AND DEVELOPING 
COUNTRIES ± NEEDS FOR FURTHER RESEARCH 
 
Overall, the above analysis has presented the impact of TRIPS on 
pharmaceutical patents systems worldwide. The progressive framing of TRIPS 
as a public health issue has been explained, and the development of a strong 
literature aimed at analysing the legal options left to states for protecting their 
public health while respecting the prescriptions of TRIPS has been introduced. 
However, a large part of the value of the literature presented throughout rests 
on a few assumptions that might need to be challenged. In particular, the 
appropriateness of the views generally presented as the situation of all 
³GHYHORSLQJ FRXQWULHV´ FDQ EH TXHVWLRQHG 7KH fact that many of the views 
presented above were developed essentially by studying the situation of states 
with an existing generic industry, and with a patent system pre-existing TRIPS 
that will need to be revised, is crucial to keep in mind when considering how 
far the questions asked would remain pertinent in a different social network. In 
addition, most case studies that have analysed and questioned the role of 
TRIPS and pharmaceutical patents in relation to health have concentrated on 
countries with institutional and health related structures and problems of a 
specific nature, that might not be shared by other least developed countries. 
The limits and uniformity of existing literature, in addition, lie in the fact that it 
has been essentially doctrinal and concentrated more specifically on the 
dispositions of TRIPS and the written dimension of patent law than on 
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empirical analysis to understand the actual effects and mechanisms of TRIPS 
and pharmaceutical patents. 
 
This research aims to compare the findings made in these few industrialised 
developing states with empirical data collected in a small least developed 
country. It seeks to question to what extent the issues that appeared in countries 
such as India, Brazil or South Africa would be shared by a state in a different 
legal, social, political and economic situation. This will be done by analysing 
the links between TRIPS, patents and health in the Republic of Djibouti. In 
order to do so, specific tools and methods will be needed. In this research, most 
of these tools have been borrowed from ANT, which now needs to be 
explained. 
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CHAPTER 2 - INTRODUCING ACTOR-NETWORK THEORY 
 
The story of TRIPS in developing countries is a story that has been widely told. 
Or rather, one story of TRIPS in developing countries has been widely 
performed151, and Chapter 1 introduced some of its key aspects. It is a story 
about TRIPS as a global text, as an instrument widely reshaping the 
international system of drugs, and having a series of more or less clearly 
defined expected outcomes on health in poor countries. But in many regards, 
this story is only one incomplete and imperfect version of what a complex 
object is doing in many places and many networks. This study aims to avoid 
some of the shortcuts that are widely performed by the dominant narrative on 
TRIPS and pharmaceutical patents. It aims to go back to a particular set of 
FRQQHFWLRQVJHQHUDWHGE\DQGDURXQG75,36DQGE\ORRNLQJ³GRZQ´LQWRWKLV
set of connections, to question what this might be teaching us about TRIPS, 
about what it is doing, and about how these widely performed views of TRIPS 
and pharmaceutical patents as public health agents have arisen. It is directed at 
moving away from the assumption that studies on transnational law should aim 
to uncover a certain form of overall movement, to analyse a whole, and provide 
a framework for the parts to become clearer.  
 
By contrast, this research remains very small. It is aimed at considering a 
limited set of local relations, and understanding what locality can teach us 
                                                 
151
 2QWKHQRWLRQRISHUIRUPDWLYLW\VHH/DZ-DQG6LQJOHWRQ9³3HUIRUPLQJ
7HFKQRORJ\¶V6WRULHV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU8QLYHUVLW\
Lancaster LA14YN, UK, at http//www.comp.lancs.ac.uk/sociology/soc036jl.html 
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about relations that have been so widely performed by commentators that they 
have become taken for granted as quasi-natural. This study is about relations, 
about understanding how relations shape TRIPS in Djibouti and how TRIPS 
transforms other connections and networks. It is also about pharmaceutical 
patents, about how they are performed in Djibouti, what they become and how 
WKH\DFW,WGRHVQRWFODLPWREH³JOREDO´EHFDXVHLWDLPVWRXQGHUVWDQGDVHWRI
objects and relations that are limited and relevant to Djibouti. On the other 
hand, it is not truly local because none of these relations is isolated. Rather, 
these relations are all shaped by the integration of action taking place 
elsewhere, which generate the objects under scrutiny in a particular way. 
 
The story of TRIPS and pharmaceutical patents that emerges from this analysis 
is complex. Both TRIPS and pharmaceutical patents appeared through traces 
that were unexpected and revealed their multiple dimensions, and it soon 
became clear that the complexity and mobility of social orderings were 
essential features of the phenomena under scrutiny. 
 
As mentioned in the introduction, the story of TRIPS and pharmaceutical 
patents that will be provided throughout this research is inspired by ANT. This 
chapter explains some key ideas of this approach, and highlights how they have 
been influential in this research. This is a difficult task in part because the 
emphasis of ANT on change, flexibility, and the fragility of meaning make it 
almost self-contradictory to try to provide a specific understanding of the 
approach in explicit terms. However, this chapter aims to introduce some of its 
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ideas and concepts, and to consider how it can be useful for socio-legal 
research.  
 
This chapter will address the role of ANT in this research in two main steps. 
First, it will provide an introduction to the main ideas and concepts, and will 
explain the meaning of this approach in terms of the way it understands social 
life and the role of sociologists (Section 1). Secondly, it will discuss how this 
project has used the key concepts of ANT in practice (Section 2). The specific 
issues raised by the links between methodology and ANT will be discussed in 
the next chapter, when explaining the methods chosen in this research. 
  
SECTION 1: SOCIOLOGICAL RESEARCH AND MOBILITY OF 
ORDERINGS 
 
ANT has challenged existing understandings of society in several ways. A key 
aspect of this approach lies in the views it puts forward of social networks as 
mobile and fragile sets of heterogeneous connections and associations. This 
section will emphasise this key aspect of the approach, and explain why it 
results in an understanding of social relations based on change, complexity and 
interdependency- DQGRQWKHLGHDRILQWHUGHWHUPLQDF\RIWKH³VRFLDO´ 
 
WHAT IS ANT? 
 
Before introducing the key ideas of ANT, two points need to be tackled. First, 
the origins of ANT need to be introduced. Second, the difficulties of 
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identifying, defining and explaining ANT as one stable and unique object need 
to be presented.  
 
Origins 
 
ANT originated in the sociology of science and technologies. Its initial aim 
was to understand the life of scientific objects within and outside the 
laboratory152. Scientific objects were therefore the centre of the analysis, and 
ANT was developed as a sociological method to understand their role and 
PRGHVRIDFWLRQ6LQFHLWVILUVWDSSHDUDQFHLQWKHODWH¶V$17KDVHYROYHG
significantly and in different directions, and nowadays the term ANT covers a 
range of approaches with a common denominator. This introduction to ANT 
will aim to uncover this common denominator, and to illustrate the key aspects 
that have been used in this particular project. A key element for sociologists of 
science when developing ANT was to bring science back to the centre of their 
analysis, and to move away from the human-based type of analysis that had 
predominated in sociology. Actor-networks were thought of as a way to 
overcome some of the most central divisions of social theories, such as that of 
object/subject, structure/agency or human/non-human153. The theory aims to 
                                                 
152
 Latour, B. (1993) We Have Never Been Modern, Brighton; Harvester Wheatsheaf; Latour, 
B. (1987) Science in Action: How to Follow Scientists and Engineers Through Society. Milton 
Keynes: Open University Press; Latour, B. (1988) The Pasteurization of France. Cambridge, 
Mass.: Harvard University Press; Latour B. (1979) Laboratory Life: the Social Construction of 
Scientific Facts, Los Angeles: Sage Publications. 
153
 /DWRXU%³2Q5HFDOOLQJ$17´SXEOLVKHGE\WKH'HSDUWPHnt of Sociology, 
Lancaster University, LA1 4YN, UK, at http://www.lancs.ac.uk/fss/sociology/papers/latour-
recalling-ant.pdf , also published in an earlier version in as Latour B. (1999) in Law J. and 
Hassard J. (eds) Actor-network Theory and After, Oxford: Blackwells, pp.15-25. 
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analyse how the relative stability of a particular network can be achieved, and 
how it participates in the emergence of further actor-networks and 
connections154. It provides a new complex way of thinking about social 
relations through the definition of particular networks. 
 
7KH WHUP³VRFLRORJ\RI DVVRFLDWLRQ´XVHGE\%UXQR/DWRXU155 to illustrate the 
focus of ANT is a useful way of understanding the most central elements of the 
approach. Derived from semiotics and the emergence of meaning from 
relations156, ANT aims to understand how associations and connections make 
actors what they are, and act the way they do. It is based on the notion that 
nothing is truly stable and pre-defined, but always co-dependent on what 
surrounds it. 
 
 
                                                 
154
 /DZ-³1RWHVRQWKH7KHRU\RIWKH$FWRU-Network: Ordering, Strategy and 
+HWHURJHQHLW\´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU8QLYHUVLW\/DQFDVWHU
LA1 4YN, UK, at http://www.lancs.ac.uk/fss/sociology/papers/law-notes-on-ant.pdf³This 
theory ± also known as the sociology of translation ± is concerned with mechanics of power´
p.1. 
155
 Latour B. (2005) Reassembling the Social: an Introduction to Actor-Network Theory, 
Oxford: Oxford University Press. 
156
 ³$OOHQWLWLHVLWVD\VDFKLHYHWKHLUVLJQLILFDQFHE\EHLQJLQUHODWLRQWRRWKHUHQWLWLHV7KLV
means that in ANT entities, things, people, are not fixed. Nothing that enters into relations has 
fixed significance or attributes in and of itself. Instead, the attributes of any particular element 
in the system, any particular node in the network, are entirely defined in relation to other 
elements in the system, to other nodes in the netZRUN$QGLWLVWKHDQDO\VWµVMREDWOHDVWLQ
part, to explore how those relations ± and so the entities that they constitute ± are brought into 
EHLQJ´ /DZ-³1HWZRUNV5HODWLRQV&\ERUJVRQWKH6RFLDO6WXG\RI7HFKQRORJ\´
published by the Centre for Science Studies, Lancaster University, Lancaster LA14YN, UK, at 
http://www.comp.lancs.ac.uk/sociology/papers/law-networks-relations-cyborgs.pdf, on p. 4. 
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How to explain ANT? 
 
One of the emphases of ANT, as will be developed below, is on the instability 
of the social and the fragility of meaning of social networks and objects. A 
consequence of this is the constant questioning of whether an object can ever 
be described in truthful terms, since it is always likely to change and be 
reshaped when enrolled in new networks. Numerous studies have emphasised 
this fragile character of objects, and John Law has questioned what this might 
mean in relation to descriptions of ANT itself157. How can ANT ever be 
described as a single approach, when its meaning and content is constantly 
reshaped by each network in which it is enrolled, with each performance of 
authors integrating it into their research? This is an important question, and the 
LGHDWKDW LW LVSUREDEO\LPSRVVLEOHWRSURYLGHRQH³WUXH´YHUVLRQRI$17DVD
whole, while remaining faithful to some key ANT concepts, is undeniable. 
However, for the purpose of this research, it is necessary to try to highlight 
some key concepts of the version of ANT that has been enrolled in this study. 
$OWKRXJK ³WUDGXFWLRQ LV DOVR WUDKLVRQ´158, and the story of ANT given here 
only represents one version of ANT, this section will aim to explain some of 
the key ideas that have been used in this research. It will provide an 
introduction and some ideas of what ANT is in this particular project.  
 
                                                 
157
 6HH/DZ-³7UDGXFWLRQ7UDKLVRQ1RWHVRQ$17´SXEOLVKHGE\WKH&HQWUHIRU
Science Studies, Lancaster University, Lancaster LA14YN, UK 
http://www.comp.lancs.ac.uk/sociology/stslaw2.html, Department of Sociology, Lancaster 
University 
158
 See Law-³7UDGXFWLRQ7UDKLVRQ1RWHVRQ$17´RSFLW 
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COMPLEXITY OF HETEROGENEOUS NETWORKS 
 
When presenting ANT in its dimensions most relevant to this project, several 
speFLILFHOHPHQWVQHHGWREHFRQVLGHUHG)LUVWWKHQRWLRQRI³QHWZRUN´DVXVHG
in this particular approach needs to be defined and explained. This will allow 
for a comment on one of the recurrent elements discussed in relation to ANT ± 
LWV UHODWLRQ WR WKH ³VWUXFWXUHDJHQF\´ GHEDWH 7KH QRWLRQV RI ³KHWHURJHQHLW\´
DQG ³V\PPHWU\´ ZLOO WKHQ QHHG WR EH H[SODLQHG 7KH TXHVWLRQ RI QHWZRUN
stability, in its achievement and in the questions it raises in relation to notions 
RI³IDLOXUH´RUSRZHUZLOOEHGLVFXVVHG)LQDlly, the relation between ANT and 
notions of space will be covered. Overall, what will be emphasised in this 
section are the ideas of mobility, complexity and fluidity put forward by ANT. 
 
³$FWRU-QHWZRUN´8QGHUVWDQGLQJWKHRULJLQDOLW\RIWKHQRWLRQRIQHWwork 
 
Network theories as a whole have been highly popular in the social sciences 
IURP WKH ¶V159. They have also been considered in a wide range of 
disciplines, such as geography and International Relations160. The emphasis on 
                                                 
159
 See for example: Radcliffe-Brown A. R. (1952) Structure and Function in Primitive 
Society: essays and Adresses/RQGRQ&RKHQDQG:HVW%DUQHV-$³&ODVVDQG
Committees in a Norwegian IslaQG3DULVK´Human Relations (7) pp.307-312; Beshers J. M. 
DQG/DXPDQQ(2³6RFLDO'LVWDQFH$1HWZRUN$SSURDFK´American Sociological 
Review (32) pp. 225-236; Bott E. (1957) Family and Social Networks, London: Tavistock 
Publications; Epstein A. L³7KH1HWZRUNDQG8UEDQ6RFLDO2UJDQL]DWLRQ´Rhodes-
Livingstone Journal (29) pp. 29-62. 
160
 %HDYHUVWRFN-96PLWK5*DQG7D\ORU3-³:RUOG&LW\1HWZRUNDQHZ
0HWDJHRJUDSK\"´Millenial Issue of the Annals of the Association of American Geographers, 
90, March 2000, pp. 123-&RORQRPRV$³7UDQVQDWLRQDO1HWZRUNV2OG*DPH
1HZ5XOHV´LQ6PRXWV0&HGVThe New International Relations: Theory and Practice, 
 92 
the need to understand connections between actors has been common to all 
approaches. The world is analysed as made up of inter-relations and any social 
system can be understood through the analysis of these connections, as well as 
in relation to the question of inclusions in and exclusions from particular 
QHWZRUNV+RZHYHUDXWKRUV¶ UHODWLRQ WR WKHVWUXFWXUHDJHQF\GHEDWHDQG WKHLU
varied emphasis on the respective importance of the whole and the parts has in 
fact been highly different. In reality, a wide range of varied assumptions can be 
found within network theories, in spite of their common emphasis on 
connections as crucial to the understanding of society. 
 
7KHGDQJHURIXVLQJWKHWHUP³QHWZRUN´KDVEHHQHPSKDVLVHGE\$17ZULWHUV
willing to explain the risk of following a dominant terminology and way of 
thinking ± ³LWDOVRVXJJHVWVWKDWZHDUHEHLQJFDXJKWXSLQDhegemonic way of 
UHSUHVHQWLQJ DQG « SHUIRUPLQJ WKH ZRUOG´161. However, it is useful at this 
VWDJHWRUHIOHFWRQWKHVSHFLILFLW\RIWKHWHUP³QHWZRUN´LQ$17DVFRPSDUHGWR 
other sociological understandings. One of the main differences between the 
understanding proposed in ANT and other ± including most recent - accounts 
of the meaning of the term, lies in the concept of stability. While many 
understandings of networks tend to refer to a rather stable set of connections, 
the emphasis of ANT was originally on the fact that what can appear as stable 
is in fact always a set of fragile associations. In addition to this, a key aim of 
the notion was originally to understand movement and changes, by 
                                                                                                                                 
London: Hurst, pp. 112-125; 6PLWK5³:RUOGFLW\$FWRU-QHWZRUNV´ Progress in 
Human Geography  27(1) pp 25-44. 
161
 /DZ-³1HWZRUNV5HODWLRQVDQG&\ERUJVRQWKH6RFLDO6WXG\RI7HFKQRORJ\´RS
cit. on p. 5.  
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understanding circulations and transformations that reshape every set of 
associations in a dynamic way. Very recent changes, and in particular the 
increasing use of the term that has followed the development of the 
³LQIRUPDWLRQVRFLHW\´162 are in clear contrast with this understanding, and the 
term network is now often understood as a set of connections through which 
information can circulate in an unmodified and stable way. ³1HWZRUN DW WKH
time clearly meant a series of transformations ± translation, transductions -; 
now, on the contrary, it clearly means a transport without deformation, an 
LQVWDQWDQHRXVXQPHGLDWHGDFFHVVWRHYHU\SLHFHRILQIRUPDWLRQ´163 Although 
this criticism made of the term network by Latour essentially refers to its use in 
relation to cyber space and information technologies, broader implications can 
be drawn in relation to other sociological uses of the term network. Indeed, the 
concept of stability of relations and the building of long term relations between 
actors is found in many comments on networks. A clear example lies in the 
concept of policy-network that is widely used, and clearly refers to stable sets 
RI FRQQHFWLRQV WKDW DUH EXLOW LQ RUGHU WR JHQHUDWH D VWDEOH ³ZKROH´ DEOH WR
negotiate164.  
 
                                                 
162
 See Castell M. (1996) The Rise of the Network Society: the information age, Cambridge, 
MA.: Blackwells Publishers. 
163
 /DWRXU%³2Q5HFDOOLQJ$17´RSFLWRQS 
164
 )RUH[DPSOH5KRGHV5$:³3ROLF\-1HWZRUNVD%ULWLVK3HUVSHFWLYH´Journal of 
Theoretical Politics, 2(3) pp. 292-316; 5LFKDUGVRQ-³3ROLF\-Making in the EU: 
Interests, ,GHDVDQG*DUEDJH&DQVRI3ULPHYDO6RXS´LQ5LFKDUGVRQ-HGEuropean Union: 
Power and Policy-making, London: Routledge, pp. 3-23. 
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Finally, in addition to this, the notion of network in ANT needs to be perceived 
DVPRUHWKDQDQ³DERYH-the-LQGLYLGXDOOHYHO´WHUPDQGUHIHUVERWKWRWKHZKROH
and the parts.  Actor-networks are the gathering of connections and 
associations that create a particular entity that might appear as unified ± as an 
³REMHFW´DWRQHSRLQWLQWLPH- but remain fragile and potentially subject to re-
ordering: 
 
³The network pole of actor-network does not aim at all at designating a 
Society, this Big Animal. It designates something entirely different which is the 
summing up of interactions through various kinds of devices, inscriptions, 
forms etc, into a very local, very practical, very tiny locus´165 
 
7KHFRQFHSWRIQHWZRUNDQGHYHQPRUHVRWKHQRWLRQRI³DFWRU-QHWZRUN´KDV
generated important questions in relation to the traditional structure/agency 
debate that has largely mobilised sociologists. ANT does not as such locate 
LWVHOI RQ DQ\ ³VLGH´ RI WKH GHEDWH DQG DXWKRUV KDYH GLVPLVVHG WKLV LVVXH DV
irrelevant and inappropriate. However, it is important to specify how this 
dismissal was reached, as it is important for what it reveals about the notion of 
                                                 
165
 /DWRXU%³2Q5HFDOOLQJ$17´SXEOLVKHGE\WKH'HSDUWPHQWRI6RFLRORJ\
Lancaster University, LA1 4YN, UK, at http://www.lancs.ac.uk/fss/sociology/papers/latour-
recalling-DQWSGIRQS,WVKRXOGEHQRWHGKRZHYHUWKDW/DWRXU¶VGHILQLWLRQRIWKHWHUP
network in its most recent publication is slightly distinctive as compared to what appears here 
and in earlier lLWHUDWXUH,QSDUWLFXODUKHHPSKDVLVHVWKHLGHDRI³QHWZRUN´DVDTXDVL-
methodological tool than can help retracing connections under scrutiny. For more detail on this 
position, see Latour B. (2005) Reassembling the Social: an Introduction to Actor-network 
Theory, Oxford: Oxford University Press, p. 131. In this particular project, the term network is 
essentially used to refer to objects of study themselves rather than to the result of their 
observation, and borrows in that respect more clearly from earlier writings in ANT research.  
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network, as well as for other ideas that will be continually used throughout this 
project. 
 
What has been presented as central to ANT analysis is the constant relations 
between the whole and the parts as well as the interdependency of actors and 
networks. In addition, the notion of power as flux that will be explained below 
is in clear contradiction to the idea of making a decision about whether 
structures or agency holds most power in social change. In ANT, the 
distinction between structure and agency is therefore largely irrelevant. ANT 
sidesteps the issue as the social order is constituted by a constant dynamic in 
which actors model networks and networks define actors ± and in which all 
actors are also networks and all networks are themselves actors. The relation 
between actors and networks is more complex than in many studies 
emphasising the impact of structure over agency, as each network is only the 
result of other actor-QHWZRUNV¶LQWHUDFWLRQV166. Any association is therefore only 
understood as the result of further connections happening elsewhere and of the 
embedment167 of multiple effects, associations and actors into what appears 
temporarily as a stable hybrid168. 
 
                                                 
166
 /DWRXU%³2Q5HFDOOLQJ$17´RSFLW 
167
 The notion of embedment is widely used in ANT to refer to the unsaid integration of actors 
or concepts in particular actor-networks ± for examples of its early use, see Law J. (1999) 
³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU
University, LA14YN, UK, at http//www.comp.lancs.ac.uk/sociology/soc029jl.html or Law J. 
³7RSRORJ\DQGWKHQDPLQJRIFRPSOH[LW\´SXEOLVKHGE\WKe Centre for Science Studies, 
Lancaster University, LA14YL, UK, at http://www.comp.lancs.ac.uk/sociology/papers/law-
topology-and-complexity-pdf. It will be used and illustrated throughout chapters 6 and 7. 
168
 7KHQRWLRQRI³K\EULGLW\´LVERUURZHGIURP/DWRXU%We Have Never Been Modern, 
op. cit. 
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Consequently, social analysis should not have ± and cannot claim - to be either 
micro or macro, but should aim to understand social relations as mobile along 
specific networks, without ever being conceived as specific to a certaLQ³OHYHO´
of scrutiny: 
 
 ³$FWRUDQGQHWZRUN «GHVLJQDWHV WZR IDFHVRI WKH VDPHSKHQRPHQRQ OLNH
wave and particles, the slow realization that the social is a certain type of 
circulation that can travel endlessly without ever encountering either the 
micro-level ± there is never an interaction that is not framed ± or the macro-
level ± there are only local summing´169 
 
Materiality and heterogeneous networks 
 
One of the most central claims of ANT is that sociology needs to be understood 
as a science of continuity and symmetry, and ANT authors therefore challenge 
some of the dichotomies traditionally accepted in sociology. The starting point 
of this challenge is the critic of the gap between nature and society. Originating 
LQ /DWRXU¶V HDUO\ ZRUN170, this idea emphasises the continuity of what has 
traditionally been portrayed as two distinct spheres, and the idea that, while 
nothing is ever purely social, nothing is ever purely natural either. Nature and 
VFLHQWLILF ³IDFWV´ DUH DOO VRFLDOO\ ELDVHG DQG FDQ RQO\ EHXnderstood through 
their links with society ± society makes science and influences what become 
                                                 
169/DWRXU%³2Q5HFDOOLQJ$17´SXEOLVKHGE\WKH'HSDUWPHQWRI6RFLRORJ\
Lancaster University, LA1 4YN, UK, at http://www.lancs.ac.uk/fss/sociology/papers/latour-
recalling-ant.pdf on p. 3. 
170
 Latour B. (1993). We Have Never Been Modern, op. cit; Latour B. (1988) The 
Pasteurization of France. Cambridge, MA.: Harvard University Press. 
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seen as natural facts. Similarly, society cannot be conceived separately from a 
natural, material world, and every aspect of social life is shaped by constant 
interrelations with materiality. Rather than understand nature and society as 
two distinct elements, sociologists therefore need to understand nature/society 
as the continuity of each other, and as fully interdependent.  
 
More specifically, the idea of continuity has  resulted in a challenge to the 
divide between humans and non-humans. Translated in ANT terms through the 
notion of heterogeneity, this idea emphasises the fact that social networks are 
all constituted of, and co-dependent on, both humans and non-human 
elements171. Materiality is central to society, and covers a range of elements: 
objects, bodies and quasi-objects, such as information and media.172 Without 
contesting the specificities of human beings as thinking actors, ANT argues 
that without materialLW\ WKHUH ZRXOG EH QR VRFLDO UHODWLRQV QR ³VRFLHW\´ DQG
that any form of human interaction necessarily relies on material elements to 
VXFK DQ H[WHQW WKDW WKH\ FDQ EH VDLG WR ³H[LVW´ RQO\ WKURXJK WKHP
Consequently, in order to analyse social events of any kind, one needs to 
consider not only the role of humans but also that of non humans in shaping 
events and relations. 
 
                                                 
171
 See for example Latour B. (³2Q5HFDOOLQJ$17´RSFLWRUVLPLODUO\LQWKHYHUVLRQ
of this text published in 2004.) 
172
 See Latour on quasi-objects in Latour, B. (1993) We Have Never Been Modern, op. cit.. See 
DOVRRQPDWHULDOLW\/DZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLW³Materiality 
is about stuff, the stuff of the world. Straightforwardly, we can imagine three kinds of stuff. 
)LUVWWKHUHDUHREMHFWV«%XW>VWXII@LVDOVRDERXWERGLHVWRR± for bodies are material -«
So objects and bodies are stuff. They are material. But so too are information and media, and 
WKLVLVRXUWKLUGFDWHJRU\RIPDWHULDOLW\´ on p.2. 
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 ³This is a radical claim because it says that these networks are composed not 
only of people, but also of machines, animals, texts, money, architectures ± any 
PDWHULDO WKDW\RXFDUHWRPHQWLRQ6RWKHDUJXPHQW LV WKDW WKHVWXIILVQ¶WRQO\
human. It is all these other materials too. Indeed, the argument is that we 
ZRXOGQ¶WKDYHDVRFLHW\DWDOOLILWZHUHQ¶WIRUWKHKHWHURJHQHLW\RIWKHQHWworks 
of the social. So in this view the task of sociology is to characterise these 
networks in their heterogeneity, and explore how it is that they come to be 
patterned to generate effects like organisation, inequality and power´173 
 
The central consequencHRIWKH³LQGHWHUPLQDF\RIDFWRUV´LVWKDWDQ\SDUWLFXODU
actor, human or non-human, within a network could become influential at any 
stage, depending on their own actions and that of the network.174 
 
Translation and power 
 
When studying networks and objects, a necessary step is to understand what 
makes them what they are ± what makes their shape stay still for a while, so 
that they can become a defined matter of inquiry. Therefore, we now need to 
come back to the key question raised by ANT ± how do sets of connections 
turn into apparently stable actors; how are networks created? In other words, 
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 /DZ-³1RWHVRQWKH7KHRU\RI$FWRU-network: Ordering, Strategy and 
+HWHURJHQHLW\´RSFLWRQS 
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 &DOORQ0³$FWRU-network Theory ± WKH0DUNHW7HVW´SXEOLVKHGE\WKH'HSDUWPHQW
of Sociology, Lancaster University, LA14YL, UK, at 
http://www.comp.lancs.ac.uk/sociology/papers/callon-market-WHVWSGI³The most important is 
that ANT is based on no stable theory of the actor; in other words it assumes the radical 
LQGHWHUPLQDF\RIWKHDFWRU)RUH[DPSOHQHLWKHUWKHDFWRU¶VVL]HQRULWVSV\FKRORJLFDOPDNH-up 
nor the motivations behind its actions are predetermined´RQS 
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how do networks manage to stabilise and hold together their different 
components? By contrast, what makes networks crumble and what makes 
REMHFWVRUWHFKQRORJLHV³IDLO´RUGLIIHUIURPZKDWWKHLUFUHDWRUVZHUHH[SHFWLQJ
them to be?  
 
These questions call for two sets of answers. The first will look at the issue of 
QHWZRUN FUHDWLRQ DQG VWDELOLW\ 7KH VHFRQG UDWKHU WKDQ H[SODLQLQJ ³IDLOXUH´
will question the concept of failure itself, and offer an alternative 
understanding for the unexpected action of technologies in society, and the 
unexpected shape that specific networks choose to adopt. Finally, this will take 
us to a discussion of the notion of power in ANT, where the circulating nature 
of power in this approach will be re-emphasised. 
 
Network creation and stability  
 
$17XVHVWKHWHUP³WUDQVODWLRQ´WRGHVFULEHWKHPRPHQWWKURXJKZKLFKDVHWRI
entities turns into what appears as a single, unified network, and consequently 
becomes a stable ± and successful ± network. The network can itself then 
EHFRPHFRQFHLYHGDVDZKROHDVZKDW-RKQ/DZFDOOVD³SXQFWXDOLVHGDFWRU´ 
 
 ³This, then, is the core of the actor-network approach: a concern with how 
actors and organisations mobilise, juxtapose and hold together the bits and 
pieces out of which they are composed; how they are sometimes able to prevent 
those bits and pieces from following their own inclinations and making off; and 
how they manage, as a result, to conceal for a time the process of translation 
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itself, and so turn a network from a heterogeneous set of bits and pieces each 
with its own inclinations, into something that passes as a punctualised 
actor´175  
 
One of the key questions of ANT thus becomes to know how translation occurs 
± and the relation between translation, action and power. Several elements can 
be put forward, that have to do both with the nature of the actors concerned, 
and with strategies developed by networks. However, what makes a strict and 
definite listing of what participates in network stability a difficult task, is the 
idea of interdependency and fragility of networks, as well as the fact that, while 
some theories could have discussed the nature and stability of materials as an 
accepted element, this remains purely circumstantial in ANT. Therefore, a key 
element in the success of translation processes is the relative stability, or 
durability of relevant materials. Whether materials are strong and stable 
enough to participate in the stability of a given network, although crucial, is 
itself relational, as the stability of these materials is in fact fully dependent on 
the links they establish with others. Similarly, the potential of materials to 
move across space-time, while retaining their own shape, is essential in 
allowing successful translations to occur in many cases.176 In particular, the 
UROH RI WKHVH PDWHULDOV LQ DOORZLQJ IRU GHOHJDWLRQ IURP ³FHQWUH´ WR SDUWV KDV
been highlighted as a crucial element of successful networks.177 Other key 
elements needed for successful translation relate to strategies and orderings, as 
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 /DZ-³1RWHVRQWKH7KHRU\RI$FWRU-netwoUN´RSFLWRQS 
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 6HHWKHFRQFHSWRI³LPPXWDEOHPRELOHV´LQ/DWRXU%³'UDZLQJ7KLQJV7RJHWKHU´LQ
M. Lynch and S. Woolgar (Eds.) Representation in Scientific Practice. Cambridge, Mass, MIT 
Press, pp. 19-68.  
177
 /DZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLW 
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well as the need for networks to develop ways to adapt to future changes and 
new enrolments and circumstances. In addition, anticipation is central within 
the network, and key actors need to be able to expect and address the potential 
divergence of other actors from the overall action of the network. 
 
A relevant question when dealing with translation is its relation to power. This 
requires an explanation to briefly explain the position of ANT on power. One 
key element is that translation and the creation of relatively stable networks 
should be understood more as the origin, rather than the consequence of, a 
certain type of power. Power in ANT can never be fully retained ± it does not 
exist as a definite and stable element, but is expressed by circulating through 
connections and associations. It does not pre-exist these connections in any 
ZD\ FDQQRWEH FRQVLGHUHG WR ³EHORQJ´ WR DQ\SDUWLFXODU DFWRU EXW UHPDLQV D
fluid type of circulation through networks and associations. To that extent, 
connections create the circulation and expression of power, and power will be 
expressed in a particular way depending on the set of connections that are 
WDNLQJ VKDSH ³ANT is all about power - power as a (concealed or 
misrepresented) effect rather than power as a set of causes´178 
 
Overall, by translating into what appear as punctualised networks, associations 
adopt a shape that can be taken for stable, although they are always exposed to 
the risk of seeing their parts drift away, and the network, as it was known, 
³IDOOLQJDSDUW´ 
 
                                                 
178
 /DZ-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³Networks patterns that are widely performed are often those that can be 
punctualised. This is because they are network packages ± routines ± that can, 
if precariously, be more or less taken for granted in the process of 
heterogenous engineering. In other words, they can be counted as resources, 
resources that may come in a variety of forms: agents, devices, texts, relatively 
standardised sets of organisational relations, social technologies, boundary 
protocols, organisational forms ± DQ\ RU DOO RI WKHVH « 3XQFWXDOLVDWLRQ LV
always precarious, it faces resistance and may degenerate into a failing 
network´179. 
  
7KLVFLWDWLRQEULQJXVDGLVFXVVLRQRIWKHFRQFHSWRI³IDLOLQJQHWZRUN´Dnd to 
question how ANT evolved into challenging this notion itself, and opposing to 
it the idea that change in network configurations should be understood as 
unavoidable transformation rather than failure. It will help us understand the 
concept of co-existing realities put forward more recently in ANT, and the 
argument that the contrasts between expectations and happenings in relation to 
translation should not necessarily be understood as synonymous with failure. 
 
Network failure and co-existing realities. 
 
0RVW$17OLWHUDWXUHKDVFRQFHQWUDWHGRQH[DPSOHVRI³VXFFHVVIXO´WUDQVODWLRQV
and has been devoted to explaining a posteriori the relative stability of 
SDUWLFXODUQHWZRUNV7KH LVVXHRI WKHSRWHQWLDO³IDLOXUH´RIQHWZRUNVKDVEHHQ
                                                 
179
 /DZ-³1RWHVRQWKH7KHRU\RI$FWRU-QHWZRUN´RSFLWRQS 
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less explored180. One possible reason for this is the fact that discrepancies 
between expectations and networks action have often been explained through 
the idea of co-existing realities, rather than in terms of failure. This section 
aims to explain the difficulties of using the concept of failure in ANT studies, 
and to introduce how the idea of co-existing realities is more appropriate in 
describing the potential contrasts between expectations and outcomes. 
 
A useful way to discuss the concept of co-existing realities is to refer back to 
the original field of ANT, and to discuss how this can be most clearly 
understood when dealing with technologies. The creation of a particular 
technology is often associated with a set of aims and expectations from its 
creators. These expectations are partly built around the idea that the technology 
will work in a certain way, and will create a range of relations with other actors 
that will participate in it, working in the way foreseen by its creators. Certain 
types of networks will emerge, and shape the action and role of a given 
technology in social networks. However, in many cases, this set of relations 
will not be exactly as planned, and the technology will therefore not 
necessarily act in the way expected. This can result in minor discrepancies 
between expectations and realities, but can also result in the technology 
DSSHDULQJ DV GRLQJ VRPHWKLQJ IXQGDPHQWDOO\ ³GLIIHUHQW´ IURP ZKDW LW LV
supposed to do. A good example of this is given by Marianne de Laet and 
                                                 
180
 )RUH[DPSOHVRIVWRULHVRIIDLOLQJQHWZRUNVVHH/DZ-³/DGEURNe Grove, or How to 
7KLQNDERXW)DLOLQJ6\VWHPV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU
University, UK, at http//www.comp.lancs.ac.uk/sociology/papers/law-ladbroke-grove-failing-
V\VWHPVSGIRU6WDU6/³3RZHU7HFKQRORJLHVDQGWKH Phenomenology of 
&RQYHQWLRQVRQEHLQJ$OOHUJLFWR2QLRQV´LQ/DZ-HGA Sociology of Monsters, London: 
Routledge, pp. 26-56. 
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Anne-Marie Mol181 ZKHQ ORRNLQJ DW WKH ³=LPEDEZHDQ %XVK 3XPS´ 7KH\
analyse the changes that this technology goes through once implemented in the 
African village for which it was designed, and observe how the absence of key 
actors that were necessary to the stability of the network as originally 
conceived resulted in the pump being transformed by each network in which it 
was enrolled. One of the questions raised by this case study is whether the 
transformed versions of the bush pump in Zimbabwe mean that the original 
version of the pump failed, or whether it has taken a new shape, that it has been 
adapted in ways unexpected by its creators that are nevertheless fully part of 
WKH VDPHREMHFW¶V UHDOLW\6LPLODUO\ E\ HPSKDVLVLQJ WKHYDULRXV ³GHILQLWLRQV´
that could be provided of this particular technology and emphasising the 
difficulty of defining clearly its boundaries with specific networks, the authors 
emphasise the inherent fluidity of this particular object, and therefore highlight 
some of its potential complexities. The ideas put forward in this case study in 
relation to the fluidity and indeterminacy of technologies is taken up again in 
several studies182.  Overall, studies  in ANT emphasise the idea that the 
contrasts between expectations and actions should not be understood as a 
failure of a system, but as the expression of another aspect of a multi-
dimensional object. This new aspect, even if unforeseen by its creators, is 
nevertheless part of a reality that needs to be studied on its own183. 
 
                                                 
181
 GH/DHW0DQG$0RO³7KH=LPEDEZH%XVK3XPS0HFKDQLFVRID)OXLG
7HFKQRORJ\´Social Studies of Science (30) pp. 225-263. 
182
 For example: Akrich, M. (1993) Inscription et Coordination Socio-Techniques: 
Anthropologie de Quelques Dispositifs Énergétiques, Thèse pour le doctorat Socio-Economie., 
Paris: École Nationale Supérieure des Mines de Paris. 
183
 Some dimensions of WKHLGHDRI³UHDOLW\´ZLOOEHGLVFXVVHGIXUWKHULQ&KDSWHU 
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Overall, technologies come to be conceived as fluid objects that adapt to new 
networks, and can become active in a fundamentally different way from their 
FUHDWRUV¶H[SHFWDWLRQV± and their existence itself becomes co-dependent on this 
fluidity. This needs to be fully understood, for realities need to be portrayed 
throughout this multiplicity of objects and through the idea that technologies 
cannot be moved while fully maintaining their shape. One idea associated with 
WKLVIRUPRIDQDO\VLVLVWKDW³WKHUHLVQRVXFKWKLQJDVWHFKQRORJ\WUDQVIHU´184. 
As technologies are displaced from one network to another, they change, and 
the sets of relations established around technological objects are themselves 
modified. 
 
+RZHYHU WKH LGHD RI ³PXOWLSOH UHDOLWLHV´ UDLVHG LQ WKH DERYH SDUDJUDSK UXQV
deeper than the notion of transformation or transfer itself, and carries 
consequences essential to ANT. It emphasises the fact that any object, any 
actor-network, is fully reshaped by each network of which it is a part. (This 
does not necessarily imply any material displacement, but the contrast between 
networked space and Euclidian space will be discussed again below.) When 
looking at any object ± and this was very clearly illustrated by Vicky Singleton 
and John Law when looking at diseases185± D QXPEHU RI LWV ³VWRULHV´ DSSHDU
through each network of which it has become part and in which it is acting. 
7KRVH GLVWLQFW VRPHWLPHV VXSHUILFLDOO\ ³FRQWUDGLFWRU\´ VWRULHV DUH DOO SDUW RI
the reality of this particular object, of its inherent complexity, and each of these 
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 /DZ-³7UDGXFWLRQ7UDKLVRQ1RWHVRQ$17´RSFLW
http://www.comp.lancs.ac.uk/sociology/stslaw2.html, Department of Sociology, Lancaster 
University 
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 Law J. and Singleton V. (2000) ³7KLVLVQRWDQ2EMHFW´RSFLW 
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stories and dimensions need to be understood if the aim is to provide a 
complete account of this object. This will be particularly important throughout 
this research.  
 
SPACE AND ANT 
 
The question of the relation between space and networks is a complex issue. It 
is however a key question to address when aiming to relate ANT based 
research to existing writings that have widely adopted the notion of 
globalisation, and when the aim is to apply ANT to the study of transnational 
law. One of the key elements characterising ANT is that networks appear as 
necessarily a-geographical, in the sense that they can never be defined in 
relation to a particular geographical unit. Through the example of the locality 
of a railway system, Latour highlighted how networks present this necessary 
characteristic of being indefinable in terms of geographical unit186. The 
understanding of space in ANT has thus become a debated issue, and the 
importance of place in these discourses remains unclear. 
 
ANT emphasises that concepts of time and space as absolutes are neither useful 
nor realistic, and that those two phenomena depend on the constitution of 
specific networks. Consequently, traditional Euclidian geography becomes 
meaningless for ANT theorists187 - and can even become a hindrance to the 
development of network based analysis. For example, while two things can be 
³FORVH´LQ(XFOLGLDQWHUPVWKH\FRXOGEHFRPSOHWHVWUDQJHUVWRHDFKRWKHU%\
                                                 
186
 Latour B, (1993) We Have Never Been Modern, op. cit. 
187
 Latour B. (1993) We Have Never Been Modern, op. cit. 
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FRQWUDVW RWKHUV ³JHRJUDSKLFDOO\´ IDU DSDUW FRXOG EHFRPH VWURQJO\
interconnected if embodied in a common network188. ANT thus requires a full 
revision of traditional visions of space as absolute reality, and implies the need 
IRUDQHZQHWZRUNEDVHG³WRSRORJ\´)RU$17VSDFHEHFRPHVUHODWLRQDODQG
is consequently a product of networks, as opposed to a pre-existing reality. 
While it is generally assumed that space pre-exists networks, and influences the 
constitution of networks to some extent, it is in fact necessary to accept that 
space is in itself fully relational, and that networks impact centrally on the 
constitution of space. They participate in connecting elements regardless of 
notions of distance.  
 
³:HZDQWWRVXJJHVWWKDWPDNLQJDFWLRQDQGNQRZOHGJHDWDGLVWDQFHQRWRQO\
makes action, knowledge and global asymmetry ± although it certainly does all 
these things. In addition we want, and somewhat counter-intuitively, to suggest 
that it also makes distance or space, performs these into being. Which means 
WKDWGLVWDQFHDQGVSDFHGRQ¶WH[LVWE\WKHPVHOYHVDVSDUWRIWKHRUGHURIWKLQJV
%XWUDWKHUWKDWWKH\DUHFUHDWHG´189 
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 )RUFRPPHQWVVHH0XUGRFK-³7KH6SDFHVRI$FWRU-1HWZRUN7KHRULHV´Geoforum 
29(4) pp. 357-374. 
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 Law -³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLW6HHDOVRLQ/DZ-
³2EMHFWV6SDFHVDQG2WKHUV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU
University, LA14YL, UK, at http://www.comp.lancs.ac.uk/sociology/papers/law-objects-
spaces-others.pdf³No doubt there are particular configurations which predate objects in that 
space. It is, however, also possible to make another argument; to say that the performance of 
an object-shape as stable and continuous in Cartesian terms also helps, at the same time, to 
perform a space, a world, that is Cartesian in form´RQS 
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A related question considers the way ANT proposes to respond to the notion of 
³JOREDOLW\´ DQG KRZ LW RIIHUV DQ DOWHUQDWLYH DSSURDFK WR WKH VWXG\ RI
transnational networks. It puts forward the idea that global events cannot be 
analysed only as a form of pure supranational element, but that one must 
consider how they relate to specific associations, and how specific networks 
WUDQVODWHLQWRZKDWDSSHDUVWRVRPHDVD³JOREDOQHWZRUN´³To address global 
concerns it is often best to be local, specific and material190 ´7KHQRWLRQRI
³JOREDOLW\´ORVHVDQ\UHDOVXEVWDQFHDVWKHLQWHUDFWLRQRIORFDOKDSSHQLQJVDQG
complex networks is argued to be the only way to approach transnational 
networks. In practice, it becomes necessary to analyse the detail and local 
manLIHVWDWLRQRIZKDWLVLQDSSURSULDWHO\GHILQHGDV³JOREDOSKHQRPHQD´UDWKHU
than aim for the development of an overarching framework that would be used 
to explain the whole.  
 
³To talk of globalisation is at best a risky shortcut and at worst seriously 
misleading. It is a risky shortcut because it implies some kind of totality, some 
NLQGRIJOREDOV\VWHP«$³JOREDOVRFLHW\´D³JOREDORUGHU´(YHQDJOREDO
GLVRUGHU%XWWKLVPLVVHGRXW«ERWKRQWKHHQDFWHGPDWHULDOLW\RIWKDWRUGHU
and also the complH[VSDWLDOLWLHVLPSOLHGLQWKDWHQDFWPHQW´191 
 
 Similarly, the notion of locality loses its traditional meaning and comes to be 
seen as the result of actions and connections in other places. The notions of 
                                                 
190
 /DZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLW 
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 LaZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLWRQSVHHDOVR/DZ-
³$QGLIWKH*OREDOZHUH6PDOODQG1RQ-Coherent? Method, complexity and the 
%DURTXH´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU8QLYHUVLW\/$<L, UK, at 
http/www.comp.lancs.ac.uk/sociology/papers/law-and-if-the-global-were-small.pdf    
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global and local are replaced by the idea of constant relations between 
FRQQHFWLRQV LQZKDWPLJKW WHPSRUDULO\ DSSHDUDV³ODUJHU´RU³VPDOOHU´EXW LQ
fact remain either more or less connected192. 
 
Overall, ANT puts forward ideas of mobility and fragility of social networks 
and orderings, and emphasises the need to understand social life by analysing 
sets of heterogeneous and complex networks that create specific orderings. It is 
now necessary to reflect on what this means in practice for empirical research. 
 
ANT AND EMPIRICAL RESEARCH  
 
The practical impact of ANT on specific methods will be discussed in detail in 
Chapter 3. However, a few general points need to be made here, that will help 
understand how the key ideas and concepts put forward above relate to general 
issues raised by empirical research. 
 
ANT has been developed essentially as a method, and has wide-ranging 
consequences for empirical research. One of its key components is its emphasis 
on description as a way to approach and narrate a particular story of social life. 
The aim of empirical work, when following an ANT framework, is to provide a 
story of an object or a situation as it appears for a researcher willing to 
understand its multiple dimensions. It is to provide a rich description of a 
                                                 
192
 See Latour B. (2005) Reassembling the Social: an Introduction to Actor-network Theory, 
op. cit. This obviously relates to what was said earlier in this chapter on the challenges brought 
by ANT to the structure/agency debate, although in terms more specifically relevant to this 
particular research.  
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system in its complexity, and in the different dimensions that appear to the 
researcher - dimensions that the researcher should aim observe without ever 
generating. Analysis needs to be done without attempting to rely on a heavy 
framework to understand the object under scrutiny, which would risk changing 
the meaning of the network as it is lived/created by those that make up the 
network.  
 
This means, first, that empirical work and sociological analysis should be 
modest193, and that researchers should follow informants through their 
connections, and trust that the system as they see it, present it, describe it, 
appear to make it, is the centre of the story to be told.  
 
 ³Far from being a theory of the social or even worse an explanation of what 
makes society exert pressure on actors, [ANT] always was, and this from its 
very inception, a very crude method to learn from the actors without imposing 
on them an a priori definition of their world-building capacities´194 
 
The idea of modest sociology, DQG $17¶V HPSKDVLV RQ WKH QHHG WR DYRLG
adding outside elements to the story has two further consequences. First, it 
implies that researchers should not attempt to simplify what appears as 
complex, and should accept this complexity as part of the realities of the 
network studied, and provide a faithful description of the network studied195. 
Second, it also implies that conclusions should not be stretched further than the 
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 Law J. (2000) Organizing Modernity, Oxford: Blackwells.  
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 We will see in Chapter 3 the practical difficulties of this idea. 
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story told, and that each description should remain essentially useful for the 
story it tells, and the potential questions it raises196. One question that could be 
opposed to the essentially descriptive task encouraged by ANT is that of the 
role of critique. If the role of researchers is essentially to describe a situation, is 
there any space left in ANT for critical analysis? The position taken in this 
research is thDWDVSHFLILFDQGIDLWKIXOGHVFULSWLRQ LQZKLFKDFWRUV¶YRLFHVDUH
presented in detail, will result in controversies and discrepancies becoming 
apparent. By highlighting these various discrepancies between views, actions 
or outcomes, the potentiality for critique will remain intact. 
 
Some of the ideas developed above can clearly be related to the practical 
implications of the principle of symmetry, and the idea that the role and 
function of each actor in a given network should not be assumed on the basis of 
their nature, but should be empirically observed. Once again, actors and 
networks cannot be deemed to have a certain type of function once and for all, 
or internal mechanics, but only take a certain shape because of the connections 
they establish with others. It is for researchers to understand the relevant set of 
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WRGHVFULEHDVZHOO,W¶VQRWDQRWKHUOD\HUWKDW\RXZRXOGKDYHWRDGGWRWKHµPHUHGHVFULSWLRQ¶
'RQ¶WWU\WRVKLIWIURPGHVFULSWLRQWRH[SODQDWLRQVLPSO\JRRQZith the description. What your 
own ideas are about your company is of no interest whatsoever compared to how this bit of the 
FRPSDQ\LWVHOIKDVPDQDJHGWRVSUHDG´RQS 
 112 
connections and interactions that locate a specific object within a larger 
network. Only from this position can the role of the object be deduced. This is 
of clear practical impact, and means that researchers should consider and study 
each object within the system under scrutiny, without undue assumptions as to 
what the object is, what it does, or what it should do. 
 
Finally, in addition to this, it is worth reemphasising the idea of actor-network 
itself, and the notion that the whole can only be studied by considering the 
parts and vice versa. Empirical research is conceived as necessarily dynamic in 
that researchers need to constantly move through the connections that appear in 
their study, and need to give attention to each actor-network that appears 
relevant, each part and dimension of this actor-network, and each larger actor-
network of which it is part. This necessarily involves a practical emphasis on 
the dynamics of the research process more generally, to understand and 
question what appears to count as relevant connections, relevant actors, and 
where attention should be next directed ± although, as will be commented upon 
in the conclusion, this can create practical difficulties when deciding where the 
process should stop. 
 
We will see in the next chapter that these ideas, although they appear as 
perfectly linked to the concepts introduced earlier, raise complex issues when 
considering methods more specifically. First, however, the meaning of ANT 
for socio-legal research needs to be questioned. 
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SECTION 2: UNDERSTANDING TRIPS AND PHARMACEUTICAL 
PATENTS THROUGH ANT 
 
As mentioned earlier, ANT was originally created by sociologists of Science 
and Technology. It has rarely been applied to within empirical socio-legal 
research197, and several questions remain about its application to the study of 
legal tools ± and in particular to the study of transnational objects. This section 
will review questions raised by the use of ANT used in this particular study to 
understand the mechanisms of socio-legal objects. The idea of complexity will 
be developed, by looking in particular at the contrast between the dominant 
story of TRIPS and pharmaceutical patents and the approach undertaken in this 
project. 
 
Before entering this analysis, the relation between this research and existing 
analyses based on approaches other than ANT needs to be specified. It is 
understood that other theories could certainly have overlapped with some key 
questions and concepts of this research198. However, one of the strength of 
                                                 
197
 For exceptions see Latour B. (2002) La Fabrique du Droit, Paris: La Decouverte; or 
Strathern M. (1³:KDWLV,QWHOOHFWXDO3URSHUW\$IWHU"´,Q/DZ-	-+DVVDUG-HGV
Actor- network Theory and After, Oxford: Blackwells, pp. 156-180. 
198
 For example, Implementation Theory proposes a comparable approach to the study of the 
potential gap between the expected role of policy tools and their actual action in society (for 
examples showing the various approaches to implementation see: Pressman J. and Wildavsky 
A. (1973) Implementation, Berkeley, CA: University of California Press; Hogwood B. W. and 
Gunn L. A. (1984) Policy Analysis for the Real World, Oxford: Oxford University Press; 
(OPRUH5³%DFNZDUGPDSSLQJLPSOHPHQWDWLRQUHVHDUFKDQGSROLF\GHFLVLRQV´
Political Science Quarterly, 26(2), pp. 185-228). Although implementation studies (in 
particular in the strands concentrating on individual action in order to understand the various 
effects of policies (Elmore R. (1980)) could have offered significant insights on the study 
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ANT for this particular project resides in fact in the origins of the approach in 
Science and Technology Studies. As this project is interested in the interaction 
between legal tools and sciences (medicine), it was felt that the symmetrical 
analysis provided by ANT would be particularly useful as a way to understand 
the complex interaction of this variety of objects.  It was perceived as having 
the potential to provide a useful way to conceive of both socio-legal and 
scientific tools as they interacted. Throughout this research, and as will be 
demonstrated, it provided a highly relevant tool for the study, conceptualisation 
and description of each of the objects under scrutiny. 
 
Transnational law, scientific objects and socio-legal tools - how to study 
TRIPS and patents in Djibouti? 
 
At this stage it is useful to reflect on the application of ANT to an 
understanding of TRIPS and pharmaceutical patents in Djibouti, and to provide 
a brief introduction to the focus of analysis of this research. In particular, it is 
this section will present the way in which ANT has participated in making the 
mechanics of both objects ± TRIPS and pharmaceutical patents - appear 
clearer. A full description of both objects as they appeared in Djibouti from this 
empirical research is given throughout the remainder of this thesis. However, 
this section will highlight why the dominant analysis of TRIPS and 
pharmaceutical patents put forward in most analyses mentioned in Chapter 1 
                                                                                                                                 
undertaken here, ANT provided further tools for understanding the action of non-policy and 
non-legal objects that were relevant to this research. Its emphasis on the need to analyse 
symmetrically these various objects through their interaction was perceived as essential in this 
project. 
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needs to be revised in light of the key ideas put forward by ANT. For readers to 
follow the subsequent analysis, it is necessary to return to the objects of study 
chosen here and question why this analysis does not stop at the doctrinal legal 
definition of both objects. TRIPS and patents, although they might appear as 
simple objects, generating chains of causality ± DV WKH WHUP ³OHJDO´ RIWHQ
implies ± are in fact highly complex and multi-dimensional actors. One of the 
aims of this analysis is, once again, to question the appropriateness of the 
legal/social dichotomy that is sometimes assumed. Before more specifically 
discussing how this was done in practice in Djibouti, it is necessary to reflect 
on the idea of complexity and fluidity of both TRIPS and pharmaceutical 
patents. 
 
There are two elements discussed below. First, both TRIPS and pharmaceutical 
patents are multi-dimensional ± QRWRQO\ DUH WKH\ ³XQGHUVWRRG´GLIIHUHQWO\ LQ
different networks, but each of these understandings forms part of their 
multiple reality. Second, TRIPS and pharmaceutical patents can only be 
understood by reference to other actors, and to the connections created between 
various sets of entities.  
 
The first understanding of TRIPS which might be presented is what can be 
GHVFULEHGDVWKH³GRFWULQDO´version of TRIPS. An initial view of TRIPS, and 
therefore one of the dimensions this analysis is aimed at understanding, is that 
TRIPS is a set of written rules ± of prescriptive rules - a text of law open to 
analysis and criticism. In addition, TRIPS is also a set of rules carrying 
consequences and requiring a range of social mobilisations which are part of all  
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accounts (although some of their aspects might be simplified in ways that this 
analysis aims to solve).  
 
In particular, the text of TRIPS and the prescriptions it carries are understood 
DVJHQHUDWLQJDFHUWDLQFKDLQRIUHDFWLRQV$V³SUHVFULSWLRQ´LVXVHGWKURXJKRXW
this project, in particular in Chapter 5, this term is briefly considered here. The 
WHUP ³SUHVFULSWLRQ´ KDV EHHQ XVHG LQ $17 HVVHQWLDOly in relation to 
technologies, when discussing the view that technologies are shaped and built 
in such a way that they tend to bind and determine the actions of others. 
&UHDWRUV RI WHFKQRORJLHV ³EXLOG LQ´ H[SHFWDWLRQV DQG HQVXUH WKURXJK VSHFLILF
characteristics of the technology itself that those interacting with it will be 
directed towards acting in a certain way199: 
 
³« WKH EHKDYLRXU LPSRVHG EDFN RQWR WKH KXPDQ E\ QRQKXPDQ GHOHJDWHV
prescription. Prescription is the moral and ethical dimension of 
mechanismV´200 
 
Throughout this research, and as will be explained again in Chapter 5, the term 
³SUHVFULSWLRQ´ZLOOEHXVHG WR UHIHU WR WKH LGHDRI UXOHVDQGDQWLFLSDWHGVRFLDO
regulation expected from the creators of TRIPS. 
 
                                                 
199
 Akrich M. and Latour B. ³$&RQYHQLHQW9RFDEXODU\IRUWKH6HPLRWLFVRI+XPDQ
and Non-KXPDQ$FWRUV´LQ%LMNHU:DQG/DZ-HGVShaping Technology, Building Society: 
Studies in Sociotechnological Change, Cambridge MA: MIT Press, pp. 205-224. 
200
 Akrich M. and Latour B. (1992) op. cit. on p. 232. 
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From the understanding of TRIPS presented above, the main difference 
between the dimensions of TRIPS emphasised in most literature reviewed in 
Chapter 1, and the position adopted in the remaining chapters, is that in the 
former, the chain of reactions is sometimes summarized and framed as an 
almost automatic causal link. TRIPS is implemented, which generates 
pharmaceutical patents to act, which in turns might make drugs more expensive 
and less accessible201. This research tries to avoid such a causal account by 
focusing on complexity. Existing accounts that portray TRIPS mainly/only as 
an official set of binding rules obscure the range of connections which need to 
be understood in order to appreciate not only what TRIPS does, but also what 
TRIPS is. Throughout the remainder of this thesis, this expanded meaning of 
TRIPS will be discussed and clarified ± while acknowledging that some of its 
GLPHQVLRQVPLJKWUHPDLQ³RWKHUHG´LQVSLWHRIDFRQVWDQWDWWHPSWWRXQGHUVWDQG
the associations in which it is enrolled and enrolling202. At this stage, and in 
order to make the aim of the following chapters clearer, it should be observed 
                                                 
201
 The links between TRIPS, patents and access to drugs commonly drawn when dealing with 
75,36FDQEHLGHQWLILHGLQWKHIROORZLQJTXRWH³The concern is that, when the patent 
provisions of the TRIPS agreement come fully into force in developing countries on 1 January 
2005 and patent protection is extended to all pharmaceutical products, including many 
HIV/AIDS anti-retroviral drugs, the effect will be increased prices that will further reduce 
DFFHVVWRHVVHQWLDOPHGLFLQHV´ Matthews D. ³,V+LVWRU\5HSHDWLQJ,WVHOI"7KH2XWFRPH
of Negotiations on Access to Medicines, the HIV/AIDS Pandemic and Intellectual Property 
5LJKWVLQWKH:RUOG7UDGH2UJDQLVDWLRQ´Law, Social Justice and Global Development 
Journal (1), available at http://www2.warwick.ac.uk/fac/soc/law/elj/lgd/2004_1/matthews/ (on 
p. 2) 
202
 7KHQRWLRQRI³RWKHULQJ´ZLOOEHXVHGWKURXJKRXWWKLVUHVHDUFKWRUHIHUWRWKHSURFHVVRI
exclusion of certain aspects of realities in accounts and research. The term is borrowed from 
/DZ-³0DNLQJD0HVVZLWK0HWKRGV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV
Lancaster University, LA14YL, UK, at http://www.comp.lancs.ac.uk/sociology/papers/law-
making-a-mess-with-method.pdf   
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that the dominant version obscures some of the complexities that need to be 
better understood.  
 
While TRIPS is certainly a text, it is also the result of actions within a 
particular organisation ± the WTO ± itself related to actions and connections 
happening largely outside of the WTO offices. Chapter 1 has explained the 
influence of the pharmaceutical industry in making TRIPS. TRIPS can 
therefore be understood as is the embodiment of a certain set of ideas, 
pressures and debates203. All of these might have materialised ± partly ± in a 
text, but it is essential to remember that their stabilisation in this material form 
should not result in these aspects being completely forgotten or ignored in 
analysing TRIPS. The text of TRIPS has also gained further complexity 
through its own subsequent relations with newly emerging networks, and 
through the reactions it generated in relation to public health, in particular. In a 
range of discourses, as explained once again in Chapter 1, TRIPS has therefore 
become an inherent part of public health networks, and needs to be understood 
in part by looking at its action in public health networks. It has mobilised 
actors linked to public health in various ways, and has reshaped both 
understandings of IPR and access to medicines (amongst others). This second 
dimension is particularly important in this project, and will be developed in 
more detail in Chapter 7.  
 
The action of TRIPS, in addition, also needs to be understood in relation to its 
implementation in specific countries. In particular, the prescriptions created by 
                                                 
203
 Sell S. (2003) Private Power, Public Law, Cambridge University Press: Cambridge. 
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75,36 DOWKRXJK WKH\ DUH ³RIILFLDOO\´ ³LQ ZULWLQJ´ GLUHFWHG DW ³PHPEHU
VWDWHV´DUHLQIDFWGHSHQGHQWRQWKHPRELOLVDWLRQRIDFRPSOH[UDQJH of actors 
in order to be realised. The complexity of TRIPS can be understood, in that 
respect, by emphasising the complex range of actor-networks with which it 
needs to connect and through which it needs to circulate in order to be 
transformed into national law ± and the range of actors it needs to mobilise in 
RUGHU WR PDLQWDLQ LQ QDWLRQDO FRQWH[WV LWV ³SXEOLF KHDOWK´ GLPHQVLRQ 7KLV LV
particularly interesting and necessary in this project in order to emphasise 
where TRIPS can be expected to leave traces, and what it means to investigate 
75,36³HPSLULFDOO\´3RWHQWLDOO\LWLVZKHQWU\LQJWRXQGHUVWDQGWKLVODVWFKDLQ
of reactions, that the discrepancies between the causality of some existing 
accounts of TRIPS and its empirical investigation becomes most clear. While 
some accounts of TRIPS chose to assume the triggering of particular 
connections, this analysis aims at empirically observing some of them in 
Djibouti. In particular, it is considered as essential to question who/what 
TRIPS has been mobilising in Djibouti, and how its connections can be 
understood and undone.  This study aims to understand how TRIPS circulates 
in Djibouti, through which specific offices, desks, actors. It is directed at 
analysing and questioning each trace left by TRIPS in Djibouti, and follow the 
threads of the journey made by TRIPS across networks in the country. This 
investigation will consider the places through which TRIPS has entered the 
country, the forms in which it has entered specific networks and the new 
connections it has triggered. It will also question the extent to which these 
different directions, connections and mobilisations might appear as a challenge 
to the causal chain of reaction drawn upon in some dominant trends of 
 120 
literature highlighted in Chapter 1. However, before doing so, the need for 
empirical accounts of pharmaceutical patents has to be explained.  
 
Once again, the complexity of patents is something that has been partly 
discussed in Chapter 1, where the dominant dimensions in the existing 
literature were explained. However, it is also important to explain some other 
aspects of the complexity of patents because those aspects have been 
investigated in more detail in this research, as will be presented throughout the 
next chapters. Once again, the prescriptive dimension of pharmaceutical 
patents has sometimes been translated into causal terms while some of their 
complex dimensions and modes of action were partly othered ± partly excluded 
from understandings of reality. However, part of this complexity has also 
necessarily transpired from the number of perspectives from which patents 
have been discussed ± and in particular, by the contrast between the 
GLPHQVLRQV RI SDWHQWV HPSKDVLVHG E\ ³WKH LQGXVWU\´ RQFH DJDLQ WKLV WHUP
itself hides complexity that this particular project does not need to discuss at 
this stage, although some aspects will be questioned in Chapter 6) and actors 
working on access to medication or public health. Each of these perspectives 
has emphasised the links between patents and health (and their relation to 
TRIPS) in its own way. While these different perspectives have often 
conflicted, they need to be reconciled by understanding the complexity of 
patents, and the fact that each particular position on patents discussed in 
Chapter 1 reflects an inherent part of some dimensions of patents204. What also 
needs to be highlighted, however, is that once again the causality of some 
                                                 
204
 This relates to the idea of multiple realities in ANT writings put forward earlier. 
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accounts tends to other some elements of complexity that will need to be 
retraced throughout this particular research. In particular, when dealing with 
health, the range of elements that need to be taken into account when deciding 
whether and how patents are enrolled and enrolling in public health networks 
will be emphasised. In this research, the range of traces left by pharmaceutical 
patents in words, actions and drugs themselves will be considered in order to 
retrace some of their inherent complexity. The realities emphasised by 
discourses on patents will be considered as part of the story, although further 
dimensions will be explored. 
 
Finally, the relation between pharmaceutical patents and written rules ± 
including TRIPS ± will be undone205 and analysed throughout this project and 
cannot, once again, be assumed in a causal and pre-determined form at this 
stage. 
 
The conclusions to be drawn from the above section in relation to TRIPS and 
pharmaceutical patents are at this stage essentially negative ± the fact that they 
DUH QRW ³VLPSOH´ REMHFWV KDV EHHQ HPSKDVLVHG EXW WKH QDWXUH RI WKHLU
complexity is still to be discussed in the subsequent chapters. Both TRIPS and 
pharmaceutical patents can be retraced through wide-ranging and numerous 
associations. As will be explained in the next chapters, they are neither global - 
since they are felt in the tiniest loci ± nor local - since they are only and ever 
                                                 
205
 The term is used to refer to the process of describing networks with the aim to highlight 
each of the associations and nodes that make them in order to be able to understand how 
networks work as a whole ± for discussions on the process of describing and re-assembling, see 
for example Latour B. (2005) Reassembling the Social: an Introduction to Actor-network 
Theory, op. cit. 
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the result of many more actions and many more associations spread in many 
more places ± some of which will be identified, some of which might remain 
forgotten206. TRIPS and pharmaceutical patents are also multi-dimensional, and 
act in a number of networks, for a number of actors determine part of their 
reality. All that can be said at this stage is that the remainder of this thesis will 
be directed at questioning the meaning(s) and nature(s) of TRIPS and 
pharmaceutical patents as well as at criticising the othering nature of the causal 
chain often found in existing writings about TRIPS207. Overall, very little can 
be said about either instrument at this stage, since it is considered an empirical 
matter to be discussed throughout the following chapters.  
 
CONCLUSION 
 
As a whole, ANT offers many benefits for the analysis to be undertaken in this 
research. One key element that needs to be highlighted at this stage is the fact 
that the emphasis of ANT on flexibility and on the need to describe rather than 
assume is crucial for undertaking empirical work in a country such as Djibouti. 
It is particularly important to avoid trying to fit findings within pre-existing 
frameworks, given that very little has been written about this country. ANT 
allowed in particular for a way to approach the networks under scrutiny in 
Djibouti without undue assumptions as to the way TRIPS works ± or should 
                                                 
206
 And once again, this relates to wider ideas explained in ANT and discussed above ± see for 
exampOH/DZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLW/DZ-³$QGLI
WKH*OREDOZHUHVPDOODQGLQFRKHUHQW´RSFLW6HHDOVR/DWRXUReassembling the 
Social: an Introduction to Actor-network Theory, op. cit. (especially in Part 2). 
207
 Latour B. (2005) Re-Assembling the Social: an Introduction to Actor-network Theory, op. 
cit. 
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work ± or as to what matters or not in the system. In addition to this, ANT 
allowed for a closer look at both pharmaceutical patents and TRIPS in Djibouti 
as socio-legal agents best understood through their hybridity, reshaping 
existing connections while being reshaped by new interactions. It offered a way 
of looking into and around both instruments; of questioning at the same time 
ZKDWWKHLQVWUXPHQWVDUH³GRLQJ´LQ'MLERXWLZKDWFRQQHFWLRQVLQDQGDURXQG
'MLERXWL DUH ³GRLQJ´ WR WKHP DQG ZKDW WKH\ DUH LQ 'MLERXWL DV FRPSDUHG WR
what they are generally assumed to be. This research will address some of the 
issues that could be raised when questioning what ANT can mean for socio-
legal work. While doing so, it will also provide a particular story about ANT, 
explain what can be made of it and with it, and how the tool can be adapted to 
a new field. The next chapters will present the story of TRIPS and 
pharmaceutical patents in Djibouti. Before discussing the empirical findings of 
this research, the next chapter discusses the methodology adopted in this 
project. 
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CHAPTER 3 ± METHODOLOGY 
 
This chapter describes and explains how the analysis of TRIPS and 
pharmaceutical patents in Djibouti was carried out. Understanding and 
observing socio-legal objects is a task that can be both complex and frustrating 
± complex because the networks involved are never-ending and a specific 
focus needs to be chosen, and frustrating because the objects most central to 
the analysis are elusive and cover both very concrete and totally abstract sets of 
elements. This fluid character of the two objects under scrutiny meant that their 
presence often had to be studied through others ± through words that were 
being said, through materials that were integrating them, through connections 
that made them real. This chapter will explain how this was done. It will 
consider how an analysis of TRIPS and pharmaceutical patents was carried out 
on the ground in Djibouti by analysing the range of connections and orderings 
of which they have become key actors ± sometimes in their materiality, 
sometimes in a more unsettled and unclear way, through fragile and complex 
connections. 
 
The relationship between ANT and methods can raise many issues, and if 
research methods as a whole have been denounced as necessarily performative 
by ANT authors208, the necessity to maintain a rigorous and scientific approach 
to empirical research has also been emphasised. Overall, ethnography remains 
the discipline from which ANT research has the most obviously borrowed tools 
and strategies. This project is itself based on methods of data collection 
                                                 
208
 )RUH[DPSOH/DZ-DQG8UU\-³(QDFWLQJWKH6RFLDO´SXEOLVKHGE\WKHGHSDUWPHQW
of Sociology and the Centre for Science Studies, Lancaster University LA14YN, UK, at 
http://www.lancs.ac.uk/fss/sociology/papers/law-urry-enacting-the-social.pdf 
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inspired from ethnographic research. However, the definition and delimitation 
of ethnographic methods raises a number of questions that need to be 
addressed. Similarly, the use of ethnographic methods in practice has been 
questioned in many respects, and has evolved in recent years to suit better the 
new fields to which they have been applied. This project is based on a ten-
week period of fieldwork ± and a two-week pilot study. Data was collected 
mainly by using in-depth interviews with twenty-five actors from the public 
health and trade and industry fields. Additionally, it integrated some elements 
of observation stored through detailed fieldnotes, as well as complimentary 
document analysis. Both data collection and data analysis were carried out on 
the basis that research should remain fully grounded in data. It aimed to 
understand and describe the phenomena observed without enclosing them 
within tight frameworks or expectations. 
 
This chapter presents the key elements of the methods used in this project. It 
begins by discussing the notion of validity in qualitative research, and whether 
$17DOORZVTXDOLWDWLYHLQTXLU\WREHWKRXJKWRIDV³VFLHQWLILF´6HFWLRQ ,W
then explains the methodological choices made before fieldwork itself was 
started that narrowed down the focus of this research to an understanding of 
TRIPS and pharmaceutical patents in Djibouti (Section 2). The practical 
process of data collection is then considered (Section 3). Ethics are briefly 
addressed (Section 4). The approach to data-analysis is explained (Section 5). 
Finally, the practical steps taken to increase the validity of this research project 
are presented (Section 6).   
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SECTION 1: +2: 72 %( $ ³&216758&7,9,67´ $1' $
³6&,(17,67´" 
 
Before discussing the methods used in this research, and how they are aimed at 
increasing the validity of the claims put forward, it is essential to reflect on the 
way some aspects of ANT could recall challenges brought to the idea that 
qualitative research can be located within scientific practices. The 
³FRQVWUXFWLYLVW´SHUVSHFWLYHRI$NT, in particular, and the emphasis of some 
ANT authors on the performativity of research methods, are two related 
elements that raise issues in relation to the potentiality for a scientific approach 
in empirical research. These issues are rooted in deeper debates about 
qualitative research, in which notions of truth and validity have been 
intensively discussed. This section will start by looking at these broader 
debates before returning to the specificities of ANT, the positions put forward 
by ANT authors, and how the potential conflict between constructivist 
perspectives and the notion of validity in empirical research have been 
addressed in this project. 
 
Deciding whether the validity of empirical accounts is something that can be 
tested depends on the poVLWLRQDGRSWHGRQWKHZD\³DFFRXQWV´DQG³UHDOLW\´DUH
linked. This chapter considers later how validity can be tested; it first needs to 
discuss if it can. Whether qualitative research can claim to be scientific 
depends on whether one accepts that accounts can tend towards objectively 
SUHVHQWLQJDZRUOG³RXWWKHUH´RUZKHWKHUWKHDFFRXQWVZLOORQO\UHVXOWLQWKH
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description of a particular subjective artifact. Although the idea that accounts 
largely participate in generating realities has been widely accepted in 
qualitative research, researchers have disagreed on the consequences that 
should be drawn from this idea in relation to the potential links between 
TXDOLWDWLYHUHVHDUFKDQGYDOLGLW\6RPHTXDOLWDWLYHUHVHDUFKHUV³UHODWLYLVWV´LQ
particular, have argued that since all empirical research will produce subjective 
accounts, and since the world is only made through subjective accounts, these 
FDQRQO\EHXQGHUVWRRGDVHTXDOO\³WUXH´7KHFRQVHTXHQFHRIWKLVSRVLWLRQLQ
terms of methods and validity of research processes can be easily deduced - if 
any story is equally valid, research cannot be ranked and no data can be 
FRQVLGHUHGDVPRUHVFLHQWLILFWKDQRWKHU«209 It is useful here to provide some 
explanation of this approach, in order to clarify how ANT could be thought of 
as related to some of its ideas. However, this first impression will be dismissed 
in the following discussion. 
 
The idea that descriptions and social inquiry participate in shaping realities is 
not new210. In particular, it is the necessary consequence of the idea that society 
partly results from human understanding, and therefore is dependent on the 
REVHUYHUV¶YLHZVDQGSHUVSHFWLYHV7KHGLUHFWFRQVHTXHQFHLVWKDWVXEMHFWLYLW\
becomes central and unavoidable in empirical research ± the story being told is 
fully framed by the interpretation given by each particular researcher, and is 
therefore no more ± but no less either ± than one particular social reality. In 
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 For a clear introduction to this relativist position, see Murphy E. and Dingwall R. (2003), 
Qualitative Methods and Health Policy, New York: Aldine de Gruyter.  
210
 Its roots have been retraced to Dilthey and Weber ± IRUGHWDLOVVHH6PLWK-.³7KH
3UREOHP RI &ULWHULD IRU -XGJLQJ ,QWHUSUHWLYH ,QTXLU\´ Educational Evaluation and Policy 
Analysis 6(4) pp. 379-391. 
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terms of methods, however, the consequence of such a perspective can be 
radical. In particular, if accepting that sociological enquiry is the result of  a 
subjective understanding of reality, and can never be anything else than a 
particular perspective, the positivist idea that social science can develop criteria 
for validity is challenged. Since any interpretation is equally true, there is no 
H[WHUQDO³VXSHULRU´ZD\RIFKHFNLQJWKHYDOLGLW\RIDQ\VSHFLILFILQGLQJ6RPH
authors have tried to find a balance between relativist claims and a search for 
methodological rigour in arguing a relativist philosophy while seeking to 
establish some new and indirect methods of checking the validity of research 
projects211. However, when looking more closely into these arguments, it soon 
appears that there is no way to conciliate between radical claims on the 
subjective nature of the social and positivist-inspired strategies to establish an 
REMHFWLYH³YDOLGLW\´212. The only conclusion that can logically be drawn from 
relativist perceptions of the social as emerging from specific perspectives is 
that there can be no criteria to judge externally the validity of specific findings, 
because any finding can be justified as a subjective perception as equally 
truthful as any other213. 
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 )RU H[DPSOH *XED (  ³&ULWHULD IRU Assessing the Trustworthiness of Naturalistic 
,QTXLU\LQ(GXFDWLRQDO(YDOXDWLRQ´Educational Communication and Technology Journal (29) 
75-91. 
212
 )RUIXUWKHUGHWDLOVVHH6PLWK-.RSFLWRU6FKZDQGW7$³&RQVWUXFWLYLVW
Interpretivist ASSURDFKHV WR +XPDQ ,QTXLU\´ LQ 'HQ]LQ 1 . DQG /LQFROQ < 6 HGV
Handbook of Qualitative Research, Thousand Oaks CA: Sage publications, pp. 118-137. 
213
 :LWKSRWHQWLDOO\WKHH[FHSWLRQRILQIRUPDQWV¶FKHFNV± see Guba E. and Lincoln Y. (1994) 
³&RPSHWLQJ 3DUDGLJPV LQ 4XDOLWDWLYH 5HVHDUFK´ LQ 'HQ]LQ DQG /LQFROQ HGV Handbook of 
Qualitative Research, Thousand Oaks CA: Sage publications, pp. 105-118, although this does 
not go without its own difficulties (see Smith J. K. (1984)). 
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This form of radical thinking challenges the idea that sociological research can 
bH FDUULHG RXW DV ³VFLHQFH´ DQG KDV WKHUHIRUH EHHQ FRQWHVWHG ZLWKLQ WKH
qualitative field214. Before seeing how this position and the dilemmas it raises 
have been answered in qualitative research, I discuss whether the positions put 
forward in ANT on the notions of truth and reality can relate it to some of the 
ideas presented above. This will be considered first by discussing the concept 
RI³FRQVWUXFWLRQ´LQ$17DQGHPSKDVLVLQJZK\LWFDQEHPLVOHDGLQJ 
 
³&RQVWUXFWLRQ´RIVRFLDOIDFWV 
 
ANT is often presenteGDV³FRQVWUXFWLRQLVW´$OWKRXJKWKHWHUPLVSXWIRUZDUG
by ANT authors themselves, the meaning to be attached to the notion needs in 
this specific context to be fully understood. It is essential to avoid drawing 
premature conclusions on the implications of the use of this term in ANT for 
WKHXQGHUVWDQGLQJRI³UHDOLW\´LWRIIHUV ,QSDUWLFXODU WKHFRQWUDVWEHWZHHQWKH
QRWLRQRI³FRQVWUXFWLRQ´LQ$17DQGLWVPRUHJHQHUDOXQGHUVWDQGLQJVLQVRFLDO
sciences needs to be understood215. In ANT, the world is created ± 
³FRQVWUXFWHG´± through the circulation of associations and the fluid movement 
RI FRQQHFWLRQV $Q\ REMHFW DQ\ IDFW DQ\ RFFXUUHQFH LV ³JHQHUDWHG´
somewhere else, made through associations happening in some other place, at 
                                                 
214
 For further detail on the challenge brought by relativism to positivist approaches to 
VRFLRORJ\ VHH IRU H[DPSOH $OWKHLGH ' DQG -RKQVRQ -  ³&ULWHULD IRU $VVHVVLQJ
,QWHUSUHWLYH9DOLGLW\LQ4XDOLWDWLYH5HVHDUFK´'HQ]LQ1.DQG/LQFROQ<6HGVHandbook 
of Qualitative Research, Thousand Oaks CA: Sage publications, pp. 485-499. 
215
 )RUDQH[DPSOHRIWKHOLQNVGUDZQEHWZHHQUHODWLYLVPDQGWKHQRWLRQRI³FRQVWUXFWLRQ´LQ
sociology, see for example Guba E. and Lincoln Y. (1994) op. cit, and Schwandt T.A. (1994) 
op. cit. 
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some other time. In this perspective, the role of a sociologist is to understand 
what has made their object of study. This understanding of construction does 
not imply that the world does not exist independently of accounts ± it only 
implies that entities never exist independently from others ± and the 
constructionist views of ANT should not be taken to represent a theory of truth. 
The contrast between the two competing meanings of the term in ANT and in 
other fields of sociology is put forward by Latour in these terms: 
 
³« for other colleagues in the social as well as natural sciences the word 
construction meant something entirely different from what common sense had 
WKRXJKWXQWLO WKHQ7RVD\VRPHWKLQJZDV³FRQVWUXFWHG´LQWKHLUPLQGVPHDQW
that something was not true. They seemed to operate with the strange idea that 
you had to submit to this rather unlikely choice: either something was real and 
not constructed, or it was constructed and artificial, contrived and invented, 
PDGHXSDQGIDOVH«:KHQZHVD\WKDWDIDFWLVFRQVWUXFWHG we simply mean 
that we account for the solid objective reality by mobilizing various entities 
whose assemblage could fail.´216 
 
Thus, the emphasis of ANT on the idea that any object of study is the result of 
something else, some other action, some other association, is fundamentally 
different from the idea that these same objects of study are not real. The 
constructivist views of ANT do not challenge the notion of truth but the notion 
of stability. It does not imply that there is no reality outside of accounts, and 
WKHUHIRUH GRHV QRW UHTXLUH WKH ³VFLHQWLILF SURMHFW´ WR EH GURSSHG +RZHYHU
                                                 
216
 Latour B. (2005) Reassembling the Social: an Introduction to Actor-network Theory, 
Oxford: Oxford University Press, on p. 90. 
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neither does it either reject the idea that accounts can play a part in shaping 
certain orderings.  
 
Texts and representations of reality 
 
In particular, although it accepts that there is something real out there, some 
connections that might be identified and reflect something that really is, ANT 
raises issues as to the extent to which this reality might be reflected faithfully ± 
without transformation - in research and in texts. It emphasises the idea, in 
particular, that although a real world pre-exists/co-exists with research, any 
WUDQVODWLRQ RI DQ REMHFW RI VWXG\ ZLOO QHFHVVDULO\ WUDQVIRUP LW ³Traduction is 
always trahison´217, and any transfer of a phenomenon to paper will 
necessarily generate a particular version of this phenomenon. The 
consequences of this trahison are not neutral, because it results itself in a new 
version of reality ± and the performance of a new reality: ³Social inquiry and 
its methods are productive: they (help to) make social realities and social 
ZRUOGV7KH\GRQRW VLPSO\GHVFULEH WKHZRUOGDV LW LVEXWDOVRHQDFW LW´218 . 
The compatibility of this approach with the earlier discussion of constructivism 
can now be clarified . How can ANT claim that it wishes to steer away from 
social constructivism while stating that realities are re-constructed in the 
process of social research? The answer to this question has already been 
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 /DZ-³7UDGXFWLRQ7UDKLVRQ1RWHVRQ$17´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH
Studies, Lancaster University, Lancaster LA14YN, UK 
http://www.comp.lancs.ac.uk/sociology/stslaw2.html  
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 /DZ-DQG8UU\-³(QDFWLQJWKH6RFLDO´SXEOLVKHGE\WKHGHSDUWPHQWRI6RFLRORJ\
and the Centre for Science Studies, Lancaster University LA14YN, UK, at 
http://www.lancs.ac.uk/fss/sociology/papers/law-urry-enacting-the-social.pdf , on p. 1 
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anticipated above - the idea of performativity of research does not imply that 
anything FDQ EH ³made up´ QHLWKHU GRHV LW FODLP WKDW IDFWV GR QRW H[LVW
independently from research ± or objectively. What it implies is that some 
elements of the realities ± of the many co-existing and multiple realities of the 
social ± will be re-ordered in the process of telling any story, producing any 
data219. At the same time some concepts, even some facts, will only become 
real after social scientists have performed them.  
 
But not everything can be performed by social research ± indeed this is the 
main difference between relativist accounts and the approach adopted in ANT. 
$VPXFKDVUHVHDUFKLVFRQVWUDLQHGE\WKHUHVHDUFKHU¶VVLWXDWLRQDQGDVPXFK
as researchers are limited by what social science allows them to do, see and 
describe, social scientists are also limited in what they can perform by the 
³ZRUOG RXW WKHUH´ E\ IDFWV WKDW ZLOO RSSRVH VRPH IRUP RI resistance. This 
means that social scientists cannot perform any reality they choose, and that 
stories will not have the same validity220. ANT accepts that a world exists 
independently of social research ± facts exist, although their stability is 
challenged more often than assumed. It is only by understanding how they are 
constructed (how they are created) by circulations and connections that they 
can be fully understood. However, the fact of telling a story itself, of providing 
one version of facts, necessarily limited and necessarily unfaithful, will 
produce a new form of reality ± it will perform a new reality, within the 
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 -RKQ/DZSURYLGHVVRPHH[DPSOHVRIWKLVLQ/DZ-³0DNLQJD0HVVZLWK0HWKRG´
published by the Centre for Science Studies, Lancaster University, at 
http://www.comp.lancs.ac.uk/sociology/papers/law-making-a-mess-with-methods.pdf 
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 And it is already possible to relate the ideas put forward in Murphy E.and Dingwall R. 
(2003) op. cit. when criticising relativism (p.12). 
 133 
possibilities created by the social as circulation. The impact of the research 
process, and of the material creation of texts, should not, however, mean that 
qualitative research should drop its quest for scientific rigour: 
 
³Since we are all aware that fabrication and artificiality are not the opposite of 
truth and objectivity, we have no hesitation in highlighting the text itself as a 
PHGLDWRU %XW IRU WKLV YHU\ VDPH UHDVRQ ZH GRQ¶W KDYH WR DEDQGRQ WKH
traditional goal of reaching objectivity simply because we consider with great 
care the heavy textual machinery. Our texts, like those of our fellow scientists, 
UXQWKHSDUDOOHOFRXUVHRIEHLQJDUWLILFLDODQGDFFXUDWH´221 
 
Therefore, the search for truth does not need to be dropped. It should still 
remain an ultimate aim, although unavoidable constraints might always prevent 
us from representing a complete view of reality.  
 
Before discussing how specific methods fit with these attempts to describe 
realities, one last element needs to be considered, as it emphasises more 
specifically the constraints within which academic projects need to remain 
located. When presenting the common aspects of realities performed by 
sociological research, and although the diversity of methods imposes limits to 
any generalisation, Law puts forward the idea that, in the current context of 
academic research, the inherent messiness of the social world, the result and 
H[SUHVVLRQ RI LWV FRPSOH[LW\ WHQGV WR EH RWKHUHG E\ WKH UHLJQ RI ³RUGHU´222. 
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 Latour B. (2005) Reassembling the Social: an Introduction to Actor-network Theory, op. cit. 
p. 124. 
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 /DZ-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2QHRIWKHPRVWFHQWUDO³trahisons´FRPPLWWHGE\UHVHDUFKHUVDQGRQHRf the 
most difficult to avoid in the current context of academic research, is to try to 
fit the social world in categories, order and simplified stories. The necessity to 
³PDNH´DVWRU\UHDGDEOHZLWKLQDOLPLWHGDPRXQWRIVSDFHDQGWLPHFHUWDLQO\
limits the ways the social can be portrayed. This should be kept in mind as the 
approach chosen in this research is explained, and as the need to combine 
flexibility and rigour in empirical research is put forward.  
 
Balancing flexibility and rigour 
 
The position taken in this project is that there is nothing incompatible between 
the perception of the social put forward by ANT and the location of social 
research in scientific practice. Indeed, ANT not only argues for rigorous 
(although flexible) research methods but in fact implies their necessity. 
Constructed facts and objects ± in the ANT common-sense inspired 
understanding of construction ± exist, and limit researchers in what they can 
claim to be valid in observing the social world. The messiness of the social 
world might call for a limit to order and categorising in the writing process of 
academic research, but should in no case justify a lack of rigour in methods for 
data collection and analysis. In fact, the complexity of the social and its 
inherent instability, and the need to remain close to connections without adding 
unjustified and pre-determined ideas as to what directs the social (as already 
explained in Chapter 2) also mean that methods need to be adapted to this new 
version of sociology. The answer provided in ANT seems simple but calls for 
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precisions and explanations that will be offered throughout this chapter on 
ZKDWQHHGVWREHGRQHLQSUDFWLFH³IROORZWKHDFWRUVWKHPVHOYHV´223.  
 
The position taken in this research is, once again, that this can only be done by 
adopting a scientific and carefully described process of data-collection. The 
GLIILFXOWLHVRI³IROORZLQJ WKHDFWRUV´ZKLOHXQGRLQJUHOHYDQWQHWZRUNVZLOOEH
emphasised throughout this project, and discussed critically in the conclusion. 
Some aspects of the potential difficulties raised, however, need to be discussed 
at this stage, relating to the difficulty of writing complete and faithful ANT 
accounts mentioned before. In that respect, it is essential to emphasise how far 
it is possible/feasibOHWRIROORZWKH³$17SURJUDPPH´DVIDUDVLWJRHVZLWKRXW
having to be restrained by the necessity of academic outputs. One of the claims 
of ANT is that objects are always and only the result of complex sets of 
associations and circulation. These make their stability constantly likely to be 
challenged. A direct consequence of this idea is that there is always more to a 
particular object than what can be directly perceived. However, the boundaries 
set by academic conventions involve limits to how far an analysis can be 
developed. Although each object considered throughout this analysis contains 
more than one could expect, emphasising in detail the associations that make it 
would require more space and time than is allowed by academic requirements. 
In addition to this, there will necessarily be some limits set by the need to make 
a narrative readable. Terms will need to be used, some of which might 
temporarily obscure the complexity of a particular object of study. ANT sets 
significant intellectual and theoretical challenges. Furthermore, it 
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acknowledges the necessity to combine intellectual/theoretical debates with 
practical issues. In particular, as will become apparent, some limits must be set 
to the amount of detail and explanation that can be provided. Some terms will 
be used in a punctualised fashion before their full complexity is unravelled. 
This process does not need, however, to be totally arbitrary ± and one solution 
for this is to follow once more the advice put forward by Bruno Latour that 
research should follow the actors.  
 
At times throughout empirical research, some objects are understood as stable 
by actors themselves. Their complexity is left aside in the routines of those 
being studied. While the purpose of this particular research is to understand the 
complexity of TRIPS and pharmaceutical patents, other objects will necessarily 
be considered. They will be looked at in detail in relation to the connections 
that make them relevant to TRIPS. However, some of their dimensions will be 
left un-investigated. Essentially because they are taken as stable by those who 
deal with them and are being studied, and practically because the focus of this 
analysis needs to be maintained on what is relevant to understanding TRIPS 
and pharmaceutical patents.  
 
This section has started by relating the issue of truth and validity to wider 
debates from qualitative research. It has then jumped into the specific, into the 
vision of reality put forward by ANT, and demonstrated that it should not be 
confused with the relativist argument that validity loses meaning in the face of 
³FRQVWUXFWLRQ´± and this depended on diverging understandings of the notion 
of construction itself. It is interesting, however, to return now to qualitative 
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research more generally, and to observe how while moving away from 
relativism, the position on validity adopted in this research within the ideas of 
ANT can in fact be related to the same perspectives that responded to 
relativism:  
 
³6XEWOH UHDOLVWV DFFHSW WKDW HYHU\WKLQJ FDQ EH UHSUHVHQWHG IURm a range of 
GLIIHUHQW SHUVSHFWLYHV WKURXJK GLIIHUHQW ³FXOWXUDO-ELRORJLFDO OHQVHV´ 6HYHUDO
representations may coexist and be potentially true. Unlike the relativist, 
however, the subtle realist does not assume that all representations are equally 
valid. «6FLHQFHLQWKLVYLHZLVDSURFHGXUDOFRPPLWPHQW´224 
 
Because of its emphasis on the complexity of the social and the need to provide 
a story as told by those living it, without undue simplification, and while 
limiting othering, ANT has traditionally been associated with ethnographic 
methods. The links between both have appeared clearly throughout Chapter 2, 
and will be re-emphasised in this chapter. This particular approach provides 
significant opportunities for integrating fluidity and complexity in telling a 
process as lived and expressed by the network under scrutiny. This chapter will 
explain how every significant methodological choice was made in this project, 
and how the data on which it is relying has been collected. Although this 
research does not claim to avoid the range of limitations that are associated 
with any attempt to present a part of the social world, this chapter aims to 
provide enough information and reflection on the choices made and their 
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consequences to offer readers the elements that need to be grasped in order to 
locate and understand this story. 
 
SECTION 2: NARROWING DOWN THE FOCUS OF ANALYSIS  
 
The first aspect of the methodology chosen in this project that needs to be 
explained relates to the way this research was narrowed down to the study of 
TRIPS and pharmaceutical patents in Djibouti. This section discusses the 
choice of using a case study for analysing both types of legal instruments, and 
explains how the example of Djibouti was chosen225. It emphasises in 
particular how this choice was linked to theoretical issues, and to some of the 
ideas put forward in ANT. It reinforces the fact that the definition of the 
specific focus of this research and the clarification of the approach chosen were 
shaped progressively and in parallel, rather than in a definite chronological 
order. 
 
This research has been aimed from its start at providing a story of TRIPS and 
pharmaceutical patents and of their links to health in poor countries.  
 
One of the first methodological choices to be made was therefore to decide 
which type of story should be told. When working in the area of IP and health, 
options are diverse. As explained in Chapter 2, the theoretical view adopted in 
                                                 
225
 )RUDGHILQLWLRQRIFDVHVWXGLHVVHH+DPPHUVOH\0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Hammersley M. :KDW¶V Wrong with Ethnography, Methodological Explorations, London: 
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this project emphasises the need to study and understand transnational events 
by looking at their localized manifestations, before discussing how these relate 
to longer networked effects226. This explains why choosing a case study based 
DQDO\VLV³ZRUNHG´LQUHODWLRQWR$17 
 
However it is difficult to explain whether ANT participated in the original 
choice of working on a case study or not. It is of course a complex task to 
reflect back on how methods and perspective came into being, and in particular 
whether the approach or the methods came first ± as far as the choice of a case 
study was made. In particular, while a case-study based project appeared as the 
best choice to analyse TRIPS and pharmaceutical patents from an ANT 
perspective, it can also be said that ANT appeared as the most appropriate 
method to study TRIPS and pharmaceutical patents on the ground in a 
particular networked system. It is fair to say that the choices and strategies 
developed below came into shape while the approach to be chosen was still 
EHLQJ H[SORUHG ,Q DGGLWLRQ WR WKLV LW LV DOVR FHUWDLQ WKDW $17 ZDV ³FKRVHQ´
only as far as it best represented some of my own understandings of the aim of 
research, and formulated in an articulate way some elements that fit more 
broadly with my own perceptions. Overall, what needs to be demonstrated is 
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 6HH IRU H[DPSOH /DZ - 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Centre for Science Studies, Lancaster University, LA14YN, UK, at 
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that this particular approach appeared to fit the system under scrutiny 
particularly well. 
 
Although they have at times been criticised for lack of generalisability, case 
studies are often valued and perceived as a necessary and useful way to study 
specific issues. The potential relevance of case studies can be based on several 
elements227. First, in many cases, the interest of case studies is essentially 
intrinsic ± they are interesting because the story they tell is useful in their own 
right. They do not necessarily have to make a broader point to be pertinent. 
Without being symbolic of a particular issue, and without being a particular 
example of a widely spread situation, some case studies will therefore 
successfully provide an example of particularity, and will be relevant for their 
uniqueness228. Second, particular stories can be useful for what they tell about a 
broader phenomenon ± their role runs further than the particular story told, and 
is a specific step in understanding a range of events or situations229. Finally, the 
relevance of case studies can come from what they tell about a particular 
theory or method.230 In many cases, however, the relevance of a given case 
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 See foUH[DPSOHWKHFODVVLILFDWLRQVSURYLGHGE\6WDNH5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N and Lincoln Y eds, The Handbook of Qualitative Research, Thousand Oaks: Sage 
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 2Q WKH JHQHUDOLVDELOLW\ RI FDVH VWXGLHV +DPPHUVOH\ VWDWHV ³It may be claimed that the 
particular setting investigated is typical of some larger whole or aggregate´DQG³The second 
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study will borrow from several elements ± and will often depend as much on 
what the reader is looking for as on what the researcher has wanted to 
emphasise.  
 
The approach called for by ANT and adopted throughout this research 
emphasises the relevance ± and necessity ± of particular studies in their own 
rights. In fact, it emphasises the conceptual difficulties of studies that claim to 
be representative, and highlights the specificity and uniqueness of any 
particular network, any given story. The mobility and diversity of social 
orderings makes generalisability itself an elusive concept, and one that should 
not become unnecessarily central in empirical research231. The study presented 
in this research does not claim to be generalisable or representative ± it is not a 
story about least developed countries and their relation to TRIPS, but a study 
about TRIPS and pharmaceutical patents in a specific least developed state. 
However, it is not an isolated study and finds some of its relevance by 
opposition to existing research. The value of this project is in fact partly to 
demonstrate why those existing studies that claim to talk about IP and health in 
developing countries are losing part of their own value by doing so, and put 
forward claims and generalisations that cannot be sustained by their findings. 
Therefore, in addition to being relevant for the story it tells about TRIPS and 
pharmaceutical patents in Djibouti, this case study can be perceived as a 
                                                                                                                                 
and quite different way that ethnographers may seek to give their work general relevance is by 
drawing conclusions about one or more social scientific theories from the features of the local 
events they observe and describe´ LQ +DPPHUVOH\ 0  ³7KH *HQHUDOLVDELOLW\ RI
(WKQRJUDSK\´RSFLWSDQGS 
231
 See for example Latour B. (2005) Reassembling the Social: an Introduction to Actor-
network Theory op. cit in Chapter 2. 
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counter example to most existing research in the field. Finally, this research 
aims to provide an illustration of ANT as a tool for socio-legal research and 
some of the methods and concepts used in this project are believed to be of 
relevance for other projects. The justifications for choosing Djibouti as a 
particular case study now need to be discussed in order to understand how this 
DLPWRSURYLGHD³FRXQWHUH[DPSOH´ZDVILOled. 
 
Why Djibouti? 
 
Selecting a basis from which to explore the story of TRIPS, pharmaceutical 
patents and health represented the second methodological step in organising 
this research. The choice of working on Djibouti as a particular case study was 
based on a number of elements, and essentially on the remaining gaps left by 
existing literature ± and in particular by the lack of research on the smallest, 
poorest countries. The decision to look at a least developed state was 
essentially made as a way to look for difference, by looking at a network 
fundamentally different from what has been looked at in existing research, and 
observing the comparability of findings.  
 
When choosing which state in particular to concentrate on, Djibouti appeared 
as a strong option for several reasons, both practical ± it had to be feasible to 
collect data in the country chosen - and theoretical ± as far as possible, the case 
study had to be chosen so that it added something new to existing research.  
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Practical elements considered were both specific to research in a small least 
developed state, and common to what is generally looked at when settling on a 
particular case study. The questions specific to the problems raised by 
collecting data in a least developed state could be related to the fact that the 
country chosen would by definition have poor infrastructures in terms of 
communications and transport. It was necessary to choose a country in which 
actors to be met could be centralised enough for these issues not to become a 
real hindrance to data collection. Safety issues also had to be considered, and in 
particular, the political situation of many least developed countries makes 
fieldwork locally unsafe or uncertain. Language was an issue that needed to be 
taken into account too, and it had to be certain that all relevant actors could be 
approached in a language that I could speak. Finally, if considering a country 
on which very little has been written ± in terms of academic literature but also 
institutional reports etc, as is the case for most least developed states ± it was 
absolutely crucial to ensure that opportunities for fieldwork would not turn out 
to be too limited, and a possibility to have reliable contacts at an early stage 
appeared essential.  
 
In response to all of these elements, the situation of Djibouti appeared as highly 
positive and made it one of the few possible options considered. Djibouti is a 
French-speaking country. Although several official languages co-exist, almost 
every relevant actor could be approached in French, and most of those living in 
the capital city speak French fluently. Similarly, all policy and legal documents 
are produced in French (and Arabic). The country enjoys a relatively safe and 
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stable situation as compared to many other least developed countries232, and 
carrying out fieldwork there did not present any particular risk. It is also a 
small country, in which the difficulties of using public transport are only an 
issue when travelling to the most remote areas. All relevant institutions and a 
large majority of the population are based in the capital city, where places are 
close enough to one another to travel without difficulty233. Contacts could be 
made in relevant fields at an early stage with key actors, and a pilot study 
followed by email contacts proved that they would be willing to participate in 
further research, and help me obtain access to other relevant people. In addition 
they proved willing to provide access to important documents. This will be 
developed below. Finally, Djibouti is a country in which I had spent time 
before undertaking this research, which I felt would be a strong advantage 
when trying to fit within local practices and culture. 
 
 
However, in addition to these practical considerations, more theoretical 
elements came into play when choosing this case study, and were determinant. 
Once again, the idea behind investigating one small least developed country 
was essentially to provide a useful complement to what had been written so far, 
and to consider to what extent the generalizations made in existing literature 
could be challenged by a counter-example. In many respects, the situation of 
Djibouti soon appeared as a very good example of a country in a fundamentally 
different situation from that of the other states on which research has been 
                                                 
232
 At least this has been the case since the end of the civil war, as mentioned in Chapter 4. 
233
 More information will be provided on Djibouti in Chapter 4, and the information given here 
is only that necessary to understanding how this case study was chosen. 
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carried out. The first, and potentially the most relevant, of these elements of 
difference relates to the IP situation of Djibouti. Djibouti is one of the few 
states that have never implemented any effective type of IP system, and never 
adopted any type of patent law. While in most of the countries studied so far it 
has been a rational policy choice to exclude pharmaceuticals from the 
patentability field, in the case of Djibouti patents are just legally non-existent. 
The implementation of TRIPS is thus likely to raise issues fundamentally 
different from those discussed so far.  Djibouti faces a public health situation as 
critical as that of most Sub-Saharan African countries, as appeared from the 
first phase of empirical research described below. It has a very weak industrial 
base, and no pharmaceutical industry at this stage, which means that the role of 
pharmaceutical patents in the development process of the local industry is 
unlikely to be an immediate issue for policy makers. All these different 
elements made the example of Djibouti one of the most relevant that could be 
isolated from background research, and also one of the most feasible234.  
 
One issue that might be raised, however, is the idea that Djibouti as a state is 
taken as the central unit of analysis. In particular, as was explained in Chapter 
2, if wanting to work within ANT, and accepting that the world is fully 
constituted of overlapping networks, territorial classifications appear highly 
irrelevant235. To that extent, it could be argued that a state-based case study is 
inappropriate in relation to the theoretical framework undertaken. It sounds 
artificial to suppose that the territorial borders of Djibouti could coincide with 
                                                 
234
 And once again, each of these elements will be introduced in more details in Chapter 4. 
235
 6HHIRUH[DPSOH/DZ-³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´RSFLWDQGWKHGLVFXVVLRQ
provided in Chapter 2 on Space and ANT. 
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any kind of end to relevant networks and this assumption could present the risk 
of buying into one of the key performative aspects of research methods 
currently used236. However, the specific choice of a state based approach can 
be justified with regard to the area analysed in this research, and does not have 
to be understood as strictly limitative. This analysis is focused on the impact of 
TRIPS on the public health system of Djibouti. As the text will be implemented 
at national level, by national institutions, it is useful to use as a starting point 
the networks created by and including these institutions. However, the focus of 
this analysis will extend beyond and within state institutions, and will consider 
how the ramifications of TRIPS can be felt in Djibouti ± including ramification 
and effects originating in other loci. 
  
SECTION 3:  METHODS FOR DATA COLLECTION 
 
The data collected in this project was gathered essentially from in-depth 
interviews, although observation and document analysis were also used within 
the practical limits set by this case study. Although ethnography has 
traditionally adopted observation as its most symbolic and primary method of 
data collection ± and although observation is essential to the claims of ANT ± 
interviews appeared as the method that could be most systematically used in 
this project, and from which most data could be derived. This related both to 
the object of analysis itself and to the fact that one of the difficulties to be 
                                                 
236
 ³7KXVWKHPRGHUQQRWLRQRI³VRFLHW\´JUHZXSZLWKLQWKHVRFLRORJLHVZKLFKHPHUJHGLQWKH
era of (XURSHDQ QDWLRQDOLVP 7KH ³QDWXUDO´ XQLW IRU VRFLRORJ\ ZDV LQGHHG ³VRFLHW\´ DQG
VRFLHW\LWVHOI³QDWXUDOO\´PDSSHGRQWRWKHERXQGHGUHJLRQRIWKHQDWLRQVWDWH´LQ/DZ-DQG
8UU\-³(QDFWLQJWKH6RFLDO´RSFLWRQS 
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VROYHGZDVWKH³PXOWL-VLWHG´GLPHQVLRQRIWKLVSURMHFWDQGWKHIDFWWKDWWKRVHWR
be considered were located in many different settings. The need to follow 
networks and connections through these different settings made it particularly 
crucial to adopt throughout this project methods that would be reflexive and 
flexible but rigorous. 
 
1. Pilot study 
 
The empirical part of this project started with a short pilot study carried out in 
Djibouti in April 2003. The aim of this pilot study was to determine whether or 
not field research would be feasible in Djibouti and, in particular, whether 
access could be negotiated with key actors. As the aim of the research was to 
observe the manifestations of TRIPS and pharmaceutical patents in relation to 
health as widely as possible, a flexible and extensive sample needed to be 
accessed. In addition to this, it was directed at evaluating whether the situation 
of Djibouti was likely to raise enough substantive issues to be used as a main 
case study. 
 
This pilot study was carried out by interviewing some of the key actors 
working on health or on the import of pharmaceuticals in the country. 
Interview schedules were flexible enough to leave informants free to raise what 
they thought were the key issues in the country in relation to TRIPS and 
pharmaceutical patents. Broadly speaking, they brought interviewees to discuss 
their understanding of TRIPS (whether informants knew about TRIPS, and 
what they knew; how they thought it was likely to affect Djibouti) issues of 
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public health (what are the main public health issues facing Djibouti? Is access 
to medication an issue, and why?) and some more general questions on the 
political and economic situation of the country. At that stage, six key actors 
were met, and issues of access to other potential informants were also 
discussed in detail.  
 
Two crucial points came out from this first contact with the network to be 
studied. First, it appeared clear that access would not cause difficulties. The 
informants met were all high ranking officials, who were happy to give me 
access to their institution and to assist me in identifying and meeting other 
relevant actors. Second, the issues raised during interviews were fundamentally 
different from what is often discussed in existing literature in relation to 
TRIPS, pharmaceutical patents and access to medicines. It became clearer that 
many elements, if studied and analysed in depth, would provide a highly 
relevant complement to existing research. In particular, the reaction of all 
informants to TRIPS was essentially one of indifference, and of doubts as to 
whether or not it would mean anything to Djibouti. The fact that the public 
health situation of the country was very different from that of larger and more 
industrialised developing countries was also raised by several informants. 
Similarly, the lack of meaning of patent policies for those involved in the 
industry was emphasised by all informants aware of the local situation in 
relation to the pharmaceutical industry ± or rather in relation to the attempt to 
start a basic form of industry.  
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Broadly, informants emphasised that the situation in Djibouti was not what is 
RIWHQH[SHFWHGIURP³GHYHORSLQJFRXQWULHV´7KLVODWWHUSRLQWZDVHVVHQWLDOLQ
convincing me that this was an interesting case study to undertake. It was likely 
to challenge many of the assumptions that are often constructed in relation to 
ZKDW³KHDOWK´DQG³ODZ´DUHDERXWLQ$IULFD7KLVSDUWLFXODUH[DPSOHDQGWKH
IDFW WKDW LW ZDV SUREDEO\ ³QRW UHSUHVHQWDWLYH´ ZDV FRQVLGHUHG XVHIXO WR
highlight a need for challenges in a field highly dominated by a few examples, 
and for the emphasis on diversity as part of understanding law ± and health ± in 
Africa237.  
 
2. Main period of data collection 
 
The main period of data collection took place from January to May 2004. It 
mainly involved in-depth interviews, although detailed fieldnotes based on 
observation were taken during the course of this research and used widely in 
understanding the data collected.  Documents were also used to support and 
complement some specific ideas. This section will explain the process of data 
collection adopted in this project, and emphasise in particular how the reflexive 
dimension of this fieldwork was essential to follow the key ideas of ANT. 
Although some aspects of in-depth interviews and observation are 
fundamentally different, the boundaries between both approaches are 
sometimes difficult to draw and both strategies can overlap in some of their 
aspects. This section addresses a number of issues common to all aspects of 
                                                 
237
 This can be related more generally to the limits of the existing field covered in academic 
research on law in Africa ± and in particular the rarity of examples of French-speaking African 
countries in existing research. 
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data-collection ± such as sampling and note-taking ± it will also present 
elements specific to each strategy. The meaning of using multiple methods of 
data collection needs to be addressed. This will be done in section 6, when 
explaining why, although considered as essential to the completeness of the 
story provided, it was not used as a way to increase validity through what is 
RIWHQGHVFULEHGDV³WULDQJXODWLRQ´ 
 
Sampling and access 
 
A first element to address in relation to both interviews and observation is the 
issue of sampling and access, and the associated question of the exact focus of 
data-collection. In this particular project, both elements were facilitated by the 
FKDUDFWHULVWLFV RI WKH FRXQWU\ )LUVW WKH LVVXH RI ³UHSUHVHQWDWLYLW\´ WKDW
researchers often have to deal with was not a consideration in this project, since 
the small size of the country made it possible to meet virtually every actor 
directly concerned with pharmaceutical patents in one way or another, as the 
range of actors involved with the government or with health and industrial 
structures is very limited238. In addition to this, access was facilitated by the 
LQIRUPDO³ODLG-EDFN´DWPRVSKHUHWKDWGRPLQDWHGLQPRVWRIWKHVHWWLQJVYLVLWHG
This meant that actors were particularly helpful in introducing me to different 
people to whom I wanted to speak. It became was similarly easy to knock on a 
SHUVRQ¶VGRRUDWDQ\WLPHRQFH,KDGEHFRPHD³IDPLOLDU´ILJXUHLQWKHVHWWLQJV
                                                 
238
 Although representativity is a more central issue in quantitative research, it arises in many 
qualitative projects involving a large number of potential informants.  
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considered239. Another consequence of this atmosphere was the fact that actors 
never seemed to be working to a tight schedule, and were very happy to take 
their time and talk for as long as necessary, as often as necessary. This allowed 
me to meet most actors several times, in different settings, and to discuss 
different issues in a different format. This allowed for the addition of an 
interactive dimension to the research. Issues that appeared throughout the 
course of data collection could be addressed with actors with whom they had 
not been discussed before.  
 
In terms of identifying the actors that I wanted to interview, the process was 
progressive, and took place on the ground, by slowly mapping out the range of 
relevant institutions, and those in charge of particular issues in each institution. 
This was considered crucial in order to translate into practice the idea that 
³UHOHYDQW DFWRUV´ VKRXOG QRW EH SUH-determined, and should be empirically 
considered. Actors involved in this project were identified both by finding out 
LQIRUPDWLRQ RQ GLIIHUHQW SHRSOH¶V UROH DQG E\ WKHP FRQWDFWLQJ PH
spontaneously. In addition to this, many informants provided me with contact 
details of other actors they believed to be relevant to the focus of my research, 
DQG WKH ³VQRZEDOO´ VWUDWHJ\ RIWHQ XVHG LQ ILHOG UHVHDUFK ZDV LPSRUWDQW KHUH
Overall, this project started by analysing as broadly as possible the different 
networks in which TRIPS and pharmaceutical patents have been enrolled in 
Djibouti ± and the networks in which they could be expected to have been 
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 2QHDFWRU WKXV WROGPHE\HPDLOEHIRUH , VWDUWHGP\ ILHOGZRUN ³There is nothing 
to worry about, Djibouti is not like France and we know each 
other very well. There are no formalities as such. I am in a 
position to introduce you with all these others you would like 
to meet´ 
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enrolled on the basis of existing literature. Within each network, actors were 
interviewed or observed, and their respective role was then questioned on the 
EDVLV RI LQIRUPDQWV¶ XQGHUVWDQGLQJ RI WKH UROH RI 75,36 DQG SKDUPDFHXWLFDO
patents, and of additional observations240. 
 
The key question in relation to sampling, however, was to determine the 
starting point ± which networks should EHFRQVLGHUHGDV³UHOHYDQW´"7KLVKDG
to depend on the specific aims of this research. Once again, this research aims 
to understand what TRIPS and pharmaceutical patents are in Djibouti. It 
explains throughout how both objects have become enrolled into different 
networks, and how their nature, modes of actions and mechanisms can be 
understood differently if looking at them from these different viewpoints. 
Following the pilot study described above, it became clear that the shape of 
public health, import, and trade and industry networks, as well as some local 
understandings of specific concepts were all elements that could impact on the 
role and mechanisms of both objects in the country, and needed further in-
depth investigation. In relation to the specific sample chosen for interviews - 
and observational data - the focus of analysis can be divided into two main 
areas, for the purpose of this particular chapter. 
 
First, the public health network and pharmaceutical import system of Djibouti 
have been looked at ± and through them each of the different components and 
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 ,W LV LQWHUHVWLQJ KHUH WR UHIHU WR WKH VWUDWHJ\ RI ³IROORZLQJ WKH PHWDSKRU´ SUHVHQWHG E\
Maskus when dealing with ethnography in multiple settings, in Maskus G. (1998), 
³(WKQRJUDSK\ LQRI WKH :RUOG 6\VWHP´ LQ Ethnography through Thick and Thin, Princeton 
University Press: Princeton. 
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relevant actor-networks that constitute the larger health network of which 
Djibouti is part. Throughout empirical research, the focus of analysis has 
shifted and refocused to integrate new and relevant connections. Informants 
from the public health area interviewed included doctors from each of the main 
hospital structures described in Chapter 4, pharmacists ± private pharmacists, 
KRVSLWDO SKDUPDFLVWV DQG WKRVH LQ FKDUJH RI WKH QHZ ³&HQWUDO G¶$FKDWV´ -
several actors from the Ministry of Health and representatives of the WHO. 
Those related to the attempts to build a local pharmaceutical industry were also 
met. In the course of the research, some international NGOs were approached, 
although none of their action was directly relevant to Djibouti and 
representatives were therefore not met in person. Second, the intellectual 
property and trade network of Djibouti, and in particular those elements that 
were expected to participate in the integration of TRIPS in Djibouti, was 
studied. Similarly, the identification of relevant actors was done in several 
steps, by following connections and new links that were highlighted 
throughout. It will be explained in Chapter 5 that the process of identification 
of relevant acWRUVZDVPDGHPRUHGLIILFXOWZKHQZRUNLQJ³DFURVVILHOGV´± ie: 
when moving from the public health field to the trade networks. However, as 
this issue became in itself a central part of the data to be analysed, it was felt 
more appropriate to provide full explanation of this element when analysing 
the data collected. In the trade network, informants were met in the Ministry of 
7UDGHDQG,QGXVWU\WKH&KDPEUHGX&RPPHUFHHWGHO¶,QGXVWULHDQGLQFOXGHG
various actors who had been in the past involved in some decisions related to 
intellectual property issues.  
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Finally, in the course of this research a number of additional people asked to 
meet me and give me their opinion on issues that were not always related to my 
specific area of research ± these were essentially lawyers, researchers and 
members or ex-members of the government. I met each of these actors, for 
several reasons. First, it would have been perceived as very inconsiderate to 
refuse a meeting with high-ranking individuals ± especially because these 
PHHWLQJV ZHUH RIIHUHG ERWK DV D IULHQGO\ IDYRXU DQG DV D ³VRFLDO KRQRXU´
Second, I considered these further meetings to be interesting additional data on 
the way politics and law work generally in Djibouti ± something that could not 
be clarified on the basis of any type of background research and was highly 
relevant to some aspects of my research241. Data from each of these meetings 
was transcribed and kept exactly in the same way as meetings I had organised, 
as will be developed below. 
 
In-depth interviews as ethnographic data 
 
This section will explain how interviews were used in this project. Although 
interviews have been criticised as a method of data collection for several 
reasons, as will be explained later, it appeared to be the most feasible approach 
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 It is crucial for researchers to be aware of the potential bias introduced by involving many 
³VSRQWDQHRXV´ LQIRUPDQWV DV WKHVH DUH OLNHO\ WR UHSUHVHQW D VSHFLILF DQG GHILQHG VHW RI
examples from a wider social group. However, this data was mainly complementary in this 
research, and the sample from which findings were derived was determined by the strategies 
described above, apart from one informant from whom on quote was borrowed. To that extent, 
the potential bias has been kept to a minimum. For comments on this issue, see Hammersley 
0 DQG $WNLQVRQ 3  ³,QVLGHU $FFRXQW /LVWHQLQJ DQG $VNLQJ 4XHVWLRQV´ LQ
Hammersley M. and Atkinson P., Ethnography: Principles in Practice, London: Routledge, 
pp.124- 156 (in particular p. 134-135). 
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to empirical research in this project. This was essentially linked to the fact that 
data needed to be gathered from a range of settings, and could not therefore be 
observed from a single location. In addition to this, the type of data to be 
collected itseOI FRXOG VRPHWLPHV EH DFFHVVHG RQO\ WKURXJK LQIRUPDQWV¶
perspectives ± ODUJHO\EHFDXVHDZLGHSDUWRI WKLVGDWDZDVDERXW LQIRUPDQWV¶
perspectives and understandings of TRIPS and pharmaceutical patents. 
However, once again, the distinction between interviews and observation 
cannot be clearcut. Observational data was collected during interviews, and 
WKDWDFWRUV¶SHUVSHFWLYHVZHUHGLVFXVVHGRXWVLGHRI VWULFWO\GHILQHG³LQWHUYLHZ
VHVVLRQV´ 
 
³Interviews in ethnographic research range from spontaneous, informal 
conversations in places that are being used for other purposes to formally 
arranged meetings in bounded settings out of earshot of other people´242 
 
This citation summarises the range of situations that should be included and 
considered when discussing the way interviews were carried out in this 
research. Interviews have traditionally been regarded as taking a range of 
formats, from structured lists of questions to broadly guided discussions on a 
particular topic243. In this research, the approach taken was aimed at balancing 
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 +DPPHUVOH\0DQG$WNLVRQ3³,QVLGHUDFFRXQW OLVWHQLQJDQGDVNLQJTXHVWLRQV´
op. cit. on p.139. 
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 Kvale S. (1996) Interviews/RQGRQ6DJH)RQWDQD$DQG)UH\-+³,QWHUYLHZLQJ
7KH DUW RI VFLHQFH´ LQ 'HQ]LQ DQG /LQFROQ HGV Collecting and Interpreting Qualitative 
Materials, Thousand Oaks: Sage publication, pp. 47-78.; Gorden R. L.(1980) Interviewing: 
Strategy, techniques and tactics, Doresey: Homewood; Maccoby E. E. and Maccoby N. (1954) 
³7KH ,QWHUYLHZ D 7RRO RI 6RFLDO 6FLHQFHV´ LQ /LQG]H\ * HG Handbook of Social 
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the requirements to remain focused around a particular theme against the need 
to allow actors to discuss their own story without being limited by a pre-
defined list of questions. Overall, interviews were mainly carried out in a 
³FRQYHUVDWLRQDO ZD\´ 7KLV ZDV EDVHG ERWK RQ WKH WKHRUHWLFDO YLHZV SXW
IRUZDUGLQWKLVUHVHDUFKWKDWUHVHDUFKHUVVKRXOGDYRLG³DGGLQJ´WRWKHVHWWLQJDV
much as feasible, and on the need to provide opportunities for reflexive 
questioning, as well as on the social environment in which I was working. 
Although a broad interview schedule was created for each particular meeting, it 
was used more as general guidance than as a strict list of questions to be asked. 
Other than this common characteristic, interviews carried out in this project 
involved varied circumstances, ranging from brief conversations in informal 
VHWWLQJV WR OHQJWK\ GLVFXVVLRQV LQ LQIRUPDQWV¶ RIILFHV ,Q DGGLWLRQ DQG DV
mentioned, most informants were in fact met several times244, and themes were 
discussed in a range of settings and environments. Overall, the interview 
process in this project involved the main characteristics that often illustrate 
ethnographic interviewing.  
 
³(WKQRJUDSKHUV GR QRW XVXDOO\ GHFLGH EHIRUHKDQG WKH H[DFW TXHVWLRQV WKH\
want to ask, and do not ask each interviewee exactly the same questions, 
though they will usually enter the interviews with a list of issues to be covered. 
Nor do they seek to establish a fixed sequence in which relevant topics are 
                                                                                                                                 
Psychology: vol 1, Theory and Method, Reading: Addison Wesley, pp. 449-487; Spradley J. P. 
(1979) The Ethnographic Interview, New York: Holt, Rinehart and Winston; Rubin H. J. and 
Rubin I. S. (1995) Qualitative Interviewing, Thousand Oaks: Sage; Seidman I. E. (1991) 
Interviewing as Qualitative Research, New York: Teachers College Press. 
244
 Of the list provided in appendix, 8 were met only once, while others were met between 2 
and 5 times. 
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covered; they adopt a more flexible approach, allowing the discussion to flow 
in a way that seems natural. Nor need ethnographers restrict themselves to a 
single mode of questioning. On different occasions, or at different points in the 
same interview, the approach may be non-directive or directive, depending on 
the function that the questioning is intended to serve; this will usually be 
GHFLGHGDVWKHLQWHUYLHZSURJUHVVHV´245 
 
 The range of questions discussed with interviewees varied depending on the 
background of informants, and was once again kept flexible in every case. 
However, some key themes were discussed with all informants. Questions 
asked to public health actors were directed at understanding both the health 
VLWXDWLRQ DQG QHHGV RI 'MLERXWL DV ZHOO DV LQIRUPDQWV¶ XQGHUVWDQGLQJV RI 
intellectual property issues. After a first set of interviews was carried out, 
further more specific elements were discussed such as particular projects, 
diseases or the links and relations between specific actors. Themes discussed 
with informants in the trade and industry area were directed more specifically 
at the implementation of TRIPS, the view of informants in relation to the role 
patents could play in Djibouti, past experience in terms of implementing 
international law and creating new legal structures. Finally, additional 
informants provided information related more broadly to local politics, culture 
and tradition. 
 
A key question that needs to be addressed in relation to interviews is that of 
recording. It is generally considered in social research that tape-recording is the 
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 +DPPHUVOH\ DQG $WNLQVRQ ³,QVLGHU DFFRXQW OLVWHQLQJ DQG DVNLQJ TXHVWLRQV´ RS FLW RQ
p.152. 
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most complete way to record interviews. It guarantees that a faithful transcript 
of what was said by informants is kept and avoids the potential disruptions that 
note-taking can create. However, recording is not always possible, and 
thorough note-taking can in fact prove to be less disruptive in particular social 
settings than recording interviews. In this research, it was decided at an early 
stage that tape-recording could not be used and needed to be replaced by 
detailed note-taking during and after interviews. There were several reasons for 
this choice. First, it was felt early in this research that most of the interviews 
would be best carried out by maintaining the informal aspect of most local 
social relations. In addition, people familiar with local traditions, and aware of 
local events, reminded me that it was necessary to understand that local actors 
were often wary of being recorded, saying things that could be critical of 
governmental policies. While local actors are allowed freedom in most of their 
actions, it is often in their interest to ensure that they keep good relations with 
one another, and in particular with governmental actors. To that extent, people 
often tend to be more careful to what they will say if they think they might be 
recorded ± and it would probably be even more the case if they knew they were 
being recorded. Finally, some interviews were conducted in noisy settings 
where tape-recording would have been unclear, and thus could have left some 
aspects of the interview un-saved. Each of these elements made it both 
impractical and potentially obstructive to use a tape-recorder during interviews, 
and notes were used as a way to record data. As note-taking is again one of the 
issues on which interviews and observations overlapped, the process of note 
taking will be discussed below to include both research strategies.   
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The use of interviews as a central method for data collection has been 
criticised, however, and these criticisms need to be examined briefly in order to 
discuss how they have been addressed in this project. The main set of 
FULWLFLVPV LV WKDW E\ UHO\LQJ IXOO\ RQ WKH LQWHUYLHZHH¶V QDUUDWLYHV UHVHDUFKHUV
ZLOO REWDLQ RQO\ WKHLU GHVFULSWLRQ RI WKHLU RZQ RU RWKHUV¶ DFWLRQV ,QIRUPDQWV
can adapt their QDUUDWLYHVWRZKDWWKH\WKLQNWKH\³VKRXOG´EHVD\LQJ7KH\FDQ
for example try to project an image of themselves closer to what they think 
should be expected from someone in their situation. They can also genuinely 
give an account that is different from what really happened, because their 
memories are confused for any specific reason246. Overall, it is necessary for 
interviewers to keep in mind that what they are obtaining are narratives, as 
opposed to real events that could have been directly observed. While this needs 
to be understood and acknowledged, it is not necessary, however, to see it as an 
inherent and unavoidable weakness, and can be considered as a characteristic 
that needs to be addressed in order to guarantee the relevance of the method247. 
This is particularly so if it is believed that the world is constituted of multiple 
realities, since the aim of social researchers then becomes to understand 
VSHFLILF ³VXEMHFWLYLWLHV´ ,W LV RQO\ E\ XQGHUVWDQGLQJ WKHVH PXOWLSOH
                                                 
246On this set of issues, see also for example: 0LOOHU-DQG*ODVVQHU%³7KH³,QVLGH´
DQG WKH ³2XWVLGH´ )LQGLQJ 5HDOLWLHV LQ ,QWHUYLHZV´ LQ 6LOYHUPDQ ' HG Qualitative 
Research: Theory, Method and Practice, Thousand Oaks: Sage Publications, pp. 98-111; Dean 
- 3 DQG :K\WH : )  ³+RZ GR ZH .QRZ LI WKH ,QIRUPDQW LV 7HOOLQJ WKH 7UXWK"´
Human Organization 17(2) pp. 34-.YDOH6RSFLW*XGPXQGVWRWWLU6³7KH7HOOHU
WKH7DOHDQGWKH2QHEHLQJ7ROGWKH1DUUDWLYH1DWXUHRIWKH5HVHDUFK,QWHUYLHZ´Curriculum 
Inquiry 26(3) pp. 293-306; Mischler E. G. (1986) Research Interviewing ± Context and 
Narrative, Cambridge: Harvard University Press. 
247
 ³5HVHDUFK FDQQRW SURYLGH WKH PLUURU GHVFULSWLRQ WKDW SRVLWLYLVWV VWULYH IRU EXW LW PD\
provide access to the meaning people attribute tRWKHLUH[SHULHQFHVDQGVRFLDOZRUOG´ Miller 
J. and Glassner B. (1997) op. cit. on p.100. 
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subjectivities that the social world can be explained. It is in this perspective 
WKDW LQWHUYLHZV ZHUH SHUFHLYHG LQ WKLV UHVHDUFK XQGHUVWDQGLQJ LQIRUPDQWV¶
narratives as an inherent part of the reality to be studied in this project. The 
potential gap between what was being said by interviewees and what would be 
observed on the ground was accepted in the research process, and the different 
sets of data collected were used as complementary sources presenting different 
viewpoints all relevant to this project. This point will be developed again in 
Section 6, when discussing how the aim for scientific validity has been sought 
through the use of multiple methods of data collection. At this stage, the way 
observation was used in this project needs to be presented. 
 
Observational data 
 
Although interviews were originally thought of as a main method for data 
collection, and most data used in this project was indeed obtained through 
interviews, observation was used to collect further data and adopt additional 
viewpoints on the action of TRIPS and pharmaceutical patents. Overall, about 
twelve weeks were spent in Djibouti during this research ± two weeks on 
conducting a pilot research and ten weeks for the main period of data 
collection. Although a lot of this time spent in the field was used to carry out 
interviews, the period spent there was also sufficiently long to spend significant 
periods of time in the settings that were under scrutiny. This was particularly 
important because this research was carried out in a socio-cultural environment 
that has been little studied. It was therefore necessary to include data 
complementing what was being said during interviews and helping to 
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understand interview-data. Observation and interviews acted as fully 
complementary methods248. While some data could only be obtained from 
speaking with actors, other elements, in particular some human/non-human 
associations needed to be observed. In addition to this, observational fieldnotes 
were used as a way to complement the narrative provided by informants, in 
order to provide further knowledge of local politics and traditions that could 
help frame what was being said in interviews. Once again, observation in this 
research should not be understood as a different process from that of 
interviewing ± in many cases, observational data was in fact collected during 
interviews. In addition to this, the boundary between interview and observation 
data is difficult to set when considering fieldnotes on informal conversations in 
unofficial settings, for example. Overall, throughout the period of fieldwork 
carried out in this research, detailed fieldnotes were kept on what was seen and 
heard in a range of settings249 ± in particular those in which interviews per se 
were carried out. Additional data could therefore be collected on primary 
observaWLRQ RI DFWRU¶V EHKDYLRXU LQVWLWXWLRQDO VHWWLQJ RU GD\-to-day 
conversation with actors less directly involved in the key elements of this 
research 
 
Note taking 
 
The process of taking fieldnotes needs to be briefly discussed, in order to 
emphasise how the need for thorough notes had to be balanced against 
                                                 
248
 +DPPHUVOH\0DQG$WNLQVRQ3³,QVLGHUDFFRXQWOLVWHQLQJDQGDVNLQJTXHVWLRQV´
op. cit. 
249
 Ministries, hospitals, pharmacies, for example. 
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practicalities on the ground250. This is something that has been widely 
discussed in the literature, and researchers have often highlighted that the 
behaviour of informants can be affected by them noticing that researchers are 
scribbling down in front of them251. This is particularly the case in settings in 
which those observed might not be totally familiar with the research process, 
and not used to seeing people writing down what they are doing or saying. 
Once again, this was particularly the case in Djibouti, where information is 
traditionally transmitted orally, and where people are often uncomfortable with 
the need for others to keep a written record of what they are doing or saying.  
 
In this research, although it was agreed from the start that informants had no 
objection to me taking notes on what they were saying, doing, or of what I was 
seeing more generally, I felt that in many cases it would be disruptive to make 
this note-taking activity too obvious. This was not as much the case when 
meeting people formally in their office as when meeting them in more informal 
settings such as restaurants. Similarly, a number of informants came to talk to 
me in unexpected situations such as on the street, at evening parties or even on 
                                                 
250
 For comments on the practice of fieldnotes, and issues of validity and reliability, see for 
example: Emerson, R, Fretz R., Shaw L. (1995) Writing Ethnographic Fieldnotes, Chicago: 
University Press of Chicago; Lareau A. and Shutlz J. (eds) (1996) Journeys through 
Ethnography: Realistic accounts of Fieldwork, Boulder CO: Westview Press; Van Maanen J. 
(1988) Tales of the Field: On Writing Ethnography, Chicago: University of Chicago Press. 
251
 For comments on the interference between the process of note-WDNLQJ DQG LQIRUPDQWV¶
EHKDYLRXU VHH IRU H[DPSOH +DPPHUVOH\ 0 DQG $WNLQVRQ 3  ³5HFRUGLQJ DQG
2UJDQL]LQJ 'DWD´ +DPPHUVOH\ 0 DQG $WNLQVRQ 3  Ethnography: Principles and 
Practice, London: Routledge, pp. 175- ³7he conduct of note-taking must be broadly 
congruenWZLWKWKHVRFLDOVHWWLQJXQGHUVFUXWLQ\,QVRPHFRQWH[WVKRZHYHU³ZHOO-VRFLDOLVHG´
the hosts, open and continuous note-taking will be perceived as inappropriate or threatening, 
and will prove disruptive. In other contexts, fairly extensive notes can be recorded without 
XQGXHGLVUXSWLRQ´ on p.177. 
 163 
the beach. Although I kept a notebook with me at all times, I did not feel it was 
appropriate or convenient to pull it out from my bag when having an informal 
chat with someone in these circumstances. When researchers cannot for some 
reason take notes while observing a particular element, or during a 
conversation, it is essential that they do it as soon as possible after the 
observation took place, in order to keep a record as faithful as possible to what 
was observed or said252. This can be easy when it is quick and convenient to 
get away from the setting or informant observed, and was in particular not 
GLIILFXOW LQ WKH PDQ\ FDVHV ZKHUH , MXVW ³EXPSHG LQWR VRPHRQH´ LQ SXEOLF
places and had a brief conversation. It was more difficult when having a 
lengthy conversation with someone ± planned or not ± and I had to use the 
many strategies with which researchers have become familiar over the years. 
7KH³UHVHDUFKHU¶VGLVHDVH´UHIHUUHGWRE\+DPPHUVOH\253 is something I might 
have been accused of by many informants. Overall I ensured as much as 
possible that notes were taken as frequently as possible during long 
conversations and as soon as possible after relevant observations, and used any 
thinkable strategy to isolate myself when possible to do so ± which was not 
always a pleasant experience. 
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 +DPPHUVOH\0DQG$WNLQVRQ3³5HFRUGLQJDQG2UJDQL]LQJ'DWD´RSFLWS-
177. 
253
 ³A common joke about ethnographers relates to their frequent trips to the lavatory where 
such hasty notes can be scribbled in private´ LQ +DPPHUVOH\ 0 DQG $WNLQVRQ 3 
³5HFRUGLQJDQG2UJDQL]LQJ'DWD´RSFLWRQS 
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Document analysis 
 
In addition to interviews and observation, document analysis played an 
important part in this research. Documents were crucial both as a source of data 
complementing perspectives obtained from interviews and observations and 
essential in allowing for the wide ramifications of the network under scrutiny 
to be encompassed in this project. Documentary analysis was an important 
starting point in this research, prior to carrying out fieldwork in Djibouti, in 
understanding the framing of TRIPS and patents in relation to health 
internationally. This was based on analysing legal documents from different 
countries ± policy documents and laws ± as well as the range of pre-existing 
analyses of this type of documents. Academic writings were most centrally 
used, but media reports and the documents produced by different lobby groups 
were also taken into consideration. The difficulty of documentary analysis is in 
part common to those of interviews mentioned above, in that documents 
represent only a particular narrative, and cannot always be taken as facts254, as 
will be explained in more detail below. However, these narratives were in fact 
what needed to be understood as a starting point to this research ± the 
simplification and extensive generalisations provided throughout writings in 
the field needed to be understood in order to respond to it through this project.  
 
In addition to this, documentary analysis played a central role in this research 
both in complementing some of the findings made in Djibouti itself and in 
                                                 
254
 On the use of documents in ethnographic research, see for example Atkinson P. and Coffey 
$  ³$QDO\VLQJ 'RFXPHQWDU\ 5HDOLWLHV´ LQ 6LOYHrman D. (ed) Qualitative Research: 
Theory, Method and Practice, London: Sage Publications, pp. 45-62. 
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extending the data collected to the ramifications of the network analysed 
outside the country. Two types of institutional documents were used. First, 
documents from local institutions were accessed, in relation to health projects, 
IP and trade issues. These were essentially used for complementing findings 
IURP LQWHUYLHZV DQG REVHUYDWLRQ E\ VKRZLQJ WKH ³RIILFLDO´ DQG ³PDWHULDO´
version of particular stories, and illustrating the perspectives with which 
informants were faced in their own activities. In addition, documents from 
international organisations (WTO, WHO, WIPO and the World Bank) were 
used in order to understand the localized manifestations of international 
relations and happenings.  
 
The need to adapt ethnographic methods to the newly extended forms of 
international networks now under scrutiny in many fields has been highlighted 
by Maskus in particular when discussing how ethnography could be applied in 
WKH ³ZRUOG V\VWHP´255. In this research, the networks followed throughout 
involved sites and objects that could not be physically observed. Using 
documents, in association with the analysis in Djibouti of the impact of these 
different parts of the network allowed the integration of key elements in the 
data collected. 
 
                                                 
255
 ³Although multi-sited ethnography is an exercise in mapping terrain, its goal is not holistic 
representation, an ethnographic portrayal of the world system as a totality. Rather, it claims 
that any ethnography of cultural formation in the world system is also an ethnography of the 
system, and therefore cannot be understood only in terms of the conventional single-site mise-
en-scene of ethnographic research, assuming indeed it is the cultural formation, produced in 
several different locales, rather than the conditions of a particular set of subjects that is the 
object of study´0DVNXV*RSFLWRQS 
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The difficulty of using documents as data is essentially that they can only be 
taken as facts in that they exist and they become actors in the system (through 
their own shape and narrative). Their narrative, however, cannot be taken as a 
necessarily faithful reflection of other realities. The perspective adopted in this 
research meant that this was not as much of an issue as it might have been in 
other projects. In particular, it is accepted in ANT that what needs to be 
collected are sets of subjectivities, elements of perspectives, and that the social 
world is purely constituted of such elements. This can be illustrated particularly 
clearly if reflecting on the role that documents from international organisations 
played in this project. The aim of analysing such documents was, in particular, 
to understand how activities from international organisations were portrayed in 
Djibouti, and by opposition how events and networks in Djibouti were 
described in documents emanating from international organisations. In 
DGGLWLRQ GRFXPHQWV ZHUH XVHG LQ UHODWLRQ WR ORFDO LQIRUPDQWV¶ QDUUDWLYHV RI
their relations with actors based outside the country, and were designed at 
understanding the connections established between actors in Djibouti and 
wider international networks. Overall, it was understood in this project that: 
³«UDWKHU WKDQ EHLQJ YLHZHG DV PRUH RU OHVV ELDVHG VRXUFHV RI GDWD RIILFLDO
documents and enumerations should be treated as social products: they must 
be examined, not relied on uncriWLFDOO\DVDUHVHDUFKUHVRXUFH´256 
 
                                                 
256
 +DPPHUVOH\0DQG$WNLVRQ3³'RFXPHQWV´ LQ+DPPHUVOH\0DQG$WNLQVRQ3
Ethnography: Principles and Practice, London: Routledge, pp. 157-174 on p.168. Although 
this statement is essentially directed at official statistic in this particular book chapter, the idea 
holds true for other type of official data. 
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SECTION 4:  ETHICS 
 
Ethical issues were considered at various points of this research, and I followed 
appropriate ethical guidelines ± such as those provided by the ESRC257. Some 
characteristics of the fieldwork made particular elements rather complex in this 
research. Anonymity and confidentiality were made particularly crucial 
because of the political situation of Djibouti, and the fact that any form of 
criticism of the government is still very widely avoided.  In addition to this, the 
³LQIRUPDOLW\´RIDODUJHSDUWRIWKHUHVHDUFKSURFHVVUDLVHGVRPHVSHFLILFLVVXHV
in relation to informed consent.  
 
Informants were made aware of the aims of this research from the start. They 
were informed that I was interested in evaluating the role of pharmaceutical 
patents in Djibouti and the potential impact of the TRIPS agreement on the 
                                                 
257
 The ESRC guidelines propose six key principles: ³5HVHDUFKVKRXOGEHGHVLJQHGUHYLHZHG
and undertaken to ensure integrity and quality; research staff and subjects must be informed 
fully about the purpose, methods and intended possible uses of the research, what their 
participation in the research entails and what risks, if any, are involved. Some variation is 
DOORZHGLQYHU\VSHFLILFDQGH[FHSWLRQDOUHVHDUFKFRQWH[W«WKHFRQILGHQWLDOLW\RI
information supplied by research subjects and the anonymity of respondents must be 
respected; research participants must participate in a voluntary way, free from any coercion; 
harm to research participants must be avoided; the independence of research must be clear, 
and any conflicts of interests RUSDUWLDOLW\PXVWEHH[SOLFLW´257 ESRC Research Ethics 
Framework, available at: 
http://www.esrcsocietytoday.ac.uk/ESRCInfoCentre/Images/ESRC_Re_Ethics_Frame_tcm6-
11291.pdf?data=XgFbyby6cC%2feX0vvCbUzElpmty2597nOiZBNzMdyp1%2bYbb26zfuNe
A7JM%2bo6bv2pAtBPo5e%2foUUPE2EoXLiXeRvo%2bsUEx1oC1XzlQzW%2bvgvi6lWaU
RvkIfIn6B1sqq14C0lIzE42k7brIGiWRdQXayvCbl44yh9m&xu=&isAwardHolder=&isProfile
d=&AwardHolderID=&Sector=, on p. 1. 
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country. They were also made aware that in order to do so I needed to 
understand the public health system of the country as a whole, and in particular 
the mechanisms of the pharmaceutical market. Informants were also informed 
that this research was for academic purposes, and that the final findings made 
would appear in a thesis, that would therefore be in the public domain. They all 
provided their verbal consent to the use I was intending to make of the data 
provided258. The queries they had were addressed, although they were 
generally related to the content of my research and my personal aims rather 
than issues of diffusion of information. Informants were made aware that I 
ZRXOGEHWDNLQJQRWHVRIZKDW,ZRXOG³KHDURUVHH´GXULQJRXUPHHWLQJVDQG
that these notes would later be used in my research. When appropriate I asked 
informants whether they believed anyone else in their institution (such as 
MinisterVRUDFWRUVKLHUDUFKLFDOO\³DERYH´WKHPVKRXOGEHPDGHDZDUHRIWKH
existence of my research. By doing so, I made sure that adequate people in 
each of the institutions visited had appropriate information on my work. As 
mentioned earlier, some of the data collected was provided by informants 
GXULQJ ³LQIRUPDO FRQYHUVDWLRQV´ ,W VKRXOG EH FODULILHG WKDW WKLV GDWD ZDV
essentially complimentary to what had been said in formal meetings, and was 
also presented by informants in relation to our earlier conversations. Although 
GLVFXVVLRQVZHUHFRQGXFWHGRQDPRUH³LQIRUPDO´WRQHLQWKHVHFLUFXPVWDQFHV
the relation researcher/informant was still framed as such. None of the 
information on which this research was done can be considered as having been 
                                                 
258
 Although aFFRUGLQJWR(65&VWDQGDUGVFRQVHQWLV³W\SLFDOO\´JLYHQLQDZULWWHQIRUP
(ESRC Research Ethics Framework, op. cit on p. 24), it is not a compulsory condition, and was 
once again something highly unfamiliar in this setting, in which verbal and fully informed 
FRQVHQWZDVMXGJHGWRVDWLVI\WKH³WKHSULPDU\REMHFWLYH«WRFRQGXFWUHVHDUFKRSHQO\DQG
without deception´(65&5HVHDUFK(WKLFV)UDPHZRUNRSFLWRQS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obtained without the acknowledgement of informants that what they were 
telling me was directed at informing my research.  
 
 
In relation to anonymity and confidentiality, one of the difficulties is the fact 
that the country is so small that it is very hard to provide the basic and 
necessary information on who the interviewees were in this research ± 
necessary to prove the validity of this project ± while ensuring that they cannot 
be recognized. A direct consequence of this difficulty can be found in the 
presentation of the data collected made throughout this research, for which a 
balance had to be found between what could and could not be disclosed. While 
this thesis provides a list of informants stating their professional occupation 
and status (see Appendix), specifying which informants are quoted in the 
thesis, citations had to be kept anonymous throughout this research. While this 
presents some limits, it was the only way to ensure that what a particular 
informant said could not be retraced. This was essential to address the key 
concerns of my informants. In particular, while all of them were happy to be 
³RIILFLDOO\LQWHUYLHZHG´IRUP\SURMHFWPDQ\PHQWLRQHGRQFHLQDZKLOHWKLQJV
VXFK DV ³RI FRXUVH , KDYHQ¶W VDLG WKLV EXW«´ ,Q VXFK FDVHV , DVNHG WKHP
whether they had any objection in me using the information provided in my 
thesis as long as it remained anonymous, and they made it clear that this was 
not an issue as long as the statement could not be identified as emanating from 
them. As every quote provided in this thesis has been anonymous, and as 
limited information is provided throughout on the specific origin of a particular 
idea, no such statement can be attributed to specific informants. In this way, the 
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emphasis of informants on their expectation to such specific statements 
remaining anonymous was respected.  
 
 
Further elements had to be addressed. It was important to make sure that the 
data stored was fully anonymous, and stored in a safe location. In addition, 
although it was necessary to keep the data until the PhD process was 
completed, it will then be destroyed259. Confidentiality was also crucial on the 
ground, and it was essential to ensure that information provided by informants 
would not be divulged for any purpose outside those specific to the research. In 
a context where interactions, formal and informal, were frequent, it was central 
to make sure that trust would not be broken by communicating information in 
an inappropriate fashion, and that professional and ethical behaviour would be 
maintained throughout the research period. 
 
Finally, if working within an ANT framework, it is particularly crucial to 
DFNQRZOHGJHWKHWKHVLVLWVHOIDVDSRWHQWLDO³DFWRU´DQGWRHYDOXDWHLWVSRWHQWLDO
effects on the network studied. As will be explained in more detail in Chapter 
4, a fairly limited amount of research has been carried out on Djibouti, and it is 
likely that an internet search of the country could, in the future, provide 
information on my thesis. To that extent, it was essential to ensure in the 
redaction of this thesis that none of its content would risk creating difficulties 
for my informants. This could potentially have obscured some elements of the 
research if highly controversial data had appeared. Nevertheless, the key issues 
                                                 
259
 In accordance with the Data Protection Act 1998, and reminded by the ESRC Research 
Ethics Framework, op. cit. on p. 18.  
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to be discussed in this research were not specifically controversial, and it was 
felt that if anonymity was respected no particular risks would be created for 
any of the informants.  
 
SECTION 5:  APPROACH TO DATA ANALYSIS 
 
³,QHWKQRJUDSK\WKHDQDO\VLVRIGDWDLVQRWDGLVWLQFWVWDJHRIWKe research. In 
many ways, it begins in the pre-fieldwork phase, in the formulation and 
clarification of research problems, and continues through to the process of 
writing reports, articles and books. Formally, it starts to take shape in analytic 
notes and PHPRUDQGD LQIRUPDOO\ LW LV HPERGLHG LQ WKHHWKQRJUDSKHU¶V LGHDV
DQGKXQFKHV´260 
 
This quotation illustrates some of the difficulties faced when aiming to 
describe how data was analysed in this research. The main characteristics of 
what will be defined as the data-analysis process261 were that it was reflexive 
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 +DPPHUVOH\ 0 DQG $WNLQVRQ 3  ³7KH 3URFHVV RI $QDO\VLV´ ,Q Ethnography: 
Principles and Practice, London: Routledge, p. 205-238 on p. 205. 
261
 For general discussions of data analysis processes, see Miles M. B. and Huberman A. M. 
(1993) Qualitative Data Analysis: a Sourcebook of New Methods, Newbury Park: Sage; Miles 
M. B. and Huberman A. M. (1994) Qualitative Data Analysis, an Expanded Sourcebook, 
/RQGRQ 6DJH 6LOYHUPDQ '  &KDSWHU  ³,QWHUYLHZ 'DWD´ LQ Interpreting Qualitative 
Data: Methods for Analysing Talk, Text and Interaction, London: Sage Publication; Huberman 
0DQG0LOHV0³'DWD0DQDJHPHQWDQG$QDO\VLV0HWKRGV´LQ'HQ]LQ1DQG/LQFROQ
Y eds, Collecting and Interpreting Qualitative Material, Thousand Oaks: Sage publications, 
pp. 137-157261 +DPPHUVOH\0DQG$WNLQVRQ3³7KH3URFHVVRI$QDO\VLV´RSFLW 
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and on-going. It included elements and strategies that can only be broadly 
explained262.  
 
The first element to reinforce in that respect is that the way data was 
approached in this project followed closely the key ideas of ANT - in particular 
its emphasis on the need to avoid simplification as far as possible, and to 
remain as close as possible to the data collected263. In this research, it was 
considered essential to ensure that data remained at the centre of the analysis 
offered, and was not limited or directed in its interpretation by heavy 
frameworks for analysis. One of the strengths of ANT is to allow an approach 
encouraging researchers to return to their data, and to follow their data without 
relying on pre-existing concepts. It emphasises the need to understand any 
object of analysis - presented as always subject to change and highly flexible - 
in a dynamic way. It also requires researchers to provide thick descriptions 
fully based on fieldwork data, and to add as little as possible to the elements 
collected. In this research, this was followed closely, and the aim of data 
analysis was more centrally to present and explain it than to draw unwarranted 
general conclusions.  
 
A central element in doing so was to proceed to frequent thinking and analysis 
of what had been collected, and to maintain a high degree of reflexivity in the 
                                                 
262
 It is useful at this stage to specify that it was decided in this research that no use of data-
analysis software would be made. The main reason for this was that it was thought that it might 
limit some of the potential reflexivity on which data-analysis can be based, and that is crucial 
to ANT understandings. 
263
 See for example Latour B. (2005) Reassembling the Social: an Introduction to Actor-
network Theory, op. cit.  
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research process. In particular, as sets of data were collected they were also 
used to determine the direction to be taken by further data-collection, and the 
research process evolved in this way. This research started with minimal 
assumptions as to what TRIPS and pharmaceutical patents should look like in 
Djibouti. This was partly due to the fact that early assumptions that might have 
existed up to the pilot study carried out in 2004 were understood as 
inappropriate and fully left aside before the main period of data collection 
started. From then, data was collected and partly analysed throughout 
fieldwork. Research diaries were kept to register new ideas and comments that 
were developing throughout the research process. This allowed for a large part 
of the analysis to be done while in Djibouti and for the focus of analysis to be 
QDUURZHGGRZQDFFRUGLQJWRLQIRUPDQWV¶HPSKDVLVDQG early findings264. 
 
In analysing data, and in particular large sets of data collected through several 
weeks of fieldwork, coding is often presented as a useful way to proceed. It 
involves attributing particular sets of data to categories that are created as data 
is being analysed. Sets of interview scripts and pages of fieldnotes are divided 
± physically or not ± in thematic categories and each part can then be compared 
across interviews and observations. The process is ongoing, as each step of 
                                                 
264
 On the way ethnographers develop concepts and ideas during and after the data collection 
SURFHVVVHHIRUH[DPSOH+DPPHUVOH\0DQG$WNLQVRQ3³7KH3URFHVVRI$QDO\VLV´
op. citVHHDOVR6DQMHN5³2Q(WKQRJUDSKLF9DOLGLW\´LQ6DQMHN5HGThe Making of 
Anthropology, London: Cornwell University Press, pp. 345-418. 
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coding, interpretation and analysis will combine to highligh new categories to 
consider when analysing the overall data collected265.  
 
The process of data analysis used in this research was partly inspired by coding 
strategies. These were used while going through notes and interview scripts 
many times, in order to compare how different informants had been 
approaching similar issues and themes. However, it is now difficult to assess 
fully the part that formal coding played in analysing and understanding the data 
collected and, in particular, it is now uncertain what part it played as compared 
to the overall process of familiarisation with this data that I went through over 
the course of this fieldwork. Emphasising that formal techniques and more 
informal processes that allow researchers to understand their data go hand in 
hand is certainly not an original element in sociological or ethnographic 
research. In this research, it is fair to say that by the end of this fieldwork and 
the few weeks that followed it I had read most of my fieldnotes and interview 
scripts so many times that I could have quoted full sections of the most crucial 
interviews or observations made. In addition to this, the many sets of 
comments and scribbles produced throughout this fieldwork were crucial in 
making key-concepts emerge allowing the links between ideas and 
observations to take shape in a clearer way. Overall, the process of data 
analysis in this research essentially involved defining concepts, ideas and 
categories by both formal and informal strategies, and using data to provide a 
                                                 
265
 2Q ³FRGLQJ´ VHH IRU H[DPSOH (VWHUEHUJ . *  Qualitative Methods in Social 
Research, London: Mc Graw-Hill, in Chapter 8; similarly, on processes used by ethnographers 
IRULQGH[LQJVHH6DQMHN5³2Q(WKQRJUDSKLF9DOLGLW\´RSFLW 
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thick description of the key ideas that emerged in relation to TRIPS and 
pharmaceutical patents as understood by informants. 
 
SECTION 6: ASSESSING THE VALIDITY OF RESEARCH METHODS 
AND FINDINGS 
 
This chapter began by explaining that empirical research should remain driven 
by scientific rigour and aimed at validity. On this aspect, ANT could be related 
to broader debates in qualitative research ± DQG LQ SDUWLFXODU WR ³VXEWOH
UHDOLVP´ +RZHYHU LW LV QRZ LPSRUWDQW WR UHIOHct on the way in which the 
validity of this project can be evaluated, and on how the methods used in this 
research aimed at increasing this validity. Once again, the specificities of ANT 
will give way to more general questions raised by ethnographic research ± and 
by the answers given by ethnographers. This section discusses two sets of 
issues. First, the solutions put forward by ethnographers to evaluate the validity 
of qualitative research are presented ± and illustrate the means researchers 
should deploy to increase the validity of their research, as well as how they 
were used in this project. Second, the role of multiple methods in increasing 
the validity of research will be discussed ± as a whole and in this project.  
 
Discussing the validity of ethnographic research is a complex issue, because 
the flexibility of the research process itself makes it difficult to evaluate the 
methods undertaken266. Some authors have in fact rejected the idea that criteria 
                                                 
266
 For comments on the validity and reliability of qualitative research, see for example 
Altheide D. L. and Johnson J. M. (1994) op. cit.; House E. R. (1980) Evaluating with Validity, 
Beverly Hills: Sage Publications; Kirk J. and Miller M. L. (1986) Reliability and Validity in 
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can be identified to judge ethnographic research ± aQGWKHQRWLRQRI³YDOLGLW\´
itself, as has been explained early in this chapter. However, the idea that there 
FRXOG EH VXFK WKLQJ DV ³YDOLGLW\´ LQ HPSLULFDO UHVHDUFK ± including in ANT 
research ± has been defended in Chapter 1. This does not need to be 
redeveloped here. What is more relevant at this stage is to look at the way most 
ethnographers have emphasised the possibility and necessity to judge the 
validity of qualitative research, and have offered specific criteria and ideas that 
can be used in that rHVSHFW2QFHDJDLQ+DPPHUVOH\¶V³VXEWOHUHDOLVP´FDQEH
drawn upon: 
 
³From my point of view, then, the assessment of validity involves identifying 
the main claims made by a study, noting the types of claim they represent, and 
then comparing the evidence provided for each claim with what is judged to be 
QHFHVVDU\JLYHQ WKHFODLP¶VSODXVLELOLW\DQGFUHGLELOLW\6RPHFODLPVPD\EH
beyond reasonable doubt in themselves, in which case they will be judged not 
to need evidence. In other cases, evidence will be required, evidence whose 
nature will depend in part on the type of claims involved. This evidence will, in 
WXUQQHHGWREHDVVHVVHGLQWHUPVRILWVSODXVLELOLW\DQGFUHGLELOLW\´267 
 
                                                                                                                                 
Qualitative Research %HYHUO\ +LOOV 6DJH 3XEOLFDWLRQV 0LVKOHU ( *  ³9DOLGDWLRQ LQ
Enquiry-guided Research: The role of ExempODUVLQ1DUUDWLYH6WXGLHV´Harvard Educational 
Review, 60, pp. 415-6FKRILHOG-:³,QFUHDVLQJWKH*HQHUDOL]DELOLW\RI4XDOLWDWLYH
5HVHDUFK´LQ(:(LVQHUDQG3HVKNLQ$HGVQualitative Inquiry in Education, New York: 
Teachers College Press, pp. 201-232. 
267
 +DPPHUVOH\0³%\:KDW&ULWHULDVKRXOG5HVHDUFKEH-XGJHG"´LQ+DPPHUVOH\0
:KDW¶V :URQJ ZLWK (WKQRJUDSK\, Methodological Explorations, London: Routledge, pp. 57-
84, on p. 72. 
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Evidence becomes central at each level of analysis in order to sustain 
ethnographic claims. Similarly, Sanjek provides three different types of 
elements that can be used to increase the validity of ethnographic research: 
³WKHRUHWLFDO FDQGRU´ GHVFULSWLRQ RI WKH ³HWKQRJUDSKHU¶V SDWK´ DQG ³ILHOGQRWH
HYLGHQFH´268. By these, he emphasises the fact that the validity of ethnographic 
research depends on the amount of information provided by researchers on 
why they chose to collect and emphasise particular data, how they went about 
collecting it, and what this particular data was about. The need to provide 
detailed evidence is therefore central to this approach too. 
 
The position adopted in this project follows closely these perspectives; it was 
felt essential throughout to explain the path chosen to both theoretical 
exploration and methodological choices. This was done respectively through 
Chapter 2 and this chapter, and aimed to provide readers with enough 
information to understand the choices made in this research, the reasons for 
these choices, and the origin and content of the data collected. Throughout the 
remainder of this study, citations from interviews will be used to illustrate the 
ideas put forward, and will offer extracts of raw data that readers can therefore 
directly access. Although questions might remain open as in most research, it is 
hoped that this will answer most issues that could be raised in relation to the 
validity of the data collected.  
 
In addition to the way methods and strategies were discussed, and to the way 
evidence was used to sustain the validity of this project, it is essential to come 
                                                 
268
 6HH6DQMHN5³2Q(WKQRJUDSKLF9DOLGLW\´Rp. cit. 
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back to the validity of the specific methods chosen and used in this project. A 
large part of the questions to be addressed have been discussed above, in the 
section dedicated to the three methods used ± interviews, observation and 
document analysis. One issue that has not been addressed yet, however, and 
needs to be looked at now, relates to the way these different methods fitted 
together, as a whole in this project, and how this is believed to have 
participated in increasing the validity and the comprehensiveness of this 
research. 
 
However, before discussing what have been the benefits of using multiple 
PHWKRGVLWLVHVVHQWLDOWRHPSKDVLVHILUVWZK\WKHWHUP³WULDQJXODWLRQ´KDVEHHQ
left aside throughout this chapter. Triangulation has been referred to in many 
projects as a way to check one method against the other, and compare findings 
collected through each method in order to determine whether they confirm 
each other or not. The term has become so commonly used that when putting 
forward the fact that several methods of data collections were used in a 
particular project, it is more than tempting to state that findings were 
³WULDQJXODWHG´DQGKRSH WKDWPRVW UHDGHUVZLOO WKHQDVVXPHWKDW WKH\PXVWEH
valid. The temptation has become easier to resist, however, thanks to the 
SRZHUIXOFULWLTXHVRIWKH³VWUDWHJ\´7ZRRIWKHVH± and certainly two essential 
ones ± are articulated in a clear way by Bloor269. The first critique made is 
SDUWO\ ³SUDFWLFDO´ ± although conceptual issues underlie it. In most research 
projects using several methods of data collection, one is generally privileged, 
                                                 
269
 %ORRU 0  ³7HFKQLTXHV RI 9DOLGDWLRQ LQ 4XDOLWDWLYH 5HVHDUFK D &ULWLFDO
&RPPHQWDU\´ LQ 0LOOHU * DQG 'LQJZDOO 5 HGV Context and Method in Qualitative 
Research, Sage Publications: London, pp. 37-50. 
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considered as most appropriate to the aims of the research, and therefore 
VRPHKRZ ³VXSHULRU´ WR RWKHU PHWKRGV XVHG LQ WKH SURMHFW ,I ZDQWLQJ WR
³WULDQJXODWH´ WKH ILQGLQJV PDGH WKURXJK WKLV ³VXSHULRU´ PHWKRG ZLOO EH
FRPSDUHG WR WKRVH RI WKH ³QRW TXLWH DV JRRG´ DSSURDFK %XW ZKDW LI WKH\
GLVDJUHH"6KRXOGRQHVHWRIGDWDSUHYDLORYHUWKHRWKHUEHFDXVHLW LV³EHWWHU´"
Should the other one just be ignored? And if not, is it right to challenge 
findings made through the most appropriate methods with those obtained 
WKURXJKDVRPHKRZ³LQIHULRU´VWUDWHJ\"$VORQJDVQRDQVZHUFDQEHIRXQGWR
WKHVH TXHVWLRQV WKH SHUWLQHQFH RI ³WULDQJXODWLRQ´ UHPDLQV TXHVWLRQDEOH
Although this critique is already quite powerful, and probably enough to 
generate a certain wariness, a deeper conceptual issue is also suggested by 
Bloor. Different methods generate inherently different types of information, 
and can therefore never be fully compared. The specificities of each type of 
interaction, the focus of particular methods or exercises, all produce particular 
UHVXOWVWKDWFDQQRWEHH[SHFWHGWR³VXSHUSRVH´QHLWKHUGRWKH\QHFHVVDULO\DLP
at collecting the same set of answers270. If this is the case, how can the validity 
of one be judged on the basis of the other? This second argument, once again, 
highlights the weakness of the notion of triangulation. The challenges brought 
to the concept of triangulation should not, however, result in casting doubts on 
the separate advantages remaining in the use of multiple methods for data 
collection.   
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 ³All research findings are shaped by the circumstances of their production, so findings 
collected by different methods will differ in their form and specificity to a degree that will make 
their direct comparison problematic´%ORRU0RSFLWRQS 
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These benefits can be stated generally, before illustrating them more 
specifically in relation to this project. The first of these advantages is that 
although they do not provide fully comparable data, different methods of data 
collection generate complementary sets of information. In addition to this, 
multiple methods have been presented as providing the researcher with better 
opportunities to understand their data ± although data from observation cannot 
EH³WKHVDPH´DVGDWD IURP LQWHUYLHZVZKDWKDVEHHQREVHUYHGFDQFHUWDLQO\
help understand better what has been said in interviews by highlighting the 
circumstances or environment to which they relate.271 These two elements were 
central in this research. First, observation and document analysis were aimed at 
obtaining data that could not be gathered through interviews ± material 
interactions, and the manifestation of TRIPS and pharmaceutical patents in 
particular documentary forms in Djibouti, for example, as mentioned before. In 
addition to this, each of the methods of data collected presented specific 
stories, generated particular findings. Although these were never considered as 
comparable, they each provided sets of concepts, narratives, and ideas that 
helped to understand better the meaning of others. By offering wider 
perspectives on what constituted the networks under scrutiny, and on the 
agency of TRIPS and pharmaceutical patents in these different networks, the 
combination of the methods presented above aimed at ensuring that the story 
told would be based not only on valid sets of information, but also on a valid 
understanding of their meaning by always locating them within other sets of 
associations. 
 
                                                 
271
 Hammersley M. and Atkinson P. ³,QVLGHUDFFRXQWOLVWHQLQJDQGDVNLQJTXHVWLRQV´
op. cit. on p. 131. 
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CONCLUSION 
 
The methods used throughout this research were those that balanced most 
effectively the practical imperatives of empirical work, the feasibility of the 
project undertaken, and an awareness of the weaknesses of rigid methods of 
data collection. In-depth interviews were chosen as the main method of data 
collection partly because they were the most feasible way of accessing the wide 
range of data needed in this project. However, they remained understood as a 
set of perspectives that this research aims to describe. In addition to this, 
observations were produced and used throughout this project, in order to 
include elements and data that would have been inevitably excluded from 
interviews. They participated in providing complementary data that added to 
the substance of interviews, as well as to the understanding made throughout of 
what had been said and done. However, this project remains understood as a 
particular story, and although it necessarily embeds some of the inevitable 
limitations of any textual translation and provides only some elements of a 
complex and multiple reality, it aims to describe in as much detail as possible 
the elements that make up TRIPS and pharmaceutical patents in Djibouti. By 
concentrating on a rather small set of objects to consider, it offers a way to 
include as much as possible in the story of these few objects ± although it also 
presents the inevitable difficulty of excluding others. The way it hopes to 
increase its validity and limit the potential weaknesses of any research process 
is by making its focus and limits as explicit as possible, hoping that in the 
process what has been included will be defined thoroughly if not perfectly 
fully. It has set itself a limited focus and provides a story on the subject chosen 
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as FORVHDVSRVVLEOHWRWKHUHDOLW\DVSRUWUD\HGE\LQIRUPDQWV¶QDUUDWLYHVDQGE\
my own observations as a researcher, and aims to provide throughout the 
following chapters enough information for readers to be able to perceive the 
potential role of further complexities that could not be fully detailed. Before 
entering the core of this analysis, and following the approach detailed in this 
chapter to analyse TRIPS and pharmaceutical patents as they appeared in 
Djibouti, the next chapter will provide some further elements of introduction 
on this case study. It will explain some elements of the networks in which this 
case study has been carried out, by presenting some of their dimensions that 
need to be known before following how TRIPS and pharmaceutical patents are 
DFWLQJDQGFLUFXODWLQJLQZKDWLVXQGHUVWRRGDV³'MLERXWL´LQWKLVUHVHDUFK 
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CHAPTER 4 - FINDING TRIPS AND PATENTS: AN INTRODUCTION 
TO THE VIEWPOINTS CHOSEN 
 
The aim of this research, and of the specific case study undertaken, is to 
understand the action of pharmaceutical patents and the TRIPS agreement in a 
least developed country in an extreme economic situation, and with a public 
health system on which empirical data still has to be produced. The example 
chosen also provided a good opportunity to test the relevance of actor-network 
theory to the study of transnational socio-legal objects. Throughout this 
research, it became clear that TRIPS and pharmaceutical patents in Djibouti 
could not be understood as single instruments, with a clear and unified role in 
the country as a whole. Understanding their role and mechanisms in a complete 
way could only be done by analysing how they acted and interacted in the 
different overlapping networks in which they have become enrolled and are 
enrolling. This will be developed in the next three chapters, by considering the 
empirical data collected during this research.  
 
This chapter is a preamble to the main analysis of data provided in the next 
three chapters. Its double aim is to narrow down once again the focus of this 
project by introducing some elements ± some aspects of networks - that are 
crucial to understand the analysis that will follow. This will be done by 
introducing Djibouti and some aspects of the main networks under scrutiny in 
this research. Three networks will be presented ± following a brief introduction 
WR 'MLERXWL LWVHOI 6HFWLRQ  7KH ³LQWHOOHFWXDO SURSHUW\ V\VWHP´ RI 'MLERXWL
will be introduced (Section 2). The public health system will then be presented 
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(Section 3). Finally, a few words will be given on the pharmaceutical industry 
of Djibouti (Section 4). These three areas have been chosen to reflect what 
DSSHDU DV ERWK UHOHYDQW DQG VRPHKRZ ³SXQFWXDOLVHG´ ILHOGV LQ D ZLGH VHW RI
writings about TRIPS. They also represent networks that appeared as largely 
independent in many respects in this thesis, and could therefore be isolated in 
this chapter for the purpose of introductory clarification without being overly 
arbitrary. 
 
The limits to the theoretical benefits of this chapter need to be acknowledged 
E\KLJKOLJKWLQJLWVWUDQVLWRU\UROHDQGLOOXVWUDWLQJWKHGLIILFXOWLHVRI³ZULWLQJDQ
$17DFFRXQW´GLVFXVVHGLQ&KDSWHU7KLVFKDSWHULVLQWHOOHFWXDOO\± as well as 
materially ± located between two largely different - if interdependent - tasks. 
:KLOH &KDSWHU  WR  KDYH EHHQ GHDOLQJ ZLWK ³FRQWH[WV´ GHEDWHV DQG
approaches in which this empirical research is located, Chapters 5 to 7 will 
fully bring together the ideas from ANT explained earlier and the empirical 
findings made in this project. The present chapter is transitory position because 
LWLVVWLOO³LQWURGXFWRU\´VWLOO³EDFNJURXQG´IURPPDQ\SHUVSHFWLYHVWKRXJKLW
narrows down the case study clearly. However, because it is still partly 
introductory, it does not yet fully engage with particular debates that will only 
EHSURJUHVVLYHO\DGGUHVVHG ,WDFWVDVD³VWDUWLQJSRLQW´E\XVLQJIRU WKH ILUVW
time in this empirical context some terms that are still not fully defined ± and 
that this research as a whole will ultimately clarify. It presents points in the 
network studied that are also enrolled in many other overlapping networks ± 
not all of which are relevant for this particular project. This means that the 
approach and narrative undertaken in this chapter will inevitably present some 
 185 
boundaries and limits that are necessary to any academic exercise, although not 
fully engaging with the theoretical perspective. Even so, the complexity and 
dynamics of each node analysed here will be rendered more visible by 
following the connections and associations that link them to/in TRIPS and 
pharmaceutical patents as they appeared in Djibouti, in the course of this 
fieldwork. 
 
SECTION 1: INTRODUCING DJIBOUTI 
 
More than many other countries, the Republic of Djibouti needs introducing ± 
this was, at leDVW WKH LPSUHVVLRQ WKDW FDPH RXW IURP PDQ\ SHRSOH¶V ILUVW
reaction to the focus of my research. Although this section needs to be short 
DQGWKLVLQWURGXFWLRQZLOOWKHUHIRUHRQO\EHSDUWLDOLWLVKRSHGWRJLYHD³IHHORI
WKH FRXQWU\´ WR UHDGHUV XQIDPLOLDU with the place. The pictures provided 
throughout this chapter aim to participate in providing readers with a clearer 
understanding of the country. Although they mainly offer views of Djibouti 
that are relevant to this whole chapter rather than specific pages, some of them 
will be referred to more specifically throughout the text. 
 
Although its history ± in particular up to the few years following its 
independence in 1977272 ± has gathered interest from a number of writers, and 
                                                 
272
 For a detailed History of Djibouti until its independence, see Hugo P. and Oberle P. (1996) 
Histoire de Djibouti, des Origines a la Republique, Paris : Presence Africaine. See also for 
example Dubois C. (1997) Djibouti 1888-1967, Heritage ou Frustration, Paris: L'Harmattan. 
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in spite of the presence of many famous writers in the country in the past273 ± 
Djibouti has somehow fallen into disregard and become one of these countries 
that many people would dismiss as irrelevant. This is partly understandable. 
After all, it is very small, the local population is smaller than that of many 
European medium-sized cities274. It is essentially covered with rocks. The 
³PDGH LQ'MLERXWL´ ODEHOGRHVQRW UHDFKDQ\RIRXUVKRSV7R WKDWH[WHQW WKH
choice of this particular case study could be questioned for its relevance. 
However, this relevance itself needs to be understood, in addition to the many 
academic reasons that I presented in Chapter 3, partly because there is much 
more to Djibouti than what common knowledge anticipates. Because in spite of 
what is often implied275, it is a country with its own history, identity, culture, 
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 For literature on Djibouti see Monfreid H. (ed. 1994) Secrets de la Mer Rouge, Paris: 
Grasset, or more recently: Waberi A.  (2002) Balbala, Paris: Gallimard; Waberi A. (2003) 
Transit, Paris: Gallimard.   
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 Although estimates are difficult to establish due to the fact that a part of the population is 
nomadic (and there are not as many updates as for many other countries), one estimate from 
the World Bank considered that in 2000 the population would be around 700000, with an 
annual natural rate of population growth of about 2.8%± although this could not take into 
consideration the illegal influx of refugees, mainly underreported; World Bank (2001) 
Memorandum of the President of the International Development Association to the Executive 
Directors on a Country Assistance Strategy for the Republic of Djibouti. 21414 DJI, available 
at: http://www-
wds.worldbank.org/servlet/WDSContentServer/WDSP/IB/2000/12/19/000094946_001201053
0366/Rendered/PDF/multi0page.pdf) Overall, about 80% of people are thought to live in the 
Capital, while most of the others are spread between the main towns of Tadjoura, Ali Sabieh, 
Dikhil and Obock.  
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 2Q WKH DVVXPSWLRQ WKDW 'MLERXWL VKRXOGFRXOG PD\EH ³PHUJH´ ZLWK RQH RI LWV ODUJHU
QHLJKERXUVVHHIRUH[DPSOHGH:DDO$³7KHSHUYHUVHORJLFWKDWGLvides impoverished 
$IULFD´7KH*XDUGLDQth -XQH³Take Djibouti in north-east Africa. It has about half a 
million people and almost no domestic economy. It depends wholly on three things: a port and 
railway link that serve the much larger economy of landlocked Ethiopia, a French military 
base (recently augmented by a US command centre, used for keeping watch on Yemen and 
monitoring al-Qaida's attempts to infiltrate the Horn of Africa), and lastly the fact that tiny 
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that deserves to be known ± and more importantly for the purpose of this 
thesis, that needs to be understood. This section aims to provide a very basic 
but necessary introduction to a country more complex than these few 
paragraphs can explain, and which in part of those complexities will appear 
throughout the remainder of this research. 
 
Once again, part of the reputation of Djibouti ± RULWV³QRQ-UHSXWDWLRQ´- can be 
explained, and for many foreigners stepping into the country, the first wave of 
heat and a first look around will often create an immediate urge to leave. When 
listening to the constant complaints of some of the French soldiers and their 
families based in the country, there could not be a worse place to live ± and 
these complaints soon become as irritating as unjustified. Local people are 
keen to reemphasise that life is rather good in Djibouti compared to 
neighbouring Somalia, nearby Sudan, and other countries of the region from 
which stories of war and starvation constantly arrive. Djibouti is certainly a 
³FRXQWU\RIH[WUHPHV´276 but this is partly what makes it most interesting to get 
to know ± including for sociological inquiry. The weather can certainly be a 
deterrent, in a country where temperatures can reach 50C in the summer, where 
rain falls only a few times a year ± which does not eradicate the risks of 
                                                                                                                                 
Djibouti, by virtue of its sovereign independence, has a seat at the United Nations, the African 
Union and the Arab League, and therefore also has representation at the World Bank, UN 
VSHFLDOLVHGDJHQFLHVDQGELODWHUDOGRQRUV«)LYH\HDUVDJRWKHUHZDVVRPHGLVFXVVLRQWKDW
Djibouti might merge with its neighbour Ethiopia ´ 
276
 Sellen J. (ed)(2003) Djibouti, Terre des Extremes, Milan: Graphic International Publishers ± 
the picture of Ali Sabieh provided on the next page is an illustration of the most dry of its 
dimensions.  
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flooding277 - DQG ZKHUH WKH VXQ LV DOZD\V KLJKO\ ³WKUHDWHQLQJ´278. The 
economic situation is also certainly highly concerning279. Agriculture is almost 
unknown280 ± how could it be different considering the weather conditions and 
the fact than less than 0.3% of the land is cultivable281? Industry has been very 
OLPLWHG VR IDU DQG PRVW RI WKH FRXQWU\¶V HFRQRP\ LV EDVHG RQ VHUYLFHV282. 
'MLERXWL¶VORFDWLon on the Red Sea and its international port have been the main 
assets of its development, and it represents a central point of passage for goods 
travelling between Arabic countries and Africa ± in particular land-locked 
Ethiopia283. Most striking, however, is the human side of this economic crisis. 
About 50% of the population is believed to live below the poverty line284, and 
the same proportion is officially unemployed ± although estimates need to be 
looked at carefully, since the situation of refugees is often overlooked and 
difficult to establish. According to the World Bank, it could be the case that 
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 A few hours of rain while I was carrying out the last stages of my fieldwork created 
extensive damage and several deaths± for details and pictures of the damages caused, see 
http://www.who.int/disasters/repo/13002.pdf#search='photos%20hospital%20djibouti' (see 
also the picture provided in this chapter.) 
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 A particularly fair-skinned friend of mine is still remembered by some in the country 
several years after visiting it for managing to get a nasty sunburn sitting in shed, with a long-
sleeved top and in spite of having used a fair amount of sunscreen.  
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 :RUOG%DQNRSFLW³2YHUWKHSDVWWZRGHFDGHV'MLERXWL¶VVLWXDWLRQKDVEHFRPH
increasingly precarious, with stark declines in per capita income, structural problems and 
GHFOLQLQJH[WHUQDODVVLVWDQFH7KHFRXQWU\¶VUHJLRQDOHFRQRPLFLPSRUWDQFH«KDVGHFOLQHG
in recent years as neighbouring countries have adopted market oriented policy reforms and 
'MLERXWL¶VRZQHFRQRPLF situation has deteriorated´RQS 
280
 A few fruits and vegetables are grown in the limited fertile zones of the country, near 
Ambouli. 
281
 World Bank (2001) op.cit. 
282
 70 % of GDP (World Bank (2001) op. cit) 
283
 7KHFRXQWU\¶VVWUDWHJLFVLWXDWLRQKDVDOVRSODyed a part in attracting interest from France that 
led to its colonization ± see Dubois C. (1997) op. cit. 
284
 and 10% of the population is considered as extremely poor (World Bank (2001) op. cit.) 
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unemployment rates amongst certain groups are much higher when 
disaggregated, and certain age categories are particularly vulnerable ± 80% of 
those between fifteen and twenty years old are believed to be unemployed285. 
The familial and social ties that unify the relatively small and compact 
population are essential in limiting the potential disaster that this could create. 
When people are in a critical situation, family and community networks are 
considered crucial, and it is common to have a few people on which a whole 
family is almost fully dependent286. 
 
Djibouti is culturally and politically at the crossroads between East and West, 
Africa and Middle East. It has been an important centre of immigration for 
many years from neighbouring countries facing civil wars or food crisis, in 
particular since the state has enjoyed relative stability compared to others in the 
region and the diversity of the population has continued to increase. Its 
population is largely mixed, with two main ethnic groups ± Afars and Issas ± 
that have been in rivalry for many years287. The majority of the population are 
thought to be Issas - although most of the Afars maintain that the data is biased 
by the high number of Afar nomads, and that the proportions of Afars and Issas 
are almost identical288. Other ethnic groups established in the country for 
several generations include Yemenites, Indians, and Greeks. In addition to this, 
since the country became independent, a strong French presence has remained, 
                                                 
285
 World Bank (2001) op. cit. 
286
 $Q LQIRUPDQW H[SODLQHG ³Everything works through the family here. If someone cant get 
VRPHWKLQJWKH\ZLOOUHO\RQWKHIDPLO\WRJHWLWIRUWKHP´ 
287
 7KDWKDVEHHQSDUWO\DWWKHURRWRIWKHFLYLOZDUWKDWVKRRNWKHFRXQWU\LQWKH¶V 
288
 In addition, official estimates in Djibouti are often considered as biased by the Afar because 
the government is essentially Issas and might not release objective data, in their view. 
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and in particular Djibouti is still nowadays the biggest permanent military base 
abroad for France. An important number of cooperants are still provided in 
each Ministry, and French advisors still pOD\DQLPSRUWDQWUROHLQWKHFRXQWU\¶V
policies. In addition to the French presence, an important American base has 
opened in the country following the start of the so-FDOOHG³ZDURQ WHUURULVP´
and the country is used as a base from which to contain terrorist networks in 
the region. Similarly, German soldiers are based in the country, and a number 
of foreign boats ± Spanish in particular ± use the port as their main base in the 
region. Finally, and as mentioned before, crises in neighbouring countries have 
generated a large flux of refugees moving to Djibouti ± although their number 
is impossible to evaluate289. 
 
Djibouti is therefore a state in which a great mix of cultures and origins 
relate290. It is also a state that has been relatively close to a number of powers 
with possibly divergent interests. In particular, it is constantly trying to fit 
between the influence of Europe and the US, hoping to see the place becoming 
central in the development of a modern form of Islam, and between that of 
stronger Islamic powers such as Saudi Arabia or Yemen, hoping to see the 
place turn more clearly towards the Middle East. It is in Africa without feeling 
                                                 
289
 As an indication of the extent of illegal immigration from neighbouring countries, as 
compared to the size of the population, it is interesting to mention that in 2003, the government 
of Djibouti announced that it would expel 100 000 illegal immigrants ± for press report, see for 
H[DPSOH7KH*XDUGLDQ³Djibouti throws out its immigrants´th September 2003. It should 
be noted, however, that the common understanding in Djibouti is that many of those expelled 
have since then manage to re-enter the country (legally or not). 
290
 The next three pictures of Djibouti-WRZQSURMHFWVRPHLPDJHVRIWKH³IHHOLQJ´RIWKHWRZQ
partly resulting from this cultural richness.  
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fully African291, and quickly gives the impression of being characterised by a 
great mix in many respects. Finally, it is also a country where things work 
fundamentally differently from what a European might expect, where notions 
of time are as flexible as possible, where the difference between what will 
happen and what should happen is stronger than in most places, and where the 
QDWLRQDO UHOLDQFH RQ *RG¶V ZLOO TXLFNO\ EHFRPHV FRQWDJLRXV 1RWKLQJ LV HYHU
sure, what is written on paper and planned might or might not happen, no-one 
can ever be sure and especially not a foreigner trying to understand how some 
international law far from everyday concerns will be implemented. However, 
regardless of all the difficulties that the country faces, its natural beauty and 
cultural diversity make it a captivating country, rich in many respects. 
 
In spite of what might all seem unique to a particularly small, particularly poor 
DQGVRPHKRZGLIIHUHQWFRXQWU\RQHPLJKWZRQGHULI'MLERXWLLVPRUH³XQLTXH´
than any other place. That observation might lead to questioning whether or not 
ZKDWZHH[SHFW WR ILQG LQ³GHYHORSLQJ´VWDWHVRU LQDQ\VWDte for that matter, 
PLJKW EH DQ\WKLQJ HOVH WKDQ ³XQLTXH´292. The need to reconsider some 
                                                 
291
 Local people generally refer to people from other African countries as « the Africans », and 
often raise the fact that maybe they should actually see themselves as African too. 
292
 This reminds of the following comment made by Latour: ³7KHJUHDWGLYLGHEHWZHHQ8V± 
Occidentals ± and Them ± everyone else, from the China seas to the Yucatan, from the Inuit to 
the Tasmanian aborigines ± has not ceased to obsess us. Whatever they do, Westerners bring 
history along with them in the hulls of their caravels and their gunboats, in the cylinders of 
WKHLU WHOHVFRSHV DQG WKH SLVWRQV RI WKHLU LPPXQL]LQJ V\ULQJHV 7KH\ EHDU WKLV ZKLWH PDQ¶V
burden sometimes as a tragedy, but always as a destiny. They do not claim merely that they 
differ from others as the Sioux differ from the Algonquins, or the Baoules from the Lapps, but 
that they differ radically, absolutely, to the extent that Westerners can be lined up on one side 
and all the cultures on the other, since the latter all have in common that they are precisely 
FXOWXUHVDPRQJVWRWKHUV ,Q:HVWHUQHUV¶H\HV WKH:HVWDQG WKH:HVWDORQH LVQRWDFXOWXUH
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assumptions one might have on social life when hoping to understand how law 
ZLOODIIHFWSHRSOH¶VEHKDYLRXUEHFRPHVSUHVVLQJZKHQFRQVLGHULQJKRZPXFK
VRPH ³GHYHORSLQJ´ Vtates might in fact have in common. This case study is 
thus based on a country that many would dismiss as lost and irrelevant, maybe 
not worth the trouble of social inquiry, but that is also important to many and 
probably no more unique than any other. By looking at this small state in 
detail, many questions will be raised about the assumptions of a literature too 
quick in judging what developing countries have in common, rather than 
wondering what makes every social network unique. Before looking in more 
detail at the specific fields with which this research is mainly concerned, a few 
other aspects should be highlighted, as they will be central when considering 
how Djibouti might respond to the implementation of TRIPS. The first element 
to be described will be the current IPR system. I will then present the public 
health situation of the country, before introducing the status of the two attempts 
to develop a local pharmaceutical industry. 
 
SECTION 2: DJIBOUTI AND IPR LAW ± PRE-75,36³,356<67(0´ 
 
As emphasised in ANT, change is one of the most central catalysts for waking 
the sleeping connections so that they become visible to social researchers293. 
The implementation of TRIPS in the political networks of Djibouti is calling 
for new changes. It is expected to reshape the links between the many actors 
                                                                                                                                 
not merely a culture Latour B. (1993). We Have Never Been Modern, Brighton: Harvester 
Wheatsheaf on  p. 97. 
293
 See Latour B. (2005) Reassembling the Social: An Introduction to Actor-network Theory, 
Oxford: Oxford University Press. 
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WKDWPDNHXSZKDWLVRIWHQVXPPDUL]HGDV³WKHLQWHOOHFWXDOSURSHUW\V\VWHP´RI
the country. The next chapter will detail the changes taking place because of 
TRIPS, and will highlight the range of connections that generate action in 
relation to IPR in Djibouti. Before doing so, however, it is useful to introduce 
the previous events in the IPR area in Djibouti. This will be essential in order 
to understand where the changes required by TRIPS are happening. 
 
Creating IP laws 
 
In terms of competence, the Ministry of Trade is in charge of industrial 
property issues. It is thus responsible for the creation of patent laws and the 
implementation of patent-related dispositions of TRIPS. The Ministry of 
Culture is in charge of other forms of IPR, and deals in particular with the issue 
of creative and artistic rights. The next chapter will show that this is a partly 
inappropriate and unspecific presentation, and that, when looking inside the 
Ministry of Trade more detail needs to be given as to what is hidden behind 
these terms. 
 
The history of Djibouti in relation to IPR will not detain us for long. In relation 
to patents, and concentrating on the legal system of Djibouti per se, no patent 
law has been adopted since the country became independent. However, one 
aspect of the intellectual property regime of Djibouti is worth detailing. This is 
not as such for what it demonstrates in relation to its specific content, but 
mainly for the example it sets in relation to the practical application and the 
social situation of one intellectual property instrument in Djibouti. This part of 
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history relates to the protection of artistic and creative rights. In 1996, the 
Ministry of Culture put forward a law to protect artistic and literary creations. 
This law was adopted by the Parliament294. This was felt as appropriate in 
order to promote intellectual and creative activities in the country. For the first 
time, intellectual property became an active part of political debates, and 
materialised in a text of law expected to generate further mobilisations. The 
text of the law itself seems to offer a rather strong protection for authors295, and 
refers in particular to a new structure within the Ministry that would study 
applications and grant authors the named protection296. The structure is to be 
created by decision of the Council of Ministers. Since 1996, however, the 
structure has never been created ± and consequently the law has never been 
applied. The brief social role of this intellectual property concept in generating 
discourses disappeared very quickly, and the text became a set of materials put 
aside, isolated, and followed by no further impact. Lawyers questioned on this 
issue seemed to see it as rather normal in the country: 
 
 ³This kind of things happens all the time ± there are so many laws that have 
been adopted because of pressure, lobbying, or on the basis of external advice 
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 /RLQR$1H/UHODWLYHDODSURWHFWLRQGXGURLWG¶DXWHXU 
295
 $UWLFOH³/¶DXWHXUG¶XQHRHXYUHMRXLWVXUFHWWHRHXYUHGXVHXOIDLWGHVDFUHDWLRQG¶XQ
GURLWGHSURSULHWHLQFRUSRUHOOHH[FOXVLYHHWRSSRVDEOHDWRXV´$UWLFOH : « Les dispositions de 
ODSUHVHQWHORLSURWHJHOHVGURLWVGHVDXWHXUVVXUWRXWHVOHV°XYUHVOLWWHUDLUHVVFLHQWLILTXHVRX
DUWLVWLTXHV RULJLQDOHV TXHOTX¶HQ VRLHQW OH JHQUH OD IRUPH G¶H[SUHVVLRQ OH PHULWH RX OD
destination, et sans que cette protection ne soit assujettie a une quelconque formalite. » 
296
 $UWLFOH³La gestion des droits ainsi que la defense des interets moraux et materiels des 
auteurs et compositeurs seront FRQILHV D XQ RUJDQLVPH G¶DXWHXUV HW FRPSRVLWHXUV GHQRPPH
%XUHDX 'MLERXWL GX GURLW G¶DXWHXU %''$ GRQW OHV DWWULEXWLRQV HW OH IRQFWLRQQHPHQW VHURQW
IL[HVSDUGHFUHWSULVHQ&RQVHLOGHV0LQLVWUHV´ 
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from organisations for example. The Parliament passes the law, but then when 
it comes to applying it, no one knows what to do with it, and nobody is 
LQWHUHVWHGLQLWDQ\PRUHRUWKH\UHDOLVHZHMXVWGRQ¶WKDYHWKHPHDQVWRDSSO\
LW´ 
 
 However, the introduction of TRIPS is now calling for this law to be revised ± 
and applied ± and it is therefore now becoming once again a policy actor ± and 
potentially a mobilising force in future change.  
 
'MLERXWLDQG³,3RUJDQLVDWLRQV´ 
 
A second set of connections that appeared in the past few years in Djibouti in 
UHODWLRQ WR ,35 OLQNHG DFWRUV LQ 'MLERXWL WR SDUWLFXODU ³LQWHUQDWLRQDO
orgaQLVDWLRQV´ ± although, once again, this terminology hides much of the 
complex connections gathered in these systems. Until recently, Djibouti was 
not a member of any IPR organisation. However, in particular since signing the 
TRIPS agreement, it has started accessing several key treaties. First, Djibouti 
started the process to become member of the Organisation Africaine de la 
Propriete Intellectuelle (OAPI)297. However, policy-makers quickly felt that 
WKLVZDVQRWWKHULJKWFKRLFHZLWKUHJDUGVWR'MLERXWL¶VHFonomy and relation to 
other states:  
 
                                                 
297
 Loi no63/AN/94/3eL Portant Adhesion de la Republique de 'MLERXWLDO¶$FFRUGGH%DQJXL
LQVWLWXDQW O¶2UJDQLVDWLRQ $IULFDLQH GH OD SURSULHWH ,QWHOOHFWXHOOH 2$3,  For 
information on the OAPI iself and the Bangui agreement, see 
http://www.oapi.wipo.net/fr/OAPI/index.htm 
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³The Organisation covers in practice a very clearly defined geographical area 
± it mainly covers West Africa. Djibouti is located in a very different 
economical space, namely the Gulf. And in this area, countries have developed 
their laws completely independently, so we thought it would be more 
appropriate for us to work on an independent model, like our economic 
SDUWQHUV«´298 Consequently, Djibouti left the OAPI and accessed WIPO in 
2002299. In order to fulfil the conditioQV IRU MRLQLQJ VHW E\ :,32¶V WUHDW\
Djibouti had to ratify the Paris Convention, and the Berne Convention in the 
same year300. 
 
2YHUDOO ZKHWKHU WKHUH ZDV VXFK WKLQJ DV DQ ³,35 V\VWHP´ LQ 'MLERXWL XQWLO
TRIPS became part of the story is open to questioning. A number of 
connections were made and unmade, demonstrating the difficulties for any 
actor-network to remain stable in the area. The following chapters will show 
how the mechanisms of TRIPS in Djibouti can be understood if following the 
set of existing or failing connections built around the new instrument, and how 
the uncertain situation which preceded TRIPS is being modified. 
 
 
 
 
 
                                                 
298
 This example is also revealing in what it says about the complex situation of Djibouti that 
FRXOGEHGHVFULEHGDV³JHRJUDSKLFDOO\LQ$IULFD´VRFLDOO\LQWKH0LGGOH(DVW« 
299
 Loi no150/AN/02/4eme L Portant Adhesion de la Republique de Djibouti aux Conventions 
Internationales Relatives a la Propriete Intellectuelle, le 31/01/2004. 
300
 Loi no150/AN/02/4eme op. cit. 
 197 
SECTION 3: PUBLIC HEALTH IN DJIBOUTI: DEFINING SOME 
TERMS AND NETWORKS 
 
The particular focus of this research has called for an in-depth scrutiny of the 
role and action of both TRIPS and pharmaceutical patents in relation to health.  
The observation of both objects has therefore taken place largely in the public 
health field, and it is necessary to introduce briefly what is understood as 
³SXEOLF KHDOWK V\VWHP´ LQ WKLV SURMHFW 7KLV ZLOO EH GRQH LQ PRUH GHWDLO
throughout the next few chapters, but in order to provide an idea of the type of 
issues and situation with which we will be concerned, this section needs to 
introduce some aspects of this field.  
 
The field of public health is characterised by numerous ruptures and 
uncertainties in Djibouti. This makes the harmony of the narrative provided 
slightly broken at times, as, rather than the coherent and stable image that the 
notion RI³SXEOLFKHDOWKV\VWHP´WHQGVWRSURMHFWWKLVVHFWLRQZLOOGHDOZLWKD
range of networks acting fairly independently from one another. If the question 
to be answered here relates to the nature and structure of what can fall within 
WKHWHUP³SXEOLFKHDOWK´LQ'MLERXWLDWOHDVWWKUHHGLIIHUHQWHOHPHQWVQHHGWREH
considered at this stage. This section will review in turn the main 
diseases/health concerns with which the country has to deal ± the hospital 
structures  which have been developed to deal with these concerns; and finally 
where and how drugs to fight these concerns can be obtained. 
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Health concerns 
 
When wanting to discuss how TRIPS and pharmaceutical patents might be 
impacting on health in Djibouti, an important starting point is to explain what 
diseases are currently considered as forming part of the health concerns of the 
country. The relation between the treatment of these diseases and 
pharmaceutical patents will be discussed in more detail in Chapter 7, as will be 
the changes currently operating in the classification of health priorities in 
Djibouti. However, a few introductory words are needed on the type of issues 
faced by the country. As might be anticipated from the economic situation of 
Djibouti301, it is facing a serious health crisis. The specific nature and extent of 
this crisis is particularly difficult to describe because, in addition to the fact that 
little official data exist about this, it is defined in different ways by different 
sources. The data provided here aims to emphasise both common and diverging 
information which appeared in this field. Chapter 7 will return to the meaning 
of these discrepancies and their potential consequences.  
 
When looking at the diseases discussed in Djibouti ± and by those looking at 
Djibouti ± three such diseases most traditionally thought as health crises in 
Africa appear straightaway. TB is the disease most commonly put forward by 
actors met in Djibouti on the ground ± World Bank reports also put forward the 
high TB prevalence in the country, statinJ WKDW ³with 588 case of TB per 
100000 inhabitants, Djibouti has the second highest rate of TB in the 
                                                 
301
 And the picture of the centre of Tadjoura, second city of the country,  provided before can 
offer an illustration of these difficulties 
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world´302. The extent of the TB crisis was not contested by any actor met in the 
course of this research, and it is fair to say that it was framed as one of the most 
central concerns for health professionals during the fieldwork period. It was 
also a unique example of a disease portrayed as crucial both by actors in and 
outside Djibouti. Once again, few reports exist in relation to the health situation 
of Djibouti. The World Bank has produced several reports prior to funding 
some projects that will be described in Chapter 7, and the government of 
Djibouti has also produced official information ± although the most recent 
dates back from 2000. If looking at the World Bank reports, malaria is an 
LPSRUWDQWFRQFHUQLQ'MLERXWL³since 1988, malaria is steadily increasing and 
reaching areas where it was unknown before´303. This contrasts with 
statements from doctors in Djibouti, one of them stating for example that 
³thHUHZDVORWVRIPDODULD\HDUVDJREXWLQWKHODVWFRXSOHRI\HDUVWKDW,¶YH
EHHQ KHUH , KDYH RQO\ VHHQ YHU\ IHZ FDVHV ,W¶V QRW UHDOO\ D SUREOHP DW WKH
moment.´ 7KH VDPH GLVFUHSDQFLHV DSSHDU ZKHQ FRQVLGHULQJ WKH +,9$,'6
prevalence in the country. The :RUOG%DQNVWDWHVWKDW³nation-wide HIV/AIDS 
sero-prevalence rate is estimated at 3.0% of the whole population´304. In the 
same report, it also mentions that its research did not offer results as high as the 
1999 UNAIDS estimate amongst Djiboutian adults 15-49 (11.9%). For actors 
interviewed in Djibouti, however, AIDS should not be the main health priority 
yet. This will be discussed in detail in Chapter 7. Next to these three diseases, 
several cholera outbreaks have been recorded in the country in recent years, 
                                                 
302
 World Bank (2003) Report No AB7, Updated Project Information Document, HIV, Malaria 
and Tuberculosis Control Project, March 2003 on p.1. 
303
 World Bank (2003) Report No AB7, op. cit. on p.1. 
304World Bank (2003) Report No AB7, op. cit. on p.1. 
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catching the attention of both national actors ± recording that the most serious 
one in 1993 had touched 4415 people, while the latest one in 2000 concerned 
1920 patients305 ± and the WHO306. 
 
In addition, the health situation of the country needs to be understood within 
the broader difficulties that the country is facing, and in particular its economic 
situation307. The most characteristic concern linked to this environment is that 
of malnutrition308. The extent of respiratory and diarrhoeal diseases of the 
population, especially young children, is also a reflection of the broader 
problems faced by the country309. The high rate of maternal death in the 
country can similarly be read in the context of poverty and poor sanitation. 
Finally, heart problems were commonly put forward by actors interviewed, and 
related in particular to behavioural causes310. 
 
                                                 
305
 Sante publique a Djibouti ± internal document, Ministry of Health, 2003. 
306
 http://www.who.int/csr/don/1997_11_26b/en/index.html 
307
 ³Approximately 33 percent of the population lacks access to potable water and sanitary 
conditions, and many are very poor´:RUOG%DQN*URXS 5HSRUW1R$%RSFLWRQ
p.1. In addition, the following photograph offers a view of Djibouti after the floods of April 
2004 mentioned earlier in this chapter ± this picture illustrates some of the factors that can 
quickly participate in the spread of epidemics in the country. 
308
 Estimates from 1995 made on a sample population of children less than five years old, 
consider that 14% of them suffer from serious malnutrition, and 31.1% from chronic 
malnutrition. These results presented a strong increase as compared to those of a study realised 
in 1990. Although the results from 1995 are not recent, and new estimates would be useful, 
they illustrate the extent of this concern 
309
 If looking at young children and the reasons why they are taken to hospital, the three key 
factors are respiratory diseases (36.6%), diarrhoea ( 21.2%) and malnutrition (11.6%)309 - Sante 
publique a Djibouti ± internal document, Ministry of health, 2003. 
310
 More commonly than the diets of rich minorities, the consumption of Khat (a drug grown in 
Ethiopia and Yemen, chewed by most men and some women, during most of the afternoon) 
was put forward to explain the high rate of heart conditions. 
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The data presented above might not be particularly unusual, except maybe in 
the contrast and discrepancy concerning specific and well-known diseases, 
such as malaria and AIDS. To that extent, when looking at this list of health 
concerns, it might be assumed that the situation of Djibouti does not present 
anything truly contrasting with common understandings of health difficulties in 
Africa. Analysing the meaning of the impact of TRIPS in this system might 
not, therefore, be any stranger than studying its impact in many other countries. 
However, as this thesis progresses it will demonstrate how, when looking more 
closely at some of the discrepancies highlighted and at the role of TRIPS and 
patents in this system, this case study will participate in generating new 
questions in relation to this same common understanding of what makes health 
such a difficult issue in poor countries.  
 
Hospital system(s) and access to treatment 
 
The second step in understanding what will be referred to when talking about 
³SXEOLFKHDOWK´ LQ'MLERXWL LV WR LQWURGXFH WKHKRVSLWDO V\VWHP ± or rather the 
different co-existing systems ± through which diseases and poor health are 
addressed in Djibouti. This is partly peripheral to the core of the research 
questions, and is not something that needs, therefore, to be explained in full 
detail. However, it is also something that needs to be introduced, as it is an 
HVVHQWLDO SDUW RI WKH RYHUDOO ³SXEOLF KHDOWK V\VWHP´ WKDW ZLOO EH UHIHUUHG WR
throughout this project. It is also in many respects symbolic of some of the 
difficulties that will be highlighted in this field. In addition to this, and most 
importantly, understanding the distribution of patients in specific structures as 
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well as the overall medical system of the country will be central when 
discussing both import systems and changes in the pharmaceutical markets in 
Chapters 6 and 7. Finally, as the following chapters will often refer to the 
names of particular structures, it is essential to provide a more precise picture 
of what these names cover.  
 
The importance of the hospital system in the country is better understood by 
emphasising the fact that they are the first place where patients can hope to get 
access to treatment. By opposition to what is the case in many countries, 
private doctors are the exception rather than the rule, and patients will visit 
hospitals for most consultations.  Highly varied standards appear in the hospital 
system of the coXQWU\PDNLQJFOHDUWKHGLIILFXOWLHVRIJXDUDQWHHLQJ³KHDOWKIRU
DOO´ LQ WKHFRXQWU\$OWKRXJKPXFKPRUH WLPHFRXOGEH VSHQWGLVFXVVLQJ WKLV
particular range of difficulties, this section can only remain basic, essentially 
serving the aims mentioned above. When looking at hospitals in the country, 
the largest health related structures can be divided between the public hospital 
(Hopital Peltier), the semi-public structure for local workers (Organisme de 
Protection Sociale (OPS)), and the French military hospital (Hopital Bouffard). 
In addition, a number of smaller dispensaries are spread around the country. 
 
³3DWLHQWVZLOOEDVLFDOO\ILUVWWU\WRJHWLQWR%RXIIDUG,IWKH\FDQ¶WWKH\¶OOWU\WR
JHWLQWRWKH236$QGLIWKH\FDQ¶WEHDFFHSWHGLQHLWKHUWKHLURnly option will 
be to go into Peltier´ 
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This quote is a particularly clear illustration of the relative situation of the three 
main health structures of the country. The negative reputation of the Hopital 
Peltier is a crucial element. At the time of fieldwork, it was the very last option 
for everyone, and brief consideration quickly shows many reasons for this. 
$OWKRXJKXQWLOWKLUW\\HDUVDJR3HOWLHUZDVFRQVLGHUHGDYHU\JRRGKRVSLWDO³a 
reference in the region´ LWV VLWXDWLRQ KDV VLQFH WKHQ VORZO\ GHJUaded. The 
hospital is believed to be weak on many aspects, from the qualifications of staff 
to the number of beds available, the availability of drugs, or even the 
salubriousness of most of the wards. In terms of medical staff, the hospital has 
thirty five doctors, including two Djiboutians, and cooperants from several 
countries311. Several problems arise from this mix. First, the system of 
cooperation raises issues of communication and harmony312.  
 
³7KHUHLVYHU\OLWWOHFRRUGLQDWLRQEHWZHHQDQ\RQH¶VDFWLRQRU approach here ± 
donations come from here and there, different countries send a bit of money, a 
IHZVWDIIEXWQRWKLQJVHHPVFRKHUHQW´ 
 Second, the inadequacy of the staff in terms of speciality is often mentioned as 
a key problem of the hospital ± some specialities are not represented at all, 
while other key fields are under-represented313.  
 
                                                 
311
 It should be noted that changes in the hospital happen frequently, and that the situation 
described here is as it was described in 2004. 
312
 China has in particular provided medical staff most recently, although none of them speaks 
French or any other local language, which makes consultations rather chaotic. Egypt was also 
providing four doctors, who have all left recently after a conflict with the local staff ended up 
in a general fight leading to a wide diplomatic incident. 
313
 Only two surgeons are available, which is insufficient to deal with the population referred to 
them, especially in cases of emergency.  
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In terms of facilities, the hospital also has poor reputation, both amongst 
PHGLFDO SURIHVVLRQDOV DQG DPRQJVW ORFDO SHRSOH DV D ZKROH ³Trust me, you 
GRQ¶W ZDQW WR VWHp in there! Nobody wants to anyways ± LW¶V VR GLUW\ DQG VR
disgusting«´314 Facilities are getting old, inadequate, badly maintained and 
often not up to any cleanness standards. The government makes some forms of 
investment in the hospital, and a brand new building has, for example, been 
constructed recently. It contains amongst other things a new X-ray machine, of 
YHU\KLJKVWDQGDUGHYHQRQ³(XURSHDQ´FULWHULD DFFRUGLQJ WRVHYHUDOGRFWRUV
However, without any radiologist in the hospital at the moment, it is very likely 
that no-one will be able to use or maintain this machine, and many wonder why 
VRPXFKPRQH\ZHQWLQWRVRPHWKLQJWKDWZLOOEHRIYHU\OLWWOHXVH³What are 
they going to do with it now? It all looks great, and we can say that we have a 
highly modern device ± but then how to use it? How to maintain it? In a year it 
ZLOOSUREDEO\EHFRPSOHWHO\RXWRIRUGHU«´ 
 
The second hospital that will be referred to throughout this project is the semi-
public OPS (Office de Protection Sociale), which provides free health services 
to private employees in Djibouti. It is based on a health insurance system 
where employers have to pay a certain monthly amount towards the structure315 
and where employees may then benefit from the services. Most of the people 
treated there have low incomes ± many employed as maids or private guards 
for example - DQGZRXOGQRWEHDEOHRWKHUZLVHWRDFFHVVKHDOWKWUHDWPHQWV³We 
mainly treat people with little resources, people employed privately as maids 
                                                 
314
 This comment was made by a local patient shortly after I arrived, when I stated that I had 
not had visited Hospital Peltier yet. 
315
 7.2% of salaries, according to informants from the hospital. 
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for French people here, and their families´ 7KH VWDQGDUG RI VHUYLFHV LV
believed to be rather high, according to informants from the medical field, or 
from patients of the structure. Doctors are French and local doctors. Overall, 
and although the structure lacks a few specialists, it is considered an efficient 
hospital, and is now much favoured above the public hospital. 
 
The last of the main hospital structures in Djibouti is the French military 
hospital ± CHA Bouffard. The hospital is a fully French-run structure, 
administered by the central health administration of the Army, with fifteen 
French doctors, and both French and local staff. Access to the hospital is run 
both by formal and informal rules. Officially, the hospital is open to French 
military staff and their families, as well as members of the Djiboutian army and 
their families, and a number of contractors ± such as German soldiers based in 
the region, or most other employees from military boats using the port. In 
addition, local people can access the hospital according to rules which seem 
more based on customs or habits than on written regulation ± although written 
rules do, of course, exist. While I was carrying out fieldwork, the hospital had 
just been put under new management, and rules of access seemed to have 
become more restrictive316.  
 
                                                 
316
 This has been criticised both by a number of the French doctors employed in the hospital, 
and by local people and members of the Djiboutian government. Ministers have thus been 
refused access by the soldier in charge of letting people in, and had to call doctors they knew 
personally to enable them to access to facility. The issue became more controversial recently, 
when the President of the Republic of Djibouti was refused access by a soldier because he did 
not have his ID on him. 
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The basic rule for accessing the hospital was that patients needed to have an 
appointment with a doctor to be able to enter the premises of the hospital. In 
practice, people who were not officially on the main list of those who are 
allowed to enter the hospital needed to know one of the doctors or staff, in 
order to obtain a certificate of appointment signed by a doctor. Apart from 
particular controversies in determining who should be eligible as patients, the 
hospital is a well-run structure, of high quality even by European standards, 
and with most medical specialities represented. Many patients who can access 
the hospital can be exempted from payments although most medication is to be 
bought from private pharmacies once the patient gets out of hospital. In terms 
of facilities, tests or drugs available within the hospital, the structure also 
follows French standards, and does not encounter any specific difficulties.  
 
In addition to these main medical structures, a few others are worth 
mentioning. First, a few private doctors are established in Djibouti-town, as 
well as a private clinic ± access is generally, however, limited to patients with 
enough money to pay for consultation. In addition to this, smaller public 
hospitals are run ± technically, every district has its own hospital, although 
their state is as can be expected by comparison to what is considered as the 
³PDLQ´ SXEOLF KRVSLWDO RI WKH FRXQWU\ DQG DOWKRXJK VWDII DUH RIWHQ ODUJHO\
unqualified. Cooperation programs have been run to try to improve the 
situation, but it remains rather catastrophic317. Finally, some specialised 
                                                 
317
 The issue of geographical access to health has thus become a great concern. It is estimated 
that about 80% of the population lives in the capital. For the remaining part, getting into 
Djibouti town for treatment is a very serious issue. Means of transportation are limited from 
smaller towns, with very few people having private cars, and the conditions of transportation in 
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structures exist, such as the Centre for Tuberculosis, the pediatric hospital of 
Balbala, the Maternity Hospital de Dar el Hanan318  and the Centre Yonis 
Toussaint (which deals with STIs and AIDS). Each of these structures are 
public and complement the treatment available in Hopital Peltier ± in each of 
these fields, however, the two other main hospitals ± Bouffard and OPS - 
provide their own treatment. Once again, comments on these structures are 
rather frightening. The hygiene and facilities of the places are deemed to be 
fully inappropriate to the needs of the population.  
 
Overall, the standard of hospitals in Djibouti varies largely according to each 
specific infrastructure. For many patients, however, the opportunities to access 
good treatment remain limited. The size of the structures and number of staff 
might seem relatively satisfying at first sight. However, they cannot hide the 
extent of the crisis: 
 ³When you loRNDWWKH³QXPEHURIEHGVSHULQKDELWDQWV´ZKLFKLVRQHWKLQJ
the WHO for example always looks at when estimating the state of public 
health services in a country, it all seems quite good. But then when you get 
there and ask to actually look at the beds, LWVDQRWKHULVVXH«VRPHRIWKHPDUH
VLPSO\QRWWKHUH$QGPDQ\DUHWKHUHEXWKDUGO\ORRNOLNHDEHGDQ\PRUH´ 
 
                                                                                                                                 
public buses raising serious issues of safety for people with a fragile health. A number of 
people thus have to rely almost exclusively on family help for bringing over drugs if needed, 
and talk to a doctor in their place, or have to rely on traditional medicine if they fall ill. The 
following picture of the countryside of Djibouti illustrates the difficulties of circulating in the 
country. The ferry from Tadjoura to Djibouti is an important mode of transportation. 
318
 As an indication of the problems faced by smaller structure, the maternity unit del Hanan  - 
see previous picture - was provided with its first phone line in June 2002, see La Nation, 
02/06/2002. 
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To conclude, in spite of having two well-functioning hospitals ± Bouffard and 
the OPS ± the country cannot fully ensure that its population gets access to 
decent medical structures.  
 
Access to medication 
 
The last element that needs to be considered in order to understand f the 
H[SUHVVLRQ ³SXEOLF KHDOWK´ UHODWHV WR DFFHVV WR PHGLFLQHV 7KLV FKDSWHU
DGGUHVVHV LVVXHVRI ³VXUIDFH´ ± what can be gathered from a first look at the 
country, without raising problematic issues. It will not run yet deeper into the 
most complex aspects of the networks, as these will be addressed in the 
following chapters. What will be considered here is essentially the perspective 
of patients ± where do they find drugs? How likely are they to afford them? 
What do they do when they cannot afford them? Chapter 6 will then look 
deeper into issues of import, and look further into the origin and nature of the 
different drugs used.  
 
The first question to consider here is from where patients buy their drugs. 
Private pharmacies are the most central points of passage319 through which 
patients access medication ± they import their own supply of drugs, which 
carries consequences that will be explained again in Chapter 6. Three private 
pharmacies have been created in town ± two in the centre and one in the 
                                                 
319
 1RWIXOO³REOLJDWRU\SRLQWVRISDVVDJH´IRU WKHSRSXODWLRQDVDZKROHEXWFHUWDLQO\ VRIRU
most patients ± IRU DQ HDUO\ XVH RI WKH WHUP VHH &DOORQ 0  ³6RPH (OHPHQWV RI D
Sociology of Translation: Domestication of the Scallops and the Fishermen of Saint-Brieuc 
%D\´LQ/DZ-HGPower, Action and Belief: a New Sociology of Knowledge? Sociological 
Review Monograph 32, London: Routledge and Kegan Paul, pp. 196-233. 
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suburbs320. The laws on opening pharmacies and regulating their management 
are officially based on French legislation ± although a degree of flexibility is 
allowed321. Next to private pharmacies, the OPS is the second source from 
which drugs may be obtained ± but only for some, since the structure is only 
opened to private employees. Drugs are provided to patients free of charge, 
which is an essential element in facilitating access to long term treatment. 
Bouffard provides appropriate medication while patients are treated there, but 
external patients have to buy their medication from private pharmacies. The 
same is true for patients from public hospitals. At the time of fieldwork, 
however, a further source was being created, and public community 
pharmacies (see picture) were being opened to try to provide new sources of 
access for medicines (considered in detail below) and for the moment a very 
small part of what most patients encounter daily. The need for new sources of 
medicines is particularly crucial because the price of drugs in private 
pharmacies is high, compared to European prices. The result is that most drugs 
in private pharmacies are unaffordable for a considerable part of the 
population, and only a minority of the population are regular customers in 
private pharmacies. French patients and wealthy locals are largely represented 
in the queues of private pharmacies, while others are likely to remain only 
                                                 
320
 Two of them are owned by the same pharmacist. 
321
 While French law forbids a pharmacist to open more than one pharmacy on his own 
account, two of the pharmacies in Djibouti town belong to the same pharmacist ± by putting it 
XQGHU DQRWKHU SKDUPDFLVW¶V QDPH LW EHFDPH WROHUDWHG ³Everyone knows its mine, the 
JRYHUQPHQWNQRZVLWVPLQH,WVQRWOHJDOEXWLWGRHVQ¶WERWKHUDQ\RQHVRLWVILQH´ Interesting 
approach to law, where although every person concerned seems to consider the law as useless a 
³OHJDOWULFN´LVSDUDGR[LFDOO\FRQVLGHUHGDVQHFHVVDU\± one could wonder why not just openly 
ignoring the law if the government accepts it.  
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occasional visitors. As will be explained in Chapter 6, this relates to the quasi-
absence of generics from the pharmaceutical market of Djibouti, and the 
remaining role played by pharmaceutical patents in spite of their absence of 
legal existence. 
 
Surprisingly, the price of medicines legally available has not caused the 
parallel market for drugs that might have been expected. While the spread of 
counterfeit medicines, in particular in poor countries, is emphasised in many 
reports322, most informants in Djibouti said that the black market for drugs was 
very limited, and not a real concern for the state. Some also mentioned, 
however, that the real control of drugs within pharmacies was very limited. 
There was little means to know if drugs illegally imported are not occasionally 
sold in stores323. Apart from this, no drug was observed to be sold on the street 
during the fieldwork, and it is very likely that pharmacies remain the main 
place where people try to buy drugs. Consequently, the main impact of the cost 
of drugs is a non-H[LVWLQJDFFHVVIRUPDQ\ORFDOSHRSOHRURIWHQD³WHPSRUDU\
DFFHVV´± people buy some drugs but cannot afford to follow their treatment as 
prescribed for lack of funds.  
 
Traditional medicine is often considered an important element in countries 
ZKHUH DFFHVV WR ³PRGHUQ´ GUXJV LV OLPLWHG 7KLV LV DQ DUHD LQ ZKLFK RIILFLDO
                                                 
322VHH IRU H[DPSOH WKH :+2 ZHEVLWH ³&RXQWHUIHLW 0HGLFLQHV IDFWVKHHW´ DYDLODEOH DW
http://www.who.int/medicines/organization/qsm/activities/qualityassurance/cft/counterfeit_fact
sheet.htm 
323
 )ULJKWHQLQJVWRULHVRI³boutres´ZRRGHQERDWV± see picture) illegally bringing counterfeit 
drugs into the country from Yemen were mentioned, although no-one was quite sure where 
these drugs were meant to end up. 
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reports do not really exist, and apart from one research report on the pharmacy 
sector324 produced for the Ministry of Finances, the main data available for this 
research was collected during interviews. Actors interviewed emphasised that 
traditional medicine was rather limited in the country, and that most people 
living in town would spontaneously seek access to modern medicines. They 
attributed this in part tR WKH IDFW WKDW WKHUH ZHUH RQO\ UHVWULFWHG ³QDWXUDO
UHVRXUFHV´LQWKHFRXQWU\DQGLQSDUWWRWKHIDFWWKDWSHRSOHLQWRZQKDGEHHQ
used to relying on modern drugs, even if the degradation of the public hospital 
had now changed this. It was also said that outside town, traditional medicine 
remained used for many basic diseases, and the report written for the Ministry 
of Finances provided some examples of the remedies used325. 
 
Overall, at the moment, it is fair to say that access to medicines remains limited 
to the richest part of the population in Djibouti. Chapters 6 and 7 will address 
two key questions that will complement this analysis: first, what role do 
pharmaceutical patents play in this system? Second, how can the changes 
currently being implemented following an input from the World Bank be 
described? 
 
 
 
 
                                                 
324
 ,QVWLWXW 6XSHULHXU GHV $IIDLUHV GH 'MLERXWL &ROOHFWLRQ ³(WXGHV GH 0HWLHUV´ 3KDUPDFLH
available at www.ministere-finances.dj/publications/PHARMACI.HTM 
325
 TB patients are for example looked after by feeding them camel meat and goat meat; 
hepatitis is treated by making patients drink and bath with water in which local plants are 
ERLOHG:DELDOLDDQG0DKLQD)DURZKLOHVRPHSODQWVUHPDLQNQRZQRQO\E\WKH³JXHULVVHXU´ 
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SECTION 4: DEVELOPMENT OF A LOCAL PHARMACEUTICAL 
INDUSTRY IN DJIBOUTI ± IS IT A TRIPS ISSUE? 
 
As explained before, studying patents in society is almost always understood as 
involving a study of how patents impact on industrial development. However, 
in this research, it became clear early on that, although studying the 
pharmaceutical industry in Djibouti raised highly interesting questions, it was 
not truly part of the answer to questions drafted in relation to the impact of 
TRIPS and pharmaceutical patents on health in the country. This section, rather 
than introduce the links between patents and industrial development in the 
country, will explain how it became clear that this link was at the time of 
fieldwork unclear at best and should not become the centre of this analysis. 
 
Finding information on the emergence of a local industry in Djibouti was an 
interesting part of the fieldwork. The lack of awareness of many actors of what 
was happening in relation to this, or what had happened over the past few 
years, made data-gathering particularly difficult. In 1996, a first attempt was 
made to create a local pharmaceutical industry in Djibouti ± La Societe 
'MLERXWLHQQH G¶,QGXVWULH 3KDUPDFHXWLTXH ,W LQYROYHG local investors, one of 
the local pharmacists from the OPS, and later on some pharmacists from other 
countries, plus several employees ± around twenty people are said to have been 
employed originally.  A French laboratory was somehow associated to this 
initiative, although informants did not seem very clear on this issue, and were 
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in particular unable to give a name to this lab326. The structure produced four 
basic drugs - paracetamol and aspirin, chloroquine and metronidazole ± 
³because that is what we need the most around here´7KH\ZHUH DOO RXW-of-
patent drugs. The structure has now collapsed327, for various reasons that will 
be explained below.  
 
At the time of fieldwork, a second attempt to create a local industry was in 
process ± one might have expected it to be located within the premises created 
in 1996, but this was not actually the case. A new building was being built next 
to the original factory. Once again, the project involves local and foreign 
pharmacists, and is led in association with a French lab. The project aims at 
producing basic drugs, as well as some pharmaceutical solutions. As in the first 
case, the drugs to be produced are out-of-patent, and the project as it is 
currently framed does not involve research in any way. The practical 
realisation of the industry was limited, at the time of fieldwork, to a building 
only a few centimetres from the ground. 
 
The impact that TRIPS might have on the emergence of a local industry in 
Djibouti is obviously an issue that was considered closely in this project. The 
impact of TRIPS on emerging industries has been questioned centrally in the 
literature, as explained in Chapter 1, and, in particular, the impact of TRIPS in 
limiting possibilities for an emerging generic industry to grow stronger has 
                                                 
326
 The report from the Institut Superieur des Affaires de Djibouti (op. cit.) mentions 
Panpharma, although this could not be verified. 
327
 A short visit to the site, built in zone franche, showed me a building still apparently guarded 
by a few men, although it is currently officially out of use.  
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been highly controversial328. The positive effects of a legal regime in which 
pharmaceutical products are not patentable on the development of a local 
industry has been demonstrated by the experience of many countries329. The 
impact that TRIPS could have on countries which have not started developing a 
local industry can therefore be questioned in that respect. What needs to be 
considered at this stage is whether the empirical evidence collected in this case 
study on the difficulties met by the pharmaceutical industry can demonstrate a 
link between pharmaceutical patents and industrial development ± if 
pharmaceutical patents can be framed as an actor in the network developing 
around the local industry, and how this relates to health. 
 
When looking at the example of the pharmaceutical industry in Djibouti, 
several elements need to be highlighted. First, the industry considered here is 
aimed exclusively at producing some of the most common drugs with 
structures clearly known, widely available, and out-of-patent ± such as 
paracetamol and aspirin. The local industry is very far from aiming at 
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 6HHIRUH[DPSOH6HHUDWDQ11³7KHQHJDWLYH,PSDFWRI,QWHOOHFWXDO3DWHQW5LJKWV
RQ'HYHORSLQJ&RXQWULHVDQ([DPLQDWLRQRI WKH ,QGLDQ3KDUPDFHXWLFDO ,QGXVWU\´ 6W0DU\¶V
Law Review on Minority Issues (3) Spring 2001 pp.339-.RVK\6³7KH(IIHFWRI
75,36 RQ ,QGLDQ 3DWHQW /DZ $ 3KDUPDFHXWLFDO ,QGXVWU\ 3HUVSHFWLYH´ Boston University 
Journal of Science and Technology Law (4) pp. 1-56. 
329
 6HH IRU H[DPSOH +HQGHUVRQ (  ³75,36 DQG WKH Third World: The Example of 
3KDUPDFHXWLFDO3DWHQWV LQ ,QGLD´European Intellectual Property Review 19(11) pp.651-663; 
Keayla B.K. (1999) Pharmaceutical Industry and Patent System in India: A Case Study, in 
TRIPS Agreement on Patent Law: Impact on Pharmaceuticals and Health for All, New Delhi: 
Centre for the Study of Global Trade Systems and Development; Kirim A.S. (1985) 
³5HFRQVLGHULQJ 3DWHQWV DQG (FRQRPLF 'HYHORSPHQW D &DVH 6WXG\ RI WKH 7XUNLVK
3KDUPDFHXWLFDO ,QGXVWU\´ World Development 13: 219-36; LaCroix Sumner J. and Kawaura 
$  ³3URGXFW 3DWHQW 5HIRUP DQG LWV ,PSDFW RQ .RUHD¶V 3KDUPDFHXWLFDO ,QGXVWU\´
International Economic Journal, 10(1), Spring 1996, pp. 109-124. 
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producing modern drugs which are still under patents - essentially because 
those in charge believe that what the local market needs most is these few basic 
drugs, as quoted above and as will be explained again in Chapter 7. It is even 
further from considering any form of research activity, both because of a lack 
of material and financial means, and because of a lack of available expertise of 
this type. Some questions might be considered. In particular, both the 
development of expertise and the determination of the needs of the population 
could themselves be read in the light of patents ± and of the affordability of 
patented drugs. Some of this second idea, in particular, will be discussed in 
more detail in the coming chapters. However, it should be noted that, as far as 
the pharmaceutical industry is concerned, there was no empirical evidence that 
could be read as highlighting the embedment of patents in any of the decisions 
taken330. To that extent, this hypothesis will be left aside at this stage, although 
some of its dimensions will be discussed again when looking more specifically 
at the shaping of health issues. 
 
The second element to emphasise is the complexity of the issues raised when 
looking at the emergence of this industry. It is essential to consider the place 
that TRIPS can have in these questions. These can be understood more clearly 
by using the example of the first attempt to build an industry. Some of the 
reasons for the failure of this industry seemed to contrast with the complex 
issues raised by the long term effects of TRIPS. Speculation on the potential 
long term impact therefore seemed unnecessary. The problems mentioned by 
                                                 
330
 ³,Q$17LWLVQRWSRVVLEOHWRVD\³1RRQHPHQWLRQVLW,KDYHQRSURRIEXW, know there is 
some hidden actor at work here behind the scene´´/DWRXU%Reasembling the Social: 
an Introduction to Actor-network Theory, op. cit. on p. 53. 
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informants concerned the lack of local expertise, personal conflicts that 
emerged around the industry, and conflicts around what could appear as basic 
manufacturing techniques ± the quality of paracetamol was thus questioned by 
potential investors. The lack of information that most actors, including in the 
Ministry of Health, have on the industry is also striking in a country of such 
small size and where industrial projects remain very small in number.  
 
The difficulties now faced by the second attempt to build an industry already 
appear to be similar to those experienced before. They also include practical 
concerns and issues of expertise. The difficulties expressed by informants 
working on this new project were essentially basic practical issues. The actual 
authorisation to build a laboratory was apparently difficult to obtain, and was 
finally obtained directly from the president ± as some investors are close to 
him. In addition, the question of local expertise is an issue investors are 
currently struggling with, since they would like it to remain a Djiboutian 
project, but are finding it difficult to identify people with adequate expertise to 
work in the laboratory. Finally, it is worth re-emphasising that this research is 
ultimately concerned with the relation between TRIPS, pharmaceutical patents 
and health. The dimension of the project being planned is not of such an extent 
that it is at the moment likely to become a key public health actor in any case, 
and its place in the research questions appeared, in this respect as well, to be 
rather limited. Overall, it was decided in this thesis that patents in their relation 
with the industry in Djibouti were not at this stage relevant enough to be part of 
the story to be told on public health. Although it was necessary to spare some 
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time explaining this choice, we will now concentrate on IP and public health 
systems. 
 
CONCLUSION  
 
This chapter has presented the final elements of background necessary to 
XQGHUVWDQGWKHIRFXVRIWKLVUHVHDUFK7KHQRWLRQVRI³,3´DQG³SXEOLFKHDOWK´
in what they cover in this project should appear clearer. The views of TRIPS 
and pharmaceutical patents undertaken here should also be more precise. In the 
course of this project, when discussing how pharmaceutical patents and TRIPS 
have become public health actors in Djibouti, and when questioning how 
³LQWHOOHFWXDOSURSHUW\´DQG³SXEOLFKHDOWK´FDQEHSHUFHLYHGDVLQWHUGHSHQGHQW
but overlapping in Djibouti ± at least in some of their actors ± what appeared 
was a multiplicity of relevant networks, relevant connections, in which TRIPS 
and pharmaceutical patents seemed to become inherently fluid and difficult to 
define. Throughout the empirical part of this research, the complexity of 
TRIPS and pharmaceutical patents appeared progressively clearer, and the 
extent of the associations through which they exist had to be seized before the 
REMHFWV LQ WKHLU UHODWLRQ WR³KHDOWK´FRXOGEHIXOO\XQGHUVWRRG7KHQH[W WKUHH
chapters will present three dimensions of the story of TRIPS and 
pharmaceutical patents in Djibouti, and explain why these objects can be 
understood totally differently if looking at them through their many 
expressions and sometimes contradictory effects. From different viewpoints, 
TRIPS and pharmaceutical patents appeared as playing a particular role, as 
different objects or sets of prescriptions, as well as acted through different 
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mechanisms and in different directions. The following chapters will present in 
turn what TRIPS was if following the Ministry of Trade network; the political 
connections of which TRIPS as a set of written prescriptions is dependent; the 
role of pharmaceutical patents in the import system of Djibouti; and finally the 
role of TRIPS in its networked effects in the health networks of Djibouti. One 
of the difficulties of this task is that, as these networks sometimes overlap, the 
presentation and definition of their own limits can be difficult. However, it will 
be explained throughout why, in this particular case study, these appeared 
essentially as distinct spheres, and we will discuss in conclusion how the gaps 
between these spheres can explain the originality of some of the findings made 
in this research. 
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CHAPTER 5 - 75,36 $1' ³/(*$/´ $662&,$7,216 - 
UNDERSTANDING THE ROLE OF TRIPS AS PRESCRIPTION 
 
This particular chapter follows the traces left by TRIPS as a set of prescriptions 
± as a set of official rules carried on paper, expected to have a pre-defined 
impact ± in Djibouti331. Although the pre-definition and delimitation of the 
particular dimension of TRIPS under investigation here is complex and will 
pDUWO\EHFRPHFOHDUHU WKURXJKRXW WKLVFKDSWHU ³75,36DVSUHVFULSWLRQ´ UHIHUV
to TRIPS as a material punctualised on paper, carrying a set of supposedly 
prescriptive, official and written rules. It is understood that there are further 
relevant dimensions to TRIPS, and that the set of written rules that are often 
SXQFWXDOLVHGDV³75,36´DQGDUHXQGHUVFUXWLQ\KHUHREVFXUHDODUJHERG\RI
complex connections, some of which will be undone332 throughout the 
remainder of this project. However, the idea of TRIPS as prescription also 
translates a relevant and specific dimension of TRIPS ± a point of entry and a 
particular shape through which the arrival of TRIPS in Djibouti can be traced, 
and a set of expectations. It is also the most commonly studied dimension of 
TRIPS and a necessary starting point for questioning the relevance of a large 
                                                 
331
 The term prescription, as explained in Chapter 2, is used in ANT to reflect the idea of 
expected mobilisation and regulation of action ± VHH $NULFK 0 DQG /DWRXU %  ³$
Convenient Vocabulary for the Semiotics of Human and Non-KXPDQ$FWRUV´LQ%LMNHU:DQG
Law J. (eds) Shaping Technology, Building Society: Studies in Sociotechnological Change, 
Cambridge MA: MIT Press, pp. 205-224. It will be used here to refer to the idea that TRIPS is 
expected to carry effects anticipated to mobilise actors in a certain pre-defined way by its 
creators. 
332
 As explained in Chapter 2, the term is used here to refer to the process through which the 
hidden connections that make up what appears temporarily as a punctualised network can be 
highlighted through explanations, in order to make the mechanisms of the networks 
understandable. 
 220 
set of literature in this area± although the terminology used here is often 
borrowed more strongly from ANT than from other texts discussing TRIPS. 
This chapter therefore follows the set of connections and mobilisation 
generated by the arrival into Djibouti of TRIPS as a new, written set of rules, 
officially binding and prescriptive. It investigates the links created by and 
around the introduction of TRIPS as a set of written rules in Djibouti, and 
explores how far it appears to have mobilised actors directly concerned ± and 
where it stopped. It emphasises how, when investigating the role of TRIPS as a 
set of prescriptions in the different networks in which it needs to be enrolled to 
maintain its social action in its prescriptive pharmaceutical patents dimension, 
the limits to the translations and mobilisations generated by the text appeared 
as tighter than is often expected in some legal writings.  
 
This chapter is based on an investigation of the way different actors have 
modified their behaviour ± or anticipate future modifications of their actions ± 
following the integration of TRIPS as written prescription in the country. The 
question to be answered here is whether TRIPS as prescription is generating 
new associations and translations in Djibouti. This will be addressed by 
presenting the traces left by TRIPS in different loci, and by questioning its 
action and circulation.  
 
This chapter starts by presenting TRIPS as prescription in its dimension as a 
social mediator ± as an agent able to act and make others act333. It discusses the 
                                                 
333
 The term is borrowed from the distinction between mediators and intermediaries offered by 
Latour B. (2005) Reassembling the Social: An Introduction to Actor-network Theory, Oxford: 
2[IRUG8QLYHUVLW\3UHVV³An intermediary, in my vocabulary, is what transports meaning or 
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marks it is leaving in one particular office and questions what this means in 
terms of its social action (Section 1). It then questions whether traces of TRIPS 
as a set of official rules can be found when moving out of this particular office, 
by extending the range of connections to be considered (Section 2). Finally, 
this chapter discusses how the action of TRIPS as prescription needs to be read 
within the policitical networks of Djibouti and how this wider context can 
participate in understanding the issues raised throughout334 (Section 3).  
 
6(&7,2175,36,6&+$1*,1*:5,77(11$7,21$//$:« 
 
This particular section looks at what can be described as the official story of 
TRIPS in Djibouti, by explaining the changes generated by TRIPS through its 
integration as written prescription in the Ministry in charge of its 
implementation. It explains the extent of the re-orderings it generated within 
the Ministry of Trade ± although this term is partly misleading, and the 
                                                                                                                                 
force without transformation: defining its input is enough to define its output. For all practical 
purposes, an intermediary can be taken not only as a black box, but also as a black box 
counted for one, even if it is internally made of many parts. Mediators, on the other hand, 
cannot be counted just as one; they might count for one, for nothing, for several or for infinity. 
Their input is never a good predictor of their output, their specificity has to be taken into 
account every time. Mediators transform, translate, distort and modify the meaning of the 
HOHPHQWVWKH\DUHVXSSRVHGWRFDUU\´ on p.39. 
334
 The notion of context can of course provide some conceptual contradictions with ANT if 
XQGHUVWDQGLQJ WKH WHUP DV UHIHUULQJ WR D VWDEOH SUHHVWDEOLVKHG ³IUDPH´ +RZHver, the term 
EHFRPHV OHVV SUREOHPDWLF E\ XQGHUVWDQGLQJ WKH UHODWLRQ EHWZHHQ ³SDUWV´ DQG ³ZKROH´
explained in Chapter 2; the fact that every action and association can be relocated within more 
FRPSOH[ DQG RWKHU DVVRFLDWLRQV DQG UHODWLRQV ³Since they are pinpointed inside the many 
ROLJRSWLFDDQGSDQRUDPDV WKHUH LV QRWKLQJZURQJDQ\PRUHZLWKXVLQJ WKHZRUG³FRQWH[WV´
Latour B. (2005), Reassembling the Social: An Introduction to Actor-network Theory op. cit., 
p191. 
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networks followed will only travel through one particular office, in which one 
person officially works and others occasionally visit335. It is the story of TRIPS 
in this particular office and through the connections that make up both TRIPS 
as written law in Djibouti and this office as a mediator in this translation that 
needs to be given here.  
 
To begin understanding the story of TRIPS in this office, what it is doing and 
where it is, the traces left by TRIPS as written prescription need to examined336 
± its (limited) material presence as a set of rules laid on paper, the traces of the 
WTO and others left in these materials, the words, thoughts and new concepts 
it left behind (predominantly expressed by the member of staff officially in 
charge of TRIPS). There is no need here to remind the reader again of the 
extent of the changes that TRIPS should be generating in the legal system of 
'MLERXWL IRU WKH FRXQWU\ WR EH FRQVLGHUHG DV ³75,36-FRPSOLDQW´ 7KHVH QHw 
obligations, as well as the time limit for this to happen, have been detailed in 
Chapter 1. All that needs to be said here is that, for this research, TRIPS needs 
to (or needs to make others) generate pharmaceutical patents as an active tool, 
produce written rules that should circulate back to the WTO, create new 
structures that will ensure that all those that relate to TRIPS comply with its 
dispositions, and most importantly, generate some form of social mobilisation 
                                                 
335
 As far as is materially feasible, this sWXG\ ZLOO NHHS ³ORRNLQJ GRZQ´ DQG DQDO\VLQJ KRZ
circulation can be narrowed down before being deployed again ± VHH/DZ-³0HWKRG
&RPSOH[LW\ DQG WKH %DURTXH´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV /DQFDVWHU
University, LA14YL, UK, at http://www.compa.lancs.ac.uk/sociology/papers/law-and-if-the-
global-were-small.pdf 
336
 )ROORZLQJ /DWRXU¶V HPSKDVLV RQ WKH QHHG WR XQGHUVWDQG WKH VRFLDO WKURXJK WKH WUaces its 
circulation leaves ± Latour (2005) Reassembling the Social: An Introduction to Actor-network 
Theory op. cit. 
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± ³OHJDOFRPSOLDQFH´:KHQYLVLWLQJWhe office where TRIPS as a set of written 
rules is being translated from an international law text into national 
prescription that actors in Djibouti itself are expected to follow, I tried to 
understand what had been done in that respect so far. This meant following the 
URDGDOUHDG\SDYHGE\UHVHDUFKLQWKLVILHOGRIORRNLQJDWWKH³OHJDOLPSDFWRI
75,36´ - in the office implementing TRIPS, the logical starting point was to 
ILQGRXWZKDWKDGEHHQGRQHLQWHUPVRI³OHJDOLPSOHPHQWDWLRQ´ 
 
TRIPS and legal changes 
 
The answer given was itself straightforward, and did not at this stage contrast 
ZLWK P\ H[SHFWDWLRQV ³We are now working on implementing patent law ± 
because we have signed the TRIPS agreement. WIPO is offering us some 
advice when creating the law´ The fact that TRIPS as prescription should 
trigger a set of reactions was not challenged at this stage: TRIPS had been 
VLJQHGVRPHRQHNQHZDERXWLWDQGZDV³ZRUNLQJRQLW´7KHUHZDVQRPDWHULDO
RXWFRPHRIWKLV³ZRUN´\HWQRGRFXPHQWVSURGXFHGWKURXJKLt, but it did not 
DSSHDU DV WUXO\ ³ZRUU\LQJ´ DV WKHUH ZDV VWLOO D ELW RI WLPH IRU 'MLERXWL WR
implement TRIPS. In addition, WIPO was providing some assistance, as it is 
expected to do337. The general feeling that this story would conform to existing 
                                                 
337
  « WIPO has been providing a wide range of technical and legal assistance for developing 
countries and least-developed countries for the last three decades. This includes assistance for 
the establishment, modernization and automation of intellectual property offices, human 
resources development programs, the provision of legal advice on compatibility of legislation 
with relevant international treaties, and assistance in strengthening capacities to enforce 
intellectual property rules´$YDLODEOHRQKWWSZZZZLSRLQWDERXW-
ip/en/studies/publications/health_care.htm  
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understandings and expectations remained while the official story of TRIPS 
ZDVEHLQJXQIROGHGE\WKHPDQLQFKDUJH'HWDLOVRIWKH³ZRUN´FDUULHGRXWGLG
not bring any more unexpected findings. Although a number of things were 
being discussed, little was established in any definitive form at this stage. 
3KDUPDFHXWLFDOSDWHQWVZHUHRQHRIWKHVH³WKLQJV´ 
 
 ³We will also deal with questions of licences for making drugs, and the 
questions raised by generic medicines will also be in there. But for the moment, 
we are only at a discussion stage ± nothing is on paper yet.´ 
 
Pharmaceutical patents had entered the office ± at least in words. It was not 
WKHUHLQDPDWHULDOIRUP\HWDVRQFHDJDLQQRWKLQJZDVUHDG\³RQSDSHU´%XWLW
was there as a concept ± if someone could tDON DERXW LW LW ³H[LVWHG´DW VRPH
level at least. 
 
At this stage, it is useful to step back briefly and reflect on what all this means 
about the set of transformations that TRIPS as prescription has been generating 
in this office of the Ministry of Trade at the time when this fieldwork was 
carried out. The first thing it has changed, of course, resides in the new role 
given to this member of staff to implement the text, and hold meetings with 
advisors from WIPO to decide on the way to implement TRIPS. It has also 
participated in generating new issues, new concerns, that all made in turn 
³LQWHOOHFWXDO SURSHUW\´ DSSHDU DV D SROLF\ HOHPHQW LQ WKH OLPLWHG SDUW RI
networks that we have so far studied. Next to the specific case of 
pharmaceutical patents, issues of structures and expertise were mentioned 
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many times by the actors in charge of implementing TRIPS. They were all 
elements that had briefly emerged as social questions in 1996, when the law on 
artistic rights was adopted, before slowly disappearing. However, these issues 
somehow remained in the background, hidden behind what was centrally 
SUHVHQWHGDVWKHNH\SULRULW\RIWKH³JRYHUQPHQW´- the transposition of a set of 
rules visible on paper which would satisfy TRIPS requirements338. This sense 
of priority is of course understandable from the logic of TRIPS itself, and the 
common idea that its impact will be causal and ordered in a certain way ± as 
well as by the fact that the main element to be circulated back to the WTO ± 
and other interested parties - would be this written set of rules339. TRIPS was 
therefore creating work directed at writing a new law, transferring the set of 
rules created by the WTO into something made in Djibouti, for Djibouti. But 
what else was TRIPS anticipated to do? How much further was it likely to 
reshape orderings in Djibouti?  
 
Potential impact of TRIPS ± LILW³ZRUNV´DVH[SHFWHG 
 
This was the second step needed in this analysis, and this still related largely to 
SDUWVRIWKHZLGHUGHEDWHRIWKH³LPSDFWRI75,36´,QWKLVFKDSWHUWhe maybe 
more modest ± although possibly more cryptic ± terminology used will remain 
WKDWRIWKH³GLUHFWLPSDFWRI75,36DVSUHVFULSWLRQ´DVZHZLOOVHHLQ&KDSWHU
7 that the question of the impact of TRIPS as a political actor runs much 
further than what is often understood). The question of the impact of the new 
                                                 
338
 The efforts were repeatedly presented by the official as directed towards legal compliance ± 
³OHUHVSHFWGHVGLVSRVLWLRQV´ 
339
 See TRIPS Article 63. 
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set of official prescriptions carried by TRIPS ± and of the new set of rules 
created in Djibouti following TRIPS ± was first addressed with the 
representative of the Ministry of Trade in charge of its implementation, and 
those working closely with him. Once again, the first stage of answer given 
was not very different from what is often officially stated in relation to TRIPS. 
The answers provided balanced the potential benefits340 of creating an IPR 
system with the relative weaknesses of TRIPS341. With a few industries starting 
up in Djibouti, the introduction of patents was presented as something that 
could potentially benefit the country: 
 
³Until recently there was absolutely no industry in Djibouti, so we really did 
not see how patents could be useful for us. Things are changing though, and we 
are trying to develop some industries here, as well as attracting new foreign 
LQYHVWRUV´ 
 
                                                 
340
 And related to this extent to comments made in a large range of literature on the impact of 
TRIPS on industrial development or foreign direct investment ± for example, see Mansfield E 
³,QWHOOHFWXDO3URWHFWLRQ)RUHLJQ'LUHFW,QYHVWPHQWDQG7HFKQRORJ\7UDQVIHU´Journal 
of International Economics 16: 205- 0DVNXV . (  ³7KH 5ROH RI ,QWHOOHFWXDO
Property in Encouraging Foreign Direct Investment and Technology TransIHU´Duke Journal 
of Comparative and International Law (9) pp. 109-161; Primo B., Fink C. and Sepulveda C. 
 ³,QWHOOHFWXDO 3URSHUW\ 5LJKWV DQG (FRQRPLF 'HYHORSPHQW´ :RUOG %DQN 'LVFXVVLRQ
Paper no. 412, available at http://www.bvindecopi.gob.pe/colec/cbraga.pdf; Sherwood R. 
(1990) Intellectual Property and Economic Development, Boulder: Westview Press. 
341
 Once again related to wider comments on the problems generated by the agreement ± see 
IRU H[DPSOH $EERWW )0  ³0DQDJLQJ WKH +\GUD 7KH +HUFXOHDQ 7DVN RI (QVXULQJ
$FFHVV WR (VVHQWLDO 0HGLFLQHV´ LQ 0DVNXV . ( DQG 5HLFKPDQ - + HGV International 
Public Goods and Transfer of Technology under a Globalized Intellectual Property System, 
Cambridge: Cambridge University Press, pp. 393-425. See also the discussion provided in 
Chapter 1. 
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However, TRIPS itself was criticised as not being the most appropriate 
LQVWUXPHQW IRU SRRUHVW FRXQWULHV DQG WKH ³FODVVLF´ VWRU\ RI 75,36 WKXV
appeared, once again, to be repeating itself in this office:  
 
³After Doha, there were some recommendations, but since then nothing was 
done in practice. So far nothing has changed, the text is still the same. In a 
context where all we have are industries just starting to emerge, some aspects 
of the text seem inadapted. TRIPS is not flexible enough for developing states, 
and especially for least developed countries with a very small UHFHQWLQGXVWU\´ 
 
But this was also still only expectation, anticipation, based on theoretical 
discussions on whether active patent laws would benefit the country or not, and 
whether the written content of TRIPS was close to the ideal of the poorest 
countries. This was essential to consider, but when comparing this particular 
set of data to what is to follow, it started losing some of its immediate 
relevance. Although TRIPS was producing effects, opinions, work, meetings 
and new concepts amongst a few, although its effective implementation would 
potentially be loaded with effects, key questions were still not answered: was 
TRIPS actually likely to be followed by any actor? Would it actually ever 
deploy its effects and mobilise any other actor? And was it in any respects yet 
the considerable public health issue it is framed to be? This now needs to be 
discussed.  
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6(&7,21«%87'2(6,75($//<0$77(5" 
  
The role of TRIPS in the Ministry of Trade, and the anticipation of the 
potential effects of a set of written rules if it was to be obeyed, is only a small 
aspect of what needs to be looked at in order to understand what TRIPS as a set 
of prescriptions is currently doing ± and can be expected to do ± in Djibouti. 
The issue that also needs to be addressed is that of the re-orderings operated by 
TRIPS not only within the Ministry of Trade, but also around it. In particular, 
for TRIPS in its pharmaceutical patents dispositions to be active, drugs in 
breach of international standards of patents need to remain excluded from the 
territory. And this implies that those importing drugs are aware of the rules and 
made to obey them. In order to understand how TRIPS in its pharmaceutical 
patents dispositions is currently starting to act in Djibouti, it was thus central to 
move out of the office of the Ministry of Trade itself, and talk more broadly to 
actors in the public health field, the Chambre du Commerce, to other actors in 
the Ministry of Trade itself, all those that can somehow influence what goes in 
and out of the country in relation to pharmaceuticals.  This is particularly 
crucial not only because this research is interested in what TRIPS is doing as a 
whole, but more specifically in what it is doing to health ± and whether it is yet 
shaped as a public health mDWWHULQ'MLERXWL:KHQORRNLQJRXWVLGHWKH³75,36
RIILFH´KRZHYHURQO\³QHJDWLYH´WUDFHVRI75,36DSSHDUHGLQVWDWHPHQWVWKDW
emphasised the irrelevance of TRIPS, and shaped it as only one more rule that 
no one would take interest in. 
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Prescriptive value of international trade rules and mobilisation in Djibouti 
 
This section investigates the role and action of TRIPS as written prescription 
outside of the particular office where it is being implemented. Part of the 
difficulty of this section, as will appear throughout, is that it aims to some 
H[WHQW WRGHPRQVWUDWH³DEVHQFH´VRPHWKLQJZKLFKE\GHILQLWLRQ OHDYHV OLWWOH
traces for empirical research. However, it appeared in this research through 
DFWRUV¶ SHUFHSWLRQV DQG YLHZV DQG WKURXJK WUDYHOOLQJ HPSLULcally through 
associations that TRIPS would need to follow to move from the Ministry of 
Trade into further connections. Mainly, this section is a brief story of absence 
and weakness of TRIPS as a set of official prescriptions ± and we will see that 
there is more to TRIPS than that - and is offered as a reply to the common 
expectation that TRIPS as written law is a public health issue, as explained in 
&KDSWHU ,W LV DOVRRIIHUHGDVD UHSO\ WR WKH OLPLWDWLRQVRI WKHQRWLRQRI ³,3
V\VWHP´ RU ³SKDUPDFHXWLFDO SDWHQW V\VWHP´ DV D VWDEOH VRFLDO QHWZRUN DQG
demonstrates that instead of a network, several sets of sub-connections were 
identified in an unrelated fashion. This will be done in two steps, first by 
explaining how the limits to the social role of TRIPS as prescription appeared 
within the trade area, and second by moving outside this field, and watching 
what remains of TRIPS within the public health network of the country.  
 
When questions about the role of the official implementation of TRIPS were 
extended within the trade field, but outside of this particular office, the action 
of TRIPS as prescription became more doubtful, and its limits clearer. 
Interviews with actors outside the particular Ministry of Trade office ± in other 
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offices of the Ministry or in the Chambre du Commerce for example ± 
HPSKDVLVHG WKH LGHD WKDW75,36ZDVXQOLNHO\ WRPRGLI\ DFWRUV¶ UHODWLRQV DQG
behaviour outside that particular ministry. This was explained partly on the 
basis of their informed knowledge about WTO mechanisms more generally:  
 
³WKHZD\LWZRUNVLVWKDWLWGRHVQ¶WFKDQJHDQ\WKLQJXQOHVVVRPHRQHFRPSODLQV
DERXW ZKDW \RX DUH GRLQJ« ZH DUH VR VPDOO WKDW KRSHIXOO\ WKH\ ZRQ¶W
FRPSODLQ´  
 
Next to the written/official changes actually made, and on which actors such as 
WIPO representatives can have easy access to information342, they seemed 
convinced that it would indeed change nothing to local practice. However, this 
might not need to be seen as an essential point ± although probably a symbolic 
one. Indeed, TRIPS in its pharmaceutical patents dimension might still be 
highly socialised and active in political networks if extending only from the 
office where it is being implemented to public health actors. It might not 
strictly need to connect to any other actor within the trade and industry field if 
one office is aware of it and those who import and market drugs are made to 
follow new procedures closely. However, once starting to question what is 
TRIPS as prescription within the public health network of Djibouti, its relation 
to social actors becomes maybe even more doubtful. One can begin wondering 
whether TRIPS in this particular dimension has any agency in this network. 
                                                 
342
 $OWKRXJKORRNLQJWKURXJKWKH:,32ZHEVLWHFDQUDLVHVRPHTXHVWLRQVDERXWWKLV³DFFHVV´
or the interest of international institutions. The diverging information provided on the WIPO 
website was introduced in Chapter 1 and can be found at http://www.wipo.int/about-
ip/en/ipworldwide/pdf/dj.pdf and http://www.wipo.int/eds/en/ccs/pdf/dj.pdf  
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We will see in Chapter 7 that TRIPS is certainly leaving traces within the 
public health network, including in some governmental offices. However, this 
section will start by explaining how TRIPS as written prescription appeared to 
struggle to move from one office in the Ministry of Trade to wider political 
networks. 
 
TRIPS in public health policy networks ± an uncertain presence 
 
When actors in the public health area were asked about the official 
implementation of TRIPS, their answer was less moderate than the quotation 
provided above. When discussing the potential role and impact of TRIPS 
through its implementation in Djibouti, most informants stated that TRIPS 
would not have any form of impact - some of them adopted a tone particularly 
strong and convinced when making statements such as those illustrated below, 
or openly laughing at the idea that anyone could actually think it might work. 
Every informant met was convinced that the agreement would not impact at all 
RQDFWRUV¶EHKDYLRXUDWQDWLRQDO OHYHODQGVLPSO\ZRXOGQRWFKDQJHDQ\WKLQJ
to the way they work ± it would not raise any issue in relation to health and 
access to drugs. For example: 
 
 ³This will not affect us in any way. For at least one good reason: international 
ODZGRHVQ¶WPHDQDQ\WKLQJKHUHDQGQRERG\ZLOO FKDQJH WKHZD\ WKH\ZRUN
because of it. It is utopic to think it will have any effect, no one will be 
interested here.´ 
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³$V IDUDVP\ MREKHUH LVFRQFHUQHG75,36 LVQRWJRQQDFKDQJHDQ\WKLQJ ,
FDQ¶WVHHDQ\RQHEHLQJLQWHUHVWHGKHUHDQG,UHDOO\FDQ¶WLPDJLQHLWFKDQJLQJ
DQ\WKLQJ´ 
 
In terms of research and expectations, this was a bit of a stepback, as the 
mobilisation of public health actors in reaction to TRIPS is widely observed in 
other places343. The more I talked about TRIPS with all these people who buy 
drugs, choose drugs, distribute drugs, the more it appeared that they were truly 
not interested in the issue. Many of the comments made by informants related 
to further issues of the meaning of international law for Djiboutian networks. 
However, the aim of this research remains to investigate particularity rather 
than the whole, and what is at stake here is what this particular example of 
international law might be showing us about its own difficulty to stabilise in 
social relations344. Maybe further investigation on other international laws in 
the country would allow future research to draw wider conclusions, but this is 
beyond the scope of this project. What is central to understand here are some of 
                                                 
343
 The mobilisation of MSF and other organisations against TRIPS is widely known (see for 
H[DPSOH)RUG1³3DWHQWV$FFHVVWR0HGLFLQHVDQGWKH5ROHRI1RQ-governmental 
2UJDQLVDWLRQV´Journal of Generic Medicines, Vol.1 (2) pp.137-145). The WHO has produced 
several reports in the field (see for example : WTO/WHO (2002) WTO agreements and public 
health, available at 
http://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf#search= 'WTO%20agreements%20
and%20public%20health'  ) . Policies aiming at limiting the impact of pharmaceutical patents 
have emerged partly from Ministries of Health ± the South African Medical Act is one of the 
most symbolic cases of the clash between pharmaceutical patents and health concerns (for 
LQIRUPDWLRQVHHIRUH[DPSOH+DOEHUW'³0RUDOL]HG'LVFRXUVHV6RXWK$IULFD¶V
Intellectual Property FigKWIRU$FFHVVWR$,'6'UXJV´Seattle Journal for Social Justice (1) 
Fall/Winter 2002 pp. 257-288. 
344
  6RFLRORJLFDO LQTXLU\ QHHGV WR UHPDLQ ³PRGHVW´ WR UHPDLQ IXOO\ HPSLULFDO ± see Law J. 
(1994) Organizing Modernity, Oxford: Blackwells. 
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the reasons why this particular written set of rules did not seem to mobilise any 
actor ± at least through its official implementation. This is particularly essential 
in order to reinforce the distance and potential discrepancy between the 
translation of TRIPS in a material set of written rules in the country and its 
enrolment as a fully social actor in political networks. For most human actors 
interviewed in this case study, and in particular in the public health field, 
TRIPS and patents were thus a non-social issue. They did not see how it could 
affect the country; they believed that it would not become any more than a set 
of rules excluded from active networks. 
 
In order to understand better these reactions, as well as the contrasts between 
this case study and other examples used by researchers, it is essential to 
consider the issue of expertise. All actors in the public health field interviewed 
stated at least at one point that they did not consider themselves as having any 
true expertise in relation to TRIPS. The lack of expertise is something I had 
been warned about early in my research, when asking someone working for the 
Ministry of Trade what ZDVWKH,3VLWXDWLRQRI'MLERXWL³Well, our IP situation 
LV³YHU\ OLWWOH YHU\EDG´7KHUHDUHYHU\ IHZSHRSOHDZDUHRI LW DQGKDUGO\
anything is done about it´ :KHQ REVHUYLQJ WKH KHDOWK VHFWRU WKLV ZDV
particularly obvious. On several occasions, informants acknowledged TRIPS as 
something they knew about, but when asked further questions about it they 
seemed unsure what it was precisely about345. Most of them acknowledged 
having a rough idea on the issue mainly from what they had read in the press, 
and knowing essentially that it was about international law: 
                                                 
345
 This was particulaUO\REYLRXVIURPRQHLQWHUYLHZWUDQVFULSW³Of course I know what TRIPS 
LV´ DQGDELWIXUWKHU³6RFDQ\RXUHPLQGPHDJDLQZKDWGRHVLWH[DFWO\VD\"´ 
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³, GRQ¶W NQRZ PXFK DERXW WKLV ZKROH LVVXH ± only what I have read in the 
SUHVV´.  
 
³The problem here is that no one has any kind of expertise here. There are a 
IHZSKDUPDFLVWVEXWWKH\ZRQ¶WXQGHUVWDnd what it is about. TRIPS, everyone 
WDONV DERXW LW EXW QR RQH NQRZV ZKDW LW LV DERXW VR LW MXVW ZRQ¶W FKDQJH
anything!´ 
 
Most informants also mentioned having received only very little official 
information about IPR, or surprisingly sometimes about other aspects of IPR 
than pharmaceutical patents: 
 
³I am not interested in patent law, and I know hardly anything about it ± I have 
followed some training a while ago, but it had to do with software and issues 
OLNHWKDWQRWZLWKGUXJV«´ 
 
However, none of the sources that are sometimes expected to provide all 
relevant actors with information346 about TRIPS were mentioned as having 
provided appropriate detail about the text to anyone in this particular field (the 
circulation of information is something that will be discussed further below). 
TRIPS was discussed essentially as a media issue, but not as a set of rules 
binding on the country. Next to the statements of lack of relevance presented 
above, all actors emphasised was the fact that they did not know about the 
                                                 
346
 Such as the Ministry of Trade itself, thematic workshops, international organisations, 
NGOs. 
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³OHJDOVLGH´347 of TRIPS ± that TRIPS as a set of official rules had not reached 
them. TRIPS in its written/official dimension was there though at least in one 
form ± it was in the Ministry of Health, in a report published by the WTO and 
the WHO on TRIPS and public health348. But that was passive material, sitting 
at the corner of a desk, and not discussed by the official sitting at this same 
GHVNXQWLO,PHQWLRQHGLWDQGLWZDVEUXVKHGDVLGHDVVRPHWKLQJWKDW³was sent 
to us´ 7KLV H[DPSOH ZLOO EH GLVFXVVHG again in the next section when 
discussing the role of international organisations as intermediary/mediators in 
Djibouti349. 
 
Overall, the agency of TRIPS as a set of prescriptions outside the particular 
office where it is being implemented appeared largely doubtful. The impact of 
this lack of mobilisation is double ± on the one hand, if TRIPS only mobilises 
actors in one particular office, it is unlikely to be followed with practical 
effects. On the other hand, if TRIPS has not been integrated within the health 
sector, it might mean that there will not be any coordinated action in response 
to the impact of TRIPS on public health. To discuss this further, the relation 
between TRIPS and health will first have to have been fully investigated, and 
                                                 
347
 Although WKHQRWLRQRI³OHJDO´DVDQLQGHSHQGHQWVHWRIFKDUDFWHULVWLFVDQGVSHFLILFILHOGLV
FRQWHVWHGWKURXJKRXWWKLVSURMHFWLWLVXVHGKHUHWRUHIOHFWDFWRUV¶WHUPLQRORJ\ZKHQUHIHUULQJ
to TRIPS as a written set of rules. 
348
 :72:+2  ³:72 DJUHHPHQWV DQG SXEOLF KHDOWK´ DYDLODEOH DW
http://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf#search='WTO%20agreements%2
0and%20public%20health 
349
 The distinction between intermediary and mediators was introduced earlier to present the 
contrast between networks which transport others without modifications (intermediary) and 
those who participate directly to change and movement (mediators) ± the definition given by 
Latour (2005) Reassembling the Social: An Introduction to Actor-network Theory op. cit is 
given above. 
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these issues will be revisited in the following chapters.  The main elements that 
this section demonstrated is that TRIPS, through its official written 
implementation, did not generate the reactions and mobilisations it is generally 
portrayed as creating. The striking contrasts between what TRIPS as 
SUHVFULSWLRQLV³H[SHFWHGWREH´LQUHODWLRQWRKHDOWKLQSDUWLFXODUDQGZKDW LW
was in this case study, are worth investigating at this stage before drawing 
wider conclusions on the overall impact of TRIPS and pharmaceutical patents 
on health. 
 
However, one hypothesis needs to be raised at this stage - perhaps this situation 
is only due to the fact that Djibouti could decide to wait for another ten years 
before implementing pharmaceutical product patents? This is of course 
something that I considered during the course of this fieldwork ± and that I in 
fact discussed with a few informants ± but it is also a hypothesis which never 
appeared truly satisfying, although I could of course not definitely rule it out 
either. First, because this does not fully explain the contrasts between this 
example and others ± the mobilisation of public health actors is not necessarily 
expected to occur after national implementation350.  
 
There were further elements that also made this hypothesis somehow 
unsatisfactory. First, although pharmaceutical product patents are not fully 
binding yet, the implementation of other measures ± including patents for 
pharmaceutical processes ± is imminent. More crucially maybe, it is not clear 
                                                 
350
 2QFHDJDLQLIUHIHUULQJWRWKHH[DPSOHVRISXEOLFKHDOWKDFWRUV¶PRELOLVDWLRQTXRWHGDERYH
these have occurred largely before the deadline for implementation for most developing 
countries was reached. 
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yet whether the official in charge of implementing TRIPS has decided to 
exclude pharmaceutical product patents from the law to be adopted, and, as it 
currently stands, these could be introduced at any time. In addition, the range 
of developments that need to be done if TRIPS is to be implemented in 
practice, such as the development of appropriate structures, the information of 
relevant actors, the development of local expertise, will all need a large amount 
of time to be tackled. None of these were taking place at the time of fieldwork. 
International organisations are also already supposed to be working with 
developing countries, including least developed countries, to solve some of 
these issues ± although the next section will raise some questions in that 
respect. Overall, although there is no official urgency for any of the actors 
concerned to be made fully aware of the expectations of TRIPS, the findings 
presented below should not appear less surprising nor less contrasting with 
existing literature for this reason. Finally, it is crucial to reemphasise that 
DFWRUV¶ SRVLWLRQ ZDV QRW DW DQ\ SRLQW WKDW 75,36 ZRXOG WDNH ORQJ WR EH
implemented, or was still too far away to think about it; but that the concept of 
pharmaceutical patents itself would never be practically relevant to their 
activities, and that the respect of TRIPS or other international texts of this type 
was simply irrelevant to anyone in the country. For all these reasons I do not 
think we should be satisfied with the speculation that things might change, nor 
happy with the assumption that the limited time left for Djibouti to be fully 
TRIPS-compliant can on its own explain the lack of mobilisation generated by 
TRIPS as official prescription. 
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Overall, the conclusions from this section need to remain balanced in what they 
are able to claim about the future role of TRIPS, and what they emphasise in 
relation to the limits of current research. Chapter 1 has explained how TRIPS 
has largely become framed in certain discourses as a public health issue. The 
mobilisation of public health actors is not only a reaction to TRIPS and its 
impact, but also something that is necessary for TRIPS to produce effects. 
Obviously, the situation in Djibouti might change, and actors might change 
their views about TRIPS. However, at the moment, the situation that appeared 
in this case study is not one in which TRIPS ± at least in its official/written 
prescriptive dimension - is a key public health actor ± it is one of indifference. 
Can the relative non-action of TRIPS as prescription be explained? This is a 
difficult question, since explaining absence can easily turn into speculating on 
³ZKDWFRXOGKDYHEHHQGLIIHUHQW´ZKLFKLVQRWDPDWWHUIRUHPSLULFDOUHVHDUFK
However, if doubts will have to remain as to the full reasons behind the loss of 
agency of TRIPS as prescription outside the office where it is being 
implemented, some empirical elements can at least participate in bringing light 
onto the question of expertise and information. The next section will discuss 
some elements that can help in understanding the difficulties for entities to 
FLUFXODWHDFURVV³SROLF\-QHWZRUNV´LQ'MLERXWL 
 
 
 
 
 
 
 239 
SECTION 3: ACTION AND CIRCULATION IN DJIBOUTI 
 
2QJRYHUQPHQWVDV³SXQFWXDOLVHG´XQLWV 
 
As reflected in more detail in Chapter 1, most literature on the impact of 
75,36 RQ ³GHYHORSLQJ FRXQWULHV´ WHQGV WR GLVFXVV KRZ ³FRXQWULHV´ ³VWDWHV´
DQG ³JRYHUQPHQWV´ UHDFW WR WKH WH[W 7KH QRWLRQ RI VWDELOLW\ EHKLQG WKH WHUP
JRYHUQPHQW LV RQH WKDW LV RIWHQ ³IHOW´ UDWKHU WKDQ WROG ± and in some cases, 
indeed, the coherent action of governments and the stable connections that 
holds them can justify their terminological punctualisation. 
 
³,I ZH FRQVLGHU FRPSOH[LW\ DV DQ LQGH[ RI LUUHGXFLELOLW\ WKHQ RQH RI WKH
intended and imagined effects of governments has been to reduce complexity 
and to produce a unified and economic order, an order that can be summed up. 
7KHYHU\SRSXODULW\RI WKH LGHDRI³WKHVWDWH´FRQFHLYHGDVD IXQFWLRQDODQG
LQGLYLVLEOHXQLWDWWHVWVRIWKHSUHYDOHQFHRIWKLVYLHZ´351  
 
When literature on TRIPS talks aERXWWKHDFWLRQRI³VWDWHV´RU³JRYHUQPHQWV´
IHHOLQJVRIFRKHUHQWDQG³VPRRWK´DFWLRQVSUHDGWRPLQG6WDWHVDUHSRUWUD\HG
as acting as one. However, through this case study, the idea of stability through 
political networks crumbled away rather quickly, and it is now useful to 
                                                 
351
 %DUU\$³,QWKH0LGGOHRIWKH1HWZRUN´LQ-/DZDQG$0RO(GVComplexities: 
Social Studies of Knowledge and Practice, Durham, N. Ca.: Duke University Press, pp. 142-
165, on p.142. 
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explain how this happened and what this might mean for TRIPS and its 
circulation. 
 
This section presents some elements that can help in understanding why TRIPS 
as prescription is not constructed as having effects outside of the specific office 
where it is being implemented. In particular, it discusses some elements that 
clarify how TRIPS in this particular dimension remains excluded from public 
health networks as a relevant social actor. It questions whether a coherent 
governmental network could be identified in this case study, and how the shape 
of institutional connections can participate in understanding the action ± or 
absence of action ± of TRIPS as prescription in Djibouti. This section 
highlights how, when looking at pharmaceutical patents in Djibouti, it appeared 
that a number of people who could be expected to work together on this issue 
were in fact in complete isolation from one another. As mentioned earlier, the 
action of TRIPS is the result of associations involving not only the trade and 
industry area, but also, as far as pharmaceutical patents are concerned, a wide 
range of public health actors352. The mobilisation of public health actors ± even 
if in the form of open opposition and resistance ± is also often assumed when 
taONLQJ DERXW ³75,36 DQG GHYHORSLQJ FRXQWULHV´353. If TRIPS is such a big 
LVVXH IRU SXEOLF KHDOWK LQ ³GHYHORSLQJ FRXQWULHV´ DV LV IUDPHG LQ DFDGHPLF
                                                 
352
 As explained in particular in Chapter 2. 
353
 For an analysis of the opposition to TRIPS that followed its implementation, see for 
example Sell S.  ³75,36 DQG WKH DFFHVV WR PHGLFLQHV FDPSDLJQ´ Wisconsin 
International Law Journal Summer 20(2) 481-522. 
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writings and the media354 WKH ³KHDOWK VHFWRU´RIGHYHORSLQJFRXQWULHV VKRXOG
certainly be aware of it! And for them to be aware of it, TRIPS has to have 
become a social actor for them too, something that they expect to have the 
potential to act. Unless of course this is not true of all developing countries, 
and, unless in some countries TRIPS as prescription has not entered public 
health as a social actor yet, maybe because it has not reached this network at all 
yet in its prescriptive dimension. The above section has demonstrated that this 
was the case in Djibouti. This section resets this element within questions 
raised by the punctualisation of policy-networks in Djibouti ± and contrasts the 
findings made on the ground with the widespread use of notions such as 
³JRYHUQPHQWV´RU³LQWHUQDWLRQDORUJDQLVDWLRQV´WRUHSUHVHQWZKDWDSSHDUHGKHUH
as uncertain and largely unstable sets of fragile connections. It highlights how 
the difficulties found when trying to circulate between actors from different 
³ILHOGV´IRUWKHSXUSRVHRIWKLVUHVHDUFKVRRQLOOXVWUDWHGWKHODFNRIFRQQHFWLRQV
between different networks, and provided elements essential when trying to 
XQGHUVWDQG ZK\ 75,36 ZDV GHSULYHG RI DJHQF\ RXWVLGH LWV ³RIILFLDO´
implementation setting. Because the ideas discussed in this section emerged 
essentially from practical issues arising during fieldwork, this section will 
follow closely the course of this research to emphasise how weak or missing 
connections appeared. It will then question how the lack of punctualisation of 
the networks studied could be related to the circulation and action of TRIPS as 
written prescription. 
 
                                                 
354
 For media coverage of this issue, see for example Maniere de Voir (2004) Apartheid 
0HGLFDOH1RVHHDOVR5LYLHUH3³$SUHV3UHWRULDTXHOOHSROLWLTXHFRQWUHOH6,'$"´
Le Monde Diplomatique, 20th April 2001. 
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Moving across policy networks: how hard can it be? 
 
Chronologically, this empirical research started with interviewing actors in the 
public health field. Connections were made very quickly, and informants knew 
each other enough to introduce me to whomever they thought might be a 
relevant contact. Although actors from different institutions ± hospitals, 
ministry, WHO ± ZHUHQRWDOZD\VVXUHRIZKDWHDFKRWKHU¶VMREH[DFWO\ZDV
they were generally able to name some people they thought were informed 
about specific questions, and to explain roughly where they worked and what 
their responsibilities were vaguely about355. As mentioned before, actors in the 
public health sector were mainly unaware of the current steps of 
implementation of TRIPS, or of what TRIPS might mean for them ± or rather 
they all agreed that TRIPS would mean nothing to them, when discussing its 
official implementation. Although this was a rather surprising start compared 
to the findings I was expecting to make, and the background information I had 
FROOHFWHG RQ ³SXEOLF KHDOWK DFWRUV´ UHDFWLRQV WR 75,36356, their lack of 
information would become more understandable when looking at the way in 
which they relate to those officially in charge of implementing TRIPS, in the 
Ministry of Trade. When following the course of this fieldwork, it became an 
increasingly clear element that maybe TRIPS as official written prescription 
                                                 
355
 The familiarity of actors from each institution with the setting of other buildings was 
demonstrated by the facility with which they walked me from one place to the other, without 
hesitating on which door to knock on to find relevant interlocutors. 
356
 Next to the South African case, examples can be found in Brazil ( Nogueira J. (2002) 
³,QWHOOHFWXDO3URSHUW\5LJKWV WKH:RUOG7UDGH2UJDQLVDWLRQDQG3XEOLF+HDOWK7KH%UD]LOLDQ
3HUVSHFWLYH´ Connecticut Journal of International law (17) p. 311-318) or Malaysia (Third 
World Network, Tackling AIDS with cheap generic drugs, Monday 6th December 2004, 
available at www.twnside.org.sg/title2/gtrends35.htm) 
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was not entering the public health network because there was no channel for it 
to circulate from the Ministry of Trade, where it has arrived in its written form, 
to the health sector. 
 
After having met most of the actors I wanted to talk to in the public health 
VHFWRUWKHQH[WORJLFDOVWHSZDVWRWU\WRPHHW³WKHLUFRQWDFWV´LQWKHWUDGHDQG
industry field. The ease with which each informant had been able to introduce 
me to relevant colleagues made me - wrongly ± assume that meeting someone 
in the trade related field would be as simple. I truly expected that people 
creating rules on pharmaceutical imports for the Ministry of Health could 
introduce me to someone they knew working on import rules more generally. 
Considering the current president of the Chambre du Commerce is also a 
pharmacist, the relations between the two sectors must be somehow facilitated? 
At least he would certainly know who works on trade and industry issues? It 
was probably all going to be straightforward. Surprisingly, it was not the case. 
When asked to what extent they worked with other Ministries, or actors from 
different fields, informants in the public health sHFWRUZHUHDOOUDWKHUXQVXUH³I 
think the Minister here sometimes works with the Ministry of Finance to try to 
JHW VRPH WD[ OLPLWDWLRQV IRU SKDUPDFHXWLFDOV« %XW LW LV UHDOO\ SXQFWXDO
DFWLRQ«´2YHUDOO LWZDV LPSRVVLEOH WR ILQGDQ\RQH LQ WKH0LQLVWU\RI+ealth 
who could name anyone in the Ministry of Trade or the Chambre du 
Commerce ± DIWHU D IHZ GD\V RI VHDUFK ³DQ\RQH´ ZRXOG KDYH EHHQ JRRG
enough! It was finally through personal relations only, by asking different 
people until someone mentioned a name that I could find a way to meet 
someone from the Ministry of Trade. As had been the case with the health 
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sector, once one person was met things progressed quickly again, and that 
person was able to put me in touch with a number of other relevant informants. 
 
Although this does not call for as much attention, since it does not touch as 
closely the issue of pharmaceutical patents, it is worth mentioning that this 
difficulty to circulate from one field to another, from one building to another in 
some cases, was also felt in other circumstances. The emergent pharmaceutical 
industry could only be accessed by almost randomly meeting someone who 
was directly involved in it, while the Ministry of Trade and Industry, the 
&KDPEUH GX &RPPHUFH HW GH O¶,QGXVWULH DQG WKH 0Lnistry of Health had all 
been ruled out as potential sources of information and contact. No one truly 
seemed to know what was happening to this industry or who was involved in 
the project. The National Research Institute of Djibouti was also visited, to find 
out that none of the researchers had received information on IP from anyone, in 
spite of their interest in the issue, and did not know anyone in any other 
governmental agency that could provide them with information. 
 
From the very first stages of this research, it therefore appeared that the issue 
of the limited action of TRIPS as prescription could not be isolated from 
understanding the lack of stability of policy-related networks in the country. It 
was not only TRIPS that was not circulating or mobilising, it was much more 
than this ± it was most actors. The question of networking and punctualisation 
in governmental action has been raised elsewhere, including within developed 
states357, and appears clearly in this particular case study. It is crucial in an area 
                                                 
357
 6HHWKHH[DPSOHRI%DUU\¶VUHVHDUFK%DUU\$RSFLW 
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where coordinated action from different fields is necessary not only to create a 
specific regulation, but also to build a specific tool as a policy issue. These 
overall findings on the weakness of relations across fields in Djibouti can seem 
even more surprising given the size of the country358, and the small number of 
actors actually involved in any form of governmental institution359. It is also 
most surprising since actors who would not relate in any ways at work, 
although their interests could find a common ground, would often know each 
other on a personal level ± they just did not have any work-related information 
on each other. For example, many actors went to the same school, studied in 
France in the same town where a strong Djiboutian community is established, 
and are often relatives or family friends360. Personal networks seem never 
ending, but professional ones much weaker. The lack of interaction between 
actors did not stop them from manifesting some curiosity and interest as to 
what each other was doing, or where expertise and information was located. It 
was thus often the case that when discussing patent issues with actors from 
either public health or trade and industry, informants seemed truly interested in 
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 The contrasts between topological closeness and relations in a networked space interestingly 
illustrate some of the difficulties with geography when dealing with networks and relational 
theory ± VHH/DZ-³2EMHFWV6SDFHVDQG2WKHUV´SXEOLVKHGE\WKHCentre for Science 
Studies, Lancaster University, LA14YL, UK, at 
http://www.comp.lancs.ac.uk/sociology/papers/law-objects-spaces-others.pdf and Law J. 
 ³0DWHULDOLWLHV 6SDWLDOLWLHV *OREDOLWLHV´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV
Lancaster University, LA14YN, UK, at http//www.comp.lancs.ac.uk/sociology/soc029jl.html, 
for examples. 
359
 It is interesting to relate this lack of connection between actors tR5RJHUV¶DSSURDFKWRWKH
diffusion of innovation, and the difficulties for innovations to travel across heterogeneous 
groupings, while this is in fact the most efficient way for innovations to spread across society ± 
See Rogers E. (1995) The Diffusion of Innovations, New York: Free Press. 
360
 ³, VWXGLHG LQ 5HLPV EHFDXVH , NQHZ VRPH SHRSOH WKHUH IULHQGV UHODWLYHV HWF« $ ORW RI
'MLERXWLHQVOLYHWKHUH,GRQ¶WNQRZZK\´ 
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working with the other sets of actors, but completely unsure about how to go 
about it361. Informants from each field thus asked me if I could let them know 
who would be an approachable actor in the other field, and explained that they 
wanted to get information or raise awareness ± depending on whether health or 
trade was concerned ± but did not know where to start from nor who would be 
receptive. The difficulties of remaining an outside observer in this kind of 
situation of course needed to be tackled, in order to ensure that the research 
process itself would not impact on the existing situation ± this was particularly 
important if wanting to carry out further interviewing at a later stage to follow 
the evolution of the situation.  
 
Several key questions need to be addressed here: how does this lack of 
connections between actors and fields relate to the difficulties for TRIPS as 
prescription to move beyond the associations generated in the Ministry of 
Trade? Is it because actors do not relate that TRIPS does not generate action? 
Or should TRIPS itself generate this new set of connections? Does this mean 
that TRIPS is failing, since its action appears as more limited than its creators 
have been expecting? First, this issue of failure can be pushed aside, and for 
several reasons. Some reasons are practical ± the next chapter will explain that 
even before TRIPS arrived in Djibouti, pharmaceutical patents were playing 
their own commercial role. Some slightly more theoretical, relating to the idea 
of co-existing realities and dimensions ± if TRIPS in its prescriptive dimension 
limited to its emergence in Djibouti appears to be mobilising fewer actors than 
we might expect, it is certainly doing many other things in Djibouti, and 
                                                 
361
 This was also true of researchers who wanted to find out how their work could be protected, 
but did not know who they could turn to. 
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making many others do things. These effects might not be as some lawyers 
would expect, but why limit ourselves to evaluate the failure/success of TRIPS 
as an actor on the basis of pre-determined expectations? Before answering the 
other questions set here, a few more elements need to be put forward to 
illustrate the difficulties of circulation and connection in the networks studied 
here.  
 
International organisations and the circulation of TRIPS 
 
When investigating the integration of TRIPS as a set of rules in the health 
system of Djibouti, the question of the role of international organisations was 
raised. In particular, they are often presented and understood as creating some 
NLQGRI OLQNEHWZHHQ75,36DQGDFWRUV DFURVV ³JRYHUQPHQWV´ ± and this was 
assumed to include public health actors when starting this research. While 
TRIPS originated from the WTO ± DWOHDVWWKHILQDOLVHG³SULQWHGDQGVWDPSHG´
version of TRIPS - WIPO is expected to offer advice and guidance to states 
when implementing it362. The WHO has also participated in the debate on the 
impact of TRIPS363. However, in spite of general statements and assumptions 
as to what international organisations do in developing countries, specific 
details on the impact of their action are not always given. In this case study, 
                                                 
362
 See the aims of WIPO as quoted above, and available at:  http//:www.wipo.int/about-
ip/en/studies/publications/health_care.htm  
363)RUH[DPSOH:72:+2³:72DJUHHPHQWVDQGSXEOLFKHDOWK´*HQHYDDYDLODEOe at 
http://www.wto.org/english/res_e/booksp_e/who_wto_e.pdf#search='WTO%20agreements%2
0and%20public%20health:+2³*OREDOL]DWLon, TRIPS and Access to 
3KDUPDFHXWLFDOV´DYDLODEOHDWhttp://www.who.int/3by5/amds/en/regulations1.pdf  
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this appeared as part of the story to be told on the circulation of TRIPS, and it 
needs to be discussed briefly. 
 
Few international organisations have a local office in Djibouti. Most carry 
information to relevant people locally through visiting advisors or posted 
documents. The WHO is the only relevant structure to have a local office. It 
involves mainly five people. They mentioned being frequently in touch with 
their regional office, and many documents produced by the central office were 
also available in the small library of the WHO office. Whether this should be 
understood as an appropriate diffusion of information from the central office to 
representatives in Djibouti is of course contingent on them reading these 
documents. However, it is important to ask whether the WHO plays any role in 
making TRIPS an issue for pubOLF KHDOWK DFWRUV ³We are in charge of 
organising meetings on TRIPS and other issues, and we work with WIPO on 
this for example´ UHSOLHGD UHSUHVHQWDWLYHRI WKH:+2%XW IRUDFWRUV LQ WKH
0LQLVWU\RI+HDOWK³The WHO has never talked to me about anything like that. 
:HVRPHWLPHVZRUNZLWKWKHPRQVSHFLILFSURMHFWVEXWZHGRQ¶WVHHWKHPYHU\
PXFK«´ 6R WKH RIILFH RI WKH :+2 EDVHG LQ 'MLERXWL PLJKW KDYH RUJDQLVHG
meetings on TRIPS, but other public health actors in Djibouti were not 
involved. Nevertheless, the WHO still had some links to the Ministry of 
Health, at least through this unread report sitting on a desk. The contrast 
between intermediaries and mediators put forward by Latour could not be more 
striking than when thinking back about this particular trace of TRIPS. 
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The second organisation that is often perceived as central in developing IP as a 
policy issue, and in integrating TRIPS in national systems is the WIPO. It is 
important to reflect on its role in Djibouti. We have seen that it was quoted by 
the official in charge of implementing TRIPS as a source of advice. Its 
SUHVHQFH ZDV DOVR FRQILUPHG E\ RWKHU DFWRUV ³The TRIPS agreement was a 
great opportunity for WIPO! Before, noone had ever heard of them in 
developing countries, now they are everywhere. They come and give 
SUHVHQWDWLRQVHYHU\ZKHUHWKH\FDQ´ However, later comments by other actors 
working with WIPO seemed to question whether this advice was of any true 
UHOHYDQFH WR WKH FRXQWU\ ,Q IDFW WKH ³:,32´ GRHV QRW KDYH DQ\ RIILFH LQ
Djibouti, and is only temporarily part of the country when it sends 
representatives over. Their actual role and action, however, was questioned by 
many actors in Djibouti. When discussing their role, informants presented 
rather strong and passionate views on the role RI ³YLVLWLQJ DGYLVRUV´ DQG
LQVLVWHG WKDW WKH\ FRXOG QRW EH SHUFHLYHG DV ³DSSURSULDWH VRXUFHV RI
LQIRUPDWLRQ´1RQHRI WKHDGYLFHSURYLGHGFRXOGEHFRQVLGHUHGDV WDLORUHG WR
the needs of the country, and that it was therefore of no use to anyone in 
Djibouti. Examples of this were widely quoted:   
 
³Recently, in the Ministry of Finance, an international advisor came to help 
them change the tax system. You have to know that in the Ministry of Finance, 
in particular, people are all very qualified! They all have at least 4 years of 
university in France behind them! Well, this advisor came, and tried to explain 
WRWKHPWKDWZHVKRXOGLQWURGXFH9$7LQ'MLERXWL«,I\RXNQRZHYHQDELWWKH
V\VWHPLQ'MLERXWL LW LVREYLRXVWKDW LW¶V LPSRVVLEOHWR LQWURGXFH9$7KHUH at 
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WKHPRPHQW%XVLQHVVPHQGRQ¶WHYHQKDYHDQDFFRXQWDQWDQGGRQ¶WDFWXDOO\
hold anything like a real accountancy book! Everybody tried telling him, and 
WKH\ DUH DOO TXDOLILHG DQG WKH\ DOO NQRZ WKH SODFH EXW KH GLGQ¶W OLVWHQ WR
DQ\RQH« ,QVWHDGRI JLYLQg us appropriate advice on what we could actually 
do, he held onto his idea that we should introduce VAT, and wrote a very 
FRPSOHWHUHSRUWEXWSHUIHFWO\XVHOHVVIRUXV´ 
 
This idea that international advisors, not only had little knowledge of the local 
needs, but also very little respect for the opinion of local actors, or for the local 
specificities of the country was presented many times, by people from different 
backgrounds and working in different institutions: 
 
³International advisors are really funny« WKH\ FRPH KHUH VWD\ KHUH IRU D
ZKLOHFRPHWRORWVRIFRFNWDLOVDQGPHHWLQJV«WKHUHVWRIWKHGD\\RXKDUGO\
VHHWKHP:HGRQ¶WDFWXDOO\NQRZZKDWWKH\GR«DQGWKHQDIWHUDIHZGD\VRU
a few weeks, they go back home, and they send a report which is meant to be 
DGDSWHGWRWKHVSHFLILFLWLHVRIWKHFRXQWU\«WKDW¶VZK\WKH\FRPHDIWHUDOOWR
look around, talk to people, find out what our needs are, and then give us 
DGYLFHRQWKLVEDVLV«ZHOO\RXMXVWFDQ¶WLPDJLQHKRZPDQ\WLPHV,UHFHLYHGD
report with LQ LWV LQWURGXFWLRQµ'MLERXWL± Capitale: Dakar or Nouakchott or 
VRPHWKLQJ HOVH¶« 7KH\ MXVW WDNH D UHSRUW WKH\ KDG SUHSDUHG IRU DQRWKHU
FRXQWU\ DQG SXW ³'MLERXWL´ LQ WKHUH« EXW ZKDW ZRUNHG LQ &DPERGLD PLJKW
QRWZRUNKHUH«,W¶VDELWGLVFRXUDJLQJ´  
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These quotes are most interesting when reflecting on the circulation of 
information ± in particular that of TRIPS as prescription. Once again, their 
immediate impact can only be suggested ± but some questions need to be 
asked: can WIPO truly be considered as a mediator if those receiving its 
information believe that this is inappropriate? Can it extend far enough to act 
beyond its temporary presence and generate through its advice new relevant 
associations? 
 
The last organisation to look at is obviously the WTO. It is through the WTO 
that TRIPS as written law officially originated and it is also the WTO that 
should ultimately evaluate behavioural compliance with TRIPS as prescription. 
It is an integral part of TRIPS, as much as TRIPS itself only exists through the 
WTO. Djibouti has a representative in the WTO central offices in Geneva. 
However, he does not deal with TRIPS. The only way in which the WTO 
communicates about TRIPS with actors in Djibouti is through the reports it 
sends and through occasional contacts it makes in the country. When asking 
someone in the Ministry of Trade if they were made aware of changes 
³UHJXODUO\´ E\ WKH :72 WKH\ UHSOLHG ZLWK D ODXJK ³5HJXODUO\«QR EXW
sometimes! Once in a while! But things change so quickly that by the time we 
haYH EHHQ LQIRUPHG DQG GHFLGHG WR UHDFW RWKHUV KDYH DOUHDG\ PRYHG RQ´ 
When looking at the WTO it therefore also appeared that connections were 
weak or missing. 
 
As a whole, when observing more closely the role of international 
organisations in Djibouti, the image of a highly coordinated network appeared 
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as weaker than suggested by academic writings and the media. While the 
involvement of the WTO, WIPO and WHO can be found through the many 
reports they have published linking TRIPS and public health364, and while 
³JRYHUQPHQWV´DQG³FRXQWULHV´DUHZLGHO\GHVFULEHGDVEHLQJLQIOXHQFHGE\WKH
new set of rules created by TRIPS, the connections followed here all appeared 
to be coming to a complete stop at some point, and the circulation of TRIPS as 
written prescription, the necessary movement that makes social associations 
remain active could not be retraced further than a range of punctual and limited 
associations.  
 
However, if wanting to look for further explanations, to the weak circulation of 
materials and information in Djibouti, a few other elements could be put 
forward. It appears that TRIPS entered the Ministry of Trade, but did not truly 
move out of it. It is also in the WHO, in the form of many reports travelling 
from the central office, and through the awareness of the main representative. 
And it is in the Ministry of Health ± on a desk. But why did it not move from 
this desk? Certainly partly because it did not mobilise the interest of the owner 
of the desk. According to a number of other actors in the field, there was no 
need to look too deep into this issue ± the problems Djibouti is facing in terms 
of expertise mean that some of the officials given a specific job do not 
necessarily have the training and qualification that will make them fully 
                                                 
364
 6HHIRUH[DPSOH:+2:72³,PSOLFDWLRQVRIWKH75,36DJUHHPHQWVDQGWKH'RKD 
GHFODUDWLRQDQGSXEOLFKHDOWK´RSFLW:+2³*OREDOL]DWLRQ75,36DQG$FFHVVWR
3KDUPDFHXWLFDOV´DYDLODEOHDWhttp://www.who.int/3by5/amds/en/regulations1.pdf ; See also 
the WIPO weEVLWHRQSDJHVVXFKDV³6WULNLQJDEDODQFHSDWHQWVDQGDFFHVVWRGUXJVDQG
healthcare, available at: http://www.wipo.int/about-ip/en/studies/publications/health_care.htm  
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involved. The structure of some ministries is particularly complex in that 
respect, and while cooperants are employed by the government to make up for 
the lack of local trained personnel, the main posts in each ministry are held by 
a national of Djibouti. While this works perfectly well in some cases, since 
many Djiboutians are qualified in some areas ± and increasingly so ± it still 
creates tensions in others, where communication and cooperation are both 
consequently affected. In the example of this office, in which the TRIPS-
related document was observed, this was clearly the case. It was clear that if 
the actor to whom it was addressed had not been willing to read and process it, 
it was unlikely that it would be moved ± except of course maybe to clear the 
desk.  
 
A fair question to ask, at this stage, is whether any of the above ruptures and 
disconnections described above can fully explain why TRIPS is not mobilising 
PRUH DFWRUV RXWVLGH RI ³LWV´ RIILFH 7R SXW LW GLIIHUHQWO\ LI DOO RI WKH DFWRUV
mentioned above had been connected in a stable way, if international 
organisations had efficiently transmitted messages and participated in 
generating the prescriptive aspect of TRIPS in Djibouti, if the reports sent to a 
few people had travelled to more, would anyone have felt differently about 
TRIPS? The answer to be given to this question will appear as obvious from 
the positions argued from the start. I cannot claim to know and it would be 
inappropriate from the standpoint of ANT to speculate. Maybe even if 
connections had been more stable, noone would have cared about TRIPS 
outside this one office. However, in these circumstances, within this particular 
set of weak and unstable associations, the circulation of TRIPS within Djibouti 
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faced many obstacles that are often absent from existing writings, but appeared 
as crucial in this project. Maybe TRIPS as prescription would not have acted 
any more if it had circulated better, but without circulating and without being 
known, its agency disappeared without being given an opportunity to come into 
being. While it would be purely speculative to discuss what would have 
happened under other circumstances, or to claim that the circulation of TRIPS 
as written rules is the only element that stopped it from deploying full agency, 
it seems safe and relevant enough to claim that the difficult and limited 
connections in the fields concerned with TRIPS played a large part in 
preventing it from acting fully. 
 
CONCLUSION 
 
The conclusions to be drawn in this chapter need to be as modest as ANT calls 
for. They cannot overstep the limits of what was said and observed in the 
course of this research, and I do not wish to discuss too sweepingly the 
PHDQLQJ RI ³ODZ´ DV D ZKROH LQ WKH SROLF\ QHWZRUNV RI 'MLERXWL :KDW WKLV
chapter has explained relates only to TRIPS ± and only for the moment to 
TRIPS in its prescriptive, written dimension, although the next chapters will 
explain that there might be more to TRIPS than this ± and only to the networks 
that can relate to TRIPS, and that were in this respect studied in the course of 
this research. It has explained that, in contrast with its international framing as 
a public health issue, TRIPS as prescription has not become part of networks 
concerned with public health ± or at least not in its official dimension 
investigated so far. If TRIPS as written rules is modifying some orderings in 
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one particular office of the Ministry of Trade, its action in Djibouti as a new set 
of rules appears as limited to this particular localised set of connections ± 
localised in this office, in this particular action and circulation, although it 
involves associations that run from Geneva to Djibouti via the many places in 
which TRIPS was discussed before it reached Djibouti. Once moving out of 
this office, TRIPS does not leave many traces, and does not reshape many 
orderings.  It is there in words, in thoughts ± and essentially in words and 
thoughts emphasising its irrelevance. It is also occasionally there in its 
materiality, but as a clear example of passive intermediary more than anything 
else. This of course relates more broadly to questionings known in the socio-
OHJDO ILHOG RI WKH FRQWUDVWV EHWZHHQ ³ODZ RQ SDSHU´ DQG ³ODZ LQ DFWLRQ´365. 
However, these terms have been left aside here both for the specificity of their 
original use, and because Chapter 7 will explain that TRIPS might be limited in 
its action as a set of official/written prescriptions (although even then, it is 
certainly acting), but that it remains a social actor in other ways, through what 
it has generated, and in a fashion that will become understandable once 
opening the door of the effects of TRIPS in other fora.  
 
Although the absence of TRIPS as rules could not be explained with certainty 
by attempting to borrow from causal mechanisms, the links between the limited 
circulation of TRIPS as written prescription and the structures of other 
associations in policy-networks in Djibouti was also discussed. By looking 
                                                 
365
 Or approaching conceptual ideas ± see for example: 1HONLQ' ³/DZ LQ$FWLRQRU
/LYLQJ /DZ" %DFN WR WKH %HJLQQLQJ LQ 6RFLRORJ\ RI /DZ´ Legal Studies (4) pp.157-174; 
3RXQG5³/DZLQ%RRNVDQG/DZLQ$FWLRQ´American Law Review (44) pp. 12-18. 
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PRUHLQGHWDLODWWKHVH³QHWZRUNV´ZKDWDSSHDUHGZHUHLQIDFWVHWVRIUXSWXUHV
and the instability of connections that are often assumed to be stable in terms 
VXFKDV³V\VWHPV´³JRYHUQPHQW´RU³RUJDQLVDWLRQ´%\ORRNLQJPRUHFORVHO\
into particular connections, their weakness and the avoidance of their 
performance by many actors appeared as essential elements in understanding 
how TRIPS in its written/official pharmaceutical patent dimension stopped its 
circulation and social integration. The idea that the story of TRIPS and 
pharmaceutical patents in Djibouti might end just there was something that was 
briefly considered in this project ± it seemed at a time that TRIPS and 
pharmaceutical patents might just be largely irrelevant objects in Djibouti. 
However, things became both more complex and more interesting as data 
accumulated. It became clear that the questions asked in this chapter only 
covered one particular dimension of TRIPS and only considered 
pharmaceutical patents as far as they related to their official creation in 
Djibouti. Although these might be the most widely acknowledged roles and 
dimensions of both objects that have been looked at, they remain only a limited 
part of what makes the story of both instruments in Djibouti. The next two 
chapters will demonstrate why, in spite of the official situation of TRIPS and 
pharmaceutical patents in Djibouti, both instruments remain to be understood 
as social agencies ± and as social agencies in the public health field more 
VSHFLILFDOO\ $OWKRXJK GHILQLQJ WKHP DV DFWRUV LQ ³D OHJDO ZD\´366 in the 
country remains too broad and therefore uncertain, their social action through 
                                                 
366
 ³,W¶V QRW RQO\ WKDW ODZ IRU LQVWDQFH LV XQH[SODLQDEOHE\ WKH LQIOXHQFH VRFLDO IRUFHV H[HUW
RYHULWLW¶VQRWHYHQWKDWODZKDVWRH[SODLQLQWXUQZKDWVRFLHW\LVVLQFHWKHUHLVQRVRFLHW\WR
be explained. Law has much better things to do: one of them is to circulate throughout the 
landscape to associate entities in a legal way´/DWRXU%Reassembling the Social: an 
Introduction to Actor-network Theory, Oxford: Oxford University Press, on p. 239. 
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living and dynamic connections needs to be fully understood in order to 
explain what both tools mean for society in Djibouti. 
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CHAPTER 6 ± EMBEDMENT OF PHARMACEUTICAL PATENTS IN 
THE DRUGS USED IN DJIBOUTI 
 
Throughout the empirical part of this research and when investigating the 
traces left by TRIPS and pharmaceutical patents in Djibouti, other aspects than 
the prescriptive dimension of TRIPS appeared crucial to understanding the 
links between TRIPS, pharmaceutical patents and health in Djibouti. This 
chapter presents one of these aspects, and explains where pharmaceutical 
patents were found when investigating the pharmaceutical market. It discusses 
what this means in relation to the mechanisms of pharmaceutical patents, and 
speaks to the limits of some assumptions about what socio-legal objects do or 
how they work. This chapter questions the link between the existence (or 
absence) of pharmaceutical patents in written national law and the socio-legal 
role of pharmaceutical patents. 
 
 I started this research with the assumption that, because pharmaceutical 
patents had never been created in the national law of Djibouti, they were 
irrelevant to current social networks in the country. The indifference of local 
political actors to TRIPS presented in Chapter 5 seemed to sustain this idea, by 
demonstrating that the official introduction of patents did not appear to 
generate change or mobilise any relevant actor. However, the original 
impression that patents were non-existent and irrelevant in Djibouti started 
being questioned as the pharmaceutical system of the country was being 
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studied. In particular, the potential embedment367 of pharmaceutical patents in 
the drugs used in Djibouti was considered. This chapter explains how this was 
done, and reflects on the potential role of patents in the pharmaceutical market 
of Djibouti.  By doing so, it offers a way to understand further why the divide 
EHWZHHQ³OHJDO´DQG³VRFLDO´QHHGV WREHUHWKRXJKWDQGUHSODFHGE\DFOHDUHU
empirical understanding of the specific mechanisms of particular socio-legal 
objects368. 
 
This chapter is a central step in discussing how patents operate in relation to 
health in Djibouti. However, it also constitutes only one step in a reasoning that 
will be continued in the following chapter. Some elements will only be fully 
explained in the next chapter, such as the specific meaning of the role of 
patents in the pharmaceutical market of Djibouti in relation to health and 
diseases. This chapter is divided into two sections. First, the pharmaceutical 
market of Djibouti is described, and some characteristics of the specific 
medicines found in the country are presented. The embedment of 
pharmaceutical patents in the pharmaceutical market of Djibouti is introduced 
in this section (Section 1). Second, the set of connections that have participated 
                                                 
367
 As explained in Chapter 2, the term can be found in many ANT texts ± for example: Law J. 
 ³0DWHULDOLWLHV 6SDWLDOLWLHV *OREDOLWLHV´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV
Lancaster University, LA14YN, UK, at http//www.comp.lancs.ac.uk/sociology/soc029jl.html 
RU /DZ -  ³7RSRORJ\ DQG WKH 1DPLQJ RI &RPSOH[LW\´ SXEOLVKHG E\ WKH &HQWUH IRU
Science Studies, Lancaster University, LA14YL, UK, at 
http://www.comp.lancs.ac.uk/sociology/papers/law-topology-and-complexity-pdf.  
368
 The position taken by Latour (in Latour B. (2005) Reassembling the Social: an Introduction 
to Actor-network Theory, Oxford: Oxford University Press) and mentioned earlier that law acts 
LQ D ³OHJDO ZD\´ LV E\ GHILQLWLRQ not untrue ± however this case study aims to explain why 
PDQ\ XQFHUWDLQWLHV VWLOO H[LVW DV WR WKH IXOO PHDQLQJ RI ³ODZ´ DV IDU DV VRFLDO DFWLRQ LV
concerned. 
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in stabilising patents as socio-legal actors, while excluding the most 
controversial generics from the Djiboutian market, are introduced (Section 2). 
 
SECTION 1: PHARMACEUTICAL PATENTS AS DETERMINANT TO 
THE LOCAL PHARMACEUTICAL MARKET 
 
When looking at the issue of access to medicines in Djibouti in Chapter 4, it 
was made clear that only one main aspect was considered ± that of the 
availability of drugs for patients. This section needs to consider in more detail 
the pharmaceutical market of Djibouti. This will illustrate another aspect of the 
implications of ANT to the empirical study of pharmaceutical patents. When 
discussing the role of pharmaceutical patents, their complexity has been briefly 
introduced in Chapter 2. However, what has been left partly to one side is their 
DFWXDOUHODWLRQZLWK³SKDUPDFHXWLFDOV´2QFHDJDLQLWLVLPSRUWDQWDWWKLVVWDJH
to emphasise the full interconnection between actors often presented as 
independent, but who fully merge into one in many cases. In particular, when 
considering more closely both patents and drugs from a public health 
perspective, it becomes clear that the object of study is often a unique but 
complex hybrid369. Once a patent has been granted, a new hybrid is created, 
made both of the complexity of pharmaceutical patents and of drugs. The 
complexity of the drug/patent hybrid cannot be fully undone here, although 
some of its dimensions will be discussed. What is more important, at this stage, 
                                                 
369
 The notion has been introduced in Chapter 2 ± see also Latour B. (1993) We Have Never 
Been Modern, Brighton: Harvester Wheatsheaf. Although the term was originally used to break 
the human/non-human divide, it presents an interesting metaphor that could more broadly be 
applied to contest dichotomies, such as those here between law/technology.  
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is to understand that the social presence of pharmaceutical patents can be read 
within these hybrids, and that when looking for traces left by pharmaceutical 
patents, it is essential to look within the drugs found in the system studied.  
 
In Djibouti, all actors interviewed, as explained before, dismissed 
pharmaceutical patents as something that was of no social relevance to them. 
They stated many times that they were not part of any action in the country and 
were almost invisible apart from reports emanating from institutions external to 
the country and from the basic expertise of a few officials. When explaining 
this, one of my informants vehemently stated his own lack of interest in the 
concept of patents in these terms: ³3DWHQWVQRSDWHQWV«DOO WKHVDPHKHUH´ 
Although at the time I understood this statement only as an indifference 
towards the content of written law, based on the perception that introducing 
patents would not change anything ± and this statement was indeed made 
during discussions of the official introduction of patents ± for me it became 
symbolic of other elements that were progressively taking shape in the data 
collected. In particular, while introducing patents would potentially not change 
anything to social orderings in Djibouti, the fact that patents did not exist in 
Djibouti in written law did not seem to shape the pharmaceutical market any 
differently from countries in which pharmaceutical patents officially existed. In 
particular, the official absence of patents from written law in Djibouti did not 
make patents/drugs any less present in the pharmaceutical market of the 
country. 
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When investigating the pharmaceutical market of Djibouti, the inherent 
presence of patents became a clear characteristic of the network. Although 
patents were not present in words or opinions, as explained before, they were 
embedded in the range of medicines that were selected on medical 
SUHVFULSWLRQV ZLWKLQ GRFWRUV¶ DQG SKDUPDFLVWV¶ VWUDWHJLHV DQG SDWLHQWV
requirements. If pharmaceutical patents are understood as more than their 
written/official dimension, if the hybrids that patented medicines represent are 
understood as keeping patents alive, patents were certainly a crucial part of the 
pharmaceutical network of Djibouti. A brief description of this system can 
explain the extent of their presence and action.  
 
When describing the pharmaceutical system, two elements need to be 
addressed ± the rule and a minor exception. As a whole, generic medicines are 
not sold in Djibouti, or are sold only in very limited amounts: 
 
³,Q'MLERXWLZHGRQ¶WOLNHRUWKHGRFWRUVGRQ¶WSUHVFULEHJHQHULFSURGXFWV\HW
VRLQWKH5HSXEOLFRI'MLERXWLZHHVVHQWLDOO\GRQ¶WXVHJHQHULFV´ 
 
³I own two pharmacies. One has about 90% of foreign customers, the other 
100% locals. But the drugs are the same in both ± no generics.´ 
 
 Although every actor in charge of importing drugs affirmed that patents did 
not play a role in their decision-making about which drug to import and from 
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where, there were hardly any generic drugs in the country370. In the largest of 
WKHSKDUPDFLHVDGUDZHUPDUNHG³JHQHULFV´FRQWDLQHGDIHZER[HV,QWKHWLPH
spent in the pharmacy, either as a pure observer or as a patient, I never saw this 
drawer accessed ± I only observed what was inside when I asked one of the 
staff members specifically to open it371. Outside of this particular drawer, and 
ZLWK WKHYHU\IHZH[FHSWLRQVRIVRPH³EUDQGHGJHQHULFV´372, most drugs sold 
were the originally patented version of a given product. The same was true in 
the different hospitals ± with the exception of the OPS, as will be explained 
below. Most pharmacists and doctors interviewed similarly confirmed that they 
                                                 
370
 A methodological note is necessary at this stage ± in order to find out whether the drugs 
REVHUYHGZHUHEUDQGHGJHQHULFVRUWKH³RULJLQDO´YHUVLRQRIDSDWHQWHGGUXJGLIIHUHQWUHJLVWHUV
were used. Mainly, the lists provided by the Agence Francaise de securite sanitaire des produits 
de sante (AFSSAPS) were used. For access to the latest updated version of these lists, see 
http://agmed.sante.gouv.fr/pdf/5/alpha.pdf. The British National Formulary was used to 
compare whether generic versions of the drugs studied also existed in the UK. 
371
 7KLVSDUWLFXODUGUDZHUFRQWDLQHG³SXUHJHQHULFV´RQO\DVRSSRVHGWR³EUDQGHGJHQHULFV´± 
generics named under their scientific name, as opposed to a specific brand chosen by their 
producer. 
372 National law regulate the rules relevant to the commercialisation of generic medicines, 
including their denomination ± this can be either the scientific name of the compound 
FRQFHUQHG RU D ³EUDQG´ FKRVHQ E\ WKH SURGXFHU +RZHYHU LW is necessary that the generic 
version makes it clear that it is a generic. In France, the relevant article is Art. 5000 Code de la 
Sante Publique. For comments on these issues, see for example Larrieu J. and Houin G. (2001) 
³0HGLFDPHQW *HQHULTXH HW 3URSULHWH ,QWHOOHFWXHOOH´ Revue Internationale de Droit 
Economique (1). Numero Special: Brevets Pharmaceutiques, Innovation et Santé 
Publique pp.173-185. In particular, it should be noted that, although the impact of brands on 
the price of medication will be discussed again in Chapter 7, that branded generics remain 
PRUH H[SHQVLYH WKDQ ³SXUH JHQHULFV´- see 'XPRXOLQ -  ³/HV %UHYHWV HW OH 3UL[ GHV
0HGLFDPHQWV´Revue Internationale de Droit Economique, 2000/1, Numero Special: Brevets 
Pharmaceutiques, Innovation et Sante Publique pp. 45-69. In Djibouti, the exceptional generics 
IRXQGRQSKDUPDFLHV¶VKHOYHV± as opposed to those found in the unaccessed drawer ± were, in 
addition, products of large pharmaceutical companies. One of these exceptions, for example, 
was that of doxycycline ± the version found in private pharmacies was not the Vibramycine but 
the branded generic Tolexine produced by Biorga. 
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did not deal with generics ± we will see below how this can be explained. 
)LQDOO\ GRFWRUV¶ SUHVFULSWLRQV SURFHVVHG DW SULYDWH SKDUPDFLHV HTXally 
contained lists of branded medications only373. Although patents were officially 
³QRQ-H[LVWHQW´ DQG ³LUUHOHYDQW´ IRU SROLF\-makers, it is particularly difficult, 
outside of the exception that will be presented below, to find any drug in the 
country that is not a patented drug or the branded version of a drug which was 
originally its patented version ± that is not one of those hybrids mentioned 
above. On the basis of this observation, should it be assumed that patents are 
inoperative tools in Djibouti because they do not exist in written law? Or are 
there ways of acting outside and independently of their official written 
creation. Before questioning this element, it is necessary to look briefly at the 
limited exception to this rule ± in order, in particular, to explain why it remains 
a limited exception.  
 
The only current exception to the absence of generics in Djibouti ± in addition 
to the rarely-accessed drawer mentioned before - can be found in the pharmacy 
of the OPS. Doctors and pharmacists in this hoVSLWDODOODIILUPHGWKDW³we use 
almost exclusively generic medicines´ ,QGHHG WKHLU OLVWVRIPHGLFDWLRQDQGD
brief look at their stocks demonstrated that generics seemed largely 
predominant in the hospital. The two pharmacists estimated that about 75% of 
the drugs used in the hospital were generics. However, a closer look at the 
range of generics imported in the OPS highlighted once again more similarities 
than discrepancies with what could be found in Europe, for example. In order 
to understand this point, it is useful to reflect back on the different meanings 
                                                 
373
 Those observed contained only the originally patented versions. 
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DWWDFKHG WR WKH ZRUG ³JHQHULFV´ $V ZH KDYH VHHQ EHIRUH WKH WHUP JHQHULF
refers to two fundamentally different situations ± one in which these are new 
versions of a drug still under patent, the other where they are a new version of 
a drug whose patent has officially expired374 (and this second type of generics 
are those that can be found even  in countries where patents are part of the 
written legal landscape). In this respect, the generic drugs found in the OPS are 
not any different from what one would expect to find in a country where 
patents are officially part of written national law. All the generic drugs used in 
the hospital were also commercialised in generic version in France or the UK. 
In other words, none of the drugs used in the OPS and found on the lists of 
generic imports would have been infringing patents in Europe375. This could be 
checked fairly easily as the drugs provided by the pharmacy of the OPS are 
rather limited in number, and I was given full lists of what the pharmacists buy 
                                                 
374
 This distinction was introduced in Chapter 1. 
375
 From a patent perspective, the fact that generic versions exist in France (and in the UK) 
mean that the patent has expired in these specific countries. The European Patent system has 
been introduced in Chapter 1, and it explains why it could be fairly reasonably assumed that 
the patent situation is likely to be the same in the rest of the EPC members. This is not 
definitely and necessarily the case, however ± patents could theoretically have been applied for 
in France and the UK only (this is highly unlikely considering the way the patent system works 
in the EPO); patents could have been challenged at the national level in France or the UK. 
Similarly, the fact that generic versions exist in France or the UK does not necessarily mean 
that they exist in other countries yet ± marketing authorisations might take longer in other 
states for example (although even at this level EU law has partly harmonised the procedures ± 
VHH3RLOORW3HUX]HWWR6³/¶DSSRUWGX'URLW&RPPXQDXWDLUHDX[3UREOHPHV3RVHVSDUOe 
0HGLFDPHQW *HQHULTXH´ Revue Internationale de Droit Economique (1). Numero Special: 
Brevets Pharmaceutiques, Innovation et Santé Publique pp.187-196). Once again, however, the 
structure of the European system justifies the possibility to extend findings made on the basis 
RI WKH)UHQFK OLVWLQJVFRPSDUHG WR WKH%ULWLVK1DWLRQDO)RUPXODU\ LQIRUPDWLRQ WR³(XURSH´
For further comments on the EPC system, see for example Stinger M. and Stauder D. (2003) 
European Patent Convention: a Commentary, London: Sweet & Maxwell. 
 266 
and with which they provide their patients376. The drugs network created in the 
VXSSRVHG RIILFLDO ³DEVHQFH´ RI SKDUPDFHXWLFDO SDWHQWV ZDV QRW ORRNLQJ DQ\
different from the situation in states in which patents officially exist. One 
hypothesis, however, could be that this is simply the case because of the nature 
of pharmaceutical needs in the OPS, as opposed to any determinant role played 
by patents377. However, this hypothesis does not seem convincing. Mainly, it 
can be challenged because the exceptions to generic medications found in the 
OPS corresponded partly to emergencies, and partly to drugs that pharmacists 
³GLG QRW ILQG´ LQ D JHQHULF YHUVLRQ $ NH\ H[DPSOH RI WKLV VHFRQG H[FHSWLRQ
found during this fieldwork was that of HIV/AIDS medication. It was given 
immediately by pharmacists, and demonstrated that in this case where patented 
drugs are needed, the versions imported were not generics ± this example will 
be discussed again towards the end of this chapter. Finally, when looking at the 
origin of the generics imported by the OPS, the role of patents in shaping 
health priorities will need to be questioned, and the potential impact of this role 
on the imports of the OPS will be discussed. Once again, causal conclusions to 
be drawn from this example, at this stage, can only be limited, as it is not so 
much a matter of what patents cause, as a matter of where patents are, that 
                                                 
376
 Once again, this could be checked against the lists of existing generics produced by the 
AFSSAPS. 
377
 What is meant by this is that this could be understood as resulting from diseases rather than 
from the action of patents on decisions as to what medication to import ± however, even this 
statement requires the addition of a mark of caution. In particular, the example of the questions 
raised by the potential role of patents in the creation of the Essential Medicines List in the 
WTO has shown that health priorities, diseases and patents might not be fully independent 
from one another  - this is something that will be addressed again below and in Chapter 7, and 
has been discussed for example in Laing R., Waning B., Gray A., Ford N. and Hoen E. (2003) 
³\HDUVRIWKH:+2(VVHQWLDO0HGLFLQHV/LVWV3URJUHVVDQG&KDOOHQJHV´The Lancet (361) 
pp. 1723-1729. 
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needs to be investigated. The main conclusion that can be drawn from this 
example is that, even in the exceptional case where generic medicines are 
LPSRUWHG WKH\ UHPDLQ OLPLWHG WR WKRVH WKDWDUH³SDWHQW-FRPSDWLEOH´'UXJV LQ
which patents are embedded are still chosen over other versions in cases where 
patents are still officially valid in other countries. The presence of patents can 
be identified through the absence of any drug that would be incompatible with 
their legal/official standard in countries other than Djibouti. In addition to the 
first limit of this exception, it should be emphasised that the OPS represents 
only a small part of the pharmaceutical market of the country, available only to 
those allowed to access this particular hospital, and only when physically 
visiting the hospital. 
 
The situation in Djibouti, in terms of medicatiRQDQGWKHOLPLWVRID³JHQHULFV
PDUNHW´ PLJKW DSSHDU VXUSULVLQJ LQ OLJKW RI DVVXPSWLRQV DERXW WKH UROH RI
generics in the pharmaceutical markets of developing countries378, as will be 
                                                 
378
 To contrast the findings made here and the focus of other analyses on the situation of 
developing countries that rely on generic medicines ± and the potential subsequent confusion 
WKDWWKLVPLJKWEHUHSUHVHQWDWLYHRI³GHYHORSLQJFRXQWULHV´DVDZKROH- see for example : 
³« for nations such as India, Brazil and Argentina, which before 1995 granted no drug 
product patents and hosted thriving generic drug industries, the ability to supply generic 
versions of new drugs will be curbed. And for other developing nations that relied upon such 
nations for generic drugs, the ability to import the newest medicines could be limited´6FKHUHU
F.M and Watal J. (20 ³3RVW-TRIPS Options for Access to Patented Medicines in 
'HYHORSLQJ1DWLRQV´Journal of International Economic Law 5(4) pp. 313-319, on p.314. The 
generalisation sometimes made is particularly obvious in some NGO or policy reports. See for 
H[DPSOH ³These longer patent periods will delay the availability of the low-cost generic 
equivalents that traditionally supply developing-country needs; only the expensive, patented 
version of a new medicine will be available´ LQ 2[IDP ,QWHUQDWLRQDO  ³3ULFHG RXW of 
5HDFK+RZ:72SDWHQWSROLFLHVZLOO UHGXFHDFFHVV WRPHGLFLQHV LQ WKHGHYHORSLQJZRUOG´
p.6 available at www.oxfaminternational.org  
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discussed again in Chapter 7 in relation to public health. However, it does not 
contrast as strongly with research done, for example, in Chad. In particular, a 
report was published on this issue by the Ministry of Health in Chad379, and the 
lack of availability of generic medicines, in particular in private pharmacies, is 
largely emphasised. Once again, this might be an example which makes the 
issues raised in Djibouti not appear as so unique to this country. 
 
Overall, in the current market situation of Djibouti, the only generic drugs sold 
are those provided by the OPS. These are limited to out-of-patents medication, 
and represent a small part of the overall market. What might this reveal about 
the role of patents in Djibouti, and about the links between the written/official 
existence of patents and their action in Djibouti? The first observation that 
should be made is that, in Djibouti, at the time of fieldwork, there was no drug 
± or at least no drug which I came across during my research ± that would 
infringe patents if they were sold for example in Europe. Even drugs for which 
JHQHULFYHUVLRQVZHUHOHJDOO\VROGLQ(XURSHRQO\DSSHDUHGDV³JHQHULFV´LQWKH
OPS. And in the OPS, only drugs that were out-of-patents in Europe appeared 
as generics. One meaning is that patents are inherently embedded in most of 
the drugs sold in Djibouti. This is interesting given that written laws in Djibouti 
have never officially created patents ± they do not exist on paper at the 
moment, and even if they did, policy-makers explain that this would not mean 
that they will consider them prescriptive. The discrepancy between the written 
                                                 
379Direction de la Pharmacie et des Laboratoires, Ministere de la Sante Publique, Republique 
GX 7FKDG ³(QTXHWH VXU OH 3UL[ GHV 0HGLFDPHQWV DX 7FKDG´ 0DL  DYDLODEOH DW
http://www.haiweb.org/medicineprices/surveys/200405TD/survey_report.pdf#search='enquete
%20sur%20le%20prix%20des%20medicaments%20au%20tchad'  
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H[LVWHQFH RI ODZ DQG LWV DFWLRQ ³LQ VRFLHW\´ KDV EHHQ ZLGHO\ GLVFXVVHG
before380± through varied theoretical approaches. In addition, in this case the 
discrepancy between the written and official existence of legal rules and the 
action of socio-legal objects adopted an unexpected shape± a particular set of 
socio-legal objects appeared to have agency without being rooted in written 
rules. Somehow, through means and connections that we will study below, 
patents have become part of the system, which are never truly bypassed by 
importers, patients or doctors.  
 
This does not mean, however, that the pharmaceutical market in Djibouti is 
similar to that of Europe. However, the difference is not located where it was 
assumed when starting this research. In fact, in Europe some drugs at least, 
RQFH WKHLU SDWHQW KDV ³RIILFLDOO\´ UXQ RXW VWDUW DSSHDULQJ LQ QHZ JHQHULF
versions in most pharmacies± new drugs without patents. But in Djibouti, 
outside the OPS, patents socially exist independently from any written rule and 
any official, written temporal limit. Patents are not only what gives a drug 
market exclusivity for several years, but they determine which drug will or will 
not enter the territory with no pre-established time limit. One should bear this 
in mind when rethinking the links between patents and pharmaceutical 
markets. In particular, it suggests that patents cannot only be understood in 
their socio-legal action on the basis of their official, written existence and of 
the temporal limit supposedly attached to it. The case of the OPS in relation to 
this needs to be clarified. In this particular example, the only aspect of patents 
WKDW DSSHDUV WR KDYH EHHQ OLPLWHG LV WKLV ³H[WUD-OHJDO´ LQ D WHPSRUDO VHQVH
                                                 
380
 A traditional example is found in PRXQG 5  ³/DZ LQ %RRNV DQG /DZ LQ $FWLRQ´
American Law Review (44 ) pp.12 ± 18. 
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dimension ± the fact that they generally act in Djibouti far beyond the 
temporal/legal boundaries of specific patents. In the OPS, the temporal limit of 
patents in Europe has somehow overlapped with their social existence.  
 
The consequences of this analysis in relation to public health are important for 
this research. In particular, the meaning that this might have in relation to 
access to medication will need to be explored. This is essential in order to 
answer the questions asked in the field of intellectual property on the links 
between pharmaceutical patents and access to medication. However, this is 
most interesting if discussed in relation to the effects of TRIPS, and in relation 
to the impact of TRIPS on the pre-existing situation Djibouti. For this reason, 
the issue of the meaning of pharmaceutical patents for health and treatment in 
Djibouti will be studied in detail in Chapter 7. 
 
In addition, at the time of fieldwork, some reforms were being made to the 
import system, so that the import of generic medication was being encouraged. 
As these changes are also most interesting if discussed in relation to TRIPS, 
and as they were only at an early stage of development at the time of fieldwork, 
therefore of limited impact on the pharmaceutical market studied during this 
fieldwork, it is more appropriate to discuss them in chapter 7.  
 
Overall, what needs to be noted in this section is that, although a purely 
doctrinal analysis of the situation of pharmaceutical patents in Djibouti would 
SRUWUD\ WKHP DV ³QRQ-H[LVWHQW´ DQDO\VLQJ WKH Oocal pharmaceutical market 
seems to highlight their role and centrality. Through a series of connections 
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and relations, these drugs of which patents are an integral part are almost the 
only ones to enter the country. Reciprocally, no drugs that would infringe 
patents if they were to officially exist on the model set in other countries enter 
Djibouti. This is important because it forces us to reconsider the meaning of the 
³RIILFLDO´VWDWXVRISKDUPDFHXWLFDOSDWHQWVWKHPRGHVRIDFWLRQVRISDWHQWVDQG
as will be detailed in the next chapter, the links between pharmaceutical patents 
and health. In order to provide a clear understanding of the way in which 
patents become a relevant element in the pharmaceutical networks of Djibouti, 
it is useful to discuss in more detail the connections through which patents 
enter the country. This will be done by looking at some key aspects of the 
import system of Djibouti, before explaining in detail how connections 
between patents and the import network were stabilised. 
 
SECTION 2: ENROLMENT AND ACTION OF PATENTS IN THE 
PHARMACEUTICAL MARKET OF DJIBOUTI ± HOW DO THEY 
GET THERE? 
  
We have seen in the first section of this chapter that the pharmaceutical market 
of Djibouti appears to incorporate patents within its network. This section 
presents some of the key connections that explain how patents find a way of 
acting in Djibouti, although they have not been officially created by written 
law in the country. It focuses on some specific connections within the import 
system, and within the medical field more generally, that help to explain why a 
country with no official system of pharmaceutical patents has a pharmaceutical 
market almost exclusively based on branded medication, fully in compliance 
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with the strongest patent systems worldwide and in which patents are in fact 
more extensively embedded than in many countries where they are an official 
legal instrument. This will highlight the discrepancies between the idea that 
patents are somewhat dependent on their official written creation and the fact 
that, in this case study, patents appeared in most drugs used in the country, in 
spite of not being an official instrument.  
 
In order to describe the range of connections through which patents become 
embedded in drugs in Djibouti, it is essential to explain in more detail the 
origins of the drugs observed in the market of the country.  
 
Pharmaceutical imports 
 
When describing the routes followed by drugs in Djibouti, four directions need 
to be followed: first, the central role played by private pharmacists in the 
import system; second, the system of the OPS; and finally, two limited 
complementary sources ± the origin of drugs found in the Hopital Bouffard and 
the donations collected in the Pharmappro. Once again, the important changes 
that are in action will be most extensively discussed in the next chapter. 
 
At the time of fieldwork, imports in Djibouti were essentially carried out by 
private pharmacists. As mentioned in Chapter 4, private pharmacists are the 
key source from which patients can obtain their medication. In addition to this, 
drugs found in public hospitals are bought directly from private pharmacists 
(with the now limited exception of those originating from donations, as will be 
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explained below). This was confirmed by health professionals: ³$W WKH
moment, public hospitals get a bit from the Pharmappro and a lot from private 
SKDUPDFLVWV´ (Pharmappro is discussed below.) The lack of official data in the 
country makes it difficult to evaluate the actual share of imports for which 
these pharmacists are responsible, but informants all stated that it was a 
VLJQLILFDQWRQH,QGHHGDSDUWIURPWKH236³DOPRVWHYHU\GUXJ´IRXQGLQWKH
country came from private pharmacists.  
 
³At the moment, the import and distribution system in Djibouti is almost 
exclusively private ± and almost exclusively based on branded medication. 
Private pharmacists buy very few generics, and sell their drugs for a very high 
price´ 
 
Overall, informants presented pharmacists as the main source of import of 
drugs in Djibouti. When talking about private pharmacists with any 
governmental actor interviewed, one of the key elements they emphasised was 
the complete lack of power the government had over what pharmacists chose to 
import. We have seen in Chapter 4 that this meant that controls made by the 
governmental inspectors on the quality of drugs were very limited.  However, 
even these minimal controls do not extend to any type of advice or influence on 
issues such as prices of drugs, cost efficiency, or whether generics could be 
used, for example. This can result in some inconsistency between the aim of 
government policies and the reality of pharmaceutical imports in the country. 
In particular, informants in the Ministry of Health emphasised that this 
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sometimes meant that the private interests of pharmacists were privileged over 
the public interest pursued by official government policies:  
 
³The private pharmacists have a lot of power here ± and especially one of 
them. He was clearly not happy with the changes we are trying to make, and 
EORFNHGDQ\DWWHPSWWRPRYHIRUZDUGZHKDYHPDGHVRIDU$QGLW¶VQRVXUSULVH
WKDWWKLQJVZHUHKHOGIRUVRORQJE\WKH&KDPEUHGX&RPPHUFH«´ 
 
This informant implied that the fact that the Director of the Chambre du 
Commerce is one of the two private pharmacists meant that it was even more 
unlikely that any regulations on imports in the pharmaceutical field that would 
OLPLW SKDUPDFLVWV¶ LQGHSHQGHQFH FRXOG HYHU EH LPSOHPHQWHG381. Private 
pharmacists act mainly independently from the government, with limited 
control, and limited interactions with national health policies. Private 
pharmacists essentially act commercially, and remain motivated by what will 
be most convenient, practical, or financially rewarding, rather than by 
governmental policies.  
 
The second important source of imports that needs to be mentioned here is that 
of the OPS. As mentioned before, the OPS has its own pharmacy, in which 
generics have become fully integrated. The OPS has developed its own policy 
in relation to both import and distribution of medication to patients. It is once 
again a structure largely independent from the health policy network. This was 
presented as potentially damaging by one key actor in the Ministry of Health: 
                                                 
381
 This was the case in particular in relation to the changes to the import system that will be 
presented in Chapter 7. 
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³We have some issues of coordination with the OPS in relation to 
SKDUPDFHXWLFDOV´382. The OPS imported drugs fully independently from 
private pharmacists. All generics were provided by the Dutch organisation, 
IDA383, with additional supplies provided by a French wholesaler: 
 
 ³$ERXWRIRXUGUXJVare generics, and all of these come from IDA ± we 
send them two orders a year, and drugs come either by plane or by boat, which 
is of course cheaper but much slower. And then we have about 25% of branded 
PHGLFDWLRQZKHQWKHVHSDUWLFXODUGUXJVGRQ¶WH[LVWDVJHQHULFVRQ,'$¶VOLVW
In this case we buy from the CERP in Rouen´ 
 
Further details on this system will be provided below, when analysing the 
range of connections that make patents enter the networks of Djibouti. 
 
In addition to these two main sources of imports, two minor complementary 
sources need to be mentioned. First the Hospital Bouffard offers an additional 
point of entry for drugs in the country, although this only represents a very 
small part of the overall market of the country. The limited amount of drugs 
found in Bouffard itself, being a French military hospital, are supplied by the 
same centralised providers as other army bodies384. However, as explained in 
                                                 
382
 This was in particular said to be the case in relation to anti-HIV/AIDS policies and the 
development of resistance. 
383
 For information, see www.idafoundation.org  
384
 ³Drugs here come from the army supplier anyways, so it is a completely independent 
system´ )RU LQIRUPDWLRQ RQ WKH VXSSO\ V\VWHP XVHG E\ )UHQFK 0LOLWDU\ +RVSLWDOV VHH Ior 
H[DPSOH)DXUH-³/H6HUYLFHGH6DQWHGHV$UPHHVOHVGHILVGHODSURIHVVLRQDOLVDWLRQ´
5DSSRUWG¶,QIRUPDWLRQDX6HQDW IDLWau nom de la commission des Affaires étrangères, de la 
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Chapter 4, this source of medicines is limited to the treatment of patients in 
hospital, and their cost does not impact directly on patients. To that extent, this 
particular source will not need to be discussed in more detail. 
 
In addition to this, until recently, international donors participated in providing 
public hospitals with some medications, through a specific structure - the 
Pharmappro385(although this was done occasionally rather than as a coherent 
long-term programme ): 
 
 ³Until recently, the only public system of imports was the Pharmappro. But it 
had a very very limited budget, and it was almost exclusively living from 
GRQDWLRQV%XWLWZDVNLQGRIµ',<¶± bits and pieces brought together.´ 
 
This system has now largely crumbled ± excluding the building itself, some 
exceptional donations and remaining stocks. The relevance of this example lies 
maybe more firmly in its progressive disappearance than in what was its 
temporary stabilisation. The Pharmappro was created as a structure through 
which international donations ± from France essentially, but also Yemen, 
Egypt or India for example ± could be received, managed and distributed in 
                                                                                                                                 
défense et des forces armées, available at http://www.senat.fr/rap/r98-458/r98-458.html . Five 
suppliers are named in Annexe 3: « la pharmacie centrale des armées et l'établissement central 
des matériels à Orléans, les établissements centraux de ravitaillement de Chartres, Marseille 
et Vitry-le-François, la pharmacie-magasin du port de Brest, l'établissement central de 
matériels de mobilisation de Caen-Mondeville ». 
385
 For a more general discussion of international pharmaceutical donations, see for example 
SchereU)0DQG:DWDO-³RSFLWVHHDOVR*UDERZVNL+³3DWHQWV,QQRYDWLRQ
DQG$FFHVV WR1HZ3KDUPDFHXWLFDOV´ Journal of International Economic Law 5(4) pp. 849-
860. 
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public hospitals. The system was considered beneficial for a while, until France 
VWDUWHG OLPLWLQJ LWV GRQDWLRQV 7KH UHPDLQLQJ ³JLIWV´ IURP FRXQWULHV WKHQ
became rather criticised by people in charge of dealing with the stocks. One of 
the reasons for this was that doubts started emerging on the quality of the drugs 
given ± no test could be carried out locally as Djibouti does not have any 
laboratory in which this could be done, and there was not always any guarantee 
from donor governments that tests had been carried out at home. The main 
reason, however, was that the donations were very often completely 
inappropriate to the needs and facilities of the country. For example, when 
visiting the buildings of the Pharmappro, the pharmacist in charge showed me 
a number of ophthalmologic materials that could not be used in any of the 
public hospitals since none of them had an ophthalmologist, or anyone 
qualified to use these materials. In addition, a donation from India had just 
been obtained by the President, and was being distributed to representatives of 
different public hospitals ± most of the drugs were unsuitable to the needs of 
the country, for example because they targeted diseases almost non-existent in 
Djibouti, or because they needed to be used in combination with products or 
materials unavailable in the country, or given by a specialised doctor that the 
country did not have. Overall, most of the people present seemed reluctant to 
take any of the boxes with them, but had to in order to make sure that political 
sensibilities would not be hurt by refusing a donation obtained by the President 
himself. $V D ZKROH WKH 3KDUPDSSUR¶V HIILFLHQF\ GLPLQLVKHG RYHU WKH \HDUV
with changes in the flows of medication, themselves entangled in wider 
political and practical changes that cannot be fully developed here. Its lack of 
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coherence and harmony made it a weak network and its independent parts are 
now becoming more clearly characterised as such. 
 
Finally, and as has been mentioned several times in the course of this research, 
next to the existing systems of imports, and partly replacing the Pharmappro 
system, a new centralised network was being set up for imports, at the time of 
fieldwork. It is directly aimed at importing more generics, and is in that respect 
an essential step in relation to the role of patents in the country. However, it is 
something that will be described and discussed in full detail in Chapter 7. What 
this section focuses on is the system as it stands at the moment.  
 
Embedment of patents/drugs in the import system of Djibouti 
 
Following this brief introduction to the import system of Djibouti, it is now 
essential to question and understand the set of connections through which 
patented drugs have become omnipresent in the country, and to emphasise how 
these connections have become stable enough for the import network of 
Djibouti to appear to exclude any generic version of patented drugs ± and 
exclude any generic in a predominant part of the market. The enrolment of 
patents within the pharmaceutical system of Djibouti - without facing the 
temporal limit existing when patents are created in written law as far as the 
private market is concerned - is the result of complex sets of relationships and 
connections, shaped by a range of personal, practical and commercial 
relationships, some of which are embedded into habits and routines linking 
)UDQFH DQG 'MLERXWL LQ D VRPHZKDW ³SRVWFRORQLDO´ ZD\ ,W LV QHFHVVDU\ WR
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present and discuss these different connections in a way that illustrates best the 
complexity of the links while maintaining a clear narrative that highlights the 
key mechanisms that have stabilised some of the networks described above. 
The importance of understanding dislocated386 actions, and the effect of 
multiple connections on a particular network will be emphasised387. 
 
Private pharmacists and patents 
 
The first set of connections that needs to be detailed links private pharmacists 
to patents/drugs. This link is stabilised by a range of practical and commercial 
connections that have to do with information and advertising, shipping 
FRQGLWLRQV LPSRUWHUV¶ KDELWV DQG WUXVW 7KH\ DOVR KDYH WR GR ZLWK GRFWRUV¶
KDELWV DQG SDWLHQWV¶ H[SHFWDWLRQV 7KLV UDQJH RI FRQQHFWLRQV ZLOO QRZ EH
studied, before questioning further how the limited market of generic drugs of 
the OPS is regulated, and why it is limited to out-of-patent medications ± 
thereby restraining the potential exception set by generic medicines to the role 
of patents in Djibouti.  
 
 
 
                                                 
386
 Understood as actions taking place in loci other than the direct object of analysis and 
³PDNLQJRWKHUVDFW´± see Latour B. (2005) Reassembling the Social: an Introduction to Actor-
network Theory op. cit. 
387
 To that extent, part of this analysis will integrate some ideas put forward by ANT when 
discussing the impossibility of notiRQVRI³JOREDOLWLHV´RU³ORFDOLWLHV´± see for example Law J. 
 ³$QG LI WKH *OREDO ZHUH 6PDOO DQG 1RQ-Coherent? Method, complexity and the 
%DURTXH´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU8QLYHUVLW\/$</8.DW
http/www.comp.lancs.ac.uk/sociology/papers/law-and-if-the-global-were-small.pdf    
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Advertising and information 
 
When discussing with private pharmacists why they only imported branded 
medication, a number of suggestions were made by them. The first was that 
SULYDWHSKDUPDFLVWVLQIDFW³ZRUNHG´RQO\ZLWKDIHZFRPSDQLHVPDLQO\ODUJH
multinational companies, and bought their drugs essentially from branches 
based in France. Smaller generic producers were not generally used as sources 
of medication, and a large set of drugs were therefore already excluded by the 
strong links between large multinational companies and Djibouti.  When 
asking for explanations as to why the range of exporters was so limited, and 
why private pharmacists were so close to large multinational companies, 
several elements were presented. A key element to highlight related to the 
circulation of information between drug producers and pharmacists based in 
Djibouti. To put things simply, pharmacists in Djibouti imported and 
distributed drugs they knew about. Only drugs that had been brought to their 
knowledge will enter the country ± and the quasi-monopoly of the two private 
pharmacists might have made it rather unnecessary for them to go out of their 
way to find out about new products. Therefore, questions to address here are 
the following: how do importers in Djibouti hear about specific drugs? How do 
they find out what is available, reliable, and worth buying? To answer these 
questions, it is useful to have a look at the way multinational companies make 
their products known in Djibouti388 - or rather at the way importers in Djibouti 
                                                 
388
 This is not fundamentally different from strategies deployed in other countries, although the 
impact might be even stronger in Djibouti were private pharmacists hold a particularly central 
place. See for comparison on advertising strategies (although essentially directed at doctors in 
France) Kapferer J.N. (1997) « Marque et Medicaments : le Poids de la Marque dans la 
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receive the information provided by companies. When asked how they found 
out about particular drugs, or how they chose which drugs to import, private 
pharmacists listed spontaneously the range of strategies used by large 
pharmaceutical producers to advertise their products. They talked first about 
the range of leaflets that large companies were sending them from France. 
They also mentioned that representatives from large pharmaceutical companies 
were regularly visiting Djibouti, and that Sanofi even had a permanent local 
representative in charge of organising monthly meetings with health 
professionals where specific products would be displayed ± not necessarily new 
products, but from what was observed during the meetings I attended, some of 
their well-known products and original brands. In addition to this, one of the 
two private pharmacists explained that he attends the Pharmagora meetings 
held in Paris every year389. For him, this was the best way of developing 
contact with companies that had been in touch through the profusion of 
leaflets, posters, advertising pens and writing pads that are sent over by 
pharmaceutical companies mostly from France. Each of these strategies is 
summarized in the following quotation: 
 
³7KHUH DUH WZR LPSRUWDQW ZD\V WR ILQG RXW DERXW GUXJV ± the first one is to 
attend those big meetings held in France once, sometimes twice, a year. The 
other is through the permanent or non-permanent representatives of companies 
ZKRFRPHWR'MLERXWL´ 
                                                                                                                                 
Prescription Medicale », Revue Francaise du Marketing (165) pp. 43-51; see also Belot L 
(1998) « Une etude met en evidence les « facteurs psychologiques » qui influencent les 
prescriptions medicales » Le Monde 17th July 1998. 
389
 For information and lists of companies represented, see www.pharmagora.com 
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This enrolment of pharmacists in strong connections with large French-based 
companies runs even further in one case. One of the private pharmacists in 
Djibouti mentioned that he owned an advertising company through which he 
promoted the medication of some of these French-based companies:  
 
³,RZQDQDGYHUWLVLQJFRPSDQ\IRUSKDUPDFHXWLFDOV«EDVLFDOO\,KLUHSHRSOH
WRJRDQGLQWURGXFHQHZGUXJVWRGRFWRUV´ 
 
The information he provided was rather vague, and the conversation we had 
about this could not move into more detail than the information he was willing 
to disclose. However, it is an interesting and highly symbolic element which 
illustrates how this particular actor remains entangled with large companies. 
 
Routes and Shipping 
 
Although the strong links between private pharmacists and multinationals in 
terms of advertising do not necessarily mean that generic companies could not 
find a way to reach Djibouti390, importers explained that they chose to import 
drugs from large companies based in France for several additional reasons. 
These had to do with the practicalities of importing drugs in Djibouti. One 
element that was mentioned many times was that shipping drugs to Djibouti 
can be particularly lengthy, and that once importers can be convinced that the 
                                                 
390
 Although the fact that Djibouti is a small market means that generic companies with limited 
advertising budgets might not find it worth investing in getting their products advertised in this 
particular country. 
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medication they ordered will reach them as planned, they tend to remain with 
the same provider. Informants thus emphasised several times that they tend to 
NHHS WKH VDPH SURYLGHUV EHFDXVH ³$W OHDVW ZH NQRZ LW ZRUNV´ This is an 
interesting example of the way some general economic and practical 
difficulties faced by Djibouti impact on the creation of particular sets of 
relationships, and on the stability of these same connections. This point 
provides a good opportunity to reflect on one issue that has only been 
discussed in Chapter 1, and left to one side when presenting data on Djibouti. 
One of the latest evolutions of the post-TRIPS debates related to compulsory 
licences, and to the doubts left by TRIPS and the Doha declaration as to 
whether the poorest countries with no pharmaceutical industry could take 
advantage of compulsory licences391. In August 2003, as explained in Chapter 
1, the TRIPS council agreed that in cases of emergency, countries with no 
industry ± under certain conditions ± could grant producers in another country 
an authorisation to produce a patented drug392. Doubts were expressed about 
this move, as it was unclear whether the proposed system could in fact work, 
for many practical reasons as detailed in Chapter 1393. The comments of 
                                                 
391
 For details and comments on the role and limits of compulsory licences, and the questions 
UDLVHG LQDQG IROORZLQJ'RKDVHH$EERWW)0³7KH'RKD'HFODUDWLRQRQ WKH75,36
DJUHHPHQWVDQG3XEOLF+HDOWK/LJKWLQJD'DUN&RUQHUDWWKH:72´Journal of International 
Economic Law, 469-$EERWW)0³&RPSXOVRU\/LFHnsing for Public Health Needs: 
WKH 75,36 $JHQGD DW WKH :72 DIWHU WKH 'RKD 'HFODUDWLRQ RQ 3XEOLF +HDOWK´ 4XDNHU 81
Office, Occasional Paper 9 available at http://www.accessmed-
msf.org/upload/ReportsandPublications/25620021018167/fred%20abbott.pdf 
392
 WTO document IP/C/W/405, available at 
http://www.wto.int/english/tratop_e/trips_e/imple_para6_e.htm 
393
 And highlighted by NGOs: Oxfam International (2003) ³:72SDWHQW UXOHVZLOOVWLOOGHQ\
PHGLFLQHV WR WKH SRRU´ th August 2003, available at: 
http://www.oxfam.org/eng/pr030827_wto_patents.htm 
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importers in Djibouti on the difficulties they encounter when dealing with any 
³QHZ´SURYLGHUIRUSUDFWLFDOUHDVRQVDQGRQWKHIDFWWKDWVKLSSLQJDQ\SURGXFW
without delay through new routes is particularly difficult, can be related to this 
issue. One questions whether in the current situation Djibouti would be likely 
to adopt a compulsory licence and expect supply from generic producers with 
which they have never had any contact before. In addition to this, what we 
have seen in Chapter 5 and in this chapter, of the difficulties for different actors 
to connect and create a coherent network, adds substance to the argument that 
the system created by the WTO is unlikely to be of relevance to Djibouti ± at 
least in the near future. As it is hoped that this issue has become clearer, we can 
return to discussing imports and their connections.  
 
The importance of advertising and shipping issues explain why large 
companies are privileged over smaller generic producers by pharmacists in 
Djibouti. However, in order to understand the omnipresence of branded 
medication on pharmacy shelves, further connections need to be explained. The 
IDFW WKDW HYHQ ³EUDQGHG JHQHULFV´ DUH YHU\ UDUHO\ IRXQG LQ 'MLERXWL LV QRW
explained by this link between private importers and a few large companies ± 
as companies such as Merck for example produce their own branded generics. 
In order to understand what shapes the embedment of patents in Djibouti,  it is 
                                                                                                                                 
and MSF, 27th $XJXVW³&KDLUPDQ¶V WH[WEULQJVQHZGLIILFXOWLHV WR:72SDUDJUDSK´
available at:  06)³&KDLUPDQ¶VWH[WEULQJVQHZGLIILFXOWLHVWR:72 SDUDJUDSK´th 
August 2003 
http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=77830ACA-
8EC5-419A-82AB7D7ED6A2E1ED&method=full_html 
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now important to reflect on the role of doctors in stabilising key connections 
between patients, diseases and patented drugs.  
 
Doctors, patients and patented drugs 
 
When looking back at the presentation of the health system given in Chapter 4, 
it is clear that French doctors represent an important part of the public health 
network, through their exclusive role in Bouffard and partial role in Peltier, and 
in fact determine largely the direction of the prescribing system. Although they 
are by no means the only doctors in the territory, their share in the prescribing 
system is significant enough for their behaviour to influence the actions of 
pharmacists. In addition to this, Djiboutian doctors working at the time of 
fielwork had also been trained in French universities. As mentioned earlier in 
this chapter, prescriptions written in Djibouti generally refer to a branded drug, 
and not to its generic version. This finding compares to research carried out in 
)UDQFH RQ GRFWRUV¶ EHKDYLRXU WKDW KLJKOLJKWHG KRZ WKH\ WHQG WR SUHIHU
prescribing branded medication394. In Djibouti, the training and habit of French 
doctors are two of the factors that impact on what doctors will write on 
prescriptions, and several doctors have thus explained why they generally 
prescribe branded drugs: 
 
 ³7KDW¶VZKDWZH¶YHEHHQ WDXJKWDW XQL DQGPD\EH IRU \RXQJHUGRFWRUV LW LV
different, but if I need to prescribe Prozac RU 3ULPSHUDQ , FDQ¶W WHOO \RX WKH
gHQHULFQDPHDQG,GRQ¶WKDYHWLPHWRJRDQGORRNLWXS´ 
                                                 
394
 See Larrieu J. and Houin G. (2001) op. cit  ; Kapferer J.N. (1997) op. cit. 
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Patents were therefore fully embedded in prescriptions themselves, in the same 
way as they have appeared to be an inherent part of drugs materially found in 
the country. However, their embedment in prescriptions should not necessarily 
mean that they are unavoidably and causally embedded in drugs. If we 
compare once again one aspect of the situation in Djibouti with that of France, 
from which laws in the pharmaceutical field in Djibouti are largely inspired, 
the right of substitution of the pharmacist established by French law means that 
the specific content of a medical prescription will not be the only determinant 
to the final version of drug officially dispensed395. In Djibouti, officially, 
pharmacists require the consent of doctors before they can change a particular 
medication396. Pharmacists interviewed, however, emphasised that this was not 
their main concern, and in particular that they would not consider themselves 
DV³OHJDOO\´XQDEOHWRUHSODFHD branded version of a drug by its generic version 
± and emphasised once again the flexibility of legal rules in their field of 
activity. However, they also suggested other factors that stopped them from 
doing so. One of the main elements of this was that, according to the 
pharmacists I met, patients would not accept generics ± or replacement of 
drugs by any equivalent medicine, for that matter. Patients who are offered a 
FRPSHWLWRU¶V SURGXFW LQ WKH SKDUPDF\ ZRXOG RIWHQ UHIXVH DQ\WKLQJ HOVH WKDQ
what was written on the prescription: 
 
                                                 
395
 Article L.512-&RGHGHOD6DQWH3XEOLTXH³Le pharmacien ne peut delivrer un medicament 
ou produit autre que celui qui a ete pUHVFULSW TX¶DYHF O¶DFFRUG H[SUHV HW SUHDODEOH GX
SUHVFULSWHXUVDXIHQFDVG¶XUJHQFHHWGDQVO¶LQWHUHWGXSDWLHQW7RXWHIRLVLOSHXWGHOLYUHUSDU
VXEVWLWXWLRQDODVSHFLDOLWHSUHVFULWHXQHVSHFLDOLWHJHQHULTXH«´ 
396
 Article 24: Loi n°145/AN/91 /2ème L relative aux conditions d'exercice de la pharmacie 
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³3DWLHQWVGRQ¶WZDQWJHQHULFV7KH\ZDQWZKDW¶VZULWWHQRQWKHSDSHU´397 
 
 This was explained in various ways by different doctors or pharmacists, and a 
range of factors can be considered as important to keep in mind. According to 
pharmacists, as far as French patients are concerned, most of them would not 
be interested in buying cheaper versions since they would be fully refunded by 
the Securite Sociale on their health expenses398. As far as Djiboutians are 
concerned, one idea often put forward emphasised that Djiboutians who had 
managed to access a doctor they trusted, in the difficult situation presented in 
&KDSWHU  ZRXOG EH XQZLOOLQJ WR VHH WKHLU SUHVFULSWLRQ ³RYHUUXOHG´ E\
pharmacists or pharmacy staff, and would not want anything other than the 
specific drug that had been prescribed. Overall, it appeared clearly that the 
relations between doctors, patients and drugs were set in such a way, and 
stabilised in such a fashion, that generic medicines were almost necessarily 
excluded from the network in which private pharmacists were involved.  
 
As a whole, it is difficult to explain fully the causality between the shape of the 
private pharmaceutical imports system of Djibouti and the quasi-omnipresence 
of patent/drugs actor-networks in the country. However, the range of relations 
and connections highlighted above has provided what appeared in this research 
                                                 
397
 It should be noted, however, that whether generics had in fact ever been proposed by private 
pharmacists to their patients may be doubtful, since they did not actually import generics at any 
stage ± and since the example of the OPS shows that this specific structure managed to start 
providing some generics ± the exact weight of this particular factor therefore needs to be 
balanced and might not be as significant as other factors. 
398
 For information on the mechanisms of the Securite Sociale in relation to medical expenses, 
see Code de la Securite Sociale, Titre 6 ± Dispositions relatives aux prestations et aux soins ± 
Controle medical ± Tutelle aux prestations sociale. 
 288 
as the key elements explaining the embedment of patents in drugs, 
prescriptions and private import networks. These emphasise and explain why 
some of the assumptions held about the consequences of the absence of 
³ZULWWHQOHJDO´SDWHQWV\VWHPVRQSKDUPDFHXWLFDOPDUNHWVKDGWREHUHWKRXJKW
In particular, this research highlighted how the tight links between some agents 
in Djibouti and others in France resulted in connections between actions in the 
import system of Djibouti and patents as official agents in France being 
established. In particular, the central and independent role of private 
pharmacists, the connections between medicine in Djibouti and training in 
France, drugs in Djibouti and multinational companies based in France ± 
themselves resulting from multiple enrolments and exclusions - all resulted in 
sets of associations through which routines that can be understood as emerging 
from pharmaceutical patents, as official tools in France were repeated and 
embedded in habits of actors in Djibouti. Overall, although officially 
pharmaceutical patents are non-existent in Djibouti, these connections and 
associations resulted in them being fully embedded in drugs, prescriptions, 
routines and actions relevant to the pharmaceutical network of Djibouti. Before 
concluding this chapter, however, I shall consider the elements that can explain 
why the system of imports offered by the OPS does not enrol any generic 
versions of drugs still under patent in other countries. 
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Import network of the OPS ± how have connections stabilised around one 
European generics-provider? 
 
We have seen above that the OPS essentially works with generic medicines. 
However, this is not exclusively so, and in particular it only concerns drugs 
which are out-of-patent in Europe. To that extent, although pharmaceutical 
patents might not appear as a central actor for most of the imports carried out 
in this network, they remain embedded in at least some of the drugs bought and 
distributed by the OPS. The OPS is a small system of distribution, and it is thus 
not necessary here to give it as much attention as has been given to private 
pharmacists. However, it is also important to consider why, in spite of the 
attempts made in the OPS to keep the price of drugs as low as possible through 
generic medicines, it in fact only imports generic versions of drugs that are out-
of-patent in other countries. The main reason for this appears to relate to the 
fact that imports realised by the OPS, as far as generics are concerned, are 
made through IDA, a Dutch non-profit organisation that provides cheap drugs 
to poor countries399. The main list of medication, at the time of fieldwork, 
provided by IDA400, showed exclusively out-of-patent medication401. The lists 
created by IDA were based on the WHO Essential Medicines List402. The 
                                                 
399
 For full information on IDA and listings of the drugs and prices they offer see 
www.idafoundation.org  
400
 This does not include the additional but separate system dedicated to AIDS that will be 
discussed below. 
401
 Once again, information on the products sold by IDA can be found on their website, at 
www.idafoundation.org; in this research, the primary source of information used, however, 
was the lists sent by IDA to the OPS itself (to which are attached further information 
documents such as the Bulletin IDA.) 
402
 http://www.idafoundation.org/en-us/content.aspx?cid=71 
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WHO list of essential medicines is itself considered as made up of around 
ninety percent of out-of-patent medicines403.  
 
The link between this list and patents could be understood in two different 
ways. First, it could be read to mean that patents play a minor role in access to 
medication, since essential drugs are almost all out-of-patent. Second, and in 
the alternative, it could be understood as resulting from patents and their 
impact on the price of drugs, in the sense that the list is partly established as a 
result of a balance between a range of concerns, including cost and 
affordability404. Therefore, the main list of drugs provided by IDA ± with the 
recent exception that will be explained below ± might itself have been 
established so that it excludes patented drugs. What is most relevant is the fact 
that, whichever explanation is correct, the OPS buys generic drugs from a list 
from which patented drugs are mainly excluded. This partly explains why 
generic versions of drugs patented elsewhere have not entered the OPS.  
 
Two further points can be made at this stage. First, it is important to question 
why the OPS has not sought routes of generic imports outside this particular 
list. The reasons why the OPS exclusively deals with are essentially practical, 
and relate to a large extent to practical issues raised above. For example, 
longevity was a relevant factor: 
 
                                                 
403
 See Laing R., Waning B., Gray A., Ford N. and Hoen E. (2003) op. cit. 
404
 This result in particular from the fact that cost and affordability are some of the factors that 
the WHO takes into account when creating its EML. For comments, see Laing R., Waning B., 
Gray A., Ford N. and Hoen E. (2003) op. cit. 
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 ³:HKDYHZRUNHG with IDA for six years, we know them. We have had so many 
problems before that, now that at least we know it works,  we decided to stay 
ZLWKWKHP´ 
 
In a similar way to private pharmacists, they then explained that practical 
transport issues were essential for them to consider, as it could be complicated 
to import drugs in a reliable way in Djibouti.  
 
Second, the range of medication offered by IDA was being extended while this 
fieldwork was carried out to include some HIV/AIDS medication which are 
still under patent in some countries. These new drugs were dependent on a 
particular system, and not integrated into the main list of medication on which 
actors in the OPS were working ± although this parallel system was part of 
IDA. While this fieldwork was carried out, this was still at an early stage and 
not fully organised yet. However, even this new source of medication, although 
officially part of the broader IDA system, was not considered as relevant and 
immediately useful by the pharmacists of the OPS. In particular, although this 
was underway and already advertised in different countries, the pharmacists of 
the OPS emphasised that they still regarded this as speculative and not 
something they would consider straightaway as they had only been given 
limited information on the matter. Moreover, they had not received lists of 
price or specific explanation on steps to take to participate in this new system 
yet405:  
 
                                                 
405
 for details on these administrative steps, see http://www.idafoundation.org/fr-
fr/content.aspx?cid=134 
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³It is all very new, and therefore very complicated, so at the moment we are 
buying branded anti-retroviral and we will probably do that for a while still´ 
 
The difficulties of adapting import systems to changing situations in Djibouti 
can be understood through this example, and although IDA is now starting to 
by-pass the limits set by pharmaceutical patents, these changes are not yet 
integrated in Djibouti. Overall, the only generic drugs that the OPS currently 
buys are those offered by IDA on its most traditional list of imports, and 
through the means that they have used for six years. The OPS does not 
consider sources of imports of generics apart from this particular system, which 
results in the fact that patents remain embedded in the drugs found in the OPS 
WKDW DUH VWLOO ³XQGHU SDWHQW´ LQ RWKHU FRXQWULHV 2YHUDOO EHFDXVH RI WKLV
exclusive relation to the main list of medicines offered by IDA, the exception 
to generic medicines offered by the OPS remains limited to some medicines 
only ± all out-of-patent worldwide.  
 
CONCLUSION 
 
The relation between the absence of national written law on pharmaceutical 
patents and the embedment of pharmaceutical patents in the market of Djibouti 
raised important issues about the role and modes of action of patents as socio-
legal objects. Some more general issues will be discussed in the conclusion of 
this project, although some elements can be summarised already at this stage. 
In particular, it is important to reflect on the contrast between the original idea 
that could have been derived from the absence of written law on 
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pharmaceutical patents in Djibouti and the traces left by patents within the 
pharmaceutical networks of Djibouti. Overall, patents appeared in this example 
as a complex set of connections, as the result of social circulation that made 
patents social actors in many ways, gaining agencies in a number of fashions 
not necessarily related to their written/official status in the country. The 
DUWLILFLDOLW\RIWKHSRWHQWLDOGLYLGHEHWZHHQ³VRFLDO´DQG³OHJDO´DSSHDUWKURXJK
the investigation of these connections that emerged as as blurred, uncertain, 
and neveU GLFKRWRPLF :KLOH /DWRXU VWDWHG WKDW OHJDO REMHFWV DFW LQ D ³OHJDO
ZD\´406, it appeared here that the definition of the modes of action of so-called 
³OHJDO´REMHFWVFRXOGQRWEHSUH-defined and certainly not perceived as acting in 
an inherently different, independent or unique way that could be isolated from 
RWKHU VRFLDO FRQQHFWLRQV 7KH ³OHJDO´ ZD\ QHHGV WR EH XQGHUVWRRG KHUH DV D
socio-legal range of connections fully embedded in various types of practices 
and networks. 
 
 As a whole, the embedment of patents in drugs sold in Djibouti, in each 
GLPHQVLRQ RI LWV ³SKDUPDFHXWLFDO PDUNHW´ DQG LQ WKH URXWLQH DFWLRQ RI
importers ± to take only a few examples of the locations where patents could be 
³IRXQG´ - appeared as fully co-dependent on a range of connections. The 
weakness of shipping networks, of material connections between Djibouti and 
other places where drugs are being produced, the unreliability of many systems 
of transport, the crumbling system of international donations, are all examples 
of some of these connections, and more specifically of limited networks, less 
extended and less stable than found in other locations. Next to these somewhat 
                                                 
406
 Latour B. (2005) Reassembling the Social: an Introduction to Actor-network Theory, op. cit.  
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restrained networks, several stable systems have developed. The first one is 
built around two private pharmacists and their shops, obligatory points of 
passage407 for most drugs entering Djibouti, which are entangled in sets of 
strong and well run connections that they expect to remain stable and foresee 
as unlikely to crumble. This set of stable connections has involved actor-
networks of which patents are an inherent part, and have been reshaped in such 
a way that patents have become materialised and present through most drugs in 
the country. Bypassing their non-existence in written national law in Djibouti, 
this tool that officially emerged on paper in other countries, supposedly for 
other countries, has become centrally realised through the connections lived 
and relived by private importers in Djibouti408. Patents have not even been 
fully by-passed by the OPS, although they have created their own stable 
network, of which generics are an official part, and in which a different set of 
actors is therefore present that could be expected to exclude pharmaceutical 
patents. In particular, when dealing with drugs under patent, the OPS uses the 
patented version. This is circumstantial, however, and might be modified if the 
new network created by IDA around some anti-HIV/AIDS drugs reaches 
Djibouti. But this was not the case when fieldwork was carried out.  In addition 
to this, other aspects of the import system of drugs and pharmaceutical policies 
                                                 
407
 &DOORQ 0  ³6RPH (OHPHQWV RI D 6RFLRORJ\ RI 7UDQVODWLRQ 'RPHVWLFDWLRQ RI WKH
Scallops and the Fishermen of Saint-%ULHXF%D\´LQ/DZ-HGPower, Action and Belief: a 
New Sociology of Knowledge? Sociological Review Monograph (32) London: Routledge and 
Kegan Paul, pp. 196-233. 
408
 7KLV LQ IDFW UHODWHV WRFRPPHQWVPDGHHOVHZKHUH³While technically it is true that patent 
laws in Africa have had little to do with access to medication, patent laws elsewhere in the 
world have made all the difference´+DOEHUW'³0RUDOL]HG'LVFRXUVHV6RXWK$IULFD¶V
,QWHOOHFWXDO3URSHUW\)LJKW IRU$FFHVV WR$,'6'UXJV´ Seattle Journal for Social Justice (1) 
Fall/Winter 2002 pp. 257-288. 
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of Djibouti are currently being changed. These changes will aim, in particular, 
at introducing generics in Djibouti for a wider range of pharmaceuticals. Their 
result will be to create a new network from which patents are actively 
excluded, and in which generics are given a central and stable role. Although 
this change might appear in isolation, resulting from changes linked to health 
rather than patents, and seemingly taking the country in WKH³ZURQJGLUHFWLRQ´
when it is supposed to be officially implementing pharmaceutical patents to 
become TRIPS compliant, these changes can be particularly interesting if 
thought of in the light of TRIPS, as will be discussed. The next chapter will 
aim to question further the changes brought in by TRIPS in Djibouti, and will 
determine how, when reading TRIPS as a complex and fluid actor-network, 
rather than as a set of prescriptions to be followed by specific consequences, a 
different aspect of its links to public health might appear. This research is 
concerned with the potential links between TRIPS, pharmaceutical patents and 
public health, and the following chapter will explain how, after having 
understood the complexity of the role of TRIPS and pharmaceutical patents in 
both political and trade networks of Djibouti, it is now possible to go further in 
discussing what TRIPS is and does in the public health network of Djibouti.  
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CHAPTER 7 - TRIPS, PHARMACEUTICAL PATENTS AND HEALTH 
IN DJIBOUTI - UNDERSTANDING TRIPS IN ITS NETWORKED 
EFFECTS 
 
The key question that this project aims to address relates to the links between 
TRIPS, pharmaceutical patents and health in Djibouti. The two previous 
chapters have presented sets of connections that are essential to understand 
before discussing what TRIPS and pharmaceutical patents might mean in 
relation to public health in the country. This chapter builds on the descriptions 
presented above, and explains how the links between patents, TRIPS and 
health in Djibouti need to be understood. It argues that these links are not 
necessarily where they might be expected to be found. While on the one hand 
the links between diseases and patents in Djibouti can only be understood in 
relation to the current social action of patents in Djibouti ± partly independent 
from their written creation, as explained in Chapter 6 - TRIPS appeared to have 
left some additional traces in the public health network, as manifestation of its 
action in many other places.  By following these traces, further complexity 
appears in the TRIPS-network, and in the task of understanding its impact. The 
role of TRIPS in Djibouti in relation to health can only be understood by 
recognising that TRIPS remains a complex network in spite of its apparently 
punctualiVHG DVSHFW 7KH GHVFULSWLRQ RI 75,36 DV D ³JOREDO´ DFWRU LV QRW
appropriate to the frame of this research, and the gaps left by the idea of 
globality have been discussed before409. However, TRIPS is also something 
                                                 
409
 6HH IRU H[DPSOH IRU FRPPHQWV RQ WKH QRWLRQ /DZ -  ³0DWHULDOLWLHV 6SDWLDOLWLHV
*OREDOLWLHV´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV/DQFDVWHU8QLYHUVLW\/$<18.
at http//www.comp.lancs.ac.uk/sociology/soc029jl.html. 
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that happens in many places, that generates changes in many networks, that is 
embedded in multiple actions and networks, and in order to understand what it 
does in Djibouti, it is essential to have a clearer idea of the effects it has in 
these many other places. 
 
This chapter is divided in two main sections. The first section brings together 
findings made in Chapters 5 and 6 and the links between modern drugs and 
disease in Djibouti. It looks at the current links between health and patents in 
Djibouti on the basis of the pastiche we have drawn, in particular, of the import 
network of the country. It will emphasise the difficulties in establishing clearly 
the relation between TRIPS, patents and health, and will discuss how they can 
only be understood by considering the role of patent/drugs hybrids in Djibouti 
(Section 1). The second section questions whether the embedment of TRIPS in 
a range of policies and lobbying can impact on Djibouti. It considers whether 
TRIPS can be found as embedded in Djibouti itself through complex relations 
happening in other places. This is done by questioning the dislocated effects of 
TRIPS, and by considering whether two specific health projects implemented 
in Djibouti at the time of fieldwork can be read in the light of these effects 
(Section 2). This chapter provides an important aspect of the socio-legal role of 
both TRIPS and pharmaceutical patents in public health networks in Djibouti, 
and will bring us to question how this understanding of both instruments calls 
for a wider vision of the mechanics of socio-legal objects. 
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SECTION 1:  UNDERSTANDING THE LINKS BETWEEN TRIPS, 
PATENTS AND HEALTH  
 
Chapter 5 has explained the role of TRIPS as prescription± and its limits ± in 
the public health policy networks of Djibouti. It emphasised why it appeared 
that TRIPS and pharmaceutical patents had limited effects in shaping actions in 
public health related offices, discourses, and reports. However, it has also been 
emphasised that this was only one aspect of the picture to be drawn, and that 
the connections linking pharmaceutical patents to public health should be 
followed wherever they may lead. Chapter 6 has therefore explained how 
following drugs in Djibouti could take us back to patents, through complex set 
of hybrid connections. One question that now needs to be addressed, and can 
only be addressed by following the connections highlighted in the previous 
chapters a little further, is that of the links between pharmaceutical patents and 
diseases.  
 
The task of analysing the links between patents and health in Djibouti is made 
particularly difficult by the fast-changing dimension of the area, and the range 
of complex and overlapping connections that need to be highlighted. These are 
all highly co-dependent and circumstantial, which makes their narrative 
particularly difficult.  All the connections presented in this section are also 
dependent on the enrolment of each relevant actor in further networks and 
relationships. In order to understand the overall meaning of each of these 
instruments for Djibouti, it is necessary to understand the intersection of 
several networks in which patents and TRIPS have different meanings and 
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dimensions. Finally, it should be re-emphasised that all the links presented here 
are likely to change or disappear at any time. We will see below how some new 
connections are already appearing and reshaping public health networks, and 
the role of patents within them.  
 
The theoretical links that are drawn between patents and health in existing 
comments and literature have been discussed in the previous chapters, and only 
need to be briefly mentioned here. First, a common expectation is that patents 
relate to access to health. The basic reasoning behind this assumption is that 
since patents impact on the price of drugs, they impact on access to medicines, 
and therefore on access to treatment ± which in turn limits opportunities to 
eradicate diseases410. When TRIPS creates patents, it is therefore expected to 
generate a causal chain that will end in disease being unavoidable. The key 
question to be answered here is whether or not this chain can be followed in 
                                                 
410
 The links between TRIPS, patents and access to drugs commonly drawn when dealing with 
TRIPS have been discussed in Chapter 1, and their apparent immediate causality in some 
academic writings has been illustrated in Chapter 2 by a quote from MattheZV'³,V
History Repeating Itself? The Outcome of Negotiations on Access to Medicines, the 
+,9$,'63DQGHPLFDQG,QWHOOHFWXDO3URSHUW\5LJKWVLQWKH:RUOG7UDGH2UJDQLVDWLRQ´Law, 
Social Justice and Global Development Journal (1), available at 
http://www2.warwick.ac.uk/fac/soc/law/elj/lgd/2004_1/matthews/. It can similarly be read in 
VRPH 1*2V GRFXPHQWV )RU H[DPSOH ³With the implementation of TRIPS in nearly all 
countries in 2005, pharmaceutical products will be given patent protection for 20 years, and 
developing countries will have far more difficulty in accessing affordable generic versions of 
patented drugs´ LQ )RUG 1  ³3DWHQWV $FFHVV WR 0HGLFLQHV DQG WKH Role of Non-
JRYHUQPHQWDO2UJDQLVDWLRQV´Journal of Generic Medicines, Vol.1 (2) pp.137-145, on p. 140; 
for a general discussion of the links between patents and health, see for example Velasquez G. 
(2000) « Medicaments Essentiels et Mondialisation », Revue Internationale de Droit 
Economique, 2000/1. Numero Special: Brevets Pharmaceutiques, Innovation et Sante Publique 
pp.38-5R]HN5DQG%HUNRZLW]5³7KH(IIHFWVRI3DWHQW3URWHFWLRQRQWKH3ULFHVRI
Pharmaceutical Products: is Intellectual Property Raising the Drug Bill in Developing 
&RXQWULHV´Journal of World Intellectual property (1) pp. 179-244. 
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Djibouti. The approach adopted here is to analyse in detail elements and 
connections that explain the action and mechanisms of pharmaceutical patents 
in Djibouti, rather than assuming the causality and simplicity of their links. 
Next to this first perspective of patents as allowing diseases to spread, a 
diverging understanding presented before makes patents a condition for 
treatment ± without patents, there would not be any new drugs, and without 
new drugs, there would certainly be more diseases411. Once again, this first 
section needs to consider if this causal relation holds any truth in relation to the 
links between health and patents in Djibouti. 
 
This section tests the assumption that the links between patents and health can 
be established in either of these simplified and causal ways. Once again, it 
attempts to avoid drawing definite and causal links between networks that are 
more complex than any account can fully reflect. To that extent, it emphasises 
its own limits as ideas are developed.  The roots of this section in empirical 
data need to be re-emphasised. In order to follow the links between health and 
                                                 
411
  See in particular the position of the pharmaceutical industry ± IRU H[DPSOH ³The 
commercial sector discovers and develops nearly all new drugs and vaccines, and the 
dependence of pharmaceutical and vaccine discovery and development on adequate and 
enforceable intellectual property rights is the highest amongst various industry sectors´
International Federation of Pharmaceutical Manufacturers (200 ³75,36 3KDUPDFHXWLFDO
Patents and Developing Countries: Implications for Healthcare Access, Drug Quality and Drug 
'HYHORSPHQW´ DYDLODEOH DW http://www.ifpma.org/documents/NR86/TRIPS.pdf, on p.2; see 
DOVR 0DQVILHOG ( 6FKZDUW] 0 DQG :DJQHU 6  ³,PLWDWLRQ &RVW DQG 3DWHQW DQ
(PSLULFDO6WXG\´(FRQRPLF-RXUQDOSS-918; Scherer F. M. (2000) « Le systeme des 
EUHYHWV HW O¶LQQRYDWLRQ GDQV OH GRPDLQH SKDUPDFHXWLTXH », Revue Internationale de Droit 
Economique, 2000/1, Numero Special: Brevets pharmaceutiques, Innovation et Sante Publique 
pp.109-'LPDVL-$+DQVHQ5DQG*UDERZVNL+³7KH3ULFHRI,QQRYDWLRQ1HZ
HVWLPDWHVRI'UXJ'HYHORSPHQW&RVW´Journal of Health Economics, 22:151-185. 
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SDWHQWV LW LV LPSRUWDQW WR UHWXUQ WR DFWRUV¶ SHUVSHFWLYHV ZKHQ GLVFXVVLQJ
specifically how they perceived the links between patents and health:  
 
³7KH GUXJV ZH QHHG DUH YHU\ EDVLF PHGLFDWLRQ WKH\¶UH QRW XQGHU SDWHQWV
anymore´ 
 
³If you look at the health situation here, most problems could be solved without 
DFFHVVWR³PRGHUQGUXJV´:KDWZHUHDOO\QHHGLVSDUDFHtamol, aspirin, a few 
antibiotics, some antiseptic and some anti-diarrheic. All of these are in the 
SXEOLF GRPDLQ DQ\ZD\V DQG GRQ¶W FRVW DQ\WKLQJ 2XU UHDO FRQFHUQ LV ILUVW
how to get those to the population? We are really far from there, so modern 
drugs ZLOOSUREDEO\QRWEHDFRQFHUQIRUDYHU\ORQJWLPH«´412 
 
Thus we should consider whether health priorities themselves need to be 
considered as determined by patents ± this issue, as mentioned briefly in 
Chapter 6, has been raised in relation to the international definition of 
³HVVHQWLDOPHGLFLQHV´ ,QSDUWLFXODUWKH:+2OLVWZDVHVWDEOLVKHGE\NHHSLQJ
in mind the cost of medication. That has raised the issue that the absence of 
patented drugs from the list might be due to their price rather than to the fact 
                                                 
412
 This similar to comments made by the industry when pleading that patents are not the cause 
of limited access to medicines in poor countries ± although this argument can be criticised 
when coming from the industry which also argues, as explained above, that patents are 
important for R&D that could matter to developing countries. Although as we will see below 
WKH DUJXPHQW GRHV QRW KROG IXOO\ LQ WKH FDVH RI 'MLERXWL ³Patents do not, in fact, have a 
significant impact on access to the drugs which most of the population in developing countries 
actually consumes, which are primarily off-patents drugs´ ,QWHUQDWLRQDO )HGHUDWLRQ RI
Pharmaceutical Manufacturers (2001) op. cit. on p.15. 
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WKDWWKH\ZRXOGEH³OHVVLPSRUWDQW´WKDQRWKHUV413. Although this issue has been 
considered, it did not seem to be significant in Djibouti itself. When discussing 
with doctors what their main concerns were, they constantly stated that what 
most people need are the range of medications quoted above. They emphasised 
the impact that untreated diarrhoeas or fevers had on the overall health crisis. 
To that extent, the empirical findings made in this research did not at any point 
seem to suggest that this opinion was based on a concern for the cost of 
particular drugs rather than for the actual medical needs of a large part of the 
population414. If returning to the quotations given above, the two sets of causal 
chains presented early in this chapter are fully challenged, because the basic 
assumption that treatment depends on modern drugs itself is contested.  
 
Since modern drugs are not necessary to treat diseases in Djibouti, access to 
modern drugs is not crucial for health, and therefore patents should not be an 
issue in relation to the predominant diseases of the country. Similarly, if 
Djibouti does not need new drugs to treat diseases, the argument that patents 
are important for research and development, and are consequently essential to 
tackle diseases with much needed new drugs, does not hold true in Djibouti 
itself. The diseases that need to be addressed in Djibouti have treatment that 
has been available in the public domain for several years. The role that might 
be played by patents in relation to health in Djibouti would therefore appear to 
be necessarily limited. But this is itself based on an assumption ± very 
                                                 
413
 See for example for comments on the structure and evolution of the WHO Essential 
0HGLFLQHV/LVW/DLQJ5:DQLQJ%*UD\$)RUG1DQG+RHQ(³<HDUVRIWKH
:+2(VVHQWLDO0HGLFLQHV/LVWV3URJUHVVDQG&KDOOHQJHV´The Lancet (361) pp. 1723-1729. 
414
 The only potentially debatable case was that of AIDS, which will be discussed again below. 
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reasonable, nevertheless, from a common sense perspective and found in a 
range of texts quoted in Chapter 6415 ± that appeared to be wrong in the case of 
Djibouti. The above statement therefore assumes that, since new drugs are not 
an issue when trying to address the diseases that Djibouti has to face, patents 
do not relate to drugs needed in the country, and therefore do not relate to 
diseases. In other words, it assumes that, if patents are not embedded in the 
diseases present in Djibouti, they cannot be embedded in the drugs used for 
treating them.  Consequently, since they cannot be embedded in drugs needed 
in Djibouti, they cannot participate in determining their price nor access to 
them. However, once again, some elements need to be added to this reasoning. 
In particular, it is important to ask whether the fact that new drugs are not 
needed to address most illness in Djibouti should imply that patents do not 
relate to these illnesses in any way. To answer this question, it is essential to 
reflect on what was demonstrated in Chapter 6 on the role of patents in the 
pharmaceutical market of Djibouti.  
 
As explained in that chapter, the impact of pharmaceutical patents on the 
largest part of the current market of Djibouti ± if excluding so far the limited 
exception of the OPS - is such that, once a patent has been granted on a drug, it 
will in fact remain determinant of this drug being the version imported in 
'MLERXWLHYHQDIWHULWKDVRIILFLDOO\³H[SLUHG´LQRWKHUFRXQWULHV± and after the 
                                                 
415
 )RUH[DPSOH6FKHUHU)0DQG:DWDO-³3RVW-TRIPS Options for Access to Patented 
0HGLFLQHV LQ 'HYHORSLQJ 1DWLRQV´ Journal of International Economic Law 5(4): 313-319; 
2[IDP,QWHUQDWLRQDO³Priced out of Reach: How WTO patent policies will reduce access 
WR PHGLFLQHV LQ WKH GHYHORSLQJ ZRUOG´ available at 
http://www.oxfam.org.uk/what_we_do/issues/health/downloads/priced.rtf, as quoted in 
Chapter 6. 
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GUXJLVFRQVLGHUHGDV³RII-SDWHQW´3DWHQWVDUHWKHUHIRUHFULWLFDOLQGHWHUPLQLQJ
which version RI³RXW-of-SDWHQW´GUXJVZLOOHQWHUWKHFRXQWU\ 416. To that extent, 
in spite of the fact that there is no essential link between modern drugs and 
disease in Djibouti at the moment, this should not rule out a potential link 
between disease and patents.  
 
Patents are inherently embedded into most of the drugs entering the country, 
apart from the exceptional source of generics that we have seen before. The 
consequences of this in terms of access to medication need to be drawn in order 
to understand the links between patents and health in Djibouti. In order to do 
so, it is central to reflect on the role of patents in terms of price not only during 
the official term of a patent, but also once generic versions start appearing. 
Indeed, branded versions of drugs remain more expensive than new generic 
versions entering the market. This has been attributed to the value attached by 
patients to drugs they already know by name417. Even once the official term of 
a patent has run out, the original producer of a drug will maintain a market 
advantage that will allow them to charge higher prices than its less widely 
                                                 
416
 $WKRXJKWKHWHUP³RXW-of-SDWHQWV´LVEHFRPLQJKLJKO\FRQIXVLQJLWLVHVVHQWLDOWRXVHLWDW
times in order to locate the findings from this case study by comparison to statements made 
elsewhere. 
417
 6HH'XPRXOLQ-³/HV %UHYHWVHWOH3UL[GHV0HGLFDPHQWV´RSFLW6HHDOVR&DYHV
R. E., Whinston M. D., Hurwitz M. A. (1991) Patent expiration, entry and competition in the 
US pharmaceutical industry, Brookings Papers on Economic Activity, Microeconomics, pp. 1- 
48;  GrabowsNL+*DQG9HUQRQ-0³%UDQG/R\DOW\(QWU\DQG3ULFH&RPSHWLWLRQ
DIWHUWKH'UXJ$FW´Journal of Law and Economics (35) pp.331-350. 
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known competitors ± although prices of branded medication generally drop 
once the market opens to competitors418.  
 
The meaning of this for Djibouti is particularly important. Crucially, it means 
that patents play a role in the high price of drugs in the country.  They are 
certainly not the only factor explaining the fact that drugs are expensive in the 
country, but they are clearly part of the story419. Branded drugs are bought by 
importers at a higher price than generics would be, and are therefore also sold 
at a higher price. This in turns means that, although modern drugs are not 
needed to exclude diseases from Djibouti, patents participate in the obstacles 
that currently exist in access to medication in the country. However, caution 
needs to be maintained. One must avoid the pitfalls of generalisation that are 
criticised in this research. Patents are certainly not the only obstacle to access 
to medication: the weakness of hospital structures, the extent of environmental 
concerns, the choices of sources made by pharmacists when importing their 
drugs are all very important factors, and partly interdependent420. However, 
patents certainly should not be perceived as fully excluded from health and 
                                                 
418
 6HH'XPRXOLQ-³/HV%UHYHWVHWOH3UL[GHV0HGLFDPHQWV´RSFLW/DUULHX-DQG
+RXLQ*³0HGLFDPHQWJHQHULTXHHWSURSULHWHLQWHOOHFWXHOOH´Revue Internationale de 
Droit Economique (1). Numero Special: Brevets pharmaceutiques, Innovation et Sante 
Publique pp.173-185.  
419
 Such as the cost of various taxes, the margin of profit made by the pharmacist, potential 
ZKROHVDOHUVHWF«7RVHHDQH[DPSOHRIKRZWKLVPLJKWTXDQWLWDWLYHO\PDWHULDOLVHLQDQRWKHU
OHDVWGHYHORSHGFRXQWU\VHH³'LUHFWLRQGHOD3KDUPDFLHHWGHV/DERUDWRLUHV0LQLVWHUHGHOD
6DQWH3XEOLTXH5HSXEOLTXHGX7FKDG³(QTXHWHVXU le Prix des Medicaments au 
7FKDG´0DLDYDLODEOHDW
http://www.haiweb.org/medicineprices/surveys/200405TD/survey_report.pdf#search='enquete
%20sur%20le%20prix%20des%20medicaments%20au%20tchad' 
420
 These factors are now increasingly presented as important to treat, although this is 
sometimes not stated clearly by critics of TRIPS. 
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disease, since they make drugs a bit more expensive, and therefore make 
disease at least a bit harder to treat. 
 
The contingence of these links is particularly clear. If importers started buying 
more generic drugs, the links between patents and drugs sold in the country 
would disappear; patents would be embedded in a more limited range of drugs, 
and would be by-passed more easily when providing treatment± and the links 
between patents and health would therefore be even less obvious. We will see 
in the next section how the reforms being implemented in Djibouti at the time 
of fieldwork were already beginning to reshape part of these links. In addition 
to this, the arrival of new diseases, the reshaping of health priorities or the re-
emergence of forgotten microbes are all elements that can change the current 
links and networks.  
 
The complexity of the links between patents and health in Djibouti therefore 
needs to be fully understood before attempting to discuss how TRIPS is likely 
to re-order the existing connections. As patents do not exist officially, on paper 
and in national law in Djibouti, it could have been assumed that there were no 
connections between patents and diseases in the country. This assumption 
could have been reinforced by two elements ± first, the lack of enrolment of 
TRIPS as prescription in public health policy networks in Djibouti, and second 
the weakness of connections between modern drugs and diseases in Djibouti. 
However, the import and distribution systems of Djibouti currently enrol 
patents in a way that needs to be fully understood, and that results in patents 
having an impact in spite of their lack of official existence ± and an impact 
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running further than temporal limits that standard written patent laws would 
have set. The complexity of these links is of course co-dependent on their 
mobility, and on the fact that each of these connections is likely to be 
challenged at any time by new actors, new associations and the emergence of 
stability in new sets of relations. These re-orderings might be generated by the 
emergence of new diseases, the introduction of new drugs in the market or new 
governmental links and policies, for example. However, some of them might 
embed TRIPS or some effects of TRIPS, not only because of its official legal 
implementation, as this was proven to be of limited immediate impact, but 
IROORZLQJ LWV LPSDFWRQVKDSLQJKHDOWKSULRULWLHVDQG³7KLUG:RUOG LVVXHV´ LQ
places other than Djibouti. The next section will be devoted to questioning how 
and why the dislocated impact of TRIPS as a complex network with multiple 
effects should be taken into account when assessing the role of TRIPS in 
specific health networks.  
  
SECTION 2: RE-ORDERING OF HEALTH NETWORKS AND 
DISLOCATED EFFECTS OF TRIPS 
 
$17UHPLQGVXVRIWKHQHHGWRUHODWHZKDWDUHJHQHUDOO\SHUFHLYHGDV³JOREDO´
and ³ORFDO´ HYHQWV LQ D PRUH VXEWOH DQG LQWHJUDWHG ZD\ WKDW HPSKDVLVHV WKH
artificiality of both terms. It calls for the understanding of networks through 
their manifestation and existence in specific connections, while emphasising 
that no specific connection can be understood in total isolation from wider 
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networked space421. Any actor, any happening, is the result of other actors, 
other happenings and other connections, all embedded into what might 
temporarily appear as one. This section questions the potential embedment of 
TRIPS in public health in Djibouti, through actions and projects that can 
appear to relate to some aspects of TRIPS as a complex network. Once again, it 
necessarily has to be limited in the claims it makes for causality, and it has to 
limit itself more often to narrow questions than wide-ranging answers. It 
analyses how the effects TRIPS has had on shaping health priorities worldwide 
are felt in Djibouti, and relates local re-orderings to changes generated 
elsewhere by the enrolment of TRIPS in particular networks ± and the 
enrolment of issues or diseases as part of TRIPS. The method is essentially 
illustration - by looking at two key health projects that are currently being set 
up in Djibouti, and which highlight particularly well some of the reordering 
that health networks are currently undertaking. This section explains how these 
can be read in the light of TRIPS, and how this can be used to rethink our 
understanding of what TRIPS is or does, and how it should be studied. The 
approach accepteGKHUHLVWKDW³75,36LQ'MLERXWL´FDQRQO\EHXQGHUVWRRGDV
the gathering of the many effects of TRIPS in other places, and their 
embedment in other associations. Throughout this research, it appeared clearest 
that the punctualised and unified vision of TRIPS as one clear set of 
prescriptions in a chain of reactions ± one intermediary that would just carry 
                                                 
421
 This relates to ideas put forward in ANT when dealing with the notions of 
³JOREDOLWLHVORFDOLWLHV´ H[SODLQHG LQ &KDSWHU  DQG GHYHORSHG IRU H[DPSOH LQ /DZ - 
³0DWHULDOLWLHV 6SDWLDOLWLHV *OREDOLWLHV´ RS FLW DQG /DZ -  ³$QG LI WKH *OREDO ZHUH
small and inFRKHUHQW´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV /DQFDVWHU 8QLYHUVLW\
LA14YL, UK, at http://www.compa.lancs.ac.uk/sociology/papers/law-and-if-the-global-were-
small.pdf. 
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patents as a pre-defined entity - could not be sustained once its wide ranging 
effects start being undone and observed. 
 
The following discussion considers how the delocalised effects of TRIPS can 
be related to re-orderings currently taking place in Djibouti. This involves once 
again moving beyond the purely doctrinal analysis of TRIPS and understanding 
its multiple and complex dimensions, while accepting their mobility and 
dynamics. What will be questioned in this section is the role of TRIPS within 
what can be ± imperfectly ± GHILQHGDV³WKHLQWHUQDWLRQDOKHDOWKV\VWHP´RQFH
again, a network more complex than can be fully explained here, although this 
section will only concentrate on those aspects which are important to 
understand for this specific case study), and how TRIPS might have become 
HPEHGGHG LQ 'MLERXWL WKURXJK ³LQWHUQDWLRQDO SURMHFWV´ ,W FRQVLGHUV ZKHWKHU
some of the programmes set up currently in Djibouti can be perceived as 
bringing TRIPS in some of its dimensions to Djibouti, as suggested by other 
research in the field422. The overall meaning of this broader role and enrolment 
of TRIPS for its analysis will therefore be questioned.  
 
Two programmes will be examined. The first programme aims specifically at 
introducing generic drugs on a more institutionalised basis in Djibouti, and is 
therefore likely to re-order, at least in part, the current links between patents, 
drugs and health in Djibouti ± although it is at an early stage. The second 
                                                 
422
 Sell S. (2003) Private Power, Public Law, Cambridge: Cambridge University Press; Sell S. 
³75,36DQGWKH$FFHVVWR0HGLFLQHV&DPSDLJQ´Wisconsin International Law Journal 
Summer 20(2) pp. 481-522. 
 
 310 
project studied relates to the treatment of AIDS in Djibouti. In addition to 
raising questions related to the embedment of TRIPS in Djibouti, it raises more 
practical and political questions on the adequacy of some particular policies 
and discourses to the needs of Djibouti, and is useful to consider in order to 
illustrate more clearly the potential inadequacies between international changes 
generated by TRIPS and the local reception of these reorderings. 
 
Introducing generic drugs in Djibouti ± what does this mean for TRIPS? 
 
I have already mentioned some changes to the health system of Djibouti ± and 
in particular its pharmaceutical system ± that were being implemented as the 
fieldwork for this project was undertaken. These now need to be reviewed. In 
particular, the import system for drugs in Djibouti is currently being partly 
reshaped. This is the result of a new project financed by the World Bank 
directed at the reform of several aspects of health services423. 
 
7KH :RUOG %DQN SURMHFW KDV VHYHUDO GLPHQVLRQV DQG DLPV WR ³LPSURYH WKH
TXDOLW\ RI EDVLF VHUYLFHV´424. It has various components, but what has been 
presented by actors throughout this project as the most central ± and the aspect 
most relevant to this research - UHODWHVWRWKHFUHDWLRQRIWKH&HQWUDOHG¶$FKDWV
des Medicaments et Materiels Essentiels (CAMME)425. The first aim of this 
                                                 
423
 See for detailed information on the project World Bank (2002) Report No PID10697, 
Djibouti- Health Sector Development. 
424
 World Bank (2002) Report No PID10697, op. cit. p.2. 
425
 The centrality of this aspect can be seen both through the spreading of the financing 
proposed by the World Bank and ± mainly ± through actors understandings and actions in the 
course of this fieldwork. 
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new structure is to build a point of entry for cheaper drugs in the country. This 
is to be achieved by introducing a new centralised system of import of 
medicines, in which policies to procure cheaper drugs for patients could be 
implemented in a harmonised way426. In addition to this, the CAMME was to 
participate in developing new points of distribution for this cheaper 
medication, by creating new community pharmacies in and outside Djibouti 
town427: 
 
³The aim of this programme is to start facilitating access to medicines in the 
whole country. This will be achieved by introducing generics ± which would be 
very cheap, and therefore accessible. We also need to create a new system of 
distribution ± basically we have been given money by the World Bank to 
GHYHORSWKHVHVWUXFWXUHVDQGILQDQFHWKHILUVWRUGHURIPHGLFDWLRQ´ 
 
In order to understand the importance of the CAMME in terms of the 
pharmaceutical market, two questions need to be asked: first, where will these 
cheaper drugs come from? Second, where will they go? This will set the 
ground for further discussion on the meaning of these changes in relation to 
patents. 
 
When discussing the origin of the drugs entering the CAMME, it is important 
to emphasise that when this fieldwork was carried out, the CAMME was just 
                                                 
426
 ³CAMME will buy drugs from the cheapest quality sources and sell them to public and non-
profit health establishments with a small mark-up to finance its operating cost´:RUOG%DQN
(2002) Report No PID10697, op. cit. p.4. 
427
 World Bank (2002) Report No PID10697 op. cit. on p.4. 
 312 
starting up: the first batch of drugs had been ordered, and was expected to 
arrive in the summer. This means that it is difficult to draw long term 
conclusions on the preferred routes followed by drugs. However, looking at 
what happened in the first order and how those in charge foresaw the future 
raises interesting questions. When deciding which drugs to buy, the pharmacist 
in charge of the CAMME explained that she would consider two types of 
options: international bid or restricted bid. The first procedure will consist of 
advertising internationally the future order, and comparing the prices of 
companies all around the world. The company offering the cheapest version of 
the drug ± often a generic version428 ± will then be assigned the contract. As 
Djibouti does not yet have any structure through which drug quality can be 
tested, the company will be given its contract only if they are authorised to sell 
the drug concerned in their own country ± and only if this country has the 
structures necessary to carry out drug testing429. Under the second procedure, 
the CAMME will send details of what they are looking for only to a few 
                                                 
428
 The fact that patented drugs are more expensive than generic versions has been discussed in 
Chapter 1 ± for comments on this aspect, see Velasquez G. (2000) op. cit.; Dumoulin J. (2000) 
³/HV%UHYHWVHWOH3UL[GHV0HGLFDPHQWV´Revue Internationale de Droit Economique, 2000/1, 
Numero Special: Brevets Pharmaceutiques, Innovation et Sante Publique pp. 45-69.; Abbott F. 
0³7KH'RKDGeclaration on the TRIPS Agreement and Public Health: lighting a dark 
FRUQHUDWWKH:72´Journal of International Economic Law  5(2) pp. 469-505. It has also been 
explained above that even after a drug has run out of patents, the originally patented version 
will remain more expensive than generics ± for detail, see Dumoulin J. (2000) op. cit; See also 
Caves R. E., Whinston M. D., Hurwitz M. A. (1991) op. cit. ; Grabowski H.G. and Vernon 
J.M. (1992) op. cit. 
429
 This is not an unfamiliar approach in developing countries ± see Abbott F.M (2005) 
³0DQDJLQJ WKH +\GUD 7KH +HUFXOHDQ 7DVN RI (QVXULQJ $FFHVV WR (VVHQWLDO 0HGLFLQHV´ LQ
Maskus K. E. and Reichman J. H. (eds) International Public Goods and Transfer of 
Technology under a Globalized Intellectual Property System, Cambridge: Cambridge 
University Press, pp. 393-425. 
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companies ± companies they have worked with before ± and compare their 
prices. This will not necessarily give the cheapest results, but would be a much 
quicker option, and more realistic in the long term, with regards to the size of 
the structure430. Of course, in the context of Djibouti and of the many 
difficulties of shipment that have been explained in Chapter 6, it is highly 
plausible to imagine that, in the long term, the range of companies considered 
DV ³SRWHQWLDO SURYLGHUV´ PLJKW EH SURJUHVVLYHO\ UHVWULFWHG $W Whe time of 
fieldwork, the first procedure has been used for drugs ordered in largest 
quantities, or most expensive drugs. For others, the pharmacist in charge has 
applied the second procedure. So, at least at this stage, at least in theory, drugs 
can come to the CAMME from anywhere, from any company, and from any 
QHWZRUNLQZKLFKGUXJVRI³VDWLVIDFWRU\TXDOLW\´FDQEHSURGXFHG 
 
Now that the origin of drugs has been briefly explained, we can look at where 
these drugs will be brought locally. This relates to the second role of the 
CAMME, to create community pharmacies in which the drugs will be 
distributed at very limited cost, in parallel with the existing system based 
essentially on the private pharmacies of Djibouti town431. Eight community 
pharmacies will be built overall, in each of the districts of Djibouti. A pilot 
study has been started on four of them, built in January 2004. The results will 
be used when opening the other pharmacies. The community pharmacies will 
need to maintain very low costs, and patients will be asked to pay a purely 
                                                 
430
 The structure employs only one full-time pharmacist in charge of selecting, ordering and 
distributing internally every drug. 
431
 ³7KH SXEOLF KHDOWK HVWDEOLVKPHQWV ZLOO VHOO WKH GUXJV WKURXJK D FRPPXnity pharmacy or 
directly (in case they are legally autonomous) and the proceeds of the sales will be used to 
UHVWRFN´:RUOG%DQN5HSRUW1R3,'RSFLWRQS 
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symbolic price for the drugs they buy. Although the stocks will be limited to a 
few essential drugs ± mainly paracetamol, aspirin, a few antibiotics and anti-
diarrhoeal - those in charge hope that once fully implemented, community 
pharmacies might make a difference to access to medication across the country. 
Others remain sceptical. Those who are doubtful as to the viability of the 
project emphasise the range of problems that are still to be solved432 - amongst 
those are for example, issues of expertise433, and, in spite of the original aim to 
NHHS FRVWV DV ORZ DV SRVVLEOH WKH KLJK OHYHO RI ³FRPSOHPHQWDU\ FRVWV´434. 
However, community pharmacies should not be, in the long term, the only 
place where the drugs bought by the CAMME are expected to be distributed. In 
IDFWDOO³SXEOLFVWUXFWXUHV´VKRXOGLQWKHORQJHUWHUPEHFRPHVXSSOLHGE\WKH
CAMME. As the project is still in its earliest stages, it is currently more an 
aspiration than a reality. However, it may lead to changes in the future and 
might affect current expectations. 
 
Overall, the project set up by the World Bank aims to improve access to 
medication, by offering cheaper sources of imports through the CAMME and 
easier and more accessible points of distribution through community 
pharmacies. The impact of this new project on import networks and on the 
links between patents, drugs, and disease in Djibouti is highly relevant to this 
                                                 
432
 ³,WKDVMXVWVWDUWHGDQGDOUHDG\ZHGRQ¶WUHDOO\NQRZZKHUHWKHPRQH\LVJRLQJ.´ 
433
 As very few people in the country have expertise in the field of pharmaceuticals, it was not 
SRVVLEOH WR SXW D TXDOLILHG SKDUPDFLVW LQ DQ\ RI WKH QHZ SKDUPDFLHV ³We had a training 
session for the new staff ±but it was  a one day course!´3HRSOHLQWhe Ministry have been very 
critical of this situation, and would like to see further training implemented. 
434
 6XFK DV WKH DOZD\V LQFUHDVLQJ FRVW RI IXHOOLQJ XS WKH FDU RI WKH IRXU ³LQVSHFWRUV´ JRLQJ
around the pharmacies every day. 
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discussion. Following the presentation of this impact, the role of TRIPS in 
public health networks in this reordering of drugs networks in the country will 
be discussed ± as well as what this reveals in relation to the nature of TRIPS.  
 
TRIPS and the re-ordering of health networks  
 
What can be read into this new project is that it is likely to limit the current role 
of pharmaceutical patents in the import system of the country, and therefore to 
limit the links between patents and health. By introducing new sources of 
drugs, including generics, the programme is therefore potentially limiting the 
enrolment of branded/patented drugs in the country. When observing the list of 
sources that those in charge of the CAMME are investigating, it is very clear 
that those include both multinational research-based companies and smaller 
scale generic producers. Once again, the list might narrow down once a 
particular network has stabilised, but this is not the case yet. As explained 
above, the inscription of patents within import networks in Djibouti at the 
moment is central in linking patents to health, and if this inscription disappears 
fully, the links between patents and disease in Djibouti would lose most of their 
substance. If drugs coming into Djibouti are not anymore quasi-exclusively 
linked to patents, then patents will not find much of a way to relate to health, as 
explained above ± the making of patents as a health actor is indeed currently 
fully dependent on their embedment in drugs used/needed in Djibouti. 
However, this would only be the case if patents were to be fully excluded from 
drugs imported in Djibouti ± and it is essential in that respect to understand the 
limits of the changes created by the new project. The main limit that needs to 
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be emphasised is that the new source of import that the CAMME is creating is 
not at the moment perceived as a replacement for the private system of 
independent pharmacists. The drugs to be imported by the CAMME will 
therefore exclusively be sold in community pharmacies and public structures. 
As far as community pharmacies are concerned, as explained above, only some 
drugs will be sold435. Other drugs will have to be purchased from private 
pharmacies, and it is expected that most patients who can afford it will remain 
dependent on the imports of private pharmacists:  
 
³Private pharmacists expressed some concerns at first, but when you look into 
LW ZH UHDOO\ ZRQ¶W GHDO ZLWK WKH VDPH VKDUH RI WKH SRSXODWLRQ 2XU DLP LV
PDLQO\WRVXSSO\WKRVHZKRGRQ¶WEX\DQ\WKLQJDWWKHPRPHQW7KRVHZKREX\
IURPSULYDWHSKDUPDFLHVQRZZLOOFHUWDLQO\NHHSGRLQJWKHVDPH´ 
 
The possibility that the CAMME might supply the whole pharmaceutical 
market of Djibouti, including the private market, was considered and had to be 
abandoned because of the pressure applied by private pharmacists:  
 
³The original plan was that it would supply every drug in the country, like it is 
the case in other countries. But obviously, private pharmacists did not agree to 
that.´ 
 
                                                 
435
 This needs to be understood in particular in relation to the lack of trained personnel, as was 
explained above. 
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This is an interesting illustration of the limits of the CAMME as well as of the 
influential role played by private pharmacists in the country, and commented 
upon in Chapter 6. 
 
Although the new project is therefore unlikely to challenge the social role that 
patents play in Djibouti, it is y interesting to reflect further on its meaning in 
the context of TRIPS ± in terms of its impact on social reordering, while its 
emergence will be discussed below. Two questions need to be asked in this 
respect: first, could the activities of the CAMME create legal conflicts in 
relation to TRIPS? Second, what is the meaning of the CAMME if reflecting 
more broadly on the spirit of TRIPS and the apparent direction taken (for the 
moment, although it is necessarily open to change) by re-orderings in Djibouti?  
 
First, while TRIPS is being implemented, one might ask whether the imports of 
generic drugs from other developing countries that are considered by the 
CAMME might bring drugs that would not be compliant with TRIPS standards 
into Djibouti. In particular, since those in charge of the CAMME are amongst 
those who stated that they were not interested in TRIPS, it is therefore likely 
that compliance with TRIPS will not be an issue in their decisions. They also 
reinforced that the CAMME ³GRHVQRWKDYHDQ\UHJXODWLRQDERXWSDWHQWV$OO
ZH DUH FRQFHUQHG ZLWK LV TXDOLW\´ But the practical risks of the CAMME 
actualO\ ³PHHWLQJ´ 75,36 DUH OLPLWHG 7KH GUXJV WR EH LPSRUWHG E\ WKH
CAMME, as shown on their current listings, are for the moment all out-of-
patent, and the risk of Djibouti not being TRIPS compliant in terms of 
enforcement is therefore minimal so far. This is in harmony with the current 
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needs of the population for basic medication. The only potential exception to 
the exclusive export of out-of-patent drugs that was mentioned was once again 
that of anti-retroviral drugs. Although they had not been bought by the 
CAMME yet, the pharmacists in charge mentioned that they were expecting to 
EX\ ³DFFHVV SULFH´ PHGLFDWLRQ UDWKHU WKDQ JHQHULFV ± as the overall cost of 
getting them into Djibouti was expected to be lower. Although this is itself 
potentially subject to change and reordering, it is at the moment unlikely that 
the CAMME will import drugs which contradict the standards of TRIPS. In 
addition to this, as TRIPS is implemented in all developing countries with a 
producing capacity, the range of controversial generic drugs will slowly 
disappear.  
 
The project is most interesting, however, if reflecting on the spirit of TRIPS as 
well as on its specific dispositions. When considering the aim of the 
proponents of TRIPS and its creators, what transpires is the fact that TRIPS 
ZDVPDLQO\GLUHFWHGDW³UHLQIRUFLQJ´SKDUPDFHXWLFDOSDWHQWV- at making them 
available in more places, for longer, on a wider range of inventions. This is 
very clear when looking at the role of the pharmaceutical industry in the pre-
TRIPS era436, and it can be interpreted as meaning that patents should and will 
                                                 
436
 See Sell. S. (2003) Private Power, Public LawRSFLW6HOO6³,QGXVWU\6WUDWHJLHV
for Intellectual Property and Trade: The Quest for TRIPS and Post-TRIPS 6WUDWHJLHV´Cardozo 
Journal of International and Comparative Law. 10(1 ) pp. 79-6HOO6³75,36DQG
WKH $FFHVV WR 0HGLFLQHV &DPSDLJQ´ RS FLW. 'UDKRV 3  ³1HJRWLDWLQJ ,QWHOOHFWXDO
3URSHUW\ 5LJKWV%HWZHHQ &RHUFLRQ DQG'LDORJXH´ LQ'UDKos P and Mayne R (eds), Global 
Intellectual Property Rights: Knowledge, Access and Development. London: Palgrave, pp. 161-
182. 
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probably be more active, more important, more relevant after TRIPS becomes 
active in specific networks than before. 
 
Nevertheless, surprisingly, the current changes that are taking place in Djibouti 
following this new international project, seem to be having the opposite effect. 
While so far pharmaceutical patents were de facto inherently part of most drugs 
imported in the country, their share in the market is now becoming more 
limited. While pharmaceutical patents were central to all imports apart from 
those of the OPS, the CAMME is now creating a parallel system of imports 
from which patents are for the moment largely excluded as potential 
determinants. Their action in other connections of the pharmaceutical chain 
remains determinant. Investigation within the networks of each producer would 
probably reveal traces of pharmaceutical patents437, but these do not determine 
which drug will or will not enter the CAMME and Djibouti, or at least not at 
this early stage of its creation, when this fieldwork was carried out. The impact 
of patents on the country is therefore socially becoming more restricted, at the 
same time as they are being officially introduced in written law, as explained in 
Chapter 5.  
 
While TRIPS is making pharmaceutical patents part of the official landscape of 
Djibouti, the CAMME appears to be creating a new concurrent network from 
                                                 
437
 To some extent, it becomes almost impossible to consider any part of the pharmaceutical 
chain without at some stage coming back to the role of patents ± in the development of drugs to 
EHSURGXFHGE\RWKHUVWKDQWKHLURIILFLDO³LQYHQWRU´IRUH[DPSOH+RZHYHULWLVLPSRUWDQWKHUH
to remain focused on the impact of patents that can directly be felt as active in Djibouti, and 
can be seen as shaping patents as a determinant to the action and ordering of networks in 
Djibouti. 
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which they are newly excluded.  When analysing the meaning of this, two 
explanations can be given. The first one follows the idea of coincidence: the 
fact that patents are losing part of their social role in Djibouti at the time when 
TRIPS is being implemented is only a coincidence, an example of two 
independent and contradictory events happening at the same time. However, a 
wider reflection on the delocalised impact of TRIPS within an international 
health network can raise many questions as to whether this is coincidental or 
whether this reveals the need to understand both the text of TRIPS and the 
opposition and actions it has participated in generating as part of the same 
network. 
 
Social re-ordering and delocalised effects of TRIPS 
 
This second hypothesis now needs to be tested. We need to understand whether 
TRIPS can be perceived as linked to the World Bank project and the creation 
of the CAMME. In order to present the emergence of this hypothesis and the 
elements that participate in defending it, it is important to explain two further 
sets of ideas. First, the fact that the World Bank project was presented as truly 
originating outside Djibouti, and second the inherent embedment of TRIPS in 
the many health-related debates and policies that have emerged in the last few 
years. Once again, this section cannot impose causality on any links or 
projects, and can only suggest some correlations and embedments that made it 
difficult to conceive of the project described above without relating it to TRIPS 
in a number of ways. 
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The origins of the CAMME project can be found outside of Djiboutian 
networks. Rather than being funded by the request of the Djiboutian 
government, the project appeared to originate in the World Bank itself:   
 
³7KHZD\LWZRUNVKHUHLVJHQHUDOO\WKDWWKH:RUOG%DQNZKLVSHUVDQLGHDDQG
DVNV XV WR RIILFLDOO\ DSSO\ IRU WKLV SDUWLFXODU IXQG 7KDW¶V ZKDt basically 
KDSSHQHGLQWKLVFDVH´ 
 
The CAMME was also described as the result of ³WKH:RUOG%DQNSROLFLHVLQ
WKHSKDUPDFHXWLFDOILHOG´ 
 
It is therefore important to understand this particular project as resulting from 
international policies, and the need to question more broadly the context in 
ZKLFK ³DFFHVV WR JHQHULF PHGLFLQHV´ LV FXUUHQWO\ EHLQJ GLVFXVVHG 7KH
embedment of TRIPS within international debates and discussions about access 
to medicines, and access to generics, forms the background. It is essential to 
reflect on what has been portrayed as the relation between TRIPS and the 
development of the access to medicines campaign438. The adoption of TRIPS 
followed a long history of pressure for stronger protection of inventions, 
including those in the pharmaceutical field. For many authors, as explained in 
Chapter 1, the adoption of TRIPS revealed the lobbying power of the 
pharmaceutical industry, especially in the US. The years following TRIPS, 
                                                 
438
 The impact that TRIPS might have had in triggering the access to medication campaign is 
not a new issue, and has already been discussed and investigated ± ³Without TRIPS there 
ZRXOG EH QR DFFHVV WR PHGLFLQHV FDPSDLJQ´ VHH 6 6HOO  ³75,36 DQG WKH $FFHVV WR
0HGLFLQHV&DPSDLJQ´RSFLW See also Sell. S. (2003) Private Power, Public Law, op. cit. 
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however, are less often analysed in terms of lobbying. Nevertheless, some 
research has focused on this period. Chapter 1 has explained how TRIPS has 
changed after its adoption as a public health issue, and has been moved from 
trade networks to public health debates. New actors in the public health field 
joined around TRIPS, and connected in new ways. The mobilisation of those 
opposed to TRIPS resulted in turn in emphasis being put on new problems, 
including that of access to medicines. By triggering a new set of critics, TRIPS 
has also generated a new set of pressures on governments and international 
organisations to deal with the issues raised in poor countries, and to deal more 
specifically with the issue of access to medication439.  
 
TRIPS clearly has created not only technical debates and analyses amongst 
lawyers but also ±sometimes in an overlapping way - large networks of 
opposition440. Actors in NGOs and in a number of governments have drawn to 
the attention of others, including the general public and the media, the potential 
risk that introducing TRIPS in developing countries could represent. These 
critics have in turn had input in generating new policies, and in particular a 
new approach of industries and policy-makers to health solutions for poor 
                                                 
439
 The overall impact of TRIPS on generating new policies within international organisations 
runs beyond the purpose of this particular research; however, the triggering of access to 
medicines campaign by TRIPS has been largely proven, and the development of policies in 
recent year in this field has also been documented ± VHH66HOO³75,36DQGWKH$FFHVV
WR0HGLFLQHV&DPSDLJQ´RSFLW Sell. S. (2003) Private power, Public Law, op. cit. 
440
 ³While industry was spectacularly successful in its quest to institutionalise the link between 
intellectual property and trade, in the wake of TRIPS a number of challenges have emerged. 
7ZRRIWKHPRVWLPSRUWDQWFKDOOHQJHVDUHWKH³QRSDWHQWVRQOLIH´DQGWKH³DFFHVVWRHVVHQWLDO
PHGLFLQHV´ FDPSDLJQV´ LQ 6HOO 6  ³,QGXVWU\ VWUDWHJLHV IRU LQWHOOHFWXDO SURSHUW\ DQG
trade: the quest for TRIPS and post-75,36VWUDWHJLHV´RSFLWRQS 
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countries441)URP WKH LQGXVWU\¶V VLGHSURMHFWV LQYROYLQJ UHVHDUFK on tropical 
diseases442, restraint from enforcing some high-profile lawsuits and the 
QHJRWLDWLRQ RI ³DFFHVV SULFHV´ RQ VSHFLILF GUXJV443, have been increasingly 
appearing since the mid-¶V,QDGGLWLRQWRWKHVHWKHLPSDFWRIWKHDFFHVVWR
medicines campaign on national or international policies has been crucial444. 
TRIPS can be seen as playing a part in this evolution, and in putting at the 
forefront of international issues the problem of the conflicts of interest between 
commercial pressures in developed states and access to health in poorer 
countries. Although it cannot be stated with certainty that TRIPS is a 
determinant actor in each of these policies, there seems to be enough evidence 
                                                 
441
 ³Arguing that intellectual property rights should be construed as a public health issue, 
rather than a trade issue, this civil society campaign has scored some victories in challenging 
the corporate perspective. This group seeks to limit the expansion of intellectual property 
rights and reduce such rights for essential medicines in an effort to contain costs and increase 
access.´6HOO6³7KH4XHVWIRU*OREDO*RYHUQDQFHLQ,QWHOOHFWXDl Property and Public 
+HDOWK 6WUXFWXUDO 'LVFXUVLYH DQG ,QVWLWXWLRQDO 'LPHQVLRQV´ Temple Law Review (77) 
Summer 2004 pp.363-399 on p. 366. 
442
 Some of these based on public/private partnership initiative, such as the Novartis Institute 
for tropical diseases ± for information, see http://www.novartis.ch/special/FR/nitd.shtml 
443
  The withdrawal of the lawsuit against the South African government by the group of thirty-
nine pharmaceutical companies was presented as one of the main early victories of the 
campaign; the cuts offered on prices on the industry can also be read in the light of this 
FDPSDLJQ )RU IXUWKHU GHWDLO VHH 6HOO 6  ³75,36 DQG WKH $FFHVV WR 0HGLFLQHV
&DPSDLJQ´RSFLWS-514. 
444
 For details of US policies in the area, see Sell S. (2³75,36DQGWKH$FFHVVWR
0HGLFLQHV&DPSDLJQ´RSFLWDQG6HOO6Private power, public law, op. cit; at 
international level, specific agencies have addressed this issue, such as  UNAIDS, created in 
1996, addresses issues specific to HIV/AIDS ± for information, see 
http://www.unaids.org/NetTools/Misc/DocInfo.aspx?LANG=en&href=http://gva-doc-
owl/WEBcontent/Documents/pub/Publications/IRC-pub05/JC1117-
ExceptionalResponse_en.pdf; the involvement of the WHO, including in relation to the Doha 
Declaration, has been discussed earlier ± for detail of relevant activities, see for example 
Abbott F. M. (2002) op. cit. 
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to state that it has now become at least a part ± potentially minor but 
nevertheless unavoidable ± of policies relating to access to medication. TRIPS 
cannot nowadays be described, thought of or looked at without considering the 
access to medicines campaign. Similarly, the issue of access to medication, and 
access to generics in particular, is largely related to TRIPS and its subsequent 
action.  
 
We can now return to what this might mean in relation to the links between the 
World Bank project introducing generic drugs in Djibouti445 and TRIPS. 
Whether causal and direct links can be found between the adoption of TRIPS 
DQG WKLV SDUWLFXODU SURMHFW LV FRQWHQWLRXV DQG VWDWLQJ WKDW WKLV SURMHFW LV ³WKH
UHVXOWRI75,36´ZRXOGEHXQGXO\VLPSOLVWLF7KH:RUOG%DQNSURMHFWLVPDGH
of a wide range of other actors, all interconnected as well as linked to further 
networks ± and once again, the practical limitations of both empirical research 
and written accounts makes it impossible to look at each of these actors in 
detail. TRIPS is certainly part of these, as it is now embedded in any project or 
discourse linked to access to medications. It is necessary to maintain modest 
FODLPV LQ WKHFDXVDOLW\RI WKLVSUHVHQFH$UJXLQJ WKDW75,36³JHQHUDWHG´ WKLV
project would hide the fact that the World Bank considered health issues before 
TRIPS came into place, considered the role of generics before TRIPS was 
adopted and thought of access to medication in the past446. However, there is 
DOVR HYLGHQFH WKDW WKH :RUOG %DQN¶V DFWLRQ LV QRZ LQFUHDVLQJO\ UHODWLQJ WR
                                                 
445
 In addition to the few found in the OPS. 
446
 For an example of early project referring to generic medicines ± although not making it the 
centre of analysis ± see Foster S.D (1990) Improving the Supply and Use of Essential Drugs to 
Sub-Saharan Africa, World Bank Policy Research Working Paper WPS 456. 
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issues raised by TRIPS, and that TRIPS has therefore become fully embedded 
LQWKH%DQN¶VSROLFLHV447.  
 
Thus, the conclusions to be drawn from this section and example can only be 
modest and balanced. On the one hand, this particular project of the World 
Bank needs to be understood as the complex gathering of multiple connections, 
some happening in Djibouti, some in the World Bank offices, and many more 
in other places. On the other hand, the increasing attention brought to access to 
medicines and to generics in particular has been largely facilitated and 
generated by TRIPS, to such an extent that it becomes difficult to conceive of 
one without thinking of its other. To that extent, the World Bank project being 
set up in Djibouti at least partly embeds some of the discourses that have so 
largely proliferated since TRIPS. Reflecting on Djibouti itself in the light of 
this specific project, the impact of TRIPS can only be fully understood by 
considering the multiple effects it has been having, and highlighting its 
embedment in the notion of generics, and in access to medication.  
 
                                                 
447
 6HH IRU H[DPSOH ³In the early 2000, the Bank did not have an explicit and consistence 
practice with regard to the procurement of generic versions of ARVs that were on-patent in 
PRVWGHYHORSHGFRXQWULHV«0RUHUHFHQWO\WKH:RUOG%DQNSURGXFHGD7HFKQLFDO*XLGHWR
offer guidance to improve the performance of the agencies involved in the procurement of 
+,9$,'6 SURGXFWV ,Q WKH *XLGH¶V FKDSWHU RQ ,35V WKH %DQN RIIHUV H[plicit guidance to 
developing countries on how to use the flexibilities of the TRIPS and of their own legislation in 
order to obtain the lowest possible prices while ensuring a standard quality of the supply of 
SKDUPDFHXWLFDOV DQG RWKHU PHGLFDO SURGXFWV´ In 5RYLUD -  ³7UDGH $JUHHPHQWV
Intellectual Property, and the Role of the World Bank in Improving Access to Medicines in 
'HYHORSLQJ&RXQWULHV´Yale Journal of Health Policy, Law and Ethics 4(2) pp. 401-413, on p. 
410. 
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Two different understandings of TRIPS ± at least ± emerge from the above 
idea. While on the one hand TRIPS is a set of written rules that Djibouti needs 
to implement, it is also a crucial actor in stabilising newly emerged connections 
in the access to medicines network. It is an essential part of these networks, and 
this role is itself an integral aspect of TRIPS, a dimension that cannot be put 
aside. When understanding what TRIPS is ³GRLQJ´ to health in Djibouti, what 
needs to be appreciated is that TRIPS is more than only a written set of 
prescriptions with no further effects than what the causality of doctrinal 
analysis could foresee. It is more than a set of written rules, and covers 
networked effects that have different sets of impacts, direct or not, in Djibouti. 
Its written legal implementation and direct consequences are one crucial 
element to understand, but they remain only one element, one aspect of an 
instrument that is fully reshaping what patents are and do ± and as we will now 
see an instrument that has also the potential of reshaping what diseases are or 
should be. 
 
3DWHQWV 75,36 GLVHDVH DQG DFFHVV WR ³PRGHUQ GUXJV´ DQ H[DPSOH RI
AIDS in Djibouti 
 
The hypothesis put forward in the above section also has to be understood in 
relation to its political meaning. In particular, it seems to suggest that the 
dominant story told about TRIPS and its impact on poor countries in terms of 
access to medication might have created new opportunities in this field ± and in 
a sense performed the reality of TRIPS as a public health actor in Djibouti. If 
the above project can be read in this light, the post-TRIPS developments could 
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appear as having unexpectedly participated in improving access to generics in 
Djibouti. However, the performativity of the dominant story of TRIPS can also 
be read as having had further, more specific effects, some of which might raise 
more difficulties. Although the enrolment of TRIPS in the access to medicines 
campaign, and the reciprocal embedment of part of this campaign within 
TRIPS, appear to have brought opportunities as illustrated by the example 
given above, they have also participated in performing a particular 
understanding of specific health issues and particular diseases in developing 
countries.  
 
This section illustrates the complex relation between pharmaceutical patents, 
TRIPS and health by questioning the role of both objects in shaping health 
priorities and diseases. This will be done by presenting the current reshaping of 
AIDS as a health priority in Djibouti, and how this is perceived by local actors. 
The aim of this section is to build on the hypothesis developed above by 
showinh how one of the key fields that has been presented worldwide as 
threatened by TRIPS might have impacted on the shaping of health priorities in 
Djibouti. It follows the idea presented above that the effects of TRIPS ± and 
FRQVHTXHQWO\ ³75,36´ LWVHOI - need to be understood in relation to the 
networked nature of TRIPS, by emphasising how it can be perceived as a 
central actor in reshaping understandings of AIDS as central to public health 
priorities, and of anti-retrovirals as essential elements in access to health. This 
is an important illustration of the complexity of understanding the links 
between TRIPS and health borrowed from the most usual example used to 
explain why TRIPS is a threat to access to medication. 
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AIDS in Djibouti 
 
When fieldwork was carried out in Djibouti from January to April 2004, a 
second project financed by the World Bank was being put into place by the 
government. It was directed at financing treatment for AIDS, malaria and TB 
HVVHQWLDOO\ WDFNOHG DV ³ULVN FR-IDFWRUV´448. Once again, the project itself is 
complex, and although AIDS is officially only one of the diseases to be tackled 
with this financing, it appeared to be its most central aspect± and the project is 
UHIHUUHG WR LQ'MLERXWL DV³WKH$,'6SURMHFW´7KHFHQWUDOLW\RI$,'6FDQEH
read in the stated aims of the project: ³LSUHYHQWLQJWKHVSUHDGRI+,9$,'6
by reducing transmission, in particular among high risk groups, (ii) expanding 
access to treatment of opportunistic illnesses and malaria, and to care, support 
and treatment to People Living with HIV/AIDS (PLWHA) in Djibouti (iii) 
supporting multi-sectoral, civil society and community initiatives for HIV/AIDS 
prevention and care and malaria prevention´449 The particular emphasis of the 
project on AIDS can also be read if looking at the specific financing offered for 
this disease450. 
 
                                                 
448
 For details on the project, see World Bank (2003) Report No AB7, Updated Project 
Information Document (PID), Djibouti ± HIV/AIDS, Malaria and Tuberculosis Control 
Project, March 2003. 
449
 World Bank (2003) Report No AB7, op. cit. p.5. 
450
 On the 12 million dollars that the project is investing in Djibouti, 5.2 million dollars are 
VSHFLILFDOO\GLUHFWHGDWWUHDWLQJ$,'6PLOOLRQVWR³$,'67%DQG67,PDQDJHPHQW´7%DV
³RSSRUWXQLVWLF GLVHDVH DQG WKH UHPDLQLQJ  PLOOLRQV DUH FRPPRQ FDSDFLW\ EXLOGLQJ
investment. 
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The project is summarised by local actors as being essentially designed in 
SUDFWLFH WRRIIHU ³free HIV treatment to 250 patients in Djibouti´7KH IXQGV
officially, however, also aim to develop the infrastructure necessary to deal 
with the disease ± DOWKRXJK ³many questions remain unanswered ± and in 
particular that of social structures. It is crucial that patients get the 
DSSURSULDWHVRFLDOVXSSRUW WKDW LVQHHGHGDQG IRU WKHPRPHQWZHGRQ¶WKDYH
the means to give them that.´ 
 
Most public health actors appeared rather sceptical as to the appropriateness of 
the project to the needs of patients in Djibouti, and it was challenged by 
informants several times. In particular, the high priority of AIDS as a public 
health concern and of anti-retroviral drugs as a public health solution, in 
Djibouti has been widely questioned and challenged by actors met in the course 
of this study. Although AIDS is becoming a concern in the country and 
progressively spreading, it was not presented by any of the actors interviewed 
as one of the most urgent concerns to which the government should try to 
respond. In particular, and although prevention was presented as crucial as a 
long term policy, treatment of patients with AIDS was not generally presented 
as a priority as compared to other types of diseases ± or at least not a realistic 
priority.  
 
One of the reasons for this is that treatment is expensive. This clearly raises 
once more the questions raised above in relation to the potential role of patents 
and the price of medication in the shaping of health priorities. However, this 
idea needs to be balanced by the empirical findings made here. The cost of 
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medication was only one of the elements put forward when explaining why 
AIDS was not yet one of the highest priorities of the government. Several 
social elements were presented by informants when explaining why public 
health actors did not believe they should be concentrating too strongly on 
AIDS. The first element is that, based on the current evaluations presented in 
&KDSWHUDQGRQZKDWLQIRUPDQWVIURPWKHSXEOLFKHDOWKILHOGVWDWHG³VHHLQJ´
in Djibouti, other diseases are currently creating more damage in Djibouti. In 
addition to this, and very importantly, AIDS still also carries a cultural taboo, 
and many health actors interviewed emphasised that many patients would 
refuse to come forward and face the fact that they had AIDS, because of the 
social stigma still attached to the disease: ³7KHUHLVDELWRI$,'6EXWZHDUH
mainly concerned with TB. And to be fair, we have very few patients coming 
forward and willing to talk about AIDS, it is VWLOO D UHDO WDERR´ Finally, the 
range of social support and infrastructures that needed to be developed to offer 
treatment to patients with AIDS, and ensure that they would follow a long term 
treatment, are not yet available in Djibouti. The financial issues raised by AIDS 
were therefore not only linked to the price of medication itself, but to wider 
elements that need to be considered when dealing with AIDS. Overall, 
considering the current impact of AIDS as compared to other diseases in 
Djibouti, and considering the cost and difficulties of developing adequate 
strategies to treat AIDS in the country, most actors in the public health field 
believe that it should not be the highest priority at the moment .Other concerns 
have been placed above AIDS until now.  
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It is in this context that the AIDS project of the World Bank has been set up in 
Djibouti. The shaping of AIDS brought through the project is one of health 
priority451, and requires public health networks to enrol AIDS in a new, 
unfamiliar way. AIDS and its new embedment in the World Bank project have 
both been generated by and generating new connections, new links, new drugs, 
VWDELOLVHGLQZKDWLVNQRZQDVWKH³$,'6SURMHFW´1HYHUWKHOHVVWKLVUHPDLQV
criticised, and perceived by health professionals in Djibouti as the result of the 
embedment of AIDS in its external shaping rather than as the appropriate 
UHVSRQVHWRZKDWKDGEHHQXQWLOUHFHQWO\SHUFHLYHGDV³$,'6LQ'MLERXWL´ 
 
³From a public health point of view, it is complete nonsense. With all that 
money, we are going to cure 250 people, while it could have been used to solve 
all the problems of maternity death, which is a key problem here. It could also 
have been directed at basic treatment for childhood diseases that we cannot 
cure at the moment. %XWDWWKHPRPHQWLQWHUQDWLRQDOO\$,'6LVWKHTXHVWLRQ«
VRZHKDYHWR³GR´$,'6± it looks good´ 
 
As introduced in Chapter 4, the contrast between local framings of AIDS and 
the focus put by international policies on the disease appear essential. 
HowevHU WKH LQFUHDVLQJ HPSKDVLV SXW RQ $,'6 LQ GLVFRXUVHV RQ ³KHDOWK LQ
GHYHORSLQJ FRXQWULHV´ H[SODLQV WKLV GLVFUHSDQF\ ,Q DGGLWLRQ DSSO\LQJ WKH
framework developed above, the potential links between TRIPS, this shaping 
of AIDS and the project set up in Djibouti can be questioned.  Indeed, for the 
purpose of this research, what is most interesting is to question, once again, 
                                                 
451
 In terms of financial mobilisation, at least. 
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whether TRIPS itself might be embedded in this particular project, and to what 
extent its role in generating new resources for AIDS and a large international 
focus on the treatment of AIDS, might need to be read when questioning what 
it does in a specific developing country. Once again, the need to understand 
TRIPS in its networked effects can be emphasised, and it is interesting to 
question whether TRIPS as a network can be perceived as partly embedded in 
this particular project.  
 
Since TRIPS has been adopted, access to anti-HIV/AIDS medication has 
become one of the most intensively discussed issues both in the media and 
academic literature when dealing with TRIPS or access to treatment452. It has 
also become one central element of the access to medicines campaign, and 
projects supporting access to anti-HIV/AIDS drugs have spread around the 
                                                 
452
 The relation between access to anti-retroviral, access to medicines as a whole and TRIPS 
FDQEHLOOXVWUDWHGE\WKHIROORZLQJTXRWDWLRQ³In many respects, the debate about how best to 
ensure access to essential medicines to combat the HIV/AIDS virus has come to typify anxieties 
about the World Trade Organisation (WTO) Agreement on Trade-Related Aspects of 
Intellectual Property (the TRIPS agreement) and its potential to have adverse socio-economic 
LPSDFWVRQGHYHORSLQJFRXQWULHV´, see Matthews D. (2004) op. cit., p.2; the links between the 
specific example of AIDS and the wider issues raised by TRIPS can be found in many other 
texts ± IRUH[DPSOH6KRHOO6³:K\FDQ¶WWKH3RRU$FFHVV/LIHVDYLQJ0HGLFLQHV"$Q
Exploration of Solving the Patent Issue´0LQQHVRWD,QWHOOHFWXDO3URSHUW\5HYLHZ(4) pp. 151-
182; -RQL -  ³$FFHVV WR 7UHDWPHQW IRU +,9$,'6 D +XPDQ 5LJKW ,VVXH LQ WKH
'HYHORSLQJ :RUOG´ Connecticut Journal of International Law (17) pp.273-280; Bass N. 
 ³,PSOications of the TRIPS Agreement for Developing Countries: Pharmaceutical 
Patent Laws in Brazil and South Africa in the 21st &HQWXU\´George Washington University 
International Law Review (34) pp. 191-222; 1HUR]]L0 ´7KH%DWWOH RYHU/LIH-saving 
DrugV DUH 'HYHORSLQJ &RXQWULHV EHLQJ 75,SHG E\ 'HYHORSHG &RXQWULHV"´ Villanova Law 
Review (47) pp. 605-641. 
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world453. It is not my intention to undermine the importance of AIDS in many 
countries. In any case, TRIPS can only be one ± possibly minor - element that 
has made AIDS emerge as a key health issue for many countries, in particular 
LQ $IULFD 6LPLODUO\ WKH XQLIRUPLW\ ZLWK ZKLFK ³GHYHORSLQJ FRXQWULHV´ DUH
discussed runs further than this particular example, although it has become a 
central characteristic of TRIPS-related literature as explained earlier. Overall, 
the worsening AIDS crisis that has spread in many large African countries is 
clearly the main element that has triggered concerns about this fast-growing 
disease. The high price of medication has also been important in increasing 
FRQFHUQ IRU DFFHVV WR WUHDWPHQW ,Q DGGLWLRQ WR WKLV WKH ³3UHWRULD´ WULDO DQG
similarly emotional and intense cases have revolved around AIDS, and 
increased awareness of the devastation created by this disease454. However, the 
links between TRIPS and AIDS remain important. The reason why both actors 
have become so strongly enrolled into each other explains why this example is 
                                                 
453
 See in particular the decision by the UN general assembly to create a Global Fund to Fight 
AIDS, Tuberculosis and Malaria ± originally providing 31 countries with a total of $378 
PLOOLRQV LQ DLGV )RU PHGLD FRYHUDJH VHH%HQNLPRXQ3  ³/H)RQG*OREDO&RQWUH OH
6,'$ DFFRUGH VHV SUHPLHUV ILQDQFHPHQWV´ Le Monde, 27 Avril 2002; see also for further 
details on specific projects financed in recent years by international organisations: Fleet J. 
³81$SSURDFK WR$FFHVV WR(VVHQWLDO$,'60HGLFDWLRQV ,QWHOOHFWXDO3URSHUW\/DZ
DQG WKH :72 75,36 $JUHHPHQW´ Emory International Law Review (17) Summer 2003 pp. 
451-466. 
454
 See for comments on the PretoULD WULDO +DOEHUW '  ³0RUDOL]HG 'LVFRXUVHV 6RXWK
$IULFD¶V ,QWHOOHFWXDO 3URSHUW\ )LJKW IRU $FFHVV WR $,'6 'UXJV´ Seattle Journal for Social 
Justice (1) Fall/Winter 2002 pp. 257- DQG 6HOO 6  ³75,36 DQG WKH $FFHVV WR
0HGLFLQHV&DPSDLJQ´Rp. cit. See also for the links between this trial and access to medicines: 
0HUFXULR % &  ³75,36 3DWHQWV DQG $FFHVV WR /LIH-saving Drugs in the Developing 
:RUOG´ Marquette Intellectual Property Law Review 8(2) Summer 2004 pp. 211- ³The 
issue of access to patented medicines gained worldwide attention in 2000, when several drug 
companies challenged the legality of the South African Medical and Related Substances 
Control Act of 1997, which allowed for compulsory licences of patented pharmaceuticals´RQ
p. 224. 
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highly relevant to the wider aim of this research. The most central connection 
between TRIPS and AIDS revolves around pharmaceutical patents, and the fact 
that many anti-HIV/AIDS drugs are still under patent. This has made the links 
between patents and access to medication particularly strong in this field. AIDS 
is also a disease that is quickly evolving and mutating, and for which new 
drugs are likely to be constantly needed. For these main reasons, the debate on 
patents and access to medication has often been dominated by the more 
specific debate on access to anti-HIV/AIDS drugs.455 Because of the strong 
links between patents and AIDS, TRIPS has quickly become perceived as a 
central issue in relation to access to anti-HIV/AIDS drugs, not only in 
academic writings, but also in various policy programmes456. As the campaign 
on access to medicines started growing, one of its main impacts was the 
emphasis put on the necessity to improve access to anti-HIV/AIDS drugs 
worldwide. The role of TRIPS in the access to medicines campaign therefore 
needs to be understood as particularly relevant to the unanimous emphasis on 
$,'6 DV D NH\ GLVHDVH IRU ZKLFK GUXJV DUH XUJHQWO\ QHHGHG LQ ³GHYHORSLQJ
FRXQWULHV´ ± in a way that appeared in this particular country as potentially 
contradictory with the actual health needs of the population concerned. Once 
again, the point made here is not that AIDS is not a relevant issue in many poor 
countries, but that its shaping as an immediate priority and of access to anti-
                                                 
455
 ³In this case, consumer and health group on the front lines of the HIV/AIDS pandemic 
mobilized to protest the high cost of HIV/AIDS drugs, the subsequent lack of access to drugs 
and the danger of overly strong intellectual property protection as embodied in TRIPS´6HOO6
³75,36DQGWKH$FFHVVWR0HGLFLQHV&DPSDLJQ´RSFLWRQS 
456
 For details on the way TRIPS and AIDS have become officially embedded into each other 
in international policies, see Fleet J. (2003) op. cit. 
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HIV/AIDS drugs as a central part of health development, was contested by 
several health actors in this particular research, as far as Djibouti is concerned. 
 
Causality needs to be kept as a minimum, while the co-generation of fully 
embedded and dependent actors is put forward. AIDS is itself a complex 
network, understood and lived differently by all those that it affects. As is the 
case for any disease, and as has been demonstrated in other examples, there is 
not one story or one reality about AIDS, but multiple and co-existing stories 
that all merge together457. AIDS in TRIPS and TRIPS in discourses on AIDS 
are only part of these realities, but one that becomes difficult to by-pass in the 
current context. As appears to have become the case with access to medication, 
AIDS cannot be thought of, nowadays, without considering patenting issues 
and the impact of TRIPS. The World Bank itself, as was explained in the 
previous section, has emphasised that TRIPS as a set of rules should not 
prevent countries from treating AIDS. Although TRIPS cannot be perceived as 
KDYLQJ³JHQHUDWHG´WKH:RUOG%DQNSURMHFWSHUVHLWKDVFHUWDLQO\SOD\HGDUROH
in every aspect of the HIV/AIDS related lobbying, and of the increasingly 
unanimous agreement that AIDS is a key disease to address in order to solve 
health issues in poor countries, and that access to anti-HIV/AIDS medication is 
therefore a priority. TRIPS has become embedded in new policies and actions 
concerning AIDS, and when looking for its presence in Djibouti, its 
embedment in international framings of AIDS cannot be fully ignored. The 
                                                 
457
 This can be related to ANT writing on other diseases, highlighting the variety of realities 
that can be identified when investigating the nature of a particular disease. See for example 
/DZ-DQG6LQJOHWRQ9³7KLVLVQRWDQ2EMHFW´SXEOLVKHGE\WKH Centre for Science 
Studies, Lancaster University, LA14YL, UK, at 
http://www.comp.lancs.ac.uk/sociology/papers/law-singleton-this-is-not-an-object.pdf  
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links to be drawn might be indirect, limited, but TRIPS needs, nevertheless, to 
be understood and questioned in each of its ramifications, and access to 
medication, in particular anti-HIV/AIDS medication, is certainly one of these. 
In this particular example, the performance of AIDS as a key disease to be 
WDFNOHGLQWKH³GHYHORSLQJZRUOG´KRZHYHUGLGQRWJRZLWKRXWRSSRVLWLRQIRU
those who considered that the specificities of their environment were let down 
by the generality of this particular story. 
 
&RPSOH[LW\ RI 75,36 QHWZRUN DQG SKDUPDFHXWLFDO SDWHQWV DV ³SXEOLF
KHDOWKLVVXHV´LQWHUGHSHQGHQFHDQGUH-ordering. 
 
The conclusions to be drawn from this chapter are complex and need to be 
balanced. The co-dependency and complexity of the links between TRIPS, 
patents and health in Djibouti is striking. Health might not appear to be 
affected by the written implementation of TRIPS, and seems largely 
independent of official legislation in the country. However, health is also fully 
dependent at the moment on the socio-legal action of pharmaceutical patents 
through the complex connections described in Chapter 6. Currently, however, 
some re-orderings are taking place in the public health field in Djibouti, 
reshaping both the role of patents themselves and the prioritising of diseases in 
health policies. Whether these re-orderings can be read as direct consequences 
of TRIPS or not is something that is difficult to state empirically with certainty, 
since every particular change and connection taking place in the field is the 
result of other moves and changes that are tightly interrelated and 
indissociable. Nevertheless, it is crucial to emphasise that the embedment of 
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TRIPS within recent policies directed at what have been widely defined ± and 
performed ± DV ³GHYHORSLQJ FRXQWULHV´ LV VRPHWKLQJ WKDW QHHGV WR EH
considered when questioning what TRIPS does and where it is in a given 
network. The limits that ANT sets itself forbid conclusions to go further than a 
certain stage, and it is therefore essential to remain cautious in discussing 
ZKHWKHU WKLV LV ³WKH UHVXOW´ RI 75,36 RU QRW +RZHYHU ZKDW KDV EHHQ
emphasised in this chapter is that determining the role, impact, action or 
presence of TRIPS could only be done if accepting and understanding that 
TRIPS is embedded in more than the material form through which it travels to 
a given country. It has the potential, as pharmaceutical patents proved they had, 
to travel through other connections, and these need to be considered when 
discussing the role of TRIPS in any particular network. Now that the different 
pictures and dimensions of TRIPS and pharmaceutical patents as empirically 
illustrated in this project have been analysed, it is possible to reflect more 
broadly on the meaning of this project as a whole. This reflection concerns 
what the project illustrated both in its own field of enquiry and in relation to 
socio-legal research and the roles that ANT can play in it. 
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CHAPTER 8 - CONCLUSION  
 
 
This chapter brings together the findings and ideas laid out in this research, and 
aims to provide answers to the research questions set in this project. This 
UHVHDUFKDLPHGWRGLVFXVV WKH³role and impact of TRIPS and pharmaceutical 
patents in health networks in Djibouti´:KLOHGRLQJVR it also aimed to assess 
specifically the role of TRIPS and pharmaceutical patents through from 
different perspectives ± the role of TRIPS as an official/written text of law; the 
role of pharmaceutical patents in relation to the pharmaceutical market of 
DjLERXWLDQGWKHUROHRI75,36DVDQ³LQWHUQDWLRQDOKHDOWK´DFWRU2YHUDOOWKH
central research question was addressed by emphasising the nature of TRIPS 
and pharmaceutical patents as multi-dimensional actor-networks. The empirical 
data analysed in the preceding chapters has dealt with most of the above issues, 
and therefore largely answered the questions raised in the introduction. This 
chapter returns to each of the essential elements of the research questions, and, 
while doing so, explicitly discusses what this project revealed of the nature of 
TRIPS and pharmaceutical patents. 
 
This chapter entails a degree of summarisation of the project, and in this 
respect, the process of producing conclusions whilst remaining faithful to the 
ideas put forward by ANT, DQG LQ SDUWLFXODU WR $17¶V ZDULQHVV RI
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simplification and shortcuts458, becomes a difficult task. It is to some extent 
LPSRVVLEOH WR ³VXPPDULVH´ ZKDW KDV EHHQ VDLG WKURXJKRXW WKLV SURMHFW E\
simplifying it, while hoping to provide a shortened but faithful version of what 
has been said throughout. However, it is also necessary to bring together some 
key ideas and specific findings that can help us understand the overall meaning 
and potential consequences of this research. This conclusion will therefore aim 
to re-emphasise some of the main points put forward in this project, 
acknowledging that other elements are best left as presented throughout, and 
that the stories told and networks followed cannot be shortened in a number of 
their dimensions. It seeks to find a fair balance between the need to remind the 
reader of the key points of this research, against the risk of hiding complexity 
and therefore reality by simplifying to an undue extent a story in its entirety. I 
will also discuss the prospects for the further use of ANT in other projects 
looking at socio-legal objects. 
 
This conclusion comprises two sections. The first section emphasises some key 
findings from the case study undertaken, and explains how TRIPS and 
pharmaceutical patents have been analysed throughout and how their relation 
to health has been framed. The second section discusses the potential relevance 
of the methods and concepts used in this project for future research, and 
evaluates some aspects of ANT. 
 
                                                 
458
 This difficulty might be particularly accurate in the context of a PhD where a conclusion is 
expected to return to what has been discussed throughout. 
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SECTION 1: EXPECTATIONS AND DISRUPTIONS: TRIPS AND 
PHARMACEUTICAL PATENTS IN ACTION IN DJIBOUTI 
 
This section will return to the analysis made of TRIPS and pharmaceutical 
patents as socio-legal objects, and will emphasise the complexity and fluidity 
of their nature as they appeared throughout this project. Before looking at both 
objects, however, this section will reflect briefly on the research process itself, 
and on the progressive evolution of this research. 
 
Process and changes of the research 
 
This case study has analysed and interpreted the effects of the implementation 
of TRIPS in Djibouti, and the role of pharmaceutical patents in the country 
before and after TRIPS was created. The process of this research has 
incorporated many changes in expectations and direction. These have been of 
sufficient impact in the overall approach undertaken to merit further 
elaboration.  
 
This research was started by considering a wide range of literature that 
GLVFXVVHV WKH OLQNV EHWZHHQ 75,36 SDWHQWV DQG KHDOWK LQ ³GHYHORSLQJ
FRXQWULHV´ 0RVW RI WKHVH WH[WV adopted a common dimension, although their 
final conclusions and positions on the potential impact of TRIPS and 
SKDUPDFHXWLFDOSDWHQWVRQ³GHYHORSLQJFRXQWULHV´ZHUHRIWHQGLYHUJHQW6RPH
texts argued that if implemented in an appropriate way, TRIPS could be a 
positive development for poor countries, since pharmaceutical patents were a 
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beneficial tool both for the development of needed modern drugs459, and for the 
development of a local industry460. Many others, however, emphasised the 
potential risks of implementing or creating rigid standards for pharmaceutical 
patents across the world, in particular for developing states. The latter set of 
literature emphasised that pharmaceutical patents were only useful for 
industrial development when countries already had a strong generic local 
industry461, and that extending patent rights worldwide would have negative 
consequences on the price of medication, and therefore on access to medication 
in poor countries462. In the media, the debate has been greatly simplified, and 
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 6HHIRUH[DPSOH%DOH+(³3DWHQW3URWHFWLRQDQG3KDUPDFHXWLFDO,QQRYDWLRQ´New 
York University Journal of International Law and Politics, 29(1/2) pp. 95-107; Scherer F. M. 
(2000) « /H 6\VWHPH GHV %UHYHWV HW O¶,QQRYDWLRQ GDQV OH 'RPDLQH 3KDUPDFHXWLTXH », Revue 
Internationale de Droit Economique, 2000/1, Numero Special: Brevets Pharmaceutiques, 
Innovation et Sante Publique pp.109-124. 
460
 For examples of literature emphasising the potential role of patents in economic 
GHYHORSPHQW VHH%DUUR5-DQG/HH-+ ³6RXUFHVRI(FRQRPLF*URZWK´ Carnegie 
Rochester Conference Series on Public Policy (40) pp. 1-.RQGR(³7KH(IIHFWRI
3DWHQW3URWHFWLRQRQ)RUHLJQ'LUHFW,QYHVWPHQW´Journal of World Trade (29) 97-122; Lee Lee 
-<DQG0DQVILHOG(³,QWHOOHFWXDO3URSHUW\DQG86)RUHLJQ'LUHFW,QYHVWPHQW´Review 
of Economics and Statistics (78) 783- 0DVNXV . (  ³7KH 5ROH RI ,QWHOOHFWXDO
3URSHUW\ LQ(QFRXUDJLQJ)RUHLJQ'LUHFW ,QYHVWPHQWDQG7HFKQRORJ\7UDQVIHU´ Duke journal 
of comparative and international law (9) pp. 109-1613ULPR%DQG&DVWHUQ) ³7KH
Relationship between Intellectual Property Rights and Foreign Direct Investment, Duke 
Journal of Comparative and International law (9) 163-188. 
461
 6HHUDWDQ11 ³7KH1HJDWLYH ,PSDFWRI ,QWHOOHFWXDO3DWHQW5LJKWVRQ'HYHORSLQJ
Countries: an Examination of the Indian 3KDUPDFHXWLFDO,QGXVWU\´6W0DU\¶V/DZ5HYLHZRQ
Minority Issues (3) Spring 2001 pp.339-.RVK\6³7KH(IIHFWRI75,36RQ,QGLDQ
3DWHQW/DZ$3KDUPDFHXWLFDO,QGXVWU\3HUVSHFWLYH´Boston University Journal of Science and 
Technology Law (4) pp. 1-56; +HQGHUVRQ (  ³75,36 DQG WKH 7KLUG :RUOG 7KH
([DPSOHRI3KDUPDFHXWLFDO3DWHQWV LQ ,QGLD´ European Intellectual Property Review 19(11) 
pp.651-663. 
462
 For example: Velasquez G. (2000) « Medicaments Essentiels et Mondialisation », Revue 
Internationale de Droit Economique, 2000/1. Numero Special: Brevets Pharmaceutiques, 
Innovation et Sante Publique pp.38-44; 'XPRXOLQ -  ³/HV %UHYHWV HW OH 3UL[ GHV
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sRPHUHSRUWVKDYHHPSKDVLVHGWKHLGHDWKDW³SLUDWHV´LQ WKHGHYHORSLQJZRUOG
ZHUH ³IUHH-ULGLQJ´ RQ WKH LQYHQWLRQV RI LQGXVWULHV LQ WKH :HVW ZKLOH RWKHUV
KDYHWDNHQWKHYLHZWKDWWKH³SKDUPDFHXWLFDOLQGXVWU\´LQWKH:HVWZDVODUJHO\
contributing to difficulWLHVLQWKHKHDOWKVLWXDWLRQLQ³GHYHORSLQJFRXQWULHV´ 
 
When looking more closely into the broad range of texts analysed early in this 
project, (detailed in Chapter 1) it became clear that they were grossly 
simplifying the issues at stake. First, most research aiming to look at 
³GHYHORSLQJFRXQWULHV´RQO\FRQFHQWUDWHGRQDIHZVWDWHV± such as India, South 
Africa, Brazil. The situation of many other states remained overlooked. In 
addition to this, most research in this field provided an understanding of TRIPS 
and pharmaceutical patents that assumes that prescriptive regulations determine 
LQGLYLGXDO EHKDYLRXU ,W ZDV EDVHG RQ WKH DQDO\VLV RI ³DUWLFOHV´ RU
³GLVSRVLWLRQV´DQGGHGXFHGWKHLPSDFWRI75,36HVVHQWLDOO\IURPWKHVHZULWWHQ
and official prescriptions, therefore often leaving unquestioned potential 
discrepancies between expectations and realities.  
 
The focus of this research was originally chosen as a way to address the first 
limitation of existing literature ± it aimed to extend the questions raised by 
75,36DQGSKDUPDFHXWLFDOSDWHQWVWRDFRXQWU\IXOO\³RYHUORRNHG´E\H[LVWLQJ
                                                                                                                                 
0HGLFDPHQWV´Revue Internationale de Droit Economique, 2000/1, Numero Special: Brevets 
Pharmaceutiques, Innovation et Sante Publique pp. 45-1RJXHV-³6RFLDO&RVWVDQG
%HQHILWVRI,QWURGXFLQJ3DWHQW3URWHFWLRQIRU3KDUPDFHXWLFDO'UXJVLQ'HYHORSLQJ&RXQWULHV´
The Developing Economies, 31(1) pp. 24-53; Rozek R. and Berkowitz R. (1998) ³7KH(IIHFWV
of Patent Protection on the Prices of Pharmaceutical Products: is Intellectual Property Raising 
WKH'UXJ%LOO LQ'HYHORSLQJ &RXQWULHV´ Journal of World Intellectual property (1) pp. 179-
244. 
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literature. In particular, this was directed at questioning whether the 
KRPRJHQHLW\RI³GHYHORSLQJFRXQWULHV´WKDWDSSHDUVZKHQUHDGLQJPDQ\WH[WV
was sustainable. Thus, one of the smallest, least developed countries in Africa 
was chosen ± Djibouti - LQRUGHU WRVHHKRZ³75,36´ZDVIHOW LQ WKLV ODUJHO\
undocumented part of the world.  
 
While analysing TRIPS in Djibouti, and from the pilot study carried out in the 
first year of this research, the second limit of existing literature became clearer, 
however. One of the main elements that appeared inappropriate was the 
simplification drawn by a certain type of writings of the relations between 
TRIPS, patents, drugs and health, which has broadly defined TRIPS and 
pharmaceutical patents as entities that act according to certain pre-determined 
rules. In particular, in the case study chosen, the potential discrepancies 
between the prescriptive dimension of TRIPS and its actual impact in terms of 
social mobilisation became clear. Similarly, possible roles of pharmaceutical 
patents appeared as potentially differing from the official status of the tool in a 
given country. Consequently, the need to understand TRIPS and 
pharmaceutical patents in Djibouti as independent actors, in spite of the fact 
WKDW75,36ZRXOGRIILFLDOO\ ³FUHDWH´SKDUPDFHXWLFDO SDWHQWV LQ'MLERXWL ZDV
emphasised. Finally, the need to understand the effects of TRIPS not only 
through its prescriptive dimension, but also as a consequence of effects it has 
generated in terms of opposition and discourses was raised. 
 
As the complexity of TRIPS and pharmaceutical patents appeared, ANT 
presented itself as an invaluable tool to analyse and frame the nature and 
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modes of action of both objects. The remainder of this conclusion will explain 
in detail how the questions set in the introduction were answered throughout 
this project. It will discuss the understanding of TRIPS and pharmaceutical 
patents produced during this research, before explicitly discussing their 
meaning for health in Djibouti. 
 
Understanding TRIPS and its complex, networked effects 
 
The understandings of TRIPS and pharmaceutical patents provided in this 
research needs to be explained in two steps, as the two objects appeared partly 
independent in this project. First, the contrasts between this research and the 
story of TRIPS as told by the dominant set of literature that has considered its 
relation to health in poor countries will be discussed. In this research, the role 
of TRIPS appeared as distinct from its only official/prescriptive dimension, and 
while TRIPS as prescription in Djibouti did not mobilise actors in a convincing 
way, its impact on the country could be retraced through its action in other 
places.  
 
This case study highlighted the fact that the implementation of TRIPS as a set 
of prescriptions in Djibouti did not generate the mobilisation that might have 
been expected by its creators. Although TRIPS was in the process of being 
LPSOHPHQWHG³RQSDSHU´LQ'MLbouti, and transferred from its original form as 
international rules into national regulations, the integration of these rules into 
DFWRUV¶ GDLO\ SUDFWLFHV ZDV GHVFULEHG DV XQDFKLHYDEOH E\ DOO LQIRUPDQWV 7KH
action of TRIPS was presented as necessarily limited or inexistent. One of the 
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elements seen as explaining this lack of mobilization of actors was the strong 
limitations on communication and the restricted circulation of information 
about TRIPS throughout the country. Although information about TRIPS is 
expected to circulate across a set of pre-determined actors within and around 
governments, the structure of political networks identified in this research was 
set up in such a way that many key actors had surprisingly little information 
about TRIPS. The absence of mobilisation generated by TRIPS was at least 
partly explainable through this absence of connections and communication 
between key-actors. This may not be the only explanation to be provided. The 
poor circulation of TRIPS might not have been the only reason for its lack of 
prescriptive action. However, in the current context it appeared as a central 
element to understand the meaning of TRIPS and its role and effects on the 
country.   
 
However, as was explained in Chapter 7, this lack of mobilization around 
TRIPS in its written/prescriptive dimension should not be understood as a total 
inaction of TRIPS as a network. In particular, the effects of TRIPS appeared in 
this case study as acting through routes other than its official implementation 
³RQ SDSHU´ 7KH DFWXDO HQUROPHQW RI 75,36 LQ QHWZRUNV DQG LWV VXEVHTXHQW
action in enrolling new actors into these same networks in Djibouti was 
dependent not only on TRIPS as a set of written prescriptions but also on the 
set of discourses and actions generated by TRIPS elsewhere ± and outside of 
75,36 7KLV UHODWHG FOHDUO\ WR $17¶V DSSURDFK WR ³JOREDO´ HYHQWV DQG LWV
emphasis on the need to consider the range of actions and connections that 
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appear to gather in a given locus463. This approach is distanced from what the 
PRUH ³GRFWULQDO´ DSSURDFKHV WR 75,36 SURGXFHG LQ WKH GRPLQDQW VHW RI
literature on the text, appeared to claim. In particular, it resulted in TRIPS 
needing to be understood not only through its written dispositions, but also 
beyond its complex origins. It became necessary to understand TRIPS as series 
of connections and associations gathered under a simplified and widely used 
term, materialised originally in sets of paper and ultimately in multiple actions. 
These actions involved opposition and critics, and resulted in TRIPS taking 
directions and having impacts that its creators had potentially not foreseen, 
which reading its text alone could not highlight or explain. TRIPS came to be 
perceived as a complex network of unexpected connections, occurring in many 
loci that ultimately reached Djibouti not only in the one official way it was 
supposed to take ± through the text of TRIPS ± but also indirectly, through 
actions which are ± or are not - connected to TRIPS elsewhere. 
 
The contrast between creatoUV¶H[SHFWDWLRQVDQGWKHDFWLRQRIWHFKQRORJLHVKDV
been discussed and emphasised in ANT464. It recalls the concern of ANT 
writers for the potential gaps and discrepancies between the ideal network 
envisaged by creators of technologies and the actual set of interrelations 
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 $V H[SUHVVHG PRVW FOHDUO\ LQ /DZ -  ³$QG if the Global were Small and Non-
&RKHUHQW"0HWKRGFRPSOH[LW\DQGWKH%DURTXH´SXEOLVKHGE\WKH&HQWUHIRU6FLHQFH6WXGLHV
Lancaster University, LA14YL, UK, at http/www.comp.lancs.ac.uk/sociology/papers/law-and-
if-the-global-were-small.pdf; Law J. (1999) ³0DWHULDOLWLHV6SDWLDOLWLHV*OREDOLWLHV´SXEOLVKHG
by the Centre for Science Studies, Lancaster University, LA14YN, UK, at 
http//www.comp.lancs.ac.uk/sociology/soc029jl.html. 
464
 In theoretical ways that are more relevant to this particular research that ZULWLQJVRQ³ODZLQ
DFWLRQ´WKDWZHUHEULHIO\PHQWLRQHGLQ&KDSWHUDQG± as will become clearer throughout the 
remainder of this chapter. 
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technological objects will become enrolled into when taken out of their 
³ODERUDWRU\´465. ANT assumes the complexity and multiplicity of objects as 
part of their nature, and calls for an understanding of the potential gaps 
between expectations and multiple realities based on the idea of circulation and 
constant re-orderings, some of which the creators of technology might not have 
foreseen or expected. When emphasising the nature of TRIPS as a socio-legal 
object ± a hybrid made of complex and varied sets of connections - the need to 
understand its action through its empirical traces rather than by comparison to 
LWV FUHDWRUV¶ H[SHFWDWLRQV EHFRPHV FOHDUHVW 7KLV LV EHFDXVH 75,36 LV QRW D
QHXWUDODGGLWLRQWRDJLYHQDQGVWDEOH³VRFLDOFRQWH[W´EXWRne element within a 
circulating network. It generates power through associations with a number of 
actors that were potentially not part of what the creators of TRIPS had 
expected or hoped. This therefore results in power circulating further than 
might have been foreseen. TRIPS as a system comes to be perceived as the 
gathering of interactions between beliefs, expectations, discourses, and actors 
including pharmaceutical companies, governmental actors, drugs, patents, 
generic producers, pharmaceutical labs and others. This gathering itself 
generates new links and connections between this network and actors that were 
previously largely unrelated to it, or in a way that differed fundamentally from 
the new connections TRIPS was establishing. These new connections between 
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 )RUH[DPSOHLQGH/DHW0DQG$0RO³7KH=LPEDEZH%XVK3XPS0HFKDQLFVRID
)OXLG7HFKQRORJ\´Social Studies of Science (30) pp.225-263; Akrich M. and Latour B. (1992) 
³$&RQYHQLHQW9RFDEXODU\IRUWKH6HPLRWLFVRI+XPDQDQG1RQ-KXPDQ$FWRUV´LQ%LMNHU:
and Law J. (eds) Shaping Technology, Building Society: Studies in Sociotechnological Change, 
Cambridge MA: MIT Press, pp. 205-/DZ- ³/DGEURNH*URYHRU+RZWR7KLQN
DERXW )DLOLQJ 6\VWHPV´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV /DQFDVWHU 8QLYHUVLW\
UK, at http//www.comp.lancs.ac.uk/sociology/papers/law-ladbroke-grove-failing-systems.pdf 
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activists and patents, patents and the media, or labs and members of the public, 
for example, have in turn generated the stabilisation of new systems as 
networks, and resulted in power circulation producing new effects and 
translations in particular systems. This can be seen in the example of the 
development of generic medicines and AIDS as central to the understanding 
WKDW WKH JHQHUDO SXEOLF DQG WKH PHGLD KDYH RI KHDOWK FULVHV LQ ³GHYHORSLQJ
FRXQWULHV´,QWXUQWKLVQHZDZDUHQHVVKDVHQIRUFHGDnew type of action onto 
international organisations, so that these have become enrolled into a new type 
of public health network in which AIDS and generic medicines are key drivers. 
 
Pharmaceutical patents: action, translation and social networks. 
 
During the course of this research, the second story, concerning pharmaceutical 
patents, unexpectedly diverged from that of TRIPS. Although the mechanics of 
pharmaceutical patents are often understood, as in the case of TRIPS, as 
derived from their written/official existence, the example of their action in 
Djibouti demonstrated that understanding their role as socio-legal objects could 
only be done by moving away from this particular origin. The action of 
pharmaceutical patents was strongly separated from their written existence in 
national law in Djibouti. Therefore, while on the one hand their official 
LPSOHPHQWDWLRQ ZDV QRW OLNHO\ WR PRGLI\ DFWRUV¶ EHKDYLRXU WKHLU RIILFLDO
existence as written national law did not appear as necessary to their action.  In 
fact, the official introduction of written law creating ± in theory - 
pharmaceutical patents in the country was taking place in a context where the 
influence of patents seemed to diminish. 
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Elements of the expected mechanisms of pharmaceuticals patents have been 
discussed in Chapter 1. However, the example of Djibouti has shown how the 
³OLPLWV´ RI SKDUPDFHXWLFDO SDWHQWV QHWZRUNV FRXOG EH H[SDQGHG DQG KRZ
unexpected actors could be brought into playing a crucial role within the 
network it has illustrated. It highlighted how unexpected translations could take 
place, that would make pharmaceutical patents influential and active even 
while national texts of patent law were not in theory part of a system. In order 
to understand the unexpected and largely unofficial connections that make 
patents active in Djibouti, it was necessary to understand the complexity and 
heterogeneity of the networks that make both the import system of Djibouti and 
the pharmaceutical patent network of France complex systems. The 
heterogeneity of the pharmaceutical patent network in which importers in 
Djibouti are enrolled was one of its central characteristics. It is through the 
connections established between drugs, importers, producers, leaflets, planes 
and boats that the action of patents could transcend official boundaries, and 
reach actors that were not all directly linked to their textual existence. 
However, this role and action itself is open to challenges and modifications 
through other associations ± in this case study, through a new understanding of 
pharmaceutical needs in other instances, through the creation of new national 
policies emphasising the need for generics, and through the development of 
new structures for the import and distribution of pharmaceutical patents. The 
direct causality of various actions in different places on the role and action of 
patents in Djibouti is impossible to establish with certainty, and chains of 
events can only be described and questioned. Despite this, it emerged in this 
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case study that a variety of understandings of pharmaceutical patents ± and a 
variety of definitions and actions of pharmaceutical patents ± in different 
networks, in and outside Djibouti, were co-existing. Patents were written rules, 
part of drugs, determinant to health policies, and elements of pricing, amongst 
other things. A singular and uniform description of what pharmaceutical 
patents are or do became impossible to establish, as they are best characterised 
by their mobility and fluidity. 
 
Overall, studying pharmaceutical patents in this case study emphasised the 
DUWLILFLDO GLPHQVLRQ RI WKH ODUJHO\ DFFHSWHG ³VRFLDOOHJDO´ GLFKRWRP\ ,W
demonstrated why it was impossible to isolate any dimension of 
pharmaceutical patents ± or of TRIPS ± from varied connections and 
associations that make up the social as circulation. It became both limitative 
and inappropriate to try to define or understand socio-legal objects on the basis 
of pre-conceived assumptions stabilising their action as pre-determined, or 
stating the origin of their potentiaO ³SRZHU´ DV D VWDEOH DQG SUH-defined 
element. As ANT claims, power, objects and associations all need to be 
understood as fluid, mobile, and have to be empirically described rather than 
theoretically conceived. This proved particularly important in this case study 
through the examples of both TRIPS and pharmaceutical patents, although 
these findings raise questions broader than this case study. 
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TRIPS, pharmaceutical patents and health 
 
The story of TRIPS, pharmaceutical patents and health that arose from this 
case study is clearly different from that introduced in Chapter 1. The dominant 
story found in existing literature frames TRIPS as prescription as a highly 
UHOHYDQWDFWRULQUHODWLRQWRDFFHVVWRPHGLFDWLRQLQ³GHYHORSLQJFRXQWULHV´DQG
was challenged in several respects, as pre-existing assumptions were 
TXHVWLRQHG7KHODFNRIPRELOLVDWLRQWKDW³75,36DVSUHVFULSWLRQ´JHQHUDWHGLQ
public health networks appeared fundamentally different from what was 
predicted in the early stages of this research, on the basis of existing literature. 
However, this lack of mobilisation itself can be considered as having two 
potential meanings in relation to health. First (as highlighted in Chapter 5), if 
actors from the public health field are not informed of or mobilised by TRIPS 
or pharmaceutical patents, issues of compliance with international IP standards 
could emerge. Secondly, without a common acknowledgment of TRIPS by 
public health actors and of health issues by those in charge of implementing 
TRIPS, it is likely that a suitable framing of pharmaceutical patents 
dispositions, in a way appropriately addressing health issues, will be difficult. 
This in itself is an important element to consider when offering developing 
VWDWHV VROXWLRQV WR LPSOHPHQW ³KHDOWK-friendl\´ SDWHQW GLVSRVLWLRQV466. 
Nevertheless, in order to understand fully whether this itself is of any 
relevance, the second discrepancy between initial expectations and the 
                                                 
466
 As has been widely done in existing literature ± for example Correa C.M. (1998) 
³,PSOHPHQWLQJWKH75,36$JUHHPHQWLQWKH3DWHQW)LHOG2SWLRQVIRU'HYHORSLQJ&RXQWULHV´
the Journal of World Intellectual Property, 1(1), pp. 75-100; Scherer F.M and Watal J. (2002) 
³3RVW-75,36 2SWLRQV IRU $FFHVV WR 3DWHQWHG 0HGLFLQHV LQ 'HYHORSLQJ 1DWLRQV´ Journal of 
International Economic Law 5(4): 313-319. 
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empirical findings needs to be highlighted. In particular, the potential impact 
that the changes brought by TRIPS to developing countries could have on their 
public health system needs to be understood in contrast to pre-existing 
situations. As emphasised above, in Djibouti, and in spite of the absence of law 
on pharmaceutical patents prior to TRIPS, pharmaceutical patents were in 
effect regulating the flow of drugs entering the country. This influence ran 
further than the standards of TRIPS, as patents had the virtual effect of granting 
a monopoly to originally patented versions of drugs without temporal limits ± 
therefore influencing the price of medication in the country. Indeed, it appeared 
that the overall reshaping of health concerns that TRIPS has been generating 
might be changing the situation of Djibouti, and opening its market to generic 
medicines in a newly increased way. 
 
 The fact that TRIPS, pharmaceutical patents and health were related in 
unexpected ways, different from what most existing analysis or media 
coverage have emphasised, could appear to be neutral and no more than an 
anecdotal example of the contrasts between a given set of literature and a 
specific, different case study. However, as was emphasised in Chapter 7, some 
of the effects of TRIPS in Djibouti can be read as the result of the performative 
understanding of TRIPS in dominant discourses about the text in recent years. 
Looking at this impact from a political perspective, the conclusions to be 
drawn need to be balanced. On the one hand, the framing of TRIPS as a 
³QHJDWLYH´ GHYHORSPHQW IRU KHDOWK LQ GHYHORSLQJ FRXQWUies, explained in 
Chapter 1, and the opposition to TRIPS that appeared in that respect, can be 
considered as having participated in the introduction of generic medicines 
 353 
being brought back onto international priorities, including in Djibouti. In that 
respect, some positive outcomes might have appeared from TRIPS, in spite of 
its controversial origins ± and of its potentially negative impact in countries 
other than this, or even maybe in the longer term in this particular country. On 
the other hand, the example of AIDS as it is now being reframed in Djibouti 
illustrates one issue that will need to be addressed in the future. While the 
access to medicines campaign has emphasised the need to provide anti-
HIV/AIDS medication to poor countries, this might have resulted in the health 
priorities of some countries being left aside. Although the specific role of 
TRIPS in this case remains indirect, it can certainly be read as one of the 
HOHPHQWVWKDWKDYHVKDSHGVSHFLILFLVVXHVDVSULRULWLHVLQ³SRRUFRXQWULHV´DVD
whole, including access to anti-HIV/AIDS medication. The fact that issues 
other than access to medication, and diseases other than AIDS, need to be 
given more interest is now beginning to be discussed more widely. It is likely 
that the need for diversification in health policies and answers to health crises 
will be emphasised increasingly. Whether countries of the size and 
international status of Djibouti attract specific international interest is likely, 
however, to remain an issue. 
 
As a whole, what appeared in this case study were different stories about both 
TRIPS and pharmaceutical patents, resulting in them being understood, 
perceived, but (mainly) active in different ways in specific networks. The 
impact of this dislocation and lack of punctualisation and unity on the action of 
both socio-legal objects, and on their role in public health policies are complex. 
In particular, as explained above, some undesirable political effects can be 
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discerned in the current relation between TRIPS, pharmaceutical patents and 
health in Djibouti. If comparing this example to what has been written on other 
countries, one key issue that appears is the lack of coherence and harmony 
between policies and actions in the public health field in which TRIPS or 
pharmaceutical patents are embedded. In fact, it could be thought that this 
coherence will only be achieved if a common story of TRIPS and 
pharmaceutical patents manages to reintegrate each of the networks considered. 
If TRIPS and pharmaceutical patents in Djibouti become perceived in similar 
ways in each of the networks considered, and act in convergent ways within 
each of them, a coherent policy in which drug prices, health and patents can all 
be considered jointly and harmoniously might begin to develop.  
 
Throughout the analysis carried out in this research, ANT provided a relevant 
and useful tool to understand and describe the connections relevant to TRIPS, 
pharmaceutical patents and health in Djibouti. It is now necessary to return to 
what ANT specifically brought to this research, and what it could bring more 
generally to socio-legal studies. Its emphasis on empirical research, the 
fragility of orderings and artificiality of classifications needs to be understood 
more broadly in relation to socio-legal research.  
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SECTION 2: UNDERSTANDING SOCIO-LEGAL OBJECTS 
THROUGH ANT ± STRENGTHS AND LIMITS OF THE APPROACH 
 
This study has raised many questions in relation to the role and modes of action 
RI³VRFLR-OHJDO´REMHFWVDQGLQWKDWUHVSHFWJRHVEH\RQGWKHVSHFLILFH[DPSOH
of TRIPS and pharmaceutical patents it has analysed. However, once again, the 
ideas of ANT itself, and the position taken in this project, stress the need to 
DYRLG XQGXH JHQHUDOLVDWLRQ $W WLPHV $17 ZLOO DSSHDU DV D ³QHJDWLYH
DSSURDFK´E\HPSKDVLVLQJZKDWcannot be said rather than what can be clearly 
and definitely stated467. Nevertheless, there are important issues to be 
discussed, about the empirical study of socio-legal objects, and about the 
relevance of ANT as a theoretical and methodological framework for analysing 
such objects. This section will return to questioning the potential benefits of 
ANT in empirically examining socio-legal objects, before discussing the 
potential limits of the method. 
 
Understanding socio-legal objects empirically 
 
The example chosen in this research and the emphasis placed throughout on the 
need for empirical work to remain the basis of research calls for some final 
comments on the impact of ANT on practical issues in empirical methods.  
 
                                                 
467
 ³«$17LVILUVWRIDOODQHJDWLYHDUJXPHQW,WGRHVQRWVD\DQ\WKLQJSRVLWLYHDERXWDQ\VWDWH
RI DIIDLUV´, in Latour B. (2005) Reassembling the Social: an Introduction to Actor-network 
Theory, Oxford: Oxford University Press, on p.141. 
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On the basis of what has been said so far, it is important to ask how the 
approach undertaken in this particular project can be empirically useful for 
future research on other socio-legal objects ± including transnational objects. 
The role of socio-legal objects needs to be evaluated and understood on the 
basis of the traces they leave of particular actions and connections, which can 
empirically be observed. This is made particularly complex by the fact that, 
once again, neither the socio-legal objects under scrutiny nor pre-existing 
connections can be assumed to remain stable over time. The creation and 
action of new socio-legal objects will generate re-orderings in any pre-existing 
set of connections. At the same time, the socio-legal object under scrutiny will 
change from being that which its creators have designed it to be in an idealised 
network, to being a new object reshaped by the network in which has become 
enrolled. 
 
 Although this constant movement and total interdependency appears to 
generate a particular form of complexity, and one that cannot be fully escaped, 
focusing on description of connections and relations is a useful way to draft 
and draw this complexity, in order to understand how things happen ± rather 
than try to frame what things are or will be. The role of socio-legal analysis in 
this view becomes to determine how the range of associations that bring 
agency to socio-legal objects can be described, to discuss how these 
associations themselves need to be related to other connections in a circulating 
network; and how socio-legal objects are shaped in each of the loci where these 
connections occur. Empirical analysis comes to be about understanding how 
links are made and unmade; how the multiple nature of socio-legal objects 
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comes to be expressed within the different networks and connections into 
which they have become enrolled.  
 
The overall consequence of applying ANT to the analysis of specific socio-
legal objects is to study their mechanisms within orderings, while assuming 
neither the consequences of their supposed nature, nor the existence of an 
RYHUDUFKLQJ ³VRFLDO´ HQFRPSDVVLQJ RWKHU GLVFLSOLQHV DQG ILHOGV %RXQGDULHV
between objects become blurred, and to some extent irrelevant to empirical 
analysis, for which what becomes essential is to work from objects to their 
mechanisms, rather than deduce mechanisms from the supposed nature of 
given objects or systems. 
 
8QGHUVWDQGLQJ³WUDQVQDWLRQDO´VRFLR-legal objects 
 
One aspect of ANT that was particularly relevant in this research, and can be 
expected to remain so in the case of other empirical research on transnational 
socio-OHJDOREMHFWVUHODWHVWRWKHFKDOOHQJHVLWEULQJVWRWKHLGHDRI³JOREDOLW\´
The mechanisms of international law have often been incorporated into the 
JHQHUDOGLVFXVVLRQWULJJHUHGE\WKH³JOREDOLVDWLRQ´Saradigm in recent years. In 
WKLV UHVHDUFK KRZHYHU WKH YLHZ ZDV WKDW ³JOREDOLVDWLRQ´ ZDV QRW D KHOSIXO
notion for empirical research. The notion of space as being network-based, 
adopted by ANT were integrated in the theoretical background. The 
consequences for the understanding of transnational socio-legal objects are 
wide-ranging, and call for the reintegration of local complexity within 
explanations and descriptions. The need to understand the dislocated effects of 
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transnational socio-legal objects becomes crucial, as the action of these objects 
in a number of different places could impact on any given loci under scrutiny. 
Similarly, the shaping RIREMHFWVDV³JOREDO´DQGWKHSRWHQWLDOSHUIRUPDWLYLW\RI
this understanding need to be understood ± and potentially linked to these same 
dislocated effects. However, the range of effects and links that can be drawn by 
seeking to analyse such widely spread objects enables certain empirical 
concerns to emerge. This will now be addressed by questioning more generally 
how the emphasis of ANT on complexity and the inherent fragility of any 
network can be reconciled with the practical limits of research, and with the 
need to avoid silencing or obscuring elements that cannot necessarily be 
empirically evaluated. 
 
Reflecting on ANT in empirical research ± balancing theoretical ideals and 
empirical issues 
 
The questions raised by the empirical analysis of transnational socio-legal 
objects are a particularly relevant example of the difficulties that some of the 
claims of ANT raise in practice more generally ± and could in fact highlight 
some of its internal issues and potential contradictions. This issue has been 
partly addressed in Chapter 3, but needs to be briefly discussed again here, as it 
has consequences that extend beyond this particular project. 
 
If the intent is to remain faithful to the most central claim of ANT, it is 
essential to avoid taking any actor-network as stabilised, without investigating 
how it is constructed ± in the sense defined in Chapter 3. It is crucial to explore 
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the complexity of any object that may appear, at first, as simple and stabilised, 
as what has made it needs to be grasped in order to understand its action. In 
this particular project, this was illustrated by a need to constantly look beyond 
the punctualised image that some objects seemed to reflect ± WKH³JRYHUQPHQW´
of Djibouti was defined in its complexity. Drugs were characterised as complex 
hybrids in which patents were playing a key role. Patents were defined as 
multiple and complex, originated in connections happening in a range of 
settings including in France; TRIPS was portrayed as made up of complex 
interactions and creating new connections, themselves resulting in wide 
ranging effects. However, a number of times throughout this project, the fact 
that some aspects could not be detailed, that some connections could not be 
analysed, was also emphasised. Some objects were taken for granted, were not 
undone, not always questioned, and their complexity could not always be 
highlighted in as much detail as some aspects of ANT would have required. 
Similarly, the effects of some entities ± such as some aspects of strategies of 
pharmaceutical industries towards developing countries ± could not be 
empirically evaluated within the course of this research. One of the 
consequences of ANT was to prevent their full integration in the research 
findings, since statements need to remain empirically based. This opens 
questions about the potential limits of ANT itself, and about the fact that it 
might result in providing only a partial story in which some elements remain 
othered ± and this has been acknowledged in Chapter 2. However, it is a limit 
that almost necessarily follows the strengths of the method ± its inherent 
grounding in empirical data. On the one hand, some entities not studied in 
detail empirically might remain partly obscured by the method. On the other 
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hand, researchers are in practice prevented by making claims that cannot be 
empirically sustained. What are presented throughout are phenomena as 
expressed in the specific networks studied, and external influences are analysed 
through their local manifestations. 
 
One of the difficulties with using the key-concepts of ANT to analyse 
transnational socio-legal objects is that their dislocated effects, as well as the 
associations that make and reshape them continuously, are likely to be so 
numerous that it becomes impossible in practice to analyse in detail each 
relevant connection or mention at every step of the analysis where more 
complexity might be hidden. Part of the decision in determining which network 
to study in more detail, or which connections to take as punctualised for the 
purpose of a particular research might remain partly arbitrary. To some extent, 
with some particular objects, researchers might be faced with a choice of either 
making the research empirically feasible while accepting its potential 
imperfections, or aiming for perfect completude while taking the risk of ending 
with an unfeasible project. However, several strategies can be found to 
reconcile the potential difficulties raised here with the practicalities of 
empirical research. 
 
The first element, of strategy (put forward in Chapter 3), consists of making the 
potential limitations of the research and the choices to accept particular objects 
as punctualised as clear as possible. The reason why these choices were made 
is also an important element to facilitate understanding the potential impact this 
choice might have had. The second element needs to be found in ANT itself, 
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and FRQVLVWV RI ³following the actors themselves´ 7KHUHIRUH ZKHQ DFWRUV
consider a particular network as punctualised and take it as one stable whole, it 
sometimes becomes justified to accept this in the research itself as one object. 
This in fact highlights what might at times appear as a potential contradiction 
within ANT itself ± ZKLOH³following the actors themselves´ is constantly put 
forward by Latour as essential to the strategy468, the emphasis of ANT on 
always questioning what might appear as stable469 can sometimes lead to 
challenging some of the punctualisations that actor themselves perform. 
Nevertheless, by recognising that some punctualisations performed by actors 
can become accepted in the research process ± although the fact that they might 
hide part of other realities needs to be acknowledged ± it becomes feasible to 
understand the mechanics of transnational socio-legal objects while avoiding 
some of the potential practical limits of ANT. Once again, this can only be 
done by making potential limitations explicit, and stating clearly why some 
objects can be taken for granted, the nature of these objects, and why it does 
not impact on the actual focus of the analysis whether they are fully undone or 
not. In studying a transnational socio-legal object through the associations that 
make it in a particular network, following the actors will result in highlighting 
the multiple realities of this object in the networks chosen as examples ± 
although other dimensions, other actions and other realities of this particular 
                                                 
468
 The emphasis is particularly explicit in Latour (2005), Reassembling the Social: an 
Introduction to Actor-network Theory, op. cit.. 
469
 The necessity to question constantly the many connections that make up any actor-network 
can be found in most ANT literature referenced in Chapter 2, and is particularly explicit for 
H[DPSOH LQ /DZ -  ³$QG LI WKH *OREDO ZHUH 6PDOO DQG 1RQ-Coherent? Method, 
&RPSOH[LW\ DQG WKH %DURTXH´ SXEOLVKHG E\ WKH &HQWUH IRU 6FLHQFH 6WXGLHV /DQFDVWHU
University, LA14YL, UK, at http/www.comp.lancs.ac.uk/sociology/papers/law-and-if-the-
global-were-small.pdf  
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object might still exist. This translated in this case study into emphasising that 
what was under scrutiny here was what TRIPS and pharmaceutical patents are 
in Djibouti, and stressing that this should not be generalised to understandings 
applicable per se in other places or countries.  
 
 
Overall, this research has highlighted the complexity and fluidity of the 
mechanisms of socio-legal objects.  By looking at the way TRIPS and 
pharmaceutical patents act in Djibouti, it has participated in challenging some 
expectations built in a field where broad generalisations have been often 
accepted. The need to complete the investigation of the links between TRIPS, 
pharmaceutical patents and health in a wider range of places has been detailed. 
In addition, the need to challenge the assumption that some categories, 
groupings or dichotomies can be accepted when studying the action of socio-
legal objects was emphasised. As a whole, this research raised many questions 
in relation to the specific field of research under scrutiny, as well as in relation 
to socio-legal research and the potential role of ANT in this discipline. It called 
for a reintegration of fluidity and complexity in socio-legal analysis, and for 
the emphasis to be brought on assumption-free empirical research ± within the 
limits unavoidably set by the format of academic research.  
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